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“No greater opportunity, responsibility, or obligation can fall to the lot of a human being 
than to become a physician. In the care of the suffering he needs technical skill, scientific 
knowledge, and human understanding. He who uses these with courage, with humility, 
and with wisdom will provide a unique service for his fellow man, and will build an 
enduring edifice of character within himself. The physician should ask of his destiny no 
more than this; he should be content with no less.” 
 
Tinsley Randolph Harrison 
(1900-1978) 
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List of abbreviations 
A 
AAD  Antiarrhythmic drug 
ACE2  Angiotensin converting enzyme type 2 
AF  Atrial fibrillation 
AP  Action potential 
APD  Action potential duration 
AZM  Azithromycin 
 
C 
Ca2+  Calcium 
[Ca2+]o  Extracellular calcium concentration 
cAF  Long-standing persistent (‘chronic’) AF 
CaM  Calmodulin 
CaMKII  Calcium/calmodulin-dependent protein kinase-II 
cAMP  Cyclic adenosine monophosphate 
CASQ2  Calsequestrin 
CaT  Calcium transient 
CHO  Chinese hamster ovary 
CICR  Calcium-induced calcium release 
CoV  Coronavirus 
COVID-19 Coronavirus disease 2019 
CPVT  Catecholaminergic polymorphic ventricular tachycardia  
CQ  Chloroquine 
CRP  C-reactive protein 
CRU  Calcium-release unit 
CV  Conduction velocity 
 
D 
DAD  Delayed afterdepolarization 
DAG  Diacylglycerol 
DREAM  Downstream regulatory element agonist modulator 
 
E 
E-C  Excitation-contraction 
EAD  Early afterdepolarization 
Endo  Endocardium 
Epac  Exchange-protein activated by cAMP 
Epi  Epicardium 
ERP  Effective refractory period 
 
F 
FDA  the U.S. Food and Drug Administration 
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FKBP  FK506-binding protein 
 
H 
HDAC  Histone deacetylase complex 
HEK  Human embryonic kidney 
HF  Heart failure 
 
I 
IC50  Half-maximal inhibitory concentration 
ICa,L  L-type calcium current 
IK1  Inward-rectifier potassium current 
IK,ACh  Acetylcholine-activated inward-rectifier potassium current 
IKr  Rapid delayed-rectifier potassium current 
IKs  Slow delayed-rectifier potassium current 
IKur  Ultra-rapid delayed-rectifier potassium current 
IL  Interleukin 
INa  Fast sodium current 
INCX  Sodium/calcium-exchange current  
IP3  Inositol triphosphate 
ISO  Isoproterenol 
Ito  Transient-outward potassium current 
IQR  Interquartile range 
 
K 
K+  Potassium 
[K+]o  Extracellular potassium concentration 
 
L 
LA  Left atrium 
LTCC  L-type calcium channel 
LV  Left ventricle 
 
M 
MANTA  Maastricht ANTiarrhythmic drug evAluator 
MI  Myocardial infarction 
Mid  Mid-myocardium 
MRI  Magnetic resonance imaging 
MyBP-C  Myosin binding protein-C 
 
N 
Na+  Sodium 
[Na+]o  Extracellular sodium concentration 
NCX1  Sodium-calcium exchanger type-1 
NFAT  Nuclear factor of activated T-cells 
NLRP3  NACHT, LRR, and PYD domains containing protein-3 
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P 
pAF  Paroxysmal atrial fibrillation 
PDE  Phosphodiesterase 
PKA  Protein kinase-A 
PKC  Protein kinase-C 
PKP2  Plakophilin-2 
PLM  Phospholemman 
PLN  Phospholamban 
PMCA  Plasmalemmal calcium-ATPase 
POAF  Post-operative atrial fibrillation 
PP1  Protein phosphatase 1 
 
R 
RA  Right atrium 
RF  Repolarization failure 
RMP  Resting membrane potential 
ROS  Reactive oxygen species 
RyR2   Ryanodine Receptor type-2 
 
S 
SAC  Stretch-activated ion channel 
SARS  Severe acute respiratory syndrome 
SCaE  Spontaneous calcium release event 
SERCA2a Sarco/endoplasmic reticulum calcium-ATPase 2a 
SLN  Sarcolipin 
SK channel Small-conductance calcium-activated potassium channel 
SOICR  Store overload-induced calcium release 
SR  Sarcoplasmic reticulum 
 
T 
TA  Triggered activity 
TNF-α  Tumor necrosis factor-α 
TRPC channel Transient receptor potential canonical channel 
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The function of the heart 
“The heart is the household divinity which, discharging its function, nourishes, cherishes, 
quickens the whole body, and is indeed the foundation of life, the source of all action.” 
Sir William Harvey 
(1578 – 1657) 
 
The organ by number 
“Numero pondere et mensura Deus omnia condidit” 
(God created everything by number, weight and measure) 
Sir Isaac Newton 
(1642 – 1727) 
 
Cell: the core of life science 
“The cell concept is the axis around which the whole of modern science of life revolves” 
Paul Ehrlich 
(1854 – 1915) 
 
The art of scientific programming 
“Programming is a skill best acquired by practice and example rather than from books. 
Codes are a puzzle. A game, just like any other game.” 
Sir Alan Mathison Turing 
(1912 – 1954) 
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General Introduction 
 
Adapted from: The role of calcium in the human heart: with great power comes 
great responsibility 
 
H. Sutanto and J. Heijman  
Front Young Minds. 7:65.  
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1.1 Background 
1.1.1 Why is calcium so important for the heart? 
Calcium is present in most foods, notably dairy products, such as milk and cheese, and 
is often found in small fish and some vegetables. It has been known for a long time that 
calcium is beneficial for the strength of our bones. In addition, scientists have 
discovered that calcium also plays an important role in the heart (Figure 1.1). The heart 
beats more than 2 billion times during an average person's lifetime to circulate the 
blood, which is needed to provide energy to every part of the body. The heart consists, 
among many other things, of 3 billion heart muscle cells that squeeze together 
(“contract”) during each heartbeat and together are responsible for the pumping 
function of the heart. To make sure that each cell contracts at the right moment, the 
heart uses an electrical signal that moves from cell to cell, much like a wave in a stadium, 
where the activity of one person activates their neighbor. Research during the last 
decades has revealed that calcium particles are responsible for the link between 
electrical activation and mechanical contraction (Figure 1.1). Calcium particles, which 
have an electrical charge, enter the heart muscle cells during each beat and contribute 
to the electrical signal. In addition, these calcium particles initiate contraction by 
binding to specialized machinery within the cell. When the calcium binds, the 
machinery starts to move and makes the cell squeeze together. On the other hand, when 
the calcium particles are removed from the heart cells, this triggers relaxation, allowing 
the heart to be refilled with blood before the start of the next heartbeat. Thus, without 
calcium, our hearts would stop beating immediately, which was already shown 
experimentally by Dr. Sydney Ringer in the early 1880s. 
 
1.1.2 The heart muscle cell: a house with multiple doors and chambers 
A heart muscle cell is like a big house with multiple doors and chambers (Figure 1.2). 
Calcium particles can flow in and out of the cell through gate-like structures named ion 
channels (1). These ion channels help the cell to control the amount of calcium inside of 
it. In addition to the supply of calcium from outside the cell, there is a big chamber inside 
the cell, named the sarcoplasmic reticulum, that stores most of the calcium required for 
heart contraction. The sarcoplasmic reticulum chamber also has entrance and exit 
doors for calcium. The entrance doors to the sarcoplasmic reticulum are named SERCA 
and the exit doors are named ryanodine receptors. The calcium that enters the heart 
cell through the calcium ion channel activates the ryanodine receptor to release enough 
calcium from the sarcoplasmic reticulum to initiate heart muscle contraction. This is 
done by binding to another structure, named troponin, inside the heart muscle cell. 
During relaxation, calcium has to be detached from troponin and expelled out of the cell 
or stored back inside the sarcoplasmic reticulum. 
In addition to the calcium doors, heart muscle cells are also equipped with 
other doors responsible for the movements of other particles in and out of the cell, such 
as sodium, potassium, and chloride. Recently, scientists have found that calcium can 
regulate the activity of these other doors, making them easier or harder to open, 
highlighting the large responsibility of calcium in heart muscle cells (2).  
General introduction 
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Figure 1.1: The role of calcium in heart muscle cells. One human heart consists of more than three billion 
heart muscle cells and each cell contains its own machinery to provide contraction and relaxation of the heart 
muscle. The blue shaded area shows the important role of calcium in heart muscle cells. Calcium binds to the 
troponin complex in the cells (indicated by the large red arrow), which makes the cells squeeze together, a 
process called excitation-contraction coupling (shown by green arrows on the left-hand side of the blue 
shaded area). In addition, calcium contributes to the electrical signal which moves from cell to cell to produce 
a uniform contraction (shown on the right-hand side of the blue shaded area). 
 
1.1.3 What happens if calcium gets out of control? 
In some cases, the doors controlling the movement of calcium malfunction, causing too 
much or too little calcium to enter the cell. Sometimes, this malfunction is caused by 
advancing age or other diseases. Alternatively, changes/variations in our genes (called 
genetic mutations) can change the shape of the ion channel which, in extreme cases, 
may prevent the channel from opening or closing properly. This can lead to abnormal 
electrical signals, which may cause a group of heart diseases called heart rhythm 
disorders. 
Heart rhythm disorders happen when the electrical communication between 
cells becomes uncoordinated or when groups of cells spontaneously produce additional 
electrical signals. As we previously mentioned, electrical communication in the heart is 
similar to the wave in a soccer stadium, which also relies on clear communication. If the 
lights are off and the spectators cannot see each other, communication will not happen 
and it will not be possible to create a nice wave. The wave also only works properly if 
people move only when the wave reaches their seat. Uncoordinated, chaotic electrical 
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activity of the heart is called fibrillation. Fibrillation causes the heart to pump blood 
ineffectively, leading to a lower energy supply to a person's organs. 
 
Figure 1.2: A heart muscle cell and its components. Calcium enters the cell through “doors” called ion 
channels and interacts with various components of the cell. For example, calcium regulates the opening and 
closing of sodium and potassium doors and ryanodine receptors, and it binds to the troponin complex to make 
the heart cell squeeze together (“contract”), which produces the pumping function of the heart. In heart 
muscle cells, most of the calcium is stored inside a chamber named the sarcoplasmic reticulum. The calcium 
in the sarcoplasmic reticulum is released during heart muscle contraction and transported back inside the 
sarcoplasmic reticulum during relaxation. Red arrows indicate the movement/flow of calcium from one place 
to another. 
 
In addition, abnormal calcium movement may directly impair contraction or 
relaxation of the heart, hindering the normal pump function. Under these conditions, 
the heart cells can eventually become “tired” and fail. Heart failure can cause a wide 
range of problems, from mild (coughing and tiredness) to severe (shortness of breath 
and organ swelling). This, of course, will reduce a person's productivity. Recently, 
scientists found that calcium is strongly associated with the progression of heart failure. 
Heart failure also makes the occurrence of potentially deadly heart rhythm disorders 
more likely (3). 
 
1.1.4 What has been done by scientists so far to better understand calcium in the 
human heart? 
Given the impact of heart disease, we may wonder what scientists can do to stop those 
diseases from occurring. For several decades, scientists have been studying the role of 
calcium in heart muscle cells. They now know that in some heart diseases, such as 
fibrillation and heart failure, abnormalities in calcium regulation play a major role (2). 
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Nowadays, scientists can study calcium movement by taking single heart muscle cells 
from animals or patients and investigating these single cells using a sophisticated 
method called patch clamp, which makes it possible to measure the electrical signals 
that pass through specific ion channels. This is done by attaching a very small glass 
needle (more than 20 times smaller than a single hair) to the surface of the cell. 
Scientists can also measure the number and location of channels inside the heart cell by 
attaching light-emitting indicators to the channels, which can be visualized under a 
microscope. More recently, scientists have started to use computer models to put all 
these data together, to help them predict the effect that changes in calcium regulation 
will have within heart cells (4). 
 
Figure 1.3: The effects of calcium-handling abnormalities in the heart and currently available methods to 
detect and treat these problems. Problems with calcium handling in heart muscle cells (shown on the left) 
may result in heart rhythm disorders and/or heart failure (first set of red arrows). Several methods are 
currently available to study the role of calcium in these diseases, including calcium recording, protein 
staining/coloring, and analysis with computer models (shown in the third column). Using these methods, new 
treatments for these heart conditions are being developed, including medications to block the ion channels 
and techniques to remove the cells of the heart that produce uncontrolled electrical signals (shown on the 
right). 
 
The improved understanding of heart rhythm disorders has helped to predict 
which patients have a high risk of these problems and has also resulted in better 
therapies (5). For example, drugs can be used to block the ion channels so that the doors 
stay closed and the amount of calcium inside the cell is controlled. Alternatively, 
specialized doctors can put a small device into the heart, through the blood vessels, to 
take out the heart cells that produce unwanted signals so that they no longer cause 
fibrillation (Figure 1.3). Despite the impressive advancements in (bio)medical 
technologies, numerous important questions about the mechanisms and treatment of 
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calcium-related problems inside heart muscle cells remain. Several research groups 
across the world are working hard to answer these questions. 
 
1.2 Thesis overview 
In addition to the brief general overview of cardiomyocyte calcium handling in this 
introductory chapter, this thesis consists of other 8 chapters as follows: 
Chapter 2 summarizes the role of cardiomyocyte calcium handling in health and 
disease, focusing on the significance of calcium handling and calcium handling 
abnormalities in arrhythmogenesis and how in silico studies may support current and 
future in vitro experiments.   
Chapter 3 discusses the significance of subcellular distribution of calcium-handling 
proteins: ryanodine receptors (RyR2s) and L-type calcium channels (LTCCs) on the 
propensity of diastolic spontaneous calcium release events (SCaEs), a substrate for 
ectopic activities in the heart. 
Chapter 4 illustrates an application of the spatially-detailed model of atrial 
cardiomyocyte developed in the previous chapter to address some experimental 
questions in the setting of post-operative atrial fibrillation (POAF).  
Chapter 5 studies the consequences of calcium-dependent regulation of atrial ionic 
currents on cardiac electrophysiology, investigating the impact of such regulation on 
the action potential (AP) properties, delayed afterdepolarization (DAD) and the 
behavior of cardiac reentry using computer simulations. 
Chapter 6 demonstrated the role of multi-scale computational modeling to elucidate 
the acute effects of ethanol on cardiac electrophysiology and arrhythmogenesis at the 
cellular and tissue levels.  
Chapter 7 presents the Maastricht ANTiarrhythmic drug evAluator (MANTA), a 
computational tool developed in Maastricht to better understand the cellular effects of 
antiarrhythmic drugs (AADs). In this chapter, some applications of MANTA are also 
discussed. 
Chapter 8 exemplifies the application of computational modeling to investigate the 
effect of β-adrenergic receptor stimulation on ventricular AP in the presence of 
repolarization reserve-lowering medications (e.g., chloroquine and azithromycin). 
Chapter 9 contains the general discussion of the thesis, elaborating the previous 
chapters and underlining the role of integrative computational modeling of cardiac 
calcium handling to better understand the basic mechanisms of cardiac arrhythmias. 
Current challenges, future recommendations and the potential benefits of multiscale 
modeling are also discussed.  
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Chapter 2 
 
Cardiomyocyte calcium handling in health and 
disease: insights from in vitro and in silico studies 
 
H. Sutanto, A. Lyon, J. Lumens, U. Schotten, D. Dobrev and J. Heijman   
Prog Biophys Mol Biol. 157:54-75. 
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ABSTRACT 
Calcium plays a central role in cardiomyocyte excitation-contraction coupling. To 
ensure an optimal electrical impulse propagation and cardiac contraction, calcium 
levels are regulated by a variety of calcium-handling proteins. In turn, calcium 
modulates numerous electrophysiological processes. Accordingly, calcium-handling 
abnormalities can promote cardiac arrhythmias via various mechanisms, including the 
promotion of afterdepolarizations, ion-channel modulation and structural remodeling. 
In the last 30 years, significant improvements have been made in the computational 
modeling of cardiomyocyte calcium handling under physiological and pathological 
conditions. However, numerous questions involving the calcium-dependent regulation 
of different macromolecular complexes, cross-talk between calcium-dependent 
regulatory pathways operating over a wide range of time scales, and bidirectional 
interactions between electrophysiology and mechanics remain to be addressed by in 
vitro and in silico studies. A better understanding of disease-specific calcium-dependent 
proarrhythmic mechanisms may facilitate the development of improved therapeutic 
strategies. In this review, we describe the fundamental mechanisms of cardiomyocyte 
calcium handling in health and disease, and provide an overview of currently available 
computational models for cardiomyocyte calcium handling. Finally, we discuss 
important uncertainties and open questions about cardiomyocyte calcium handling and 
highlight how synergy between in vitro and in silico studies may help to answer several 
of these issues. 
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2.1 Introduction 
Tightly-controlled calcium handling in each cardiomyocyte is essential for optimal 
electrical and mechanical functioning of the heart. Calcium-handling abnormalities 
have been implicated in inherited cardiovascular diseases, including Timothy 
syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT) and 
arrhythmogenic cardiomyopathy, as well as acquired cardiovascular diseases such as 
heart failure (HF) and atrial fibrillation (AF) (6, 7). However, the precise mechanistic 
role of calcium in the initiation and progression of those diseases remains incompletely 
understood due to the complex interaction of calcium with many electrophysiological 
targets and signaling cascades, operating across a wide range of spatial and temporal 
scales (6). Despite significant advances in experimental techniques, many open 
questions remain due to the limitations and uncertainties associated with current 
experimental procedures (8, 9). In recent years, computational models have been 
increasingly employed to investigate numerous physiological and pathological 
phenomena, support clinical decision making, and improve the sensitivity, specificity 
and accuracy of biomedical devices and treatments (10-12). Here, we review the state-
of-the-art in our understanding of cardiomyocyte calcium handling in health and 
disease, with a focus on synergistic interactions between computational modeling and 
experimental advances. 
 
2.2 Calcium handling and excitation-contraction coupling in the 
healthy heart 
2.2.1 Cardiomyocyte calcium handling 
During systole, calcium enters the cardiomyocyte through voltage-gated L-type calcium 
channels (LTCCs) and triggers calcium-induced calcium release (CICR) through the 
calcium-dependent opening of ryanodine receptor type-2 (RyR2) channels organized 
together in local nanodomains (dyads). The interaction between multiple LTCC and 
RyR2 in calcium-release units (CRUs) strongly depends on subcellular structure. For 
example, in ventricular cardiomyocytes an extensive T-tubular network of membrane 
invaginations brings LTCC in close proximity of RyR2 located deep inside the 
cardiomyocyte. RyR2 opening leads to a much larger calcium release from the 
sarcoplasmic reticulum (SR) to the cytosolic space. The resultant calcium transient 
affects multiple targets inside a cardiomyocyte, including several transmembrane ion 
channels (including the LTCC itself, which undergoes calcium-dependent inactivation), 
contractile proteins, and calcium-dependent signaling pathways (13, 14), thereby 
controlling the electromechanical function of the heart (Figure 2.1). Store-operated 
calcium entry, the primary mechanism of calcium entry in non-excitable cells, may also 
contribute to cardiomyocyte calcium influx, specifically at the intercalated disk, and has 
recently been implicated in proarrhythmic cardiomyocyte calcium signaling (15). 
During diastole, calcium is returned to the SR by the sarco/endoplasmic reticulum 
calcium-ATPase 2a (SERCA2a), which hydrolyzes 1 ATP to pump 2 calcium ions back to 
the SR. Calcium is also extruded from the cell via the sodium-calcium exchanger (NCX), 
which exchanges 1 calcium for 3 sodium ions, and to a lesser extent via the 
plasmalemmal calcium-ATPase (PMCA), an active pump that contributes to 
approximately 5–10% of the calcium efflux in large mammals (9, 13). The activity of all 
Cardiomyocyte calcium handling in health and disease 
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these calcium-handling proteins is regulated through large macromolecular complexes 
in which numerous interacting proteins and enzymes controlling post-translational 
modifications integrate a wide range of feedback and feedforward signals. Key 
examples will be discussed in Section 2.5.1. 
 
2.2.2 Excitation-contraction coupling 
Excitation-contraction (E-C) coupling is the process by which the electrical activation 
of cardiomyocytes leads to contraction. It occurs following SR calcium release when the 
high calcium levels promote calcium binding to troponin-C, a molecule of the thin 
filament of the sarcomere. At rest, tropomyosin wraps around actin, blocking its myosin 
binding site and preventing contraction. The binding of calcium to troponin-C shifts the 
tropomyosin strand away from the actin binding sites, enabling the formation of cross-
bridges and the generation of force (13). The amount of calcium released during CICR 
largely controls E-C coupling and cardiomyocyte contraction, and depends on 
structural coupling (e.g., configurations of the dyadic space where T-tubule and SR 
interact), and functional coupling (characteristics of calcium fluxes) (9). Relaxation 
occurs with the unbinding of calcium from troponin-C, changing the filament 
conformation back to a blocked, non-force-generating state. In addition, contractility is 
regulated by myofilament calcium sensitivity. The higher this sensitivity, the larger the 
force generation, but the faster the relaxation for a given concentration of free calcium 
(16). Myofilament calcium sensitivity may be altered in pathology (e.g., hypertrophic 
cardiomyopathy), leading to abnormalities in contraction or relaxation. Various 
sarcomeric proteins such as Tn-I, myosin binding protein-C (MyBP-C) or titin also 
exhibit degrees of calcium sensitivity, therefore modulating cross-bridge formation and 
contraction. Finally, cardiac mechanics can also affect the regulation of intracellular 
calcium, with mechanical alterations potentially modifying stretch-activated ion 
channels (SACs) or calcium-buffering properties through changes in myofilament 
calcium sensitivity (17, 18). 
 
2.3 General overview of calcium-dependent arrhythmogenesis 
Conceptually, two major mechanisms control the generation and maintenance of 
cardiac arrhythmias: ectopic (triggered) activity and reentry (5, 19), both of which are 
modulated by calcium-handling abnormalities (Figure 2.2). Focal ectopic activity is the 
generation of uncoordinated electrical activity outside the physiological activation 
sequence driven by the sinoatrial node. It can be triggered through early or delayed 
afterdepolarizations (EADs or DADs, respectively), or result from abnormal 
automaticity (19). EADs are additional depolarizations occurring before full 
repolarization of the action potential (AP) and are commonly due to excessive 
prolongation of the repolarization phase of the AP, providing time for recovery from 
inactivation of LTCC. DADs are secondary depolarizations occurring after the full 
repolarization of the AP, typically due to spontaneous diastolic SR calcium-release 
events (SCaEs) (20). Reentry is considered the major arrhythmia-maintaining 
mechanism and can be initiated in the setting of unidirectional block when an activation 
wavefront propagates around anatomical or functional obstacles and re-excites the site 
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of origin. In the normal heart, reentrant activation wavefronts fail to perpetuate as they 
encounter refractory, non-excitable tissue. However, in pathological conditions 
alterations in the balance between effective refractory period (ERP) and conduction 
velocity (CV), or promotion of conduction block, may create a vulnerable substrate in 
which reentry can be maintained (5, 19). Calcium-dependent ion-channel modulation 
can alter ERP and CV via direct and indirect pathways (e.g., transcriptional regulation 
or phosphorylation by calcium-dependent kinases), thereby promoting reentry. Finally, 
calcium-handling abnormalities can promote reentry by supporting the evolution of 
structural remodeling, leading to slow heterogeneous conduction and conduction block 
(2, 21). The autonomic nervous system plays a central role in cardiac arrhythmogenesis, 
with autonomic dysbalance promoting both ectopic activity and reentry through 
calcium-dependent and non-calcium-dependent mechanisms. 
 
Figure 2.1: Schematic illustration of (ventricular) cardiomyocyte calcium handling. Membrane 
depolarization leads to the opening of L-type calcium channels (LTCCs) which trigger the release of calcium 
ions from the sarcoplasmic reticulum to the dyadic and cytosolic space. Subsequently, calcium interacts with 
many molecular targets within the cardiomyocyte, including transmembrane ion channels (e.g., the voltage 
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dependent sodium channel, rapid and slow delayed-rectifier potassium (Kr and Ks) channels, and inward-
rectifier potassium (K1) channel), contractile machineries and calcium-dependent signaling molecules. 
Additionally, intracellular calcium also plays an important role in transcriptional regulation of ion channels 
in the heart. A schematic representation of the cytosolic and nuclear calcium transients (in relation to the 
action potential of human ventricular cardiomyocyte) is also depicted in the figure. 
 
2.3.1 Calcium-handling abnormalities as determinants of triggered activity 
Under pathophysiological conditions, cardiomyocytes can exhibit spontaneous (i.e., not 
triggered by CICR due to LTCC-mediated calcium influx) calcium releases from the SR, 
occurring primarily during diastole, termed SCaEs (22). SCaEs that are restricted to a 
small local nanodomain are termed calcium sparks (23), whereas SCaEs that propagate 
over larger areas are termed calcium waves. These triggered activity-promoting SCaEs 
can result from RyR2 dysfunction or SR calcium overload. The proarrhythmic 
consequences of RyR2 dysfunction are exemplified by CPVT, an inherited 
arrhythmogenic syndrome primarily caused by mutations in RyR2 or the SR calcium-
binding protein calsequestrin (CASQ2). CASQ2 functions as a cooperative, high capacity 
and low affinity SR-calcium buffer, which can interact with RyR2 either directly or via 
triadin and junctin (24). Most CPVT-associated mutations increase RyR2 open 
probability, leading to inappropriate diastolic SR calcium release and triggered activity. 
This phenomenon is exacerbated in the presence of RyR2 hyperphosphorylation during 
sympathetic stimulation, further increasing the risk for atrial and ventricular 
arrhythmias, and sudden cardiac death (25, 26). RyR2-dysfunction-induced SCaEs have 
recently also been implicated in arrhythmogenic cardiomyopathy due to plakophilin-2 
(PKP2) deficiency and resulted from excessive connexin-43 hemichannel-mediated 
calcium influx and remodeling of calcium handling (27, 28). Pharmacological 
stabilization of RyR2 prevents calcium-handling abnormalities and has antiarrhythmic 
effects in CPVT (25). RyR2 stabilization also improves survival in pressure overload and 
myocardial infarction animal models, although HF progression and contractile 
dysfunction remain, underlining the significance of RyR2-mediated calcium-handling 
abnormalities in cardiac arrhythmias (29). 
 
Figure 2.2: Cardiomyocyte calcium handling and cardiac arrhythmias. Cardiomyocyte calcium-handling 
abnormalities may trigger cardiac arrhythmias through several mechanisms: the initiation of 
afterdepolarizations and triggered activities, direct and indirect ion-channel modulation, and structural 
remodeling. Those processes promote ectopic activity and alter the effective refractory period (ERP) and 
conduction velocity (CV), contributing to a vulnerable substrate for cardiac arrhythmias. 
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Besides RyR2 dysfunction, store overload-induced calcium release (SOICR) can 
also cause DADs (26). SOICR can result from excessive calcium influx (e.g., due to 
impaired LTCC inactivation in the setting of Timothy syndrome (30)), from inhibition 
of calcium extrusion by NCX (e.g., due to elevation of intracellular sodium by cardiac 
glycosides), or from increased SERCA activity. Phospholamban (PLN) is a small protein 
that inhibits SERCA function by reducing its calcium affinity. Phosphorylation of PLN at 
Ser16 by protein kinase-A (PKA) or at Thr17 by calcium/calmodulin-dependent protein 
kinase-II (CaMKII) reduces the inhibitory effect, permitting a faster reuptake of calcium 
in the SR, reducing the cytoplasmic calcium concentration during diastole (31). Under 
physiological conditions, PKA-mediated PLN phosphorylation occurs during β-
adrenoceptor stimulation, contributing to faster relaxation (31), but may also promote 
SR calcium overload. For example, PKA-dependent phosphorylation of PLN and SERCA 
activity are increased in paroxysmal AF, promoting SR calcium overload and SCaEs (32). 
On the other hand, SERCA stimulation may also reduce the likelihood of SCaEs and 
triggered activity by impairing the communication between RyR2 clusters, elevating 
the intra-SR threshold for the generation of calcium waves and slowing calcium-wave 
propagation (33). Antiarrhythmic effects of SERCA stimulation have been observed in 
HF rats (34) and a porcine model of ischemia reperfusion (35). The notion of SERCA-
induced stabilization of calcium handling might also explain the arrhythmogenic risk of 
PLN-R14del, a Dutch founder mutation associated with arrhythmogenic 
cardiomyopathy (36), which produces ‘super-inhibition’ of SERCA (7). In addition, 
activation of CaMKII signaling due to PLN-induced elevation of diastolic calcium levels 
may contribute to the R14del-associated arrhythmogenesis (37). Of note, both SCaE 
mechanisms may interact, with RyR2 dysfunction lowering the threshold for SOICR 
(26), highlighting the complexity of the mechanisms underlying calcium-handling 
abnormalities. 
 
2.3.2 Direct calcium-dependent regulation of ion channels and arrhythmogenesis 
Numerous macromolecular complexes of cardiac ion channel include the calcium 
sensor calmodulin (CaM), enabling direct calcium-dependent regulation of ion-channel 
function. For example, calcium influx through LTCC and SR calcium release during CICR 
promote calcium/CaM-dependent LTCC inactivation, thereby tightly controlling 
calcium influx into cardiomyocytes. Experimental and computational studies in the 
setting of Timothy syndrome-associated mutations in LTCC have demonstrated that 
calcium-dependent inactivation of LTCC represents a vital feedback mechanism 
required for proper calcium signaling in cardiomyocytes and its disruption leads to APD 
prolongation and EADs (38). In agreement, several CaM mutants suppress 
calcium/CaM-dependent inactivation of LTCCs, promoting APD prolongation and 
arrhythmogenesis (39). 
LTCC-mediated calcium-influx and SR calcium release also directly activate 
small-conductance calcium-activated potassium (SK) channels, shortening action 
potential duration (APD). Since a longer baseline APD promotes calcium influx, 
subsequent activation of SK channels may represent a feedback mechanism to prevent 
excessive APD prolongation (40). Indeed, SK2-knockout mice exhibit prolongation of 
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atrial APD, EADs and an increased propensity for AF (41). On the other hand, excessive 
SK-channel activation may shorten ERP and promote reentry. In agreement, SK3 
overexpression was found to induce atrial arrhythmias (42) and SK-channel inhibition 
has significant antiarrhythmic effects in AF animal models resulting from atrial 
tachypacing (43, 44) or β-adrenoceptor and muscarinic-receptor stimulation (45). 
Moreover, SK-channel inhibition may also slightly depolarize resting membrane 
potential (RMP), which may affect sodium-channel availability and destabilize 
reentrant activity (45). However, there have been inconsistent reports on SK-channel 
remodeling in AF patients, with both increased and decreased SK current reported (46, 
47). There have also been conflicting findings on the proarrhythmic (48-50) vs. 
antiarrhythmic (51, 52) effects of ventricular SK-channel inhibition, highlighting the 
need for more comprehensive experimental and computational studies (53). 
Accumulating evidence suggests that other ion channels are also regulated by 
intracellular calcium handling (54-56). For example, intracellular calcium enhances the 
slow delayed-rectifier potassium current (IKs) in rabbit ventricular cardiomyocytes by 
negatively shifting the voltage dependence of activation and slowing channel 
deactivation, resulting in APD shortening during increased calcium loading and β-
adrenoceptor stimulation. These data suggest that calcium-dependent regulation of IKs 
creates a repolarization reserve when depolarizing LTCC current is increased. Direct 
calcium-dependent regulation of the inward-rectifier potassium current (IK1) and 
sodium current has also been implicated in arrhythmogenesis (56-58). The binding of 
CaM to the C-terminus of human cardiac sodium channels modulates (recovery from) 
inactivation and may promote life-threatening ventricular arrhythmias (58, 59). In 
addition, recent cryo-electron microscopy structures of RyR2 revealed that 
calcium/CaM is one of the many competing regulators of RyR2 gating (60). Accordingly, 
computational modeling of direct calcium/CaM-mediated regulation of ISK, IKs and IK1 
suggests that the effects on APD and reentry are modest under basal conditions, but 
may be augmented during calcium-handling abnormalities, such as in AF and HF (61). 
Nonetheless, the relative contributions of calcium-dependent regulation of different ion 
channels to arrhythmogenesis remain incompletely understood due to the limited 
control over calcium dynamics in in vitro studies and the confounding effects of indirect 
calcium-mediated ion-channel modulations (e.g., CaMKII-mediated phosphorylation) 
(62). Therefore, the perfect control and observability provided by computer models 
may enable a more systematic approach to investigate the complex interplay between 
direct and indirect calcium-dependent regulation of ion-channel function. 
 
2.3.3 Calcium-dependent proarrhythmic structural remodeling 
Calcium-handling abnormalities and structural remodeling are closely related and 
influence each other’s progression. Mice overexpressing β1-adrenoceptors had a 
marked calcium-transient prolongation and altered intracellular calcium handling, 
which are responsible for early contractile dysfunction and interstitial fibrosis. 
Furthermore, the expression of the RyR2-interacting protein junctin was significantly 
decreased, and such reduction was closely associated with the progression of 
hypertrophic remodeling (63). RyR2-mediated SR calcium leak also drives the 
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progressive development of an AF-promoting substrate in a transgenic mouse model 
via the nuclear factor of activated T-cells (NFAT) pathway (21). Moreover, profibrotic 
mediators modulate endoplasmic reticulum calcium release and calcium influx into 
fibroblasts, resulting in an increased cytosolic calcium concentration and initiating 
fibrosis-promoting proliferation/differentiation of fibroblasts (64). Canonical transient 
receptor potential (TRPC) channels, voltage-independent calcium channels activated 
by cell stretch and other stimuli, contribute to this calcium-dependent fibrosis 
formation (65). In turn, fibroblasts can couple electrically to atrial cardiomyocytes, 
influencing the AP properties and promoting arrhythmogenesis (66, 67). Finally, 
changes in extracellular calcium can regulate desmosomes, thereby destabilizing 
anchoring cell junctions that preserve myocardium tissue integrity and promoting 
cardiac remodeling, for example in arrhythmogenic cardiomyopathy (68). 
 
2.4 Progress in the computational modeling of cardiomyocyte 
calcium handling 
Since the 1950s, significant progress has been made in the computational modeling of 
cellular electrophysiology to address unanswered experimental questions. The 
laboratory experiments by Hodgkin and Huxley in squid giant axon led to the first 
model of the AP (69, 70), which provided the basis for the >100 computational models 
of cardiac cellular electrophysiology from different species that have been developed to 
date. One of the earliest cardiac cellular models was the mammalian ventricular 
cardiomyocyte model by Beeler and Reuter, incorporating only 4 individual ionic 
currents: the excitatory INa, the slow inward current (Is), the time-independent outward 
potassium current (IK1), and the voltage-/time-dependent outward current (Ix1) (71). 
This model did not yet include calcium-handling components. Since then, the 
complexity of computational models of cardiomyocyte calcium handling has grown 
substantially, reflecting advances in experimental research. For example, DiFrancesco 
and Noble developed an integrated model with temporal details of calcium fluxes, 
which became the basic framework for other studies (72, 73). In 1994, the Luo-Rudy 
model of the guinea pig ventricular cardiomyocyte was already used to study the 
mechanisms of DADs (74). 
CICR exhibits both graded response (the SR calcium release is proportional to 
the trigger influx of calcium across the cell membrane via LTCC) and high gain (a small 
triggering calcium influx across the cell membrane results in a much larger SR calcium 
release). Both properties cannot coexist in typical common-pool models (in which the 
total influx across the cell membrane and total SR calcium release occur in the same 
compartment, either the cytosol or a dyadic subspace), without a non-physiologically 
tight control over model parameters. As such, most common-pool models produce a full 
release of calcium from the SR when the trigger influx of calcium reaches the threshold 
for CICR (all-or-none response) (75). To address this limitation, multi-compartmental 
calcium-handling models have been developed, implementing a phenomenological 
approach to simulate the graded response of CICR (Figure 2.3A). These models remain 
commonly used (e.g., for multicellular simulations) due to their low computational 
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complexity and have started to incorporate direct calcium-dependent ion-channel 
regulation (10, 61, 76) and signaling pathways related to calcium handling (77-81). 
However, these models do not simulate local control of calcium handling (82) and 
assume that all parts of the cell have identical calcium-handling behavior, precluding 
mechanistic studies into calcium sparks, SCaEs, or the subcellular distribution of 
calcium-handling proteins. Therefore, computational models with detailed spatial 
calcium-handling properties have been emerging. Initially, local-control models of a 
single CRU (Figure 2.3B) were developed to reproduce the graded response of calcium 
sparks in the T-tubule/SR junction (83, 84). These CRU models were divided into 4 
(2x2) dyadic subspaces, each containing 1 LTCC and 5 RyRs communicating via a single 
local junctional SR volume. Each subspace was treated as a single compartment with 
uniform calcium concentration and calcium could diffuse passively to neighboring 
subspaces within the same CRU (83). Over the past 15 years, these local-control models 
have become the foundation for more complex 3-dimensional ventricular 
cardiomyocyte models (Figure 2.3H-M) (85-90). 
Important differences in the subcellular structure between atrial and 
ventricular cardiomyocytes exist. In contrast to adult ventricular cardiomyocytes, atrial 
myocytes do not generally express an extensive T-tubular network and therefore 
largely rely on LTCCs around their periphery for the initiation of CICR, which then 
propagate towards the center of the cell in a centripetal manner to interact with 
contractile machineries (91, 92). These experimental findings motivated the 
development of atrial-specific configurations of spatial calcium-handling models with 
distinct transverse (93) or transverse and longitudinal (32) compartments, allowing 
simulation of centripetal calcium waves (4, 94) (Figure 2.3C and D). The 2-dimensional 
atrial cardiomyocyte models (4) also allow simulation of axial tubules, which have been 
identified recently as a common feature of atrial cardiomyocytes and promote a more 
homogeneous CICR (95). An overview of cardiac computational models with detailed 
(sub)cellular calcium-handling properties is provided in Table 2.1. 
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Figure 2.3: Representative examples of the subcellular structure of previously published computational 
models of cardiomyocyte calcium handling. A) Common-pool model with subcellular compartments but 
without explicit spatial structure. B) Local control calcium-release unit (CRU) model in which the dyadic 
space is divided into 4 subspaces, which allow diffusion of calcium from one to another and to cytosolic space. 
In Chu et al. (85), a peri-dyadic space and NCX1 were added to the model to simulate the effect of NCX 
distribution on CICR. C) The 1D spatial atrial model (93) included the centripetal wave propagation (the 
characteristic of atrial wave propagation due to lack of T-tubules). D) Such 2D spatial models of human atrial 
cardiomyocyte allow the investigation of the distribution of subcellular structures as observed 
experimentally. E) 2D CRU model with coupled and uncoupled (“rogue”) RyR2s. LTCC distribution is not 
shown. F-G) Cylindrical 3D spatial models with various arrangements of CRUs. H-M) Cuboidal 3D spatial 
models with various arrangement of subcellular compartments. Several models also incorporate the 
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experimental T-tubular structures from electron microscopy, confocal microscopy and STED. For further 
details, see Table 2.1. (CS = cytosolic space; DS = dyadic space; JSR = junctional SR; MITO = mitochondria; 
NSR = network SR; rBSS = restricted buffering subspace; SM = submembrane space; SS = sub-space). 
No. 
Region 
[Species] 
Structure 
Subcellular 
compartments 
Current use Reference 
1 
Ventricular 
[rat] 
Cylindrical 
3D CRU 
model  
(G) 
Electron 
tomography-
based calcium-
release unit 
(CRU) 
to evaluate the 
performance of a 
recently proposed 
method (the “CaCLEAN” 
method) for detecting the 
functional response of 
calcium release sites in 
live cells. 
(96) 
2 
Ventricular 
[generic] 
Cuboidal 
3D spatial 
model (M) 
Cytosol, NSR, 
JSR, dyadic 
space (DS), 
submembrane 
space (SM), 
mitochondria 
to investigate the effects 
of mitochondria on 
intracellular calcium 
cycling and action 
potential dynamics in 
ventricular myocytes. 
(88) 
3 
Ventricular 
[generic] 
Cuboidal 
3D spatial 
model 
(L) 
Cytosol, NSR, 
JSR, DS, 
subspace (SS), 
T-tubule (TT) 
to study bi-directional 
coupling between 
calcium-dependent sub-
cellular and tissue-scale 
arrhythmia phenomena. 
(97) 
4 
Ventricle 
[generic] 
Cylindrical 
3D CRU 
model  
(G) 
Calcium-release 
unit (CRU) 
to investigate the 
relationship between 
LTCC-RyR structure and 
cardiac electro-
mechanical function. 
(98) 
5 
Generic 
[generic] 
2D CRU 
model  
(E) 
Calcium-release 
unit (CRU) 
to explore how 
nonlinearity and 
stochasticity determine 
the spatial distribution of 
calcium-release events 
within a cardiac cell. 
(99) 
6 
Atrial 
[generic] 
2D CRU 
model  
(E) 
Calcium-release 
unit (CRU) 
to study the effect of CRU 
spatial structure and 
distribution 
(100) 
7 
Atrial 
[human] 
2D spatial 
model  
(D) 
100× 
longitudinal, 
18× transverse 
(banded 
pattern); 
cytosol, SR, 
subsarcolemmal 
space, SR 
release space, 
axial tubules 
to determine the impact 
of variations in 
subcellular RyR2 and L-
type calcium-channel 
distributions on calcium-
transient properties and 
SCaEs. 
(4) 
8 
Generic 
[generic] 
2D CRU 
model 
(E) 
20,000 calcium-
release units 
(CRUs) 
containing NSR, 
to investigate SR 
countercurrent and the 
role of SR TRIC 
potassium channels by 
(101) 
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JSR, 
endoplasmic 
reticulum, 
subspace, 
cytosol. 
modeling possible 
countercurrent sources 
during cardiac SR 
calcium release and 
subsequent reuptake. 
9 
Generic 
[generic] 
2D CRU 
model 
(E) 
20,000 calcium-
release units 
(CRUs) 
containing NSR, 
JSR, 
endoplasmic 
reticulum, 
subspace, 
cytosol. 
to understand the heart 
rate dependence of SR 
ion homeostasis. 
(102) 
10 
Ventricular 
[sheep] 
Cuboidal 
3D spatial 
model 
(K) 
Cytosol, NSR, 
JSR, dyadic 
space (DS), 
restricted buffer 
subspace 
(rBSS), EM 
reconstructed 
T-tubule (TT) 
to develop an approach 
to overcome the 
challenges of modelling 
spatio-temporal calcium 
dynamics using 
experimentally 
reconstructed 3-
dimensional structures 
for the TT and SR at the 
whole-cell scale. 
(103) 
11 
Ventricular 
[rat] 
Cuboidal 
3D spatial 
model 
(H) 
Dyadic junction, 
submembrane 
space, bulk 
myoplasm, JSR, 
NSR, confocal 
image 
reconstructed 
T-tubule 
to model the 
spatiotemporal 
distribution of calcium in 
ventricular myocytes and 
explore the relationship 
between T-tubule 
organization and calcium 
cycling. 
(104) 
12 
Ventricular 
[canine] 
Cuboidal 
3D spatial 
model 
(J) 
Dyadic 
subspace, 
submembrane 
space, cytosolic 
space, NSR, JSR 
to study the roles of 
stochastic RyR2 gating 
and calcium wave 
dynamics on the 
statistical distribution of 
DADs under 
pathophysiological 
conditions. 
(90) 
13 
Ventricular 
[generic] 
Local 
control 
CRU 
model 
(B) 
Dyad (4 dyadic 
subspaces), 
NSR, JSR, peri-
dyad (PD), 
cytosol 
to examine the ways in 
which differential 
placement of NCX1 into 
cytosolic, PD, and dyadic 
compartments influences 
properties of CICR and 
the cardiac AP. 
(85) 
14 
Ventricular 
[generic] 
Cuboidal 
3D spatial 
model 
(I) 
SR, JSR, DS, 
Cytosol 
to provide novel 
predictions and insights 
into the mechanisms of 
calcium alternans in 
ventricular myocytes. 
(105) 
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15 
Generic 
[generic] 
Cuboidal 
3D spatial 
model 
(H) 
Dyadic junction, 
submembrane 
space, bulk 
myoplasm, JSR, 
NSR 
to simulate the calcium 
sparks and waves in VMs 
with PLN inhibition 
(106) 
16 
Ventricular 
[generic] 
Cuboidal 
3D spatial 
model 
(I) 
SR, JSR, DS, 
Cytosol 
to investigate the effects 
of TT disruption and 
other HF remodeling 
factors on calcium 
alternans in ventricular 
myocytes using computer 
modeling. 
(107) 
17 
Atrial 
[generic] 
Cylindrical 
3D CRU 
model  
(F) 
Calcium-release 
unit (CRU) 
to follow the triggering 
and evolution of calcium 
signals within a realistic 
3D cellular volume of an 
atrial myocyte, but with 
low computational costs. 
(108) 
18 
Generic 
[generic] 
2D CRU 
model 
(E) 
Calcium-release 
unit (CRU) 
to develop a 3D, 
biophysically-detailed 
model of cardiac calcium-
release events (3D spark 
model) 
(109) 
19 
Generic 
[generic] 
2D CRU 
model 
(E) 
Calcium-release 
unit (CRU) 
To study the roles of 
RyR2 gating properties, 
spark fidelity, and CRU 
anatomy on CICR 
(110) 
20 
Atrial 
[human] 
2D spatial 
model  
(D) 
50× 
longitudinal, 
18× transverse; 
cytosol, SR, 
subsarcolemmal 
space, SR 
release space 
To study occurrence and 
mechanisms of 
sarcoplasmic reticulum 
calcium-release events in 
paroxysmal AF (pAF) 
(32) 
21 
Atrial  
[generic] 
Cylindrical 
3D CRU 
model  
(F) 
subsarcolemmal 
space and 13× 
transverse 
cytosol/SR 
To investigate the 
mechanisms underlying 
the propagation of 
cytoplasmic calcium 
waves and the genesis of 
systolic calcium 
alternans in cardiac 
myocytes lacking T-
tubules. 
(111) 
22 
Ventricle 
[generic] 
2D CRU 
model  
(E) 
Calcium-release 
unit (CRU) 
to study the effects of 
rogue RyRs on calcium 
cycling and membrane 
potential in failing heart. 
(112) 
23 
Ventricular 
[generic] 
Cuboidal 
3D spatial 
model 
(I) 
SR, JSR, DS, 
Cytosol 
to simulate calcium 
cycling dynamics, such as 
calcium sparks, calcium 
waves, and calcium 
alternans. 
(113) 
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24 
Atrial 
[generic] 
Cylindrical 
3D CRU 
model  
(F) 
Calcium-release 
unit (CRU) 
to produce a 
geometrically realistic 
model of an atrial 
myocyte to explore 
calcium-release sites 
interaction and 
involvement in calcium 
wave initiation and 
propagation. 
(114) 
25 
Atrial 
[human] 
1D spatial 
model  
(C) 
dyadic subspace 
and 8× 
transverse 
cytosol/SR 
to develop a 
mathematical model of 
the human atrial myocyte 
that, in addition to the 
sarcolemmal (SL) ion 
currents, accounts for the 
heterogeneity of 
intracellular calcium 
dynamics emerging from 
a structurally detailed 
sarcoplasmic reticulum 
(SR). 
(93) 
26 
Generic 
[generic] 
2D CRU 
model  
(E) 
NSR, JSR, 
subspace, 
Myoplasm 
to study how the 
molecular-level 
characteristics of 
individual RyR2s 
influence the emergent 
property of cellular SR 
calcium leak  
(115) 
27 
Generic 
[generic] 
Quasi-2D 
spatial 
model 
(H) 
NSR, JSR, DS, 
Myoplasm / 
Cytosol 
to study how randomly 
occurring calcium sparks 
interact collectively to 
result in whole-cell 
calcium alternans. 
(116) 
28 
Generic 
[generic] 
Cuboidal 
3D spatial 
model 
(H) 
Dyadic junction, 
submembrane 
space, bulk 
myoplasm, JSR, 
NSR 
to identify a new 
mechanism to explain 
experimental 
observations using a 
physiologically more 
realistic model where 
both luminal gating of SR 
calcium release and the 
spatially distributed 
nature of unitary calcium 
release events are 
treated explicitly. 
(87) 
29 
Generic 
[generic] 
Cylindrical 
3D CRU 
model  
(F) 
Calcium-release 
unit (CRU) 
to examine the factors 
that influence calcium 
wave initiation 
(117) 
30 
Ventricular 
[canine] 
Local 
control 
CRU 
model 
Dyad (4 dyadic 
subspaces), 
NSR, JSR, 
cytosol 
to develop a 
comprehensive model of 
the ventricular myocyte 
based on the theory of 
(83) 
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(B) local control of SR 
calcium release. 
Table 2.1: Cardiac (sub)cellular models with detailed spatial cardiomyocyte calcium-handling properties. 
Letters between parentheses under "Structure" refer to panels in Figure 2.3. 
 
2.5 Opportunities for synergy between in vitro and in silico studies 
to improve insights in cardiomyocyte calcium handling 
2.5.1 Elucidating the regulation of calcium-handling proteins by interacting 
molecules 
2.5.1.1 The SERCA2a macromolecular complex 
Sarcolipin (SLN) is a short helical peptide that is primarily expressed in the atria (118). 
Like PLN, SLN binds to SERCA2a, inhibiting its function and modulating cardiomyocyte 
calcium handling. Homozygous SLN deletion increases atrial SERCA activity, leading to 
abnormal cardiomyocyte calcium handling, SCaEs, DADs, and atrial structural 
remodeling (119). On the other hand, heterozygous SLN deletion results in a normal 
cardiac phenotype at baseline without increased AF susceptibility and a protective 
effect against chronic β-adrenoceptor stimulation-induced cardiac impairment. 
Because the activity of SERCA and other calcium-handling proteins (CASQ2, NCX1, RyR2, 
PLN) were unchanged in heterozygous knockout mice, such protective effects might 
reflect interaction of SLN with other proteins within the cardiomyocyte (120). 
Expression of SLN (but not PLN) is reduced in atrial samples of HF patients with 
reduced ejection fraction with or without long-standing persistent AF, likely 
contributing to increased SR calcium load (121, 122). A significantly reduced SLN 
expression but unchanged PLN has also been observed in post-operative AF (123). 
However, determining the functional consequences of alterations in the SERCA2a 
macromolecular complex is experimentally challenging. In contrast to ion-channel 
function, SERCA activity in an intact cardiomyocyte can only be estimated indirectly by 
subtracting the rate of decay of the systolic and caffeine-induced calcium transients 
(124). Therefore, having an in silico model of the SERCA complex able to predict the 
functional consequences of altered subunit expression or phosphorylation would be 
highly relevant. However, most cardiomyocyte models available to date simulate SERCA 
function with a Hill equation, whereby the affinity for cytosolic calcium is sometimes 
reduced to reflect PLN phosphorylation (125). A preliminary model simulating effects 
of PLN/SLN pentamerization and phosphorylation on human atrial calcium handling 
has been proposed and may provide insights in the role of these proteins (126). 
Similarly, detailed SERCA models based on Markov-chain models of various states of 
SERCA phosphorylation (127) and thermodynamics (128) are available, but none of 
those models simulates the combined PLN and SLN-mediated SERCA2a regulation. 
 
2.5.1.2 Phospholemman (PLM) 
Phospholemman (PLM) is a member of the family of FXYD proteins that inhibits the 
sodium-potassium ATPase. Similar to the effect of PLN on SERCA, phosphorylated PLM 
relieves its inhibition of the sodium-potassium ATPase, increasing pump activity (129). 
PLM phosphorylation at Ser63 and Ser68 is reduced in rabbits with rapid atrial pacing-
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induced remodeling (130). Such PLM hypophosphorylation may be a compensatory 
mechanism against the reduction of intracellular sodium resulting from the reduced SR 
calcium release, increased calcium buffering, shortened APs, and reduced ICa,L after 
rapid atrial pacing-induced remodeling (130). A rabbit ventricular cardiomyocyte 
model simulating β-adrenoceptor stimulation confirmed that enhanced sodium-
potassium ATPase activity due to an increased affinity for intracellular sodium reduced 
calcium loading and calcium-transient amplitude (131). Recent work has shown that 
HF blunts local β2-adrenoceptor control and alters the phosphodiesterase (PDE) 
2/PDE3 balance in the sodium-potassium ATPase–PLM microdomain, making it 
insensitive to cyclic adenosine monophosphate (cAMP) signaling (132). These data 
highlight the importance of local regulation of cardiac electrophysiology. Unfortunately, 
it is currently not possible to simulate the functional consequences of altered local 
signaling, as this level of detail is not yet incorporated in most models. Of note, PLM also 
regulates NCX1 and LTCC activity in cardiomyocytes. Unlike the sodium-potassium 
ATPase, PKA- and protein kinase-C (PKC)-mediated phosphorylation of PLM at Ser68 
increases NCX1 inhibition, contributing to intracellular calcium overload (133). Finally, 
PLM limits calcium influx in cardiac myocytes by reducing maximal ICa,L and 
accelerating voltage-dependent inactivation (134). These functional roles of PLM have 
also not yet been incorporated in computational models. 
 
2.5.1.3 Other macromolecular complexes 
There are many other macromolecular complexes involved in cardiomyocyte calcium 
handling. For example, the LTCC and RyR2 macromolecular complexes include 
calmodulin, as well as multiple phosphodiesterases, phosphatases and kinases 
anchored via A-kinase anchoring proteins. In addition, LTCCs also interact with Ahnak1, 
Nedd4-1, USP2-45, RGK and caveolin-3. The RyR2 macromolecular complex includes, 
among other things, junctin, triadin, calsequestrin-2, and FKBP12.6. Finally, sorcin and 
junctophilin-2 link the LTCC and RyR2 macromolecular complexes, thereby controlling 
their close interaction in dyads (6, 135, 136). At present, computational models only 
incorporate phenomenological representations of these macromolecular complexes. 
While this is likely sufficient for many studies, it makes it impossible to directly 
extrapolate the functional consequences of alterations in specific component(s), e.g., as 
obtained with Western blot studies in specific animal models or patient populations. 
 
2.5.2 Understanding the subcellular mechanisms and proarrhythmic consequences 
of SCaEs 
Despite extensive research, the mechanisms and proarrhythmic consequences of SCaEs 
remain incompletely understood. For example, several experimental studies have 
identified alterations in major calcium-handling proteins and increased SCaE incidence 
in atrial cardiomyocytes from AF patients (32, 121, 124, 137-139), whereas other 
studies have observed reduced SCaE incidence and calcium-signaling silencing (130, 
140-142). Methodological considerations as well as pronounced differences in the 
molecular mechanisms underlying different forms of AF may contribute to these 
findings (143). In patients with long-standing persistent (‘chronic’) AF (cAF), RyR2 
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dysfunction due to CaMKII-dependent hyperphosphorylation at Ser2814 appears to 
underlie SCaEs (124, 139). Despite increased RyR2 open probability, reduced SERCA 
activity, increased NCX function and reduced ICa,L, all of which would be expected to 
reduce SR calcium levels, there is only a mild, non-significant decrease in SR calcium 
load in cAF patients (121, 124). Computational modeling has suggested that 
maintenance of SR calcium load is critical for the development of propagating SCaEs, as 
RyR2 dysfunction in the absence of maintained SR calcium load led to small, non-
propagating calcium releases (32, 144). The studies which observed reduced SCaE 
proclivity in response to catecholamine stimulation in atrial cardiomyocytes from cAF 
patients compared to sinus rhythm patients also support the importance of SR calcium 
load for SCaE development. In particular, the lower incidence of SCaEs in cAF was 
attributed to impaired CaMKII-mediated regulation of LTCC and PLN (140), which 
would be expected to reduce SR calcium load (143). 
In addition, SR calcium load can be modulated by experimental conditions such 
as the extracellular calcium concentration and the sodium concentration in the patch 
pipette, which regulate NCX activity (9, 145). For example, elevation of extracellular 
calcium elicited transient-inward NCX currents and promoted early and delayed 
afterdepolarizations in zebrafish ventricular cardiomyocytes (146). Also, an increased 
frequency of relatively small calcium releases may not be able to generate 
aftercontractions, especially in the presence of additional remodeling of the contractile 
machinery, as occurs in cAF (147, 148). This limited sensitivity to detect SCaEs may in 
part explain why some experiments employing contractility as read-out observed fewer 
SCaEs in cAF samples (140, 149). In agreement, the (late) sodium current blocker 
ranolazine reduced aftercontractions in trabeculae from AF patients through an NCX-
mediated reduction of SR calcium load and inhibition of RyR2 open probability, 
highlighting the central role of sodium in cardiomyocyte calcium handling (149). On the 
other hand, it is unclear whether SCaEs that are too small to produce aftercontractions 
can have direct proarrhythmic consequences, although they may promote long-term 
calcium-dependent remodeling (discussed in Section 2.5.4). Multiscale 
electromechanical simulations may help to elucidate the number of cells, SCaE size and 
synchronicity required to produce triggered activity and aftercontractions (in the 
absence or presence of contractile remodeling), as discussed below, although not all 
models are able to accurately reproduce alterations in electrophysiology and calcium-
handling in response to changes in extracellular concentrations (150). Fluorescent 
measurements are also indirect and require careful calibration (151). Moreover, 
fluorescent indicators can act as calcium buffers and may affect calcium-transient 
properties. Different fluorescent indicators penetrate differently across the cell 
membrane and exhibit distinct subcellular compartmentalization, which can cause 
variations in the observed calcium transients and fractional shortening (152, 153). 
However, the frequency of spontaneous transient-inward currents measured in the 
absence of calcium indicators was also increased in AF patients (121), suggesting that 
the calcium-buffering effect of fluorescent calcium indicators may be limited. 
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The perfect control and observability offered by computer models may help to 
assess the relative role of SR calcium load and RyR2 dysfunction in promoting SCaEs, as 
well as the impact of different experimental conditions. However, since arrhythmias are 
inherently multiscale phenomena, multicellular simulations are necessary to study the 
role of SCaEs in arrhythmogenesis. For example, the role of triggered activity in the 
maintenance of atrial and ventricular arrhythmias remains largely unknown, and the 
therapeutic value of RyR2-targeting compounds has not yet been clinically validated 
(143). Unfortunately, the computational complexity of local-control cardiomyocyte 
models with detailed subcellular structure and stochastic RyR2 gating required to 
simulate SCaEs precludes such multicellular simulations. However, recently a novel 
computational approach with simplified cardiomyocyte models suitable for tissue 
simulations, which can produce realistic SCaEs, has been proposed (97). This approach 
has, for example, highlighted how calcium loading during reentry can promote ectopic 
activity and arrhythmia reinduction after reentry termination (97). 
SCaEs and RyR2 dysfunction are also present in patients with paroxysmal AF 
and in atria of HF patients, but are not due to increased total RyR2 phosphorylation 
levels (32, 121). Instead, altered expression of RyR2-interacting proteins, including a 
relative paucity of junctophilin-2 and overabundance of junctin have been implicated 
in paroxysmal AF and HF patients, respectively (32, 121, 137). In addition, altered 
distribution of calcium-handling proteins may play an important role (154-156). 
Advanced imaging techniques, including electron microscopy and (super-resolution) 
confocal microscopy, as well as combinations of the two (correlative light and electron 
microscopy), supported by advances in immunostaining approaches have enabled 
detailed studies of cardiomyocyte subcellular structure (157). For example, an 
increased number of RyR2 clusters per CRU and a shortening of the distance between 
clusters has been observed in sheep with persistent AF and increase the likelihood of 
propagating diastolic calcium releases (158). Fluorescent labeling of FKBP/RyR2 to 
simultaneously measure the RyR2 distribution and calcium-spark properties at the 
same site in adult cardiomyocytes also highlighted the dependence of calcium-spark 
frequencies on RyR2 cluster size. By contrast, calcium-spark amplitudes and CICR were 
independent of RyR2 cluster size (159). Advanced imaging also suggested an important 
role for axial tubules in synchronizing SR calcium release and promoting spontaneous 
SCaEs due to local RyR2 hyperphosphorylation around axial tubules, which may not be 
detected using Western blot techniques in atrial tissue homogenates (160). Whether an 
altered RyR2 distribution contributes to SCaEs in AF patients is at present unknown. 
In general, characterizing the functional consequences of altered protein 
distribution is experimentally challenging due to the different experimental setups 
involved (cell fixation for staining vs. live-cell calcium imaging), although this limitation 
can be partly resolved using fluorescent labeling of RyR2-interacting proteins (159), 
and the limited options to deliberately perturb the localization of proteins. Computer 
models make it possible to selectively redistribute calcium-handling proteins and a 
recent computational study of the human atrial cardiomyocyte showed that a 
heterogeneous RyR2 distribution increases the propensity for SCaEs, with SCaEs 
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originating from regions with high local RyR2 expression. SCaEs were also promoted 
by local RyR2 hyperphosphorylation around virtual axial tubules (4), in line with 
experimental observations (95, 160). Together, these data strongly suggest that in 
isolation, Western blot experiments using whole-tissue lysates, although often useful, 
are not always sufficient to characterize RyR2-dependent proarrhythmia. Recent work 
has shown that T-tubules have a complex 3-dimensional structure and are not only a 
docking site for LTCC, but also NCX, suggesting a central role in intracellular calcium 
cycling (161). Indeed, RyR2 calcium release may also be triggered by the NCX (86), but 
this requires close localization of the two proteins, which has been difficult to ascertain 
in studies employing diffraction-limited microscopy (162). Three-dimensional super-
resolution microscopy has been used to visualize the nanoscale organization of RyR2 in 
ventricular cardiomyocytes and enabled discernment of clusters overlapping in the z-
axis, which was not possible with conventional imaging techniques (163, 164). 
Furthermore, cardiovascular diseases such as HF lead to remodeling of the T-tubular 
network, resulting in a loss of synchronous calcium release (165). The SR itself also has 
a unique network structure spanning the entire cardiomyocyte, including connections 
with the nuclear envelope. Intra-SR calcium diffusion can regulate RyR2 function, 
thereby modulating calcium-wave propagation within cardiomyocytes (166). Faster 
calcium diffusion limits spatial SR calcium gradients and leads to more uniform release 
throughout the cell, while slower diffusion rate allows spatial inhomogeneities before 
or during SR calcium release (166). Several combined experimental and computational 
studies have attempted to characterize intra-SR calcium diffusion and its impact on 
proarrhythmic calcium-handling abnormalities in cardiomyocytes and both fast (167) 
and slow (168) diffusion have been reported. Further investigations, including detailed 
spatial calcium-handling models, are needed to better characterize intra-SR calcium 
diffusion (166-168). Several 3-dimensional computational cardiomyocyte models have 
recently been developed based on these experimental data and have provided insight 
into the role of subcellular structure in cardiomyocyte calcium handling and the 
consequences of HF-related T-tubular remodeling, highlighting the synergy between 
both approaches (97, 103, 169-172). 
 
2.5.3 Calcium-mediated signaling cascades in cardiomyocytes 
In addition to its role in E-C coupling, calcium is a major signaling molecule. Several 
calcium-dependent signaling pathways are activated under pathological conditions and 
contribute to the initiation and progression of cardiac arrhythmias, including calpain, 
PKC, CaMKII and the calcineurin/NFAT signaling pathway (Figure 2.4). The latter 
primarily controls cardiomyocyte hypertrophy and long-term transcriptional 
regulation (6, 173), which are discussed in Section 2.5.4. 
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Figure 2.4: Key calcium-dependent signaling cascades within a cardiomyocyte. The signaling cascades can 
be activated through several ways: via direct calcium-dependent regulation of signaling proteins (e.g., CaM, 
CaMKII and calpain) and via the activation of G-protein coupled receptors (e.g., β-adrenergic receptor and 
AT-1 receptor). Activation of these signaling cascades promotes the nuclear translocation of signaling 
proteins and transcription factors, including NFAT, CaN, HDAC and DREAM, to regulate the expression of 
cardiac ion channels and the adaptive response to stress/injury (structural and electrical remodeling of 
cardiomyocytes). Moreover, these signaling cascades can alter the contractile machineries of the heart, e.g., 
through phosphorylation of Tn-I. (AC = adenylyl cyclase; Ang II = angiotensin II; ATP = adenosine 
triphosphate; CaM = calmodulin; CaMKII = calmodulin-dependent protein kinase II; cAMP = cyclic adenosine 
monophosphate; CaN = calcineurin; DAG = diacyl glycerol; DREAM = downstream regulatory element agonist 
modulator; HDAC = histone deacetylase; IP3 = inositol triphosphate; NFAT = nuclear factor of activated T-
cells; PDE = phosphodiesterase; PIP2 = phosphatidylinositol biphosphate; PKA = protein kinase A; PKC = 
protein kinase C; PLC = phospholipase C; Tn-I = troponin-I; TRPC = transient receptor potential canonical 
channel; TRPM = transient receptor potential melastatin channel). 
 
2.5.3.1 Calpain 
Calpain is a calcium-activated protease involved in the calcium-dependent regulation 
of many cellular processes, including signal transduction, cell proliferation, 
differentiation, cell cycle progression, and apoptosis (174, 175). Hence, calpain 
dysregulation due to calcium-handling abnormalities during cardiac pathologies such 
as AF, HF, or hypertrophy may have a significant impact on cellular homeostasis. The 
PKC signaling pathway (discussed below) is a major target of calpain (Figure 2.4). In 
addition, calpain directly regulates LTCC (176) by cleaving the distal C-terminus, which 
plays a role in autoinhibition (i.e., calcium-dependent inactivation), leaving a truncated 
form that produces a significantly greater current than the full-length LTCC (177). 
Calpain-mediated cleavage and subsequent degradation / downregulation of other 
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calcium-handling proteins, including NCX1, SERCA and RyR2, and myofilament 
components (e.g., MyBP-C), have also been identified in ischemia reperfusion injury and 
HF (178-182). Finally, calpain also increases late sodium current (INaL) in the setting of 
HF and simulations suggest that calpain inhibition may reduce intracellular diastolic 
calcium accumulation by decreasing INaL and shortening APD (175). 
 
2.5.3.2 PKC 
The PKC family of phospholipid-dependent serine-threonine protein kinases can be 
subdivided into three groups: the conventional, novel and atypical PKCs. These groups 
differ in their activation by calcium, diacylglycerol (DAG) and phosphatidylserine. Of 
those, only conventional PKC depends on calcium for activation (183). PKCs have been 
implicated in cardiac arrhythmias due to their role in cardiac electrical remodeling 
(184). Other publications have also linked PKC activation with AF (185-188). For 
example, tachycardia-induced calcium loading and calpain activation have been 
demonstrated to downregulate PKCα (a conventional PKC isoform), contributing to an 
altered conventional/novel PKC-isoform balance. This imbalance could contribute to 
the increased constitutive activity of the acetylcholine-activated inward-rectifier 
potassium current, which shortens the APD and hyperpolarizes the RMP, which support 
reentry and AF promotion (186, 189). Moreover, an increased PKC-mediated 
phosphorylation of troponin-I and -T were observed in failing hearts, which alters the 
myofilament calcium sensitivity (190, 191). Computational models of several protein 
kinase signaling cascades (including PKA and CaMKII) have been developed and have 
provided insight in their potential proarrhythmic consequences (80, 192, 193). 
Although several papers have discussed the potential importance of including PKC-
dependent regulation in cardiac electrophysiology models (193, 194), to the best of our 
knowledge, no computational model available to date includes this calcium-dependent 
signaling cascade. 
 
2.5.3.3 CaMKII 
CaMKII consists of 4 different isoforms with the δ and γ isoforms expressed in the heart. 
CaMKIIδ is considered the main cardiac CaMKII isoform (195). In the resting state at 
low intracellular calcium levels, the CaMKII regulatory domain autoinhibits its catalytic 
domain. Once the intracellular calcium concentration rises, 4 calcium ions interact with 
CaM, separating the catalytic domain from its regulatory domain and activating CaMKII. 
Subsequent autophosphorylation at Thr287 can promote persistent, calcium-
independent activation. During cellular stress several mechanisms promote CaMKII 
hyperactivation. For example, sympathetic stimulation increases CaMKII activation via 
increased heart rate, elevated intracellular calcium concentrations, I-1-mediated 
regulation of protein phosphatase 1 (PP1, involved in dephosphorylation of CaMKII-
Thr287) and regulation of exchange-protein activated by cAMP (Epac) (78, 196, 197). 
In addition, CaMKII can be activated by oxidative stress through oxidation of 
Met281/Met282 and in the presence of hyperglycemia by glycosylation of Ser280 (198). 
Active CaMKII regulates several major components of cardiomyocyte calcium handling, 
such as LTCC, RyR2, SERCA2a, SLN and PLN (Table 2.2), and plays an important role in 
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cardiac contraction (through the phosphorylation of MyBP-C and titin), gene 
transcription, intracellular trafficking, cellular energetics, hypertrophy, inflammation 
and cell death in a tightly controlled spatiotemporal manner (198-200). CaMKII-
mediated regulation involves direct phosphorylation of targets, as well as indirect 
regulation of reactive oxygen species, nitric oxide signaling, phosphatases and 
phosphodiesterases, intracellular trafficking and gene expression (185, 199, 201). 
CaMKII-dependent phosphorylation of RyR2 is increased in transverse aortic 
constriction-induced HF and contributes to pathological SR calcium leak and HF 
progression (202, 203). The proarrhythmic consequences of CaMKII hyperactivity have 
been demonstrated in various experimental models (204). For example, CaMKII-
mediated phosphorylation of RyR2 at Ser2814 is required for the CPVT phenotype of 
engineered heart tissue derived from human pluripotent stem cell–derived 
cardiomyocytes harboring the RyR2-R4651I or RyR2-D358N mutations (205). 
Furthermore, CaMKII inhibition suppresses CPVT in mouse models and human 
pluripotent stem cells (206, 207), although the potential antiarrhythmic efficacy in AF 
patients remains a topic of debate (130, 140, 143, 185, 208-210). Additionally, CaMKII-
mediated phosphorylation of NaV1.5 increases INaL, and prolongs APD, leading to 
calcium-handling abnormalities, and promotes DADs and AF susceptibility (211). 
Subsequently, calcium-handling abnormalities may further activate CaMKII and INaL, 
creating a vicious cycle. 
Several computational models incorporating β-adrenoceptor and CaMKII 
signaling and their downstream effects have been developed to provide a better 
understanding of the complex electrophysiological effects of these pathways (78, 81, 
131, 196, 212-215). For example, a computational model of the rabbit ventricular 
cardiomyocyte has shown that CaMKII-dependent upregulation of INaL in HF leads to 
increased arrhythmia propensity, and is further exacerbated by β-adrenoceptor 
stimulation (212). Similarly, CaMKII-dependent phosphorylation of NaV1.5 increases 
INaL in a human atrial cardiomyocyte model, promoting intracellular calcium overload 
through reduced NCX, increased RyR2 open probability and proarrhythmic 
afterdepolarizations and repolarization alternans under β-adrenoceptor stimulation 
(214). These computational studies have helped characterize one of several positive 
feedback loops promoting CaMKII hyperactivity under disease conditions and suggest 
that pharmacological inhibition of intracellular sodium loading can contribute to 
normalizing calcium and stabilization of membrane potential dynamics (213). 
Nonetheless, these computational models only integrated some components of the 
complex CaMKII signaling cascade and did not consider differences in subcellular 
distribution of CaMKII. More comprehensive computational studies are needed to 
assess the antiarrhythmic potential of CaMKII modulation. 
No. 
Ion channel /  
calcium-handling protein 
Effect 
1 
L-type calcium channel / LTCC 
(CaV1.2) 
↑ ICa,L, ↓ inactivation, ↑ open probability 
(mode 2 gating), ↑ recovery from 
inactivation (acute) 
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↓ CaV1.2 expression (chronic) 
2 T-type calcium channel (CaV3.1–3) ↑ open probability, (-) SSA shift (acute)  
3 
Voltage-gated sodium channel 
(NaV1.5) 
↓ INa,T inactivation, ↑ intermediate 
inactivation, ↓ recovery from inactivation, (-) 
SSI shift (acute & chronic) 
↓ SSA 
↑ INaL 
4 Sodium-calcium exchanger (NCX) ↑ INCX (inward) 
5 
Transient-outward potassium 
channel (KV1.4, 4.2, 4.3) 
↓ inactivation, ↑ recovery from inactivation, 
(+) SSI shift (acute) 
↓ Ito, ↓ KV4.2/4.3 expression (chronic) 
Phosphorylation of SAP97, ↑ Ito 
6 
Slow delayed-rectifier potassium 
(Ks) channel (KV7.1) 
↑ IKs (acute) 
↓ IKs, (+) SSA shift, ↓ KCNE1 expression 
(chronic) 
7 
Inward-rectifier potassium (K1) 
channel (Kir2.1-3) 
↑ IK1 (acute) 
↓ IK1, ↓ Kir2.1 expression (chronic) 
8 
Ultra-rapid delayed rectifier 
potassium (Kur) channel 
↑ IKur 
9 
ATP-dependent potassium current 
(Kir6.1-2) 
↑ open probability (acute) 
↓ Kir6.2 expression (chronic) 
10 
Small-conductance calcium-activated 
potassium (SK) channel (KCa2.1-3) 
↑ ISK (acute) 
11 
Transient receptor potential (TRP) 
channels 
↑ TRPC6 current (acute) 
12 Calcium-activated chloride channel 
↑ ICl,Ca (acute) 
↓ ICl,Ca (chronic) 
13 Ryanodine receptor type 2 (RyR2) 
Phosphorylation at 
Ser2808/Ser2811/Ser2814, ↑ open 
probability, ↑ SR calcium release 
14 IP3 type 2 receptor 
Phosphorylation at Ser150, ↓ open 
probability 
15 Phospholamban (PLN) 
Phosphorylation at Thr17, ↓ PLN-mediated 
tonic inhibition to SERCA 
16 Sarcolipin (SLN) 
↓ SLN-mediated inhibition to SERCA, ↑ SR 
calcium uptake (phosphorylation at Thr5) 
17 Myosin binding protein C (MyBP-C) 
Phosphorylation at Ser302 & Ser282 (at non-
physiological calcium concentration) 
18 Titin (TTN) Phosphorylation of the N2B element 
Table 2.2: CaMKII-dependent regulation of cardiac ion channels and calcium-handling proteins. (SSA = 
steady-state of activation; SSI = steady-state of inactivation). Details can be found in (62, 185, 199, 216-218). 
2.5.4 Long-term calcium-dependent transcriptional regulation 
2.5.4.1 Nuclear calcium handling 
Calcium can enter the nucleus via passive membrane diffusion or calcium-release from 
inositol triphosphate (IP3)-receptors on the nuclear membrane (Figure 2.4). The 
nuclear calcium transient exhibits a slower and delayed upstroke, a lower peak 
amplitude, and a prolonged decay compared to its cytosolic counterpart (Figure 2.1). 
Calcium diffuses out of the nucleus via nuclear pore complexes and is taken up by 
SERCA on the outer nuclear membrane, by nearby mitochondria, or is extruded by NCX 
on T-tubules in close proximity to the nuclear envelope (14). Nuclear calcium plays 
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significant roles in long-term cardiac remodeling (219), including the activation of 
nuclear CaMKII, and calcineurin/NFAT pathways (discussed below). In addition, recent 
work has suggested that nuclear calcium regulates gene expression through several 
other transcription factors, such as CREB, HSF-1 and SRF (14). 
In line with the experimental efforts, computational modeling has also been 
employed to investigate the role of nuclear calcium signaling in health and disease 
(220). However, until recently, there was no quantitative model coupling 
cardiomyocyte electrophysiology with calcium and IP3 signaling in the cytosol and 
nucleus. In 2014, a model describing nuclear calcium dynamics and its dependence on 
intracellular calcium, nuclear calcium buffering and calcium transport via nuclear pore 
complexes and nuclear envelope was introduced (220). This model may be a stepping 
stone to study the consequences of CaM, calcineurin, and CaMKII in the nucleus, and can 
potentially be coupled to the previously described models of CaM/CaMKII/calcineurin 
signaling (221) to study the mechanisms underlying long-term calcium-dependent 
transcriptional regulation (220). 
 
2.5.4.2 Calcineurin-dependent transcriptional regulation 
Calcineurin is a serine/threonine-specific phosphatase activated by intracellular 
calcium. Activated calcineurin dephosphorylates cytosolic NFAT, leading to its 
translocation to the nucleus where it regulates gene expression. Among other targets, 
NFAT inhibits the expression of the cardiac LTCC through reduced expression of 
CACNA1, providing a negative feedback loop (222, 223). Experimentally, calcium-
induced activation of calcineurin/NFAT signaling was observed in canine atrial 
cardiomyocytes during tachypacing, leading to the transcriptional downregulation of 
LTCC (223). Although this mechanism protects cardiomyocytes from potential 
cytotoxic calcium overload, the consequent reduction in APD may have proarrhythmic 
consequences. Calcium-dependent signaling may also contribute to the increased RyR2 
expression in pAF (through a reduction in the miR 106b-25 cluster; (188, 224)) and is 
involved in the transcriptional regulation of several potassium channels. For example, 
activation of calcium/calcineurin/NFAT signaling increases IK1 through NFAT-
mediated downregulation of the inhibitory microRNA-26 (173, 225). IK1 was also 
increased in stretched neonatal rat atrial cardiomyocytes, which was also associated 
with augmented calcineurin activity and increased levels of nuclear NFAT3, as well as 
increased mRNA and protein expression of Kir2.1 (226). On the other hand, long-term 
β-adrenoceptor stimulation reduced IKs with a corresponding decrease in mRNA and 
protein expression of its β-subunit KCNE1. BAPTA-AM (calcium chelator), cyclosporine 
(calcineurin inhibitor) and INCA6 (NFAT blocker) prevented the β-adrenoceptor-
induced KCNE1 downregulation, indicating that prolonged β1-adrenoceptor 
stimulation suppressed IKs via Epac-mediated calcium/calcineurin/NFAT signaling 
(227). Interestingly, APD prolongation due to changes in potassium channel expression 
can itself increase intracellular calcium and activate calcineurin-mediated excitation-
transcription coupling. For example, knockdown of KCNE2 increased intracellular 
calcium transient, calcineurin activity and nuclear NFAT levels, and pretreatment with 
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inhibitors of LTCC or calcineurin attenuated the activation of calcineurin/NFAT and 
cardiomyocyte hypertrophy (228). 
These data highlight the complex positive and negative feedback loops 
involved in proarrhythmic calcium-dependent, calcineurin-mediated transcriptional 
regulation. Moreover, the activation of NFAT in cardiomyocytes is isoform- and tissue-
specific, and tightly controlled by nuclear export. For example, under physiological 
conditions, NFATc1 is expressed predominantly in the nucleus of both atria and 
ventricle, while NFATc3 is localized in the cytoplasm and can be translocated to the 
nucleus by angiotensin II and endothelin-1 only in the atria (229). Ventricular 
cardiomyocytes from HF rabbits showed an increased basal nuclear localization of 
endogenous NFATc3 and a reduced responsiveness of NFAT translocation to 
phenylephrine stimulation (229). In ranolazine-treated HF mice, calcineurin expression 
and NFATc3 nuclear localization were diminished (230). Finally, recent data suggest 
that nuclear translocation of calcineurin might be required for full transcriptional 
activity of NFAT. Such nuclear calcineurin can act as an intranuclear calcium sensor in 
cardiac hypertrophy, detecting local calcium release via IP3R (231). 
Several computational models have been developed for different components 
of the calcium/calcineurin/NFAT pathway. A model of the rabbit ventricular 
cardiomyocyte with dynamic interaction of calcium with CaM, CaMKII and calcineurin 
predicted that the different affinities of CaM for CaMKII and calcineurin determines 
their sensitivity to dynamic changes in local calcium in cardiomyocytes (221). 
Furthermore, a model of calcineurin-dependent nuclear NFAT translocation has been 
used to study the role of calcineurin in cardiac hypertrophy (232, 233). Finally, a recent 
computational study has evaluated the activation of calcium/CaM/calcineurin/NFAT 
pathway during β-adrenoceptor stimulation (234). The model showed that β-
adrenoceptor stimulation increases intracellular calcium concentrations, which 
activate calcineurin and promote NFAT translocation, similar to experimental 
observations (234). However, none of the available models have closed the loop and 
integrated calcineurin/NFAT signaling with transcriptional regulation of 
cardiomyocyte calcium-handling proteins or ion channels to study the role of this 
pathway in long-term proarrhythmic cardiac remodeling. 
 
2.5.4.3 CaMKII-dependent transcriptional regulation 
Calcium-dependent transcriptional regulation is also mediated by CaMKII via the 
histone deacetylase (HDAC) and MEF2 signaling cascades, as well as the downstream 
regulatory element agonist modulator (DREAM) transcription factor (14, 235). CaMKII 
regulates HDAC4 via binding to a unique docking site and phosphorylation of Ser467 
and Ser632 (236, 237). In the nucleus, HDAC4 inhibits several transcription factors, 
including MEF2, a mediator of cardiac structural remodeling. Phosphorylation of 
HDAC4 by cytosolic CaMKII prevents its nuclear import (Figure 2.4), thus releasing the 
inhibition of MEF2 (237, 238). CaMKIIδ knockout mice are protected from structural 
remodeling in response to pressure overload due to reduced HDAC4 phosphorylation, 
confirming the role of CaMKII and HDAC4 phosphorylation in pathological cardiac 
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remodeling (239). Similarly, CaMKII promotes the nuclear translocation of the 
transcriptional repressor DREAM, resulting in inhibition of various target genes. 
CaMKII-dependent DREAM translocation is part of a negative feedback mechanism 
involved in LTCC downregulation to control calcium influx within cardiomyocytes (235, 
240). Computational modeling has been employed to investigate CaMKII-mediated 
LTCC regulation via DREAM (240). In this model, simulation of dynamic DREAM-
dependent modulation of ICa,L showed that in the presence of high intracellular calcium, 
CaMKII activation gradually decreased ICa,L, thereby reducing the intracellular calcium 
and CaMKII activity as a feedback mechanism (240). These studies illustrate how 
computational modeling may be used to link intracellular calcium handling and 
arrhythmia-maintaining electrical remodeling. 
 
2.5.5 Deciphering bidirectional electromechanical interactions 
Bidirectional electromechanical interactions (E-C coupling and mechanoelectrical 
feedback) are strongly present in the heart. When altered, these interactions play a key 
role in arrhythmogenesis (241) and mechanical pump failure (18). Dysregulation of 
intracellular calcium may affect the contractile properties of the heart and lead to 
mechanical dysfunction, including impaired contraction and pump failure, but also 
diastolic dysfunction and impaired relaxation. For example, down-regulation of SERCA, 
together with reduction of calcium influx through LTCC and NCX upregulation, reduces 
SR calcium content, decreases calcium-transient amplitude and contributes to slower 
time-to-peak and calcium-transient decay in the ventricle during HF (165). Alterations 
in the myofilament calcium sensitivity also affect calcium-buffering properties and 
normal E-C coupling, contributing to cardiac arrhythmias and impaired mechanical 
function (242). For example, mutations in sarcomeric proteins such as MyBP-C 
(MYBPC3) can increase myofilament calcium sensitivity and promote diastolic 
dysfunction and cardiac hypertrophy because of the inability of the myofilament to 
release calcium and relax from contraction (243). In addition, these abnormalities in 
cardiomyocyte contraction may lead to mitochondrial calcium-handling abnormalities, 
leading to an increased mitochondrial ROS production. This may impair cellular 
electrical function by ROS-mediated signaling and oxidative damage, potentially leading 
to proarrhythmic events (244). 
The importance of the interplay between calcium handling and contraction for 
arrhythmogenesis is highlighted by studies reporting the effect of pharmacological 
electromechanical uncouplers, used for example during optical mapping experiments, 
on the inducibility of ventricular arrhythmias. Arrhythmia inducibility was greatly 
impaired by electromechanical uncouplers (245). Mechanical abnormalities may 
impact calcium handling through mechano-sensitive mechanisms including length-
dependent activation, slow force response (or Anrep effect), SACs, or myofilament 
sensitization. These may lead to potentially proarrhythmic calcium waves or modulate 
repolarization, promoting arrhythmia initiation and maintenance (3). Length-
dependent activation is the property of the cardiac muscle by which an increase in 
sarcomere length leads to a decrease in the amount of calcium required for contraction 
(246). This process is due to an increase in buffered calcium with stretch because of an 
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increased troponin-C calcium affinity and forms the basis of the Frank-Starling law of 
the heart at the organ and circulation level. The Anrep effect is another mechanism by 
which mechanics may impact calcium handling. It corresponds to the response of the 
heart to increased afterload by an increase in contractility to maintain cardiac output 
by an increase in sarcolemmal sodium upon sustained stretch, reducing NCX activity 
and leading to an accumulation of calcium in the sarcolemma and SR by SERCA uptake. 
SACs produce a current in response to mechanical stimuli and can contribute to ectopic 
activity, as well as proarrhythmic changes in APD, CV, and dispersion of repolarization 
(247). Stretch may also initiate calcium sparks, which remain localized in the normal 
heart, but may evolve into arrhythmogenic calcium waves in the situation of high 
mechanical load. Indeed, changes in cardiac mechanical load such as stretch or sudden 
release of stretched myocardium can generate calcium release from cross-bridge 
detachment in the non-uniform cardiac muscle, which may trigger calcium waves (248, 
249). The main multiscale mechanisms through which mechanics may alter 
intracellular calcium and promote arrhythmias are summarized in Figure 2.5. 
 
Figure 2.5: Effects of mechanical changes on intracellular calcium properties. At the whole organ level, 
mechanical changes observed for example in hypertrophy or heart failure affect cellular and molecular 
properties through myofilament sensitization, stretch or volume activated channels (SACs and VACs, 
respectively), length dependent sarcomere activation or acute stretch. These factors directly affect calcium 
properties and may have proarrhythmic effects through altered electrophysiology or the generation of 
calcium waves. 
Advances in experimental techniques have, to a certain extent, enabled 
investigation of the interplay between calcium regulation and mechanical function of 
the heart. Early on, calcium imaging and patch-clamp experiments in stretched 
cardiomyocytes (250-252) have revealed the direct impact of stretch on calcium-
handling properties. More recently, mechanisms such as ROS production activated by 
the microtubule network (253) have been reported to be involved in calcium-handling 
abnormalities and altered contractile function. Novel techniques such as the cell-in-gel 
system (254) also allowed the application of stress during cardiomyocyte contraction 
and the measurement of calcium and stress properties. Other experiments altering 
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mechanical load and electrical stimuli, such as quick-release protocols (255) or force 
frequency (256) experiments, have also highlighted the bidirectionality of 
electromechanical interactions. Imaging techniques such as confocal microscopy (257), 
optical mapping (258), and more recently 3-dimensional super-resolution imaging 
(164) have made it possible to visualize the structures involved. However, most 
imaging modalities, except for recent work using high-resolution 4-dimensional 
ultrasound-based strain imaging (259), require electromechanical uncoupling. For 
example, optical mapping often uses blebbistatin, a myosin-II inhibitor, to reduce 
motion artifacts during measurements (260). Newer techniques such as hydrogels or 
3-dimensional cell-in-gel setups (261) also allow to study the effects of mechanical load 
on action potential and ion channels. However, most of these experiments are 
performed in small animals such as rodents or rabbits. New techniques aiming at 
replicating human cardiac properties have emerged, such as 3-dimensional engineered 
heart tissue, but they remain relatively immature (262). Assessing calcium and 
contractile properties in human cardiomyocytes in the presence of controlled 
electromechanical feedback therefore remains a challenge. In addition, at the organ 
level, dynamic situations such as exercise have both electrical and mechanical effects. 
As such, understanding their individual contribution to arrhythmic risk under specific 
pathological conditions is challenging for current experimental techniques. 
Computational models are a powerful tool to better understand 
electromechanical coupling and the individual contributions of cardiac electrics and 
mechanics in cardiac dysfunction. Most models developed so far have focused on 
simulating electrophysiology, but some have been developed to investigate 
electromechanical interactions. Among these, most have combined an existing 
electrophysiological model (263, 264) with a model of sarcomere contraction (265-
267) (Table 2.3). Such models, developed for species ranging from rodents (268) to 
human (269), have been applied to a range of multiscale applications such as 
understanding the effect of stretch on the slow force response (268), highlighting the 
impact of strain and fibrosis on cellular electrophysiology through SAC (270), 
simulating the effect of phasic β-adrenoceptor stimulation on APD, or investigating the 
relations between force, calcium and AP alternans in heart failure (269) (Table 2.3). 
However, validation of these models remains challenging because of the sparsity and 
heterogeneity of the experimental data available, as shown in Table 2.3. Moreover, 
current electromechanical computational models have several limitations. For example, 
in all models, SACs have been implemented phenomenologically, using linear current-
voltage relationships (268, 271). Furthermore, the most widely used contraction model 
for EM model development (267) is based on a non-physiological calcium-handling 
model. Finally, prospectively designed in vitro human data for model development and 
validation is urgently needed. These computational models therefore hold great 
promise to better understand electromechanical interactions and especially the strong 
interplay between mechanics and calcium regulation, but future developments, in close 
synergy with experiments, are needed to ensure better insight in electromechanical 
coupling. 
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Electro-
mechanical 
model 
Electro-
physiological 
model 
Contraction 
model 
Application Validation Species 
Timmermann 
(270) 
Winslow et 
al., Grandi et 
al., O’Hara et 
al. 
Rice et al. 
and Land et 
al. 
Effect of strain and 
fibrosis on cellular 
electrophysiology 
(through SAC). 
Qualitative 
comparison of 
force, calcium 
and length to 
experimental 
data 
Canine 
/ 
Human 
Pueyo (272) O’Hara et al. 
and ten 
Tusscher et 
al. 
Niederer et 
al. 
Phasic β-adrenergic 
stimulation effect 
on phasic changes 
in APD 
No model 
validation in 
paper  
Human, 
rabbit 
and rat 
Zile (269) Ten Tusscher 
et al. 
Rice et al. Generation of force 
and AP alternans in 
heart failure 
No model 
validation in 
paper 
Human 
Campbell 
(273) 
Flaim et al. Rice et al. Sources of 
heterogeneous 
electromechanical 
behavior in cardiac 
transmural cells 
Qualitative 
comparison of 
calcium, AP, 
shortening and 
transmural APD 
trends for one 
beat with 
experimental 
data 
Canine 
Rice (267) Shannon et al. 
(Chicago 
model) 
Rice et al. Simulation of 
electromechanical 
coupling and its 
feedback effect 
Comparison of 
AP, calcium, and 
contraction to 
experimental 
data 
Rabbit 
Niederer 
(268) 
Pandit et al., 
Hinch et al. 
Niederer et 
al. 
Effect of stretch on 
the slow force 
response 
Based on 
previous 
validation of 
model 
components. 
Qualitative 
comparison of 
maximum 
tension and APD 
as function of 
frequency 
Rat 
Iribe (274) Noble et al. Rice et al. CaMKII 
involvement in 
calcium handling, 
interval-force 
relation and 
alternans 
Interval 
dependence of 
twitch duration, 
restitution, 
potentiation and 
staircase 
phenomenon 
Rat 
Ekaterinburg 
(275, 276) 
Noble et al. Ekaterinburg Effect of mechanical 
heterogeneity on 
APD and dispersion 
of repolarization 
No model 
validation in 
paper 
Rat 
Matsuoka 
(277) 
Shirokov et al. Negroni and 
Lascano 
Simulation of 
electromechanical 
coupling 
Qualitative 
comparison of 
sarcomere length 
with experiments  
Guinea 
pig 
Sachse (278) Priebe‐
Beuckelmann 
and Luo-Rudy 
Sachse et al.  Effect of regional 
electrophysiological 
Comparison to 
the EP model but 
no validation of 
Human 
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heterogeneities on 
force development 
the coupled 
model 
Table 2.3: Previously published electromechanical cardiomyocyte models. 
 
2.6 Conclusion 
Cardiomyocyte calcium handling is a major determinant of E-C coupling and alterations 
of one or more calcium-handling proteins may induce arrhythmias through the 
formation of ectopic activity, direct and indirect ion channel modulations, and 
structural remodeling. Computational modeling of cardiac cellular electrophysiology 
has made significant progress in the last decades and is now employed together with in 
vitro experiments to provide new insights on cardiomyocyte calcium-handling and its 
abnormalities. However, many issues remain unresolved, including the complex 
molecular interactions mediating calcium-dependent ion-channel regulation, the 
molecular mechanisms and proarrhythmic consequences of SCaEs, and the complex 
post translational calcium signaling pathways and mechanisms of long-term 
transcriptional regulation of calcium handling. Therefore, combined in vitro and in silico 
studies to address such issues will be required. Detailed experimental studies are 
needed for model development and validation. At the same time, well-validated models 
can be employed to confirm cause-effect relationships suggested by experimental 
findings, address experimental limitations (e.g., the inability to control subcellular 
structure) and to extrapolate experimental findings to a higher scale (e.g., tissue or 
organ level). Key highlights and challenges for in vitro and in silico studies of 
cardiomyocyte calcium handling are summarized in Table 2.4. 
Highlights 
1. Calcium affects multiple targets inside a cardiomyocyte, including transmembrane ion 
channels, contractile proteins, and calcium-dependent signaling pathways to ensure an 
optimal electromechanical function of the heart.  
2. Calcium-handling abnormalities trigger cardiac arrhythmias through several pathogenic 
processes: initiation of ectopic activity, ion channel modulation (direct and indirect), and 
structural remodeling. 
3. The many interacting calcium-dependent arrhythmia mechanisms, with feed-back and 
feed-forward loops operating over a wide range of spatial and temporal scales make a 
detailed experimental characterization challenging, highlighting the potential benefits of 
combining in vitro studies with in silico studies. 
4. Computational modeling has undergone major improvements in the past 80 years and is 
now being used to support in vitro studies and assist clinical decision-making. 
5. Atrial and ventricular calcium-handling models with different level of complexities have 
been developed based on experimental data and are increasingly reflecting the complex 
subcellular structure responsible for cardiomyocyte calcium handling and alterations in 
the spatiotemporal distribution of calcium-handling proteins in disease. 
6. Some cellular models have started to incorporate the electrophysiological effects of 
calcium-dependent signaling pathways (e.g., CaMKII- and calcineurin-NFAT signaling 
cascades), although long-term regulation (e.g., through calcium-dependent 
transcriptional regulation) is missing in almost all models. 
7. Computational modeling has also been employed to investigate the impact of 
electromechanical coupling and mechanoelectrical feedback on cardiac 
arrhythmogenesis and contractile dysfunction. 
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8. Computer models rely on high-quality experimental data. At the same time, they offer 
perfect observability and perfect control, making it possible to evaluate cause-and-effect 
relations that at present cannot be addressed experimentally. Studies exploiting the 
synergistic potential between both approaches will help to further our understanding of 
cardiac arrhythmias. 
Challenges 
1. Comparison of existing in vitro data is challenging, partly due to differences in 
experimental models and methodologies, resulting in apparent inconsistent findings, 
which complicate the investigation of the role of calcium-handling abnormalities in 
cardiac arrhythmias. 
2. There is increasing evidence that many ion channels undergo direct and indirect calcium-
dependent regulation, but their role in arrhythmogenesis is incompletely understood and 
not incorporated in most computational models.  
3. Many calcium-handling properties can only be measured indirectly in living 
cardiomyocytes (e.g., SERCA function), or require correlation between experiments 
under different conditions (e.g., immunocytochemistry in fixated cells and live-cell 
calcium imaging to study structure-function relationships)  
4. The bidirectional interactions between mechanical load and calcium-handling 
mechanisms remain incompletely understood.   
5. Most of the computational models of calcium handling focus on a single element and/or 
condition, due to the limited availability of in vitro data, ignoring potential relevant 
interactions between different calcium-dependent signaling cascades. 
Table 2.4: Summary of highlights and challenges for in vitro and in silico studies of cardiomyocyte calcium 
handling. 
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ABSTRACT 
SCaEs from the sarcoplasmic reticulum play crucial roles in the initiation of cardiac 
arrhythmias by promoting triggered activity. However, the subcellular determinants of 
these SCaEs remain incompletely understood. Structural differences between atrial and 
ventricular cardiomyocytes, e.g., regarding the density of T-tubular membrane 
invaginations, may influence cardiomyocyte calcium handling and the distribution of 
cardiac RyR2 has recently been shown to undergo remodeling in AF. These data suggest 
that the subcellular distribution of calcium handling proteins influences proarrhythmic 
calcium handling abnormalities. Here, we employ computational modeling to provide 
an in-depth analysis of the impact of variations in subcellular RyR2 and LTCC 
distributions on calcium transient (CaT) properties and SCaEs in a human atrial 
cardiomyocyte model. We incorporate experimentally observed RyR2 expression 
patterns and various configurations of axial tubules in a previously published model of 
the human atrial cardiomyocyte. We identify an increased SCaE incidence for larger 
heterogeneity in RyR2 expression, in which SCaEs preferentially arise from regions of 
high local RyR2 expression. Furthermore, we show that the propagation of calcium 
waves is modulated by the distance between RyR2 bands, as well as the presence of 
experimentally observed RyR2 clusters between bands near the lateral membranes. We 
also show that incorporation of axial tubules in various amounts and locations reduces 
CaT time to peak. Furthermore, selective hyperphosphorylation of RyR2 around axial 
tubules increases the number of spontaneous waves. Finally, we present a novel model 
of the human atrial cardiomyocyte with physiological RyR2 and LTCC distributions that 
reproduces experimentally observed calcium handling properties. Taken together, 
these results significantly enhance our understanding of the structure-function 
relationship in cardiomyocytes, identifying that RyR2 and LTCC distributions have a 
major impact on systolic CaTs and SCaEs. 
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3.1 Introduction 
Despite the significant advances in the treatment of cardiovascular diseases during the 
past 50 years, the frequency of cardiac arrhythmias, particularly AF, is projected to 
increase, placing a significant burden on modern healthcare systems (279-281). 
Calcium handling abnormalities play a key role in ectopic activity and reentry, the two 
major arrhythmogenic mechanisms underlying AF (2, 6, 64). Dysfunctional RyR2s, 
and/or sarcoplasmic reticulum (SR) calcium overload can promote the occurrence of 
SCaEs (2), which transiently increase the cytosolic calcium concentration, activating the 
sodium-calcium exchanger type-1 (NCX1), resulting in a depolarizing transient-inward 
current and promoting DADs and triggered activity. Although potential proarrhythmic 
effects of changes in RyR2 expression and phosphorylation have been extensively 
discussed (204, 282), these studies have generally employed tissue homogenates, 
ignoring the subcellular structure of calcium handling proteins. However, there is 
increasing evidence that differences in subcellular structure critically influence 
cardiomyocyte calcium handling. For example, there are important structural 
differences between atrial and ventricular cardiomyocytes that affect calcium handling, 
including a relative paucity of transverse T-tubular structures in atrial cardiomyocytes, 
resulting in a centripetal calcium wave propagating from RyR2 opposing LTCC at the 
sarcolemma to RyR2 in the cell center (283). On the other hand, there is increasing 
evidence for a role of axial tubules in atrial cardiomyocyte calcium handling (284-287). 
Axial tubules promote a faster calcium release from the SR in the center of the cell, 
which is partly mediated by coupling of LTCC to hyperphosphorylated RyR2 
surrounding axial tubules (160). Moreover, this axial tubular system undergoes 
extensive remodeling during cardiovascular disease, e.g., proliferating in the presence 
of atrial hypertrophy (160) or disappearing in mice with atrial-specific knock-out of 
NCX1 (287). AF-related remodeling of the RyR2 distribution has also been reported, 
with RyR2 cluster fragmentation and redistribution in sheep with AF, which was 
associated with increased calcium spark frequency (158). However, the exact impact of 
the subcellular distribution of RyR2 and LTCC on cardiomyocyte calcium handling 
remains largely unknown. It is currently experimentally challenging to study both 
(sub)cellular structure and functional calcium handling in human atrial cardiomyocytes, 
as the former usually requires fixation of the cardiomyocyte for antibody staining. The 
perfect control and observability provided by computational modeling may help to 
overcome this challenge (94). 
A number of ventricular cardiomyocyte models have been developed that are 
able to simulate local calcium handling and SCaEs (90, 103). Models of atrial subcellular 
calcium handling, on the other hand, are relatively scarce (94). We recently developed 
a human atrial cardiomyocyte model with stochastic gating of RyR2 channels and both 
transverse and longitudinal compartmentation of calcium handling. Our model has a 
simple cell-type specific subcellular structure with LTCC only present on the lateral 
membranes, reflecting the relative paucity of T-tubules in isolated atrial 
cardiomyocytes (32). However, all currently available atrial and ventricular 
cardiomyocyte models assume a homogeneous distribution of calcium handling 
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proteins. Here, we hypothesized that changes in the subcellular distribution of RyR2 
and LTCC may promote proarrhythmic SCaEs. We employed both confocal microscopy 
and computational modeling to study for the first time the impact of the subcellular 
distribution of RyR2 and LTCC on calcium handling in atrial cardiomyocytes. 
 
3.2 Materials and methods 
3.2.1 Animal model, cardiomyocyte isolation, and confocal imaging 
This investigation conformed with the Guide for the Care and Use of Laboratory 
Animals Published by the US National Institutes of Health (NIH Publications No. 85-23, 
revised 1996). All animal handling conformed with directive 2010/63/EU and 
experimental protocols were approved by the local ethical committee (DEC2014-112). 
New Zealand white rabbits (2.5–3.5 kg) were anesthetized and hearts were rapidly 
removed, excised, washed, perfused and cut into smaller pieces, as previously described 
(130). Atrial cardiomyocytes were seeded on laminin coated coverslips. RyR2s were 
labeled with primary (mouse monoclonal (C3-33), IgG1, Sigma-Aldrich®, MO, 1:50) and 
secondary (Alexa® 488, goat anti-mouse, Abcam, UK, 1:100) antibodies (288, 289). The 
RyR2-stained atrial cardiomyocytes were imaged with a Leica TCS SP8 confocal 
microscope using a 63x objective (NA 1.40, oil immersion). The RyR2-Alexa® 488 
antibody complex was detected at 420-520 nm under 488 nm laser illumination. Z-
stacks were taken with a step size of 0.26 µm and an xy-resolution of 0.07 µm. 
 
3.2.2 Image processing 
Image processing was employed to enable simulation with the experimental data 
(Figure 3.1). The raw z-stacks were deconvolved using Huygens Professional (SVI, 
Netherlands). A single slice from the z-stack was selected and rotated to obtain a 
horizontal alignment of the RyR2. The image was thresholded and overlaid with a grid 
of ~1 µm2 units, in which the mean pixel intensity was calculated for every square of 
the grid as an indirect readout of local RyR2 density. The edges of the RyR2 expression 
matrix were detected and stretched to accommodate the rectangular dimensions of the 
virtual cardiomyocyte (100x18 µm). The resulting RyR2 distribution matrix was 
implemented in the computational model and employed for simulation. 
 
3.2.3 Computational modeling 
Simulations were based on a previously published model of the human atrial 
cardiomyocyte in which local calcium handling was simulated by dividing the virtual 
cardiomyocyte into 50 segments, each containing 18 subcellular calcium domains 
located between two membrane domains (32, 94). The RyR2 expression in the 
published model was identical in every unit. We further optimized the 50-segment 
model with uniform RyR2 distribution based on experimental values (32, 124, 130, 285, 
290-292) of calcium handling properties and SCaE properties reported in previous 
publications (Figures 3.2, 3.3). In the present work, the model was extended to enable 
simulations with heterogeneous RyR2 distributions. Heterogeneity in RyR2 
distribution across all 50x18 units was incorporated by drawing a random number 
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from a Gaussian distribution with mean 1.0 and standard deviation σ for each unit and 
subsequently scaling these numbers to achieve the desired total RyR2 density.  
 
Figure 3.1: Image processing workflow. A) Single slice of the RyR2 z-stack in a rabbit atrial cardiomyocyte 
stained with Alexa® 488 antibodies, before (left) and after deconvolution (right). B) Rotated region of 
interest before (left) and after thresholding (right). C) Alignment with a regular grid of ~1 µm2 units, which 
was subsequently employed to determine the average RyR2 expression level. Smaller panels show region 
indicated in the red box at a higher magnification. 
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We also developed a model with a higher longitudinal resolution (100 segments), 
enabling simulation of the experimentally observed banded expression of RyR2. Axial 
tubules were simulated in the 100-segment model by including LTCC in axial-tubule-
associated calcium domains. Parameters of the 100-segment model with uniform RyR2 
expression were adjusted to achieve similar calcium handling properties as the 50-
segment model (Figures 3.2, 3.3) and heterogeneous RyR2 expression patterns were 
generated analogous to the 50-segment model. The values of the optimized parameters 
for both model versions are given in Table 3.1. For the LTCC, the 8-state Markov model 
was used as previously described (32, 94). Parameters of this Markov model are shown 
in Appendix A. All results in the 100-segment model are provided following pacing for 
250 beats at 0.5 Hz to achieve a quasi-steady state (Figure 3.4).  
 
 
Figure 3.2: Validation of SCaEs in the published (Ctl), adapted 50-segment (50 seg) and 100-segment (100 
seg) models. A) Membrane potential (VM), CaT and longitudinal line scan of three triggered CaTs and 5 SCaEs 
during follow-up in the 50 seg model. B) Validation of SCaE incidence, as well as velocity of calcium waves in 
longitudinal and transversal directions for the three model versions (based on n=6 simulations each) 
compared to experimental data (32, 124, 130, 285, 290-292).  
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Figure 3.3: Validation of calcium handling properties of the models. A) Membrane potential (VM) and 
intracellular calcium showing protocol used during simulation: Four triggered waves were applied prior to 
the simulated administration of caffeine to induce calcium release from the sarcoplasmic reticulum. B-G) 
Comparison of the calcium handling properties of control, 50-segment and 100-segment models to 
experimental data; [1] = (124), [2] = (32).  
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Parameter Published 
model (32) 
50-segment 
model 
100-segment 
model 
Exp. RyR2 +  
axial tubules + 
hyperphos. RyR 
𝝉diff,SRS  cyt  (ms) 12 12 10 10 
𝝉diff,seg,SRS (ms) 0.3 0.3 0.22 0.10 
𝝉diff,dom,SRS (ms) 0.125 0.125 0.16 0.10 
𝝉diff,seg,cyt (ms) 0.6 0.6 0.6 0.6 
𝝉diff,dom,cyt (ms) 0.6 0.6 0.6 0.6 
𝝉diff,seg,SR (ms) 15 15 5 5 
𝝉diff,dom,SR (ms) 15 15 5 5 
NRyRs  594,000 514,800 2,772,000 79,200,000 
SERCA2a (Kmr) 1.00 1.00 1.25 1.25 
ICaL parameters  
 
P1 = 9.45 
P2 = 49.1 
P3 = 10.349 
P4 = 26.553 
P5 = 17.5 
P6 = 3.0 
P7 = 13.825 
P8 = 6.3836 
P9 = 14.9186 
P10 = 1.100 
As in (94): 
 
P1 = 9.45 
P2 = 65.0 
P3 = 6.000 
P4 = 12.00 
P5 = 27.5 
P6 = 5.0 
P7 = 43.825 
P8 = 45.00 
P9 = 5.000 
P10 = 5.000 
As in (94): 
 
P1 = 9.45 
P2 = 65.0 
P3 = 6.00 
P4 = 12.00 
P5 = 27.5 
P6 = 5.0 
P7 = 43.825 
P8 = 45.00 
P9 = 5.000 
P10 = 5.000 
As in (32) with 
adjusted P1: 
P1 = 8.50 
P2 = 49.1 
P3 = 10.349 
P4 = 26.553 
P5 = 17.5 
P6 = 3.0 
P7 = 13.825 
P8 = 6.3836 
P9 = 14.9186 
P10 = 1.100 
 
Table 3.1: Parameters changes applied to the published model (32) with 50 segments to fit the previously 
published experimental data. Subsequently, slight modifications of the parameters, including the number of 
RyR (NRyRs), Kmr of SERCA and time constant (τ) SRS, were made to the 100-segment models to obtain 
similar physiological calcium handling properties.  
 
3.2.4 Data Analysis and Statistics 
Due to the stochastic nature of the simulations, each condition was simulated at least 6 
times and data were expressed as mean ± standard deviation. Statistical differences 
between conditions were evaluated using one- or two-way ANOVA with Tukey post-hoc 
test for multiple comparisons, or independent t-test, depending on the number of 
groups and the type of the data. Statistical analyses were performed using GraphPad 
Prism 7 (GraphPad Software Inc., La Jolla, CA). 
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Figure 3.4: Analysis of calcium handling properties for different prepacing durations in the 100-segment 
model. Simulations were run for various numbers of prepacing beats to find a value that represents a quasi-
steady state condition. Calcium handling parameters of triggered CaTs (diastolic levels, systolic levels and 
CaT amplitude; left panels) and SCaEs (incidence, longitudinal and transversal velocity; right panels) were 
documented. After prepacing for 200-250 beats, calcium handling parameters reach an acceptable steady 
state. Accordingly, results in the main manuscript for the 100-segment model are shown after 250 beats 
prepacing. 
 
3.3 Results 
3.3.1 Effects of heterogeneity in RyR2 distribution on SCaEs 
The model with uniform RyR2 distribution (σ = 0.0) produced a few large calcium 
waves and corresponding DADs during follow-up after pacing at 0.5 Hz, in line with 
experimental data (Figure 3.2). Increasing the heterogeneity of RyR2 distribution from 
σ = 0.0 to σ = 0.4 while keeping the total number of RyR2 constant substantially 
increased the incidence of SCaEs, but decreased their size (Figures 3.5A–C). For 
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example, with σ = 0.4, the incidence of SCaEs was 14x larger (3.31 ± 0.51 s-1 vs. 0.23 ± 
0.04 s-1, n = 6, p < 0.05) and the average size of a calcium wave as fraction of 
cardiomyocyte volume was 5x smaller than with σ = 0.0 (0.18 ± 0.02 vs. 0.91 ± 0.11, n 
= 6, p < 0.05). Increasing RyR2 heterogeneity also reduced the longitudinal (100.94 ± 
3.66 µm/s vs. 211.24 ± 7.24 µm/s, n = 6, p < 0.05) and transversal (102.81 ± 3.94 µm/s 
vs. 210.79 ± 14 µm/s, n = 6, p < 0.05) velocity of calcium waves. We compared the 
magnitude of the effect of altered RyR2 distribution to a 25% change in total RyR2 
expression. In line with previous results (32), increasing calcium flux led to an 
increased number of SCaEs and smaller SCaE size (Figures 3.5B, C). Likewise, a 25% 
decrease in total RyR2 led to lower SCaE incidence and bigger SCaE size. Increasing 
RyR2 heterogeneity and total expression had synergistic effects on SCaE incidence. 
Next, we investigated the origins of SCaEs in simulations with heterogeneous 
RyR2 distributions (crosses in Figure 3.6A). SCaEs preferentially arose from units with 
high local RyR2 expression. In agreement, comparison of the histograms of relative 
RyR2 expression of all 50x18 units with those of SCaE-inducing units revealed that 
SCaE-inducing units had significantly higher local RyR2 expression (Figure 3.6B). The 
difference in mean RyR2 expression between SCaE-inducing units and all units was 
most pronounced in simulations with large heterogeneity in RyR2 distribution (Figure 
3.6C), establishing units with high local RyR2 expression as foci for SCaEs. 
 
3.3.2 Simulation of experimentally characterized RyR2 distributions 
RyR2 distributions were studied in rabbit atrial cardiomyocytes. In line with previous 
results, we observed a banded RyR2 pattern with ~2 µm inter-band distance (Figures 
3.7A, B). We analyzed the average RyR2 intensity after image-processing of the 
confocal images based on a square grid with 1 µm2 units and identified a significant 
variation in RyR2 distribution along the bands (Figure 3.7C). The histogram of relative 
RyR2 expression showed a large peak at near-zero levels, reflecting the units between 
RyR2 bands and a normal distribution with standard deviation σ = 0.253 for the RyR2 
intensity within the bands (Figure 3.7D). In order to simulate this physiological RyR2 
distribution, we increased the resolution of our model, simulating 100 segments of 1 
µm with alternating pattern of RyR2 expression (Figure 3.8) and validated its calcium 
handling properties based on experimental data (Figures 3.2, 3.3). We also 
incorporated the option to simulate the regional expression of LTCC localized in axial 
tubules and the experimentally observed hyperphosphorylation of axial-tubule-
associated RyR2 (discussed below). A schematic representation of the subcellular 
structure of the model is shown in Figure 3.9. 
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Figure 3.5: Effects of RyR2 distribution heterogeneity on SCaEs in the 50-segment model. (A) Representative 
examples comparing heterogeneity (σ) of 0.0 (uniform expression, top) and 0.2 (bottom). The 50x18 matrices 
(left) show the relative RyR2 distribution. The membrane potential (VM), whole-cell calcium concentration, 
and longitudinal line scan on the right show marked differences in number of SCaEs and corresponding 
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delayed afterdepolarizations between both groups. (B–D) SCaE incidence (B) and size (C), as well as 
longitudinal and transversal velocity of calcium waves (D) as a function of RyR2 heterogeneity σ for different 
levels of total RyR2 expression (75% of control: circles; 100% of control: squares; 125% of control: triangles). 
SCaE incidence increases, while size decreases with increasing RyR2 heterogeneity. * indicates P < 0.05 vs. 
the group with heterogeneity 0.0 and # indicates statistically significant differences among three levels of 
RyR2 expression; n = 6 per condition. 
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Figure 3.6: Origins of SCaEs. (A) Two representative examples of 50x18 matrices with heterogeneous RyR2 
distribution (σ = 0.2). Red colors indicate high local RyR2 expression and blue colors low local RyR2 
expression. The origins of individual calcium waves are marked with crosses. Insets depict enlarged portions 
of the RyR2 distribution, showing that crosses mainly coincide with regions of high local RyR2 expression. 
(B) Histograms of relative RyR2 expression in all units (left) and units which were the origin of a SCaE (SCaE-
inducing units). SCaEs arise mainly from units with high local RyR2 expression. (C) Mean relative RyR2 
expression in SCaE-inducing units (squares) and all units (circles, 1.0 on average by definition) for different 
degrees of RyR2 heterogeneities. * indicates P < 0.05 vs. the group with heterogeneity 0.0 and # indicates P < 
0.05 between mean relative RyR2 expression in SCaE-inducing units and all units; n = 6 per condition. 
 
Figure 3.7: Experimental distribution of RyR2 expression in atrial cardiomyocytes. (A) Confocal image of 
RyR2 staining in a rabbit atrial cardiomyocyte. Inset shows region of interest at higher magnification, 
revealing that RyR2 clusters assemble in a regular banded pattern along the Z-band. (B) Distribution of 
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distances between RyR2 bands, showing that majority of these gaps were around 1.8–1.9 µm. (C) Image 
processing of confocal images and alignment with a regular grid of ~1 µm2 units (left) enabled quantification 
of local RyR2 expression (right panel, red indicates high local RyR2 expression and blue low local RyR2 
expression). (D) Histogram of experimental RyR2 expression distribution across all units with a large peak 
around 0, representing units between bands of RyR2 expression and a normal distribution of RyR2 
expression within bands (line shows normal distribution with standard deviation of 0.253). 
 
Figure 3.8: Comparison of RyR2 distribution in 100-segment simulations with σ = 0.0, σ = 0.2 and with 
experimental RyR2 distribution. Simulation of experimental RyR2 distribution displayed banded patterns 
with several areas with local high RyR2 expressions. 
Similar to the 50-segment model, increasing heterogeneity of RyR2 expression 
in the 100-segment model led to an increase in SCaE incidence and reduction in SCaE 
size, longitudinal and transversal velocity (Figure 3.10), with SCaEs originating from 
units with high local RyR2 expression (Figure 3.11). However, despite similar SCaE-
incidence with a uniform RyR2 distribution, the increase in SCaEs with increasing RyR2 
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heterogeneity was more pronounced in the 100-segment model (115-fold vs. 14-fold 
increase from σ = 0.0 to σ = 0.4 in the 100-segment and 50-segment models, 
respectively; Figure 3.12, Figure 3.5). Implementation of the experimentally observed 
RyR2 distribution pattern in the 100-segment model resulted in the occurrence of many 
small SCaEs, similar to our 100-segment simulations with heterogeneity (σ) 0.3 and 0.4 
(with SCaE incidence of 12.96 ± 0.28 s-1 in the experimentally observed RyR2 
distribution vs. 9.88 ± 1.16 s-1 in σ = 0.3 and 21.83 ± 2.62 s-1 in σ = 0.4, Figure 3.10B 
and Figure 3.12). Longitudinal and transversal velocity of SCaEs in the experimentally 
observed RyR2 distribution model were similar to 100-segment simulations with σ = 
0.2 (Figure 3.10D). Heterogeneities in RyR2 expression did not affect properties of the 
LTCC-triggered CaT in the absence of preceding SCaEs (Figure 3.13). 
 
 
Figure 3.9: Schematic representation of 100-segment model. The model is represented by four different 
locations in the virtual cardiomyocyte. [1] represents an RyR2 band with axial tubule and 
hyperphosphorylated RyR2 (indicated with “P” in the scheme) adjacent to the axial tubule, as reported by 
(160). [2] represents an inter-band gap with axial tubule. [3] represents an RyR2 band without axial tubule. 
[4] represents an inter-band gap without axial tubule. Each segment is divided into 18 domains, as depicted 
in the matrix on the left, but only a subset of domains is shown for clarity. Please note the expression of RyR2 
in the first and last domains in the segments located between RyR2 bands (i.e., [2] and [4]). 
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Figure 3.10: Effects of RyR2 distribution heterogeneity on SCaEs in the 100-segment model. (A) 
Representative examples comparing heterogeneity (σ) of 0.0 (uniform expression, top), 0.2 (middle), and 
experimentally observed RyR2 expression patterns (bottom) on membrane potential (VM), whole-cell CaT, 
and longitudinal line scan (right panels). The 100x18 matrices (left) of relative RyR2 expression incorporate 
the experimentally observed 2 µm inter-band distance. (B–D) SCaE incidence (B), size (C), as well as 
longitudinal and transversal velocity of calcium waves (D) in 100-segment simulations with σ = 0.0, σ = 0.2, 
and experimentally observed RyR2 expression. Incorporation of the experimentally observed RyR2 
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expression in the original 100-segment model results in a large (non-physiological) number of small SCaEs. * 
indicates P < 0.05 between indicated groups; n = 6 per condition. 
 
Figure 3.11: Origins of SCaEs. A) Two representative examples of 100x18 matrices with heterogeneous RyR2 
distribution (σ = 0.2). Red colors indicate high local RyR2 expression and blue colors low local RyR2 
expression. The origins of individual calcium waves are marked with crosses. Insets depict enlarged portions 
of the RyR2 distribution. B) Histograms of relative RyR2 expression in all units (left) and units which were 
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the origin of a SCaE (SCaE-inducing units). C) Mean relative RyR2 expression in SCaE-inducing units (squares) 
and all units (circles, 1.0 by definition) for different degrees of RyR2 heterogeneities. Consistent with the 50-
segments simulations (Figure 3.6), the spontaneous waves originated from units with local high RyR2 
expression. * indicates P<0.05 vs. heterogeneity 0.0; # indicates P<0.05 between mean relative RyR2 
expression in SCaE-inducing units and all units; n=6 per condition. 
 
Figure 3.12: Comparison of SCaE properties for various degrees of RyR2 heterogeneity and total expression 
in the 100-segment model. A-C) SCaE incidence (A) and size (B), as well as longitudinal and transversal 
velocity of calcium waves (C) as a function of RyR2 heterogeneity σ for different levels of total RyR2 
expression (75% of control: circles; 100% of control: squares; 125% of control: triangles). In line with the 50-
segment simulations, increasing the total RyR2 expression also increased the incidence and lowered the size 
of the wave. * indicates P<0.05 vs. the group with heterogeneity 0.0; # indicates significant difference among 
the three levels of RyR2 expression; n=6 per condition. 
 
3.3.3 Modulation of SCaE propagation by the distance between RyR2s and RyR2 
clusters at the lateral membrane 
Previous studies have reported a closer spacing between RyR2s around the lateral 
membrane in rat atrial and ventricular cardiomyocytes (159, 293), rabbit atrial (294), 
ventricular (294, 295) and SA nodal cells (294), and human atrial cardiomyocytes (160). 
We similarly observed a higher density of RyR2 clusters at the lateral membrane in 
rabbit atrial cardiomyocytes (Figure 3.14A) and accordingly incorporated RyR2 
expression in the first and last calcium unit of every segment of the virtual 
cardiomyocyte for the simulations of Figure 3.10. Next, we employed the model to 
assess the impact of these lateral RyR2s by comparing simulations with and without 
RyR2 in the outer calcium units for segments located between RyR2 bands. The absence 
of RyR2s in the lateral region of the cardiomyocyte prevented the propagation of SCaEs, 
resulting in a reduced longitudinal velocity and numerous small SR calcium releases 
(Figure 3.15A). This behavior could be fully restored by reducing the time constant of 
calcium diffusion between segments and normalizing the total RyR expression (SCaE 
incidence of 0.24 ± 0.04 s-1 in the group with normalized RyR2 expression and corrected 
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longitudinal velocity vs. 0.19 ± 0.02 s-1 in the control group, n = 6, p > 0.05; Figure 
3.15B). 
 
Figure 3.13: Effect of RyR2 heterogeneity on systolic calcium wave propagation in the absence of SCaEs. 
Comparison of the transversal calcium waves (A) and whole-cell CaT (B) during 0.5 Hz pacing for three 
different degrees of heterogeneity. As expected, the “V” shape pattern of atrial calcium wave propagation can 
be observed, reflecting the lack of transversal tubules. C) Quantification of time to peak and CaT amplitude 
(right) for the indicated line scan (“local”) or for the whole-cell CaT (“global”) for three levels of RyR2 
heterogeneity. RyR2 heterogeneity did not affect the characteristics of systolic calcium wave propagation. 
 
Next, we investigated the effect of alterations in the distance between RyR2 
bands by simulating two or three segments without RyR2 expression between bands 
(instead of one). Although an increased RyR2 inter-band distance indeed slowed down 
the longitudinal velocity of SCaEs, it surprisingly did not impair propagation of SCaEs 
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and resulted in an increased SCaE incidence (Figure 3.14B, left column; Figures 
3.14C–E). Subsequent analyses showed that the RyR2 expressed at the lateral 
membrane in segments without RyR2 bands are critical for the propagation of SCaEs. 
In particular, a similar increase in RyR2 inter-band distance in the model without lateral 
RyR2 between bands (but with corrected longitudinal velocity of SCaEs at baseline) 
resulted in failure of calcium wave propagation and many fragmented SCaEs (Figure 
3.14B, right column). These data strongly suggest that the closer spacing of RyR2 at the 
lateral membrane that we observed experimentally may provide a safety factor for 
synchronous SR calcium release but may also facilitate propagation of large 
proarrhythmic calcium waves. 
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Figure 3.14: Lateral RyR2s, inter-band distance and the propagation of SCaEs. (A) Confocal image showing 
an increased density of RyR2 close to the lateral membrane in a rabbit atrial cardiomyocyte. (B) 
Representative examples of membrane potential (VM), whole-cell CaT, and longitudinal line scan for the 100-
segment model with single (~2 µm; top row), double (middle row) or triple (bottom row) inter-band distance, 
with (left column) or without (right column) expression of lateral RyR2s between bands. In all panels, the 
total number of RyR2 was adjusted to achieve a density of 2,772 RyR2 per unit. The time constant of 
longitudinal calcium diffusion between SR release spaces was adjusted from 0.22 to 0.07 ms in the model 
without lateral RyR2 expression to obtain similar SCaE properties for physiological inter-band distances. (C-
E) SCaE incidence (C), size (D), as well as longitudinal and transversal velocity of calcium waves (E) for the 
six model versions. An increased inter-band distance increased the incidence of SCaEs, reduced their size and 
altered the longitudinal velocity without affecting the transversal velocity. * indicates P < 0.05 vs. the control 
model (100-segment model of single inter-band distance with lateral RyRs; blue bars), n = 6 per condition. 
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Figure 3.15: The importance of lateral RyR2s in the propagation of SCaEs. A) Membrane potential (VM), 
intracellular calcium and longitudinal line scan (top to bottom) for the baseline model with lateral RyR2 (A.1), 
the model without lateral RyR2s (A.2), and the model without lateral RyR2 after the adjustment of total RyR2 
expression and correction of longitudinal velocity (A.3). B-D) incidence (B), size (C), as well as longitudinal 
and transversal velocity (D) of SCaEs for the three model conditions. Absence of lateral RyR2 resulted in more 
and smaller waves compared to baseline, presumably due to relocation and redistribution of RyR2. After 
correction of total RyR2 expression and longitudinal velocity, the incidence and size of SCaEs recovered. * 
indicates P<0.05 between groups; n=6 per condition. 
 
3.3.4 Inter-band RyR2 expression and SCaEs 
Similar to the results described by (158), our confocal images also showed occasional 
RyR2 expression between individual bands. We employed the 100-segment model to 
better understand the functional effects of these inter-band RyR2 clusters. For any 
degree of heterogeneity, the presence of inter-band RyR2 clusters resulted in fewer, 
slightly larger SCaEs compared to simulations without inter-band clusters (Figures 
3.16A–C, compare blue and red bars), without affecting longitudinal and transversal 
velocity of SCaEs (Figure 3.16D). We hypothesized that the reduction in SCaEs was due 
to a reduction in maximal local RyR2 expression resulting from the redistribution of 
RyR2 from the bands to the inter-band clusters. RyR2 expression per unit was indeed 
lower in the homogeneous simulations with inter-band clusters (2,543 vs. 2,772 RyR2 
per unit) and increasing the total RyR2 expression of the 100-segment model with 
inter-band clusters to 2,772 in all units containing RyR2 normalized SCaE incidence for 
low levels of RyR2 heterogeneity (0.185 ± 0.015 s-1 in the normalized RyR2 expression 
group vs. 0.191 ± 0.018 s-1 in the group without inter-band clusters (σ = 0.0), p > 0.05 
and 0.470 ± 0.138 s-1 for normalized RyR2 expression vs. 0.565 ± 0.105 s-1 without 
inter-band clusters (σ = 0.1), p > 0.05; Figure 3.16B). For high RyR2 heterogeneities, 
SCaE incidence remained lower in the presence of inter-band RyR2 cluster, even after 
adjusting the total RyR2 expression. Under these conditions, SCaEs are frequent, 
suggesting that annihilation or merging of small SCaEs arising around inter-band 
clusters contributes to a lower incidence of observed SCaEs, even after adjusting RyR2 
expression. 
 
3.3.5 The impact of axial tubules on atrial calcium handling 
Axial tubules are unique to atrial cardiomyocytes, but their role in calcium handling is 
not fully understood. Axial tubules contain LTCCs, modulating CICR and centripetal 
calcium wave propagation. We incorporated various configurations of axial tubules in 
the 100-segment model and investigated their impact on depolarization-induced, 
LTCC-triggered CaTs and SCaEs. Addition of an axial tubule to the model reduced time-
to-peak of the regional LTCC-triggered CaT (based on a virtual transversal line scan 
through the region with the axial tubule) and slightly increased the CaT amplitude 
(Figure 3.17). Moreover, time to peak of the transversal-line-scan-based CaT is 
influenced by both the number of parallel axial tubules and their location. The reduction 
in time to peak was largest with an axial tubule located in the center of the virtual 
cardiomyocyte, and addition of two or more parallel axial tubules further reduced the 
time to peak (Figure 3.17). The impact of axial tubules on whole-cell CaT properties 
depended on axial-tubule length and was limited for short axial tubules (compare 
Chapter 3 
 
Henry Sutanto | 75     
 
C
h
ap
te
r 
3
 
regional and whole-cell time to peak in Figure 3.17B). However, a longer axial tubule 
network, such as that observed experimentally (160), also significantly shortened time 
to peak of the whole-cell CaT (Figure 3.17B, rightmost columns). 
 
Figure 3.16: Effects of inter-band RyR2 clusters on SCaEs. (A) Comparison of RyR2 expression matrix (left), 
membrane potential (VM), whole-cell CaT, and longitudinal line scan (right, top to bottom) in the model 
without inter-band RyR2 clusters (top) and with inter-band clusters (bottom) with uniform RyR2 expression 
(σ = 0.0). (B–D) SCaE incidence (B) and size (C), as well as longitudinal and transversal velocity of calcium 
waves (D) as a function of RyR2 heterogeneity σ (0.0–0.2) in the absence of inter-band RyR2 clusters (blue), 
in the presence of 10% inter-band RyR2 clusters (red), or in the presence of 10% inter-band RyR2 clusters 
with increased global RyR2 expression to ensure similar RyR2 density within the bands (green). * indicates 
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P < 0.05 between groups and # indicates P < 0.05 between a given level of heterogeneity and the group with 
heterogeneity 0.0; n = 6 per condition. 
There were no differences in the longitudinal calcium wave velocity between 
simulations with and without axial tubules. Similarly, the presence of axial tubules with 
LTCC did not affect the number of SCaEs (Figures 3.18A, B; compare red and blue bars), 
consistent with the idea that SCaEs result from stochastic RyR2 openings that are 
independent of LTCCs. However, a recent study (160) noted that although RyR2 
expression adjacent to the axial tubule was not different from other parts of the 
cardiomyocyte, these RyR2 near axial tubules were hyperphosphorylated. We 
simulated RyR2 hyperphosphorylation in our model by increasing RyR2 open 
probability for all RyR2 located in units surrounding axial tubules. In the presence of 
hyperphosphorylated RyR2 surrounding axial tubules, the number of SCaEs was 
increased, with a corresponding reduction in their size (Figures 3.18B, C). Of note, 
SCaEs indeed primarily originated around the axial tubule (Figure 3.18D, Figure 3.19), 
although in the presence of a heterogeneous RyR2 distribution, regions with high local 
RyR2 expression may also act as foci (Figure 3.19). 
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Figure 3.17: Effects of axial tubule(s) on centripetal calcium wave propagation. (A) Schematic 
representations of model structure: no axial tubule (LTCC only at lateral membranes), single axial tubule at 
33% of cell width, single central axial tubule at 50% of cell width, two parallel axial tubules at 33 and 66% of 
cell width, or experimentally observed axial tubules based on (160) (top) and corresponding transversal line 
scans of CICR during an AP, showing centripetal calcium wave propagation (bottom). (B) Quantification of 
time to peak (left) and CaT amplitude (right) for the indicated line scan in the four groups (“regional”) or for 
the whole-cell CaT. Increasing numbers of axial tubules and more centrally located axial tubules decrease the 
time-to-peak and slightly increase the CaT amplitude. The magnitude of the increase depends on the number 
of axial tubules. * indicates P < 0.05 vs. the 100-segment group without axial tubules (black bars); n = 6 per 
condition. 
 
Figure 3.18: Effects of axial tubules on SCaEs. (A) Comparison between the model without axial tubules and 
model with axial tubules with uniform RyR2 expression (σ = 0.0), but hyperphosphorylated RyR2 around 
axial tubules. (B, C) Number of calcium waves (B) and SCaE size (C) in the absence of axial tubules (red bars), 
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presence of axial tubules (blue bar), or presence of axial tubules with hyperphosphorylation of surrounding 
RyR2 (green bars). (D) Distribution of RyR2 expression and location of axial tubules (red lines) in relation to 
the origin of SCaEs (white crosses), showing that SCaEs primarily originated from RyR2 clusters adjacent to 
the axial tubules. * indicates P < 0.05 between groups and # indicates P < 0.05 between a given level of 
heterogeneity and the group with heterogeneity 0.0; n = 6 per condition. 
 
Figure 3.19: Distribution of RyR2 expression and location of axial tubules (red lines) in relation to the origin 
of SCaEs (white crosses) for simulations with uniform (σ=0.0) or heterogeneous (σ=0.2) RyR2 expression. 
SCaEs originated primarily from RyR2 clusters adjacent to the axial tubules or (in the case of heterogeneous 
RyR2 expression) clusters with high local RyR2 expression (e.g., see inset in which black crosses indicate the 
origin of SCaEs). 
 
3.3.6 Predicting the effects of β-adrenergic stimulation on SCaEs 
β-adrenergic stimulation is an accepted promoter of SCaE-mediated triggered activity 
(296). Here, we investigated the functional consequences of three established 
downstream targets of β-adrenergic stimulation. Chronic AF is associated with a 
hyperphosphorylation-mediated 100 – 500% increase in RyR2 open probability (124). 
Therefore, we first implemented a 100% increase of RyR2 open probability to simulate 
the effect of β-adrenergic stimulation. This resulted in smaller and more frequent SCaEs 
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compared to baseline (incidence of 2.03 ± 0.09 s-1 in the increased RyR2 open 
probability group vs. 0.19 ± 0.02 s-1 in the baseline group, n = 6, p < 0.05; Figure 3.20). 
Second, we implemented an increased SERCA2a affinity for cytosolic calcium to reflect 
phospholamban phosphorylation. In the presence of increased SERCA2a function, the 
incidence of SCaEs was increased without any statistically significant change in the size 
of SCaEs (Figure 3.21). In addition, an increase in longitudinal and transversal 
velocities of SCaEs was observed. Third, we implemented a homogenous increase of 
LTCC function by doubling the maximum conductance of the channel, which resulted in 
an increased SCaE incidence without any statistically significant changes in the size and 
velocities of SCaEs (Figure 3.22). The combination of all three modifications, reflecting 
maximal β-adrenergic stimulation, produced a dramatic increase in SCaEs (incidence of 
27.77 ± 14.92 s-1 vs. 0.19 ± 0.02 s-1 in the baseline group, n = 6, p < 0.05), including 
proarrhythmic triggered activity (Figure 3.23). 
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Figure 3.20: Effects of homogenous increase in RyR open probability. A) Membrane potential (VM), 
intracellular calcium and longitudinal line scan (top to bottom) for the baseline model (A.1) and the model in 
which RyR2 open probability was increased by 100%, by altering parameters as follows: P[0]RyR = 0.2  0.4 
(+100%); P[1]RyR = 0.22  0.24 (+9%); P[5]RyR = 0.0035  0.00805 (+130%). B-D) incidence, size and 
velocity of SCaEs in both models. * indicates P<0.05 between both groups (n=6 per condition). 
 
Figure 3.21: Increase of SERCA2a function and the propensity of SCaEs. A) Membrane potential (VM), 
intracellular calcium and longitudinal line scan (top to bottom) for the baseline model (A.1) and the model 
with increased SERCA2a activity as achieved by reduction of Kmf value by 25% (A.2). B-D) incidence, size and 
velocity of SCaEs in both models. The increase in SERCA2a activity resulted in an increased incidence of SCaEs 
with no significant change in size but significant increase in longitudinal and transversal velocities. * indicates 
P<0.05 between both groups (n=6 per condition). 
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Figure 3.22: Effects of homogenous LTCC/ICa,L hyperphosphorylation on the behavior of SCaEs. A) Membrane 
potential (VM), intracellular calcium and longitudinal line scan (top to bottom) for the baseline model (A.1) 
and the model with doubled maximum conductance of LTCC (from 1.7x10-4 as reported before to 3.4x10-4) 
(A.2). B-D) incidence, size and velocity of SCaEs in both models. The increase in ICa,L resulted in increased SCaE 
incidence without any significant change in other SCaEs parameters. * indicates P<0.05 between both groups 
(n=6 per condition). 
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Figure 3.23: The effect of simulated β-adrenergic stimulation on the behavior of SCaEs. A) Membrane 
potential (VM), intracellular calcium and longitudinal line scan (top to bottom) for the baseline model (A.1) 
and the model with increased RyR2 open probability, increased SERCA2a activity and increased ICa,L (A.2.) B-
D) incidence, size and velocity of SCaEs in both models. The simulated β-adrenergic stimulation markedly 
increases the incidence of SCaEs and reduces the size of SCaEs, longitudinal and transversal velocities of the 
spontaneous waves. * indicates P<0.05 between both groups (n=6 per condition). 
3.3.7 A computational model incorporating physiological RyR2 and LTCC 
distributions 
Finally, we combined both the experimentally observed RyR2 distribution (Figure 3.7) 
and axial tubule network with LTCC in a novel model of the human atrial cardiomyocyte. 
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When using the parameters established for the model with uniform RyR2 distribution 
and no axial tubules, this model showed a non-physiological number of small SCaEs, in 
line with the effects of the experimental RyR2 distribution in Figure 3.10A. As such, we 
performed a parameter optimization to reproduce the experimentally observed 
calcium handling properties in the combined model (Figure 3.24). 
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Figure 3.24: 100-segment model with experimental RyR2 distribution and LTCC expression based on 
experimentally observed axial tubules, with RyR2 hyperphosphorylation around axial tubules. (A) Model 
structure (left panel) and longitudinal line scan of the optimized 100-segment model (“Model”). (B–H) 
Comparison of SCaE characteristics (B) and whole-cell CaT properties (C–H) of the model to previously 
published experimental data $ = (290); ∧ = (291); & = (285); % = (292); @ = (124); # = (32); * = (130). 
 
3.4 Discussion 
Recent studies have identified a major role for cardiomyocyte calcium handling 
abnormalities in cardiac arrhythmias and have provided insight into the underlying 
molecular mechanisms (2, 6). However, the impact of the subcellular distribution of 
RyR2 and LTCC on cardiomyocyte calcium handling remains largely unknown. It is 
currently experimentally challenging to study both (sub)cellular structure and 
functional calcium handling in the same cardiomyocyte. Here, we extended a 
computational model of the human atrial cardiomyocyte with a more physiological 
subcellular structure, including heterogeneous RyR2 distributions and axial tubules 
with LTCC. Our computational analyses showed that increasing RyR2 heterogeneity 
resulted in more, smaller SCaEs arising from regions with high local RyR2 expression. 
LTCC located in axial tubules produced a faster, more synchronous CICR, which was 
modulated by the location and extent of the axial tubular network. Moreover, 
hyperphosphorylation of RyR2 surrounding axial tubules increased the incidence of 
SCaEs and DADs. Finally, we developed and validated a novel human atrial 
cardiomyocyte model with physiological RyR2 distribution and axial tubules with LTCC 
based on experimental observations, which can serve as a tool for future studies. 
 
3.4.1 Role of subcellular structure in cardiomyocyte calcium handling 
An increased SCaE incidence in atrial cardiomyocytes from patients with AF contributes 
to the initiation of DADs and cellular triggered activity (32, 124, 138), which, when 
occurring at the tissue level, may act as initiators of AF or may sustain the arrhythmia 
when occurring repetitively at high frequency (32, 297). SCaEs are promoted by 
increased SR calcium load leading to store-overload-induced SR calcium release (298). 
In agreement, SERCA2a activity is increased in patients with paroxysmal AF and is 
associated with increased SR calcium load and a higher incidence of SCaEs (32). In 
addition, RyR2 dysfunction can increase the incidence of SCaEs even in the absence of 
increased SR calcium load. RyR2 mutations leading to catecholaminergic polymorphic 
ventricular tachycardia have been associated with familial AF (299) and genetic mouse 
models with these mutations show pronounced atrial calcium handling abnormalities 
(25). Moreover, RyR2 open probability is increased, likely due to hyperphosphorylation 
of the RyR2 channel, in patients with long-standing persistent AF (124). Besides 
changes in cardiomyocyte calcium handling, AF produces structural remodeling at the 
level of the single cardiomyocyte (atrial cellular hypertrophy, myolysis, alterations in 
size and distribution of mitochondria and SR) (300-302), suggesting a potential role for 
changes in subcellular structure in regulating cardiomyocyte calcium handling. Indeed, 
Macquaide et al. (158) reported that ultrastructural reorganization of RyR2 clusters in 
atrial cardiomyocytes of sheep with persistent AF is associated with overactive calcium 
release. In addition, Lenaerts et al. (303) reported that in sheep with persistent AF, 
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there was loss of T-tubule organization, fewer calcium channel-RyR couplings, and 
reduced efficiency of the coupling at subsarcolemmal sites, which led to a reduction in 
SR calcium release despite preserved SR calcium content. Thus, there is substantial 
indirect evidence for a role of subcellular structure in cardiomyocyte calcium handling. 
However, a systematic analysis of the impact of changes in calcium handling protein 
distributions on whole-cell proarrhythmic calcium handling is lacking. 
Consistent with previous publications (287, 304), our confocal images of rabbit 
atrial cardiomyocytes showed a banded RyR2 expression with inter-band distance of ≈ 
1.9 µm. Moreover, there appears to be a substantial heterogeneity of RyR2 density along 
the z-bands. We increased the spatial resolution of our computational model to enable 
simulations of the banded RyR2 pattern and incorporated the experimentally observed 
RyR2 distribution in our model. In line with the work by Macquaide et al. (158), our 
simulations showed a pronounced impact of RyR2 distribution on SCaE incidence and 
size. Indeed, physiologically observed degrees of RyR2 heterogeneity had a larger 
impact on SCaEs than differences in total RyR2 expression observed between patients 
with sinus rhythm and paroxysmal AF (32). Of note, our simulations identified regions 
with high local RyR2 expression as foci for SCaEs, which is in line with recent 
experimental work by Galice et al. (159). 
In ventricular cardiomyocytes, LTCC are primarily (but not exclusively, (305)) 
located in T-tubules, promoting synchronous SR calcium release throughout the cell. 
Recent studies have identified a similar role for axial tubules in atrial cardiomyocytes 
(286). For example, Brandenburg et al. (160) reported the importance of axial tubules 
in atrial cardiomyocytes in maintaining calcium handling and calcium wave 
propagation to the center of atrial cardiomyocytes. Similarly, Yue et al. (287) observed 
synchronous SR calcium release in mouse atrial cells, which was ascribed to the 
presence of transverse-axial tubules. We employed the perfect control provided by 
computational models to study the exact effects of different locations, numbers, and 
distributions of such axial tubules on whole-cell calcium handling. Incorporation of 
axial tubules produced a more synchronous SR calcium release, as evident from a W-
shaped instead of V-shaped pattern in simulated transversal line scans. The W-shaped 
patterns varied with different locations of the axial tubules, consistent with 
experimental findings (285, 287) noting that the presence and location of the 
transverse-axial tubular system determined the shape of the whole-cell CaT and 
transversal calcium waves. Our simulations showed that more centrally located and/or 
higher number of axial tubules reduced the local time-to-peak. However, in order to 
affect the global time-to-peak and global CaT amplitude, the length of the axial tubules 
had to be sufficiently long to affect a large part of the virtual cardiomyocyte. 
Brandenburg et al. (160) reported that instead of an increase in the number of RyR2 
adjacent to the axial tubules, there was a selective local RyR2 hyperphosphorylation, 
which led to a faster calcium release at axial tubule locations residing inside the cell. 
Our simulations showed that the presence of axial tubules per se did not affect SCaEs, 
but that simulation of local hyperphosphorylation of RyR2 increased the number of 
SCaEs. Furthermore, we confirmed that regions with local hyperphosphorylation acted 
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as the origins of SCaEs. However, these results depended on the amount of RyR2 
heterogeneity and the number of axial tubules, with SCaEs also arising from regions 
with high local RyR2 expression independent of RyR2 hyperphosphorylation. Taken 
together, these findings underline the importance of the subcellular distribution of 
calcium handling proteins in atrial cardiomyocytes for cardiac arrhythmogenesis. 
Previous publications (160, 293-295) have reported an increased RyR2 density 
at the lateral membrane using confocal microscopy. However, the role of these lateral 
RyR2 clusters remains unknown. Here, we employed a computational model with no 
expression of lateral RyR2s to investigate their role in the propagation of SCaEs. Our 
data show that lateral RyR2s hold a very important role as “bridges” that facilitate 
calcium wave propagation. Removal of lateral RyR2 clusters impaired calcium wave 
propagation and resulted in more, but smaller SCaEs, effectively converting 
proarrhythmic calcium waves to calcium sparks. 
 
3.4.2 Comparison to previous models 
Several computational models have been developed to study cardiomyocyte calcium 
handling abnormalities. These include, on the one hand, highly detailed models of a 
single CRU to study the molecular determinants of SR calcium release. For example, 
Hake et al. (306) developed a computational model with a highly detailed, electron 
microscopy-based computational geometry of a CRU from a mouse ventricular 
cardiomyocyte to simulate local calcium sparks. Walker et al. (89) developed a detailed 
3D model of a CRU incorporating diffusion, intracellular buffering systems, and 
stochastically gated RyRs and LTCCs to simulate local calcium dynamics with a high 
spatial resolution. This work showed that perturbations to subspace dimensions 
strongly alter calcium spark dynamics. Similarly, Zahradnikova and Zahradnik (307) 
constructed virtual CRUs composed of a variable number of RyRs distributed in clusters 
in line with the experimentally observed cluster-size distribution to provide a 
description of calcium spark properties for spontaneous and triggered calcium sparks. 
These studies strongly suggest that the organization of the CRU plays a critical role in 
determining the characteristics of microscopic calcium release events (sparks) but have 
not simulated whole-cell calcium handling abnormalities, which would be relevant to 
study arrhythmogenesis. 
On the other hand, a number of models have been developed to study whole-
cell calcium handling: Walker et al. (90) developed a biophysically detailed 3D model of 
the ventricular cardiomyocyte with stochastic gating of RyR2 channels and determined 
the impact of cytosolic and SR calcium concentrations, basal inward-rectifier potassium 
current density, and gap junction conductance on DADs and triggered activity using this 
model. Likewise, Wescott et al. (308) developed a mathematical whole-cell model, 
incorporating realistic stochastic gating of LTCCs and RyRs to investigate excitation-
contraction coupling and calcium spark fidelity. Recently, Colman et al. (103) developed 
a detailed 3D multiscale model of a ventricular cardiomyocyte based on scanning 
electron microscopy data to examine the effects of a realistic SR structure on pro-
arrhythmic calcium dynamics, alternans, and SCaEs. Song et al. (309) also investigated 
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the influence of subcellular structure on calcium handling in a model with a 3D network 
of CRUs representing different transverse tubule network structures, including uniform 
and random distribution of transverse tubules, to investigate calcium sparks, DADs, and 
triggered activities. However, these studies were primarily done in ventricular 
cardiomyocytes, which have well-established differences in subcellular structures, 
notably the configuration and number of axial tubules and a different composition of 
ion channels from atrial cardiomyocytes. 
Here, we developed an atrial cardiomyocyte model with atrial-specific 
subcellular structure and electrophysiology that can simulate multiple physiological 
properties of cardiomyocyte calcium handling, as well as proarrhythmic calcium 
handling abnormalities. This model has an intermediate level of detail, incorporating 
heterogeneous distributions of calcium handling proteins with micrometer resolution, 
a level that is of the same order of magnitude as the experimental information about 
the distributions obtained with confocal imaging. This level of detail is highly suitable 
to study the structural determinants of whole-cell calcium handling abnormalities that 
are relevant for arrhythmogenesis. Moreover, because of its relatively modest 
computational complexity, this model can also be employed in future studies to 
investigate the determinants of triggered activity at the tissue level, something that is 
not possible with the previously developed, highly detailed, 3D models. 
 
3.4.3 Potential limitations 
Our model with local calcium handling strongly suggested that the subcellular 
distribution of RyR2 and LTCC has a major impact on cardiomyocyte calcium handling. 
However, the model only considered a 2D representation of the cardiomyocyte, 
equivalent to a single slice from a z-stack. Previous computational studies using simpler 
3D models have identified that persistent calcium waves can be generated through 
specific patterns of 3D calcium wave propagation (so-called “ping waves”) (310), 
suggesting a need to consider the 3D structure of cardiomyocytes. Furthermore, 
although we increased the spatial resolution of our previously published model (32) in 
order to simulate the banded pattern of RyR2 expression, the resolution of the current 
model (units of 1 µm2) was insufficient to simulate local calcium dynamics around a 
single CRU (e.g., (sub)sparks). Detailed CRU models have been developed (89, 306, 307) 
and could potentially be integrated in the present cell-level model in future studies, 
although this would significantly increase the computational complexity. Additionally, 
we acknowledge that our investigations into the effects of β-adrenergic stimulation 
represent a highly simplified approach. Implementing a complete signaling pathway 
and its downstream effects on atrial electrophysiology, such as previously described for 
ventricular cardiomyocytes (78) would be of interest, but was beyond the scope of the 
present study. 
The resolution and quality of confocal imaging is limited by physical properties 
and quality of cell-isolation and antibody staining (particularly in rabbit samples). The 
use of super-resolution microscopy would be beneficial to obtain a more detailed 
overview of the 3D RyR2 distribution. In this case, dual staining of RyR2 and axial 
Subcellular structures modulate spontaneous releases in atrial cardiomyocyte 
88 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 3
 
tubules should be performed to obtain information on both distributions in a single 
cardiomyocyte, which was not performed in the current study. Instead, a representative 
experimental axial tubule geometry from previously published work (160) was used. 
Ideally, future experiments would be performed in human atrial cardiomyocytes to 
obtain a human-specific RyR2 distribution, rather than the rabbit atrial cardiomyocytes 
employed here, although their availability and cell-quality is generally much lower. 
Indeed, the experimental RyR2 distribution that formed the basis for the model with 
physiological RyR2 and LTCC distribution (Figure 3.24) was based on a limited number 
of rabbit atrial cardiomyocytes and may not be representative for diseased human atrial 
cardiomyocytes. Likewise, the current model requires stretching of the observed RyR2 
expression pattern to match the 100x18 rectangular shape of the virtual cardiomyocyte. 
Finally, heterogeneous distributions of other calcium handling proteins such as NCX1 
or SERCA2a may also impact whole-cell calcium handling and could be studied using 
the computational framework developed in the present study. 
 
3.5 Conclusions 
We employed the perfect control and observability provided by computer models to 
overcome experimental challenges in the analysis of the subcellular determinants of 
cardiomyocyte calcium handling. Our findings highlight the importance of atrial 
subcellular structures, especially RyR2 and LTCC distributions, in the genesis of SCaEs 
and DADs, which are well-known triggers of cardiac arrhythmias. Importantly, whole-
cell calcium handling properties are determined by non-linear interactions between 
heterogeneities in the properties (expression, phosphorylation) of both LTCC and RyR2, 
highlighting the need for detailed immunocytochemistry and functional studies to 
explain differences in whole-cell calcium handling properties between conditions. 
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ABSTRACT 
Post-operative atrial fibrillation (POAF) is a common post-surgical complication, likely 
resulting from the interaction between pre-existing arrhythmogenic substrate and 
transient peri- and post-operative triggers (e.g., inflammation). However, data on pre-
existing electrical and structural remodeling in POAF patients are inconclusive. 
Calcium-handling abnormalities are closely associated with other types of AF (e.g., 
paroxysmal and persistent AF), but have not been studied in sinus-rhythm patients who 
subsequently develop POAF. Here, we performed a computational study to evaluate the 
potential proarrhythmic electrophysiological consequences of pre-existing calcium-
handling abnormalities and post-operative inflammation in the generation of POAF.  
Our model was based on recent experimental data in atrial cardiomyocytes 
from patients undergoing open heart surgery without (Ctl group) or with subsequent 
POAF. In particular, we optimized our previously published in silico model of human 
atrial cardiomyocyte calcium-handling (Chapter 3) to reproduce the baseline calcium-
handling properties observed in these experiments. Subsequently, we developed a new 
POAF model variant by incorporating major differences in calcium handling between 
Ctl and POAF patients and investigated spontaneous sarcoplasmic reticulum calcium-
release events (SCaEs) under conditions similar to experimental protocols. Under 
voltage-clamp conditions, the POAF model showed an increased SCaE incidence 
compared to the Ctl model. Simulated IL-1β application further exaggerated the 
differences in SCaE incidence between POAF and Ctl (+509% vs +122% with and 
without simulated IL-1β, respectively), consistent with experimental data. The POAF 
model also showed an increased SCaE incidence (+45%) during action potential 
simulations, but in the absence of IL-1β, these SCaEs were small and too dispersed to 
produce clear DADs. By contrast, the presence of simulated IL-1β (mimicking post-
operative conditions) resulted in a large increase in SCaEs (+84%) and more large-
amplitude DADs (+47%) in the POAF-model, which disappeared with simulated RyR2-
block.  
In conclusion, computational modeling supports the notion that post-operative 
inflammation acting on a pre-existing arrhythmogenic substrate may elicit 
proarrhythmic responses leading to POAF. 
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4.1 Introduction 
Post-operative atrial fibrillation (POAF) is a common post-surgical complication, 
affecting approximately 30% of patients undergoing open-heart surgery (311). 
Although it is traditionally considered a transient phenomenon with a peak incidence 
less than a week post-surgery (312, 313), POAF is also associated with increased short- 
and long-term morbidity and mortality (312-314). Despite a range of proposed 
preventive approaches, POAF management remains challenging, partly due to 
incomplete understanding of the underlying mechanisms (314, 315).  
Conceptually, POAF is considered a result of the interaction between transient 
peri- or post-operative triggers and a pre-existing arrhythmogenic substrate (314). 
Several potential components of the pre-existing POAF substrate have been studied in 
human atrial samples obtained during cardiac surgery, but results have been 
inconclusive. For example, while pre-operative left atrial (LA) fibrosis has been noted 
in some studies (316, 317), atrial fibrosis has not been consistently observed in right-
atrial (RA) samples (314, 316-318). Furthermore, to date, there is no evidence for pre-
existing electrical remodeling in human atrial cardiomyocytes of POAF patients (316, 
319). Calcium-handling abnormalities are an accepted trigger for arrhythmogenesis 
present in both paroxysmal and long-standing persistent (‘chronic’) AF (pAF and cAF, 
respectively) (32, 124), as well as in systolic heart failure patients with increased AF 
susceptibility (121), but have not yet been studied in sinus-rhythm patients who 
subsequently develop POAF.  
Inflammation is a major transient post-operative factor that may also trigger 
POAF. The time course of AF after surgery parallels changes in inflammatory markers 
(320-322) and a few studies have identified associations between POAF and the 
systemic level of pre-operative inflammatory biomarkers, notably interleukin (IL)-2 
and IL-6 (320, 323), although several other studies found no correlation between POAF 
and pre- or post-operative C-reactive protein (CRP), IL-2, or IL-6 (314, 318, 324). Such 
inconsistent results for blood biomarkers might be due to a primary role for local atrial, 
rather than systemic, inflammation (314). Abnormal NACHT, LRR, and PYD domains 
containing protein-3 (NLRP3) inflammasome signaling within human atrial 
cardiomyocytes has recently been implicated in the pathogenesis of pAF and cAF, partly 
by induction of abnormal calcium-handling (224). In turn, abnormal calcium-signaling 
can also trigger cardiomyocyte NLRP3 inflammasome activation (325, 326); thus the 
coexistence of low-grade chronic inflammatory changes and abnormal calcium-
signaling in the atria of patients predisposed to POAF might, particularly in the context 
of superimposed post-operative inflammatory and autonomic nervous system changes, 
initiate a positive feedback loop between abnormal atrial calcium-handling and 
enhanced NLRP3 inflammasome signaling that results in POAF. 
Here, we performed a computational study to evaluate the possible cause-
effect relationships and potential proarrhythmic electrophysiological consequences of 
a pre-existing vulnerable substrate interacting with post-operative inflammation in the 
generation of POAF. We showed that acute stimulation of this pre-existing substrate 
with inflammatory stimuli, as would occur during the post-operative period, resulted 
in proarrhythmic delayed afterdepolarizations (DADs) with the potential to form the 
basis for POAF. 
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4.2 Methods 
We incorporated the state-of-the-art experimental data from Heijman et al. (327), 
which assessed comprehensively different aspects of atrial remodeling in RA samples 
from sinus rhythm patients without (Ctl) or with POAF. Heijman et al. (327) identified 
a discrete pre-existing proarrhythmic substrate in patients who went on to develop 
POAF, including increased priming and triggering of the NLRP3 inflammasome in 
human atrial cardiomyocytes and calcium-handling abnormalities characterized by L-
type calcium-current (ICa,L) alternans (an index of reentry-supporting repolarization 
heterogeneity), reduced calcium-transient (CaT) amplitude, ryanodine-receptor 
channel type-2 (RyR2) dysfunction with enhanced sarcoplasmic reticulum (SR) calcium 
leak and frequency of spontaneous SR calcium-release events (SCaEs). In addition, 
there was a trend towards increased SR calcium-ATPase (SERCA) function, which may 
have contributed to the largely maintained SR calcium load. 
 Parameter Published 
model (4) 
Ctl (+IL-1β) 
model 
poAF (+IL-
1β) 
model 
Calcium-
diffusion 
and 
buffering 
𝝉diff,SRS  cyt  
(ms) 
10 12 (7.5) 10 
𝝉diff,seg,SRS (ms) 0.220 0.150 0.150 (0.100) 
𝝉diff,dom,SRS (ms) 0.160 0.050 0.050 (0.040) 
Calcium-buffer 
factor 
1.000 0.850 0.850 
SERCA 
JSERCA,max  
(mmol/L ms-1) 
3.187e-3 2.124e-3 2.762e-3 
SERCA2a Km,r 
(mmol/L) 
1.250 1.750 1.750 
SERCA2a Km,f 
(mmol/L) 
6.250e-4 5.000e-4 5.000e-4 
NCX 
INCX,max (pA/pF) 4.253 1.842 1.842 
[Ca2+]o 
observed 
(mmol/L) 
1.0*[Ca2+]o 0.1*[Ca2+]o 0.1*[Ca2+]o 
RyR2 
NRyRs 2,772,000 9,900,000 9,900,000 
P[0]RyR 0.200 0.620 0.85374 
P[5]RyR 0.0035 
0.0147 
(0.018375) 
0.06581 
(0.08226) 
P[7]RyR 9.000e-4 1.000e-3 1.000e-3 
P[8]RyR 8.000e-5 7.000e-5 7.000e-5 
GK1,max (mS/µF) 6.563e-2 9.188e-2 9.188e-2 
INaK,max (pA/pF) 1.260 0.630 0.630 
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Other 
ion 
channels 
ICaL  
Ctl and POAF as in Voigt et 
al.(32) with 
𝐴𝐶𝑇∞
=
1
(1 + 𝑒𝑥𝑝 (−
𝑉𝑀 − 13.56
7.0
))
∙
1
(1 + 𝑒𝑥𝑝 (−
𝑉𝑀 + 25
5.0
))
 
Table 4.1: Changes in model parameters compared to the reference model of the human atrial cardiomyocyte 
with spatial calcium handling (4). Grey shaded rows highlight parameters that are different between Ctl and 
POAF model version. Bold numbers in red represent parameter values during simulated IL-1β stimulation. 
 
4.2.1 Baseline (Ctl) model 
Our recent model of human atrial cardiomyocyte calcium-handling (4) was used as the 
basis for all simulations. The current model consists of 101 longitudinal segments of 1 
µm, each containing 18 1-µm wide transverse domains. In each of these spatial units, 
local ion concentrations, including cytosolic and SR calcium concentrations are 
simulated. RyR2 were incorporated in a banded pattern with RyR2 in every other 
segment, resulting in a 2 µm distance between RyR2 bands, in line with experimental 
observations (4). We employed homogeneous expression of RyR2 within a band. 
Stochastic opening of individual RyR2 was simulated using a 4-state Markov model that 
reproduces single-channel recordings, as previously described (32). All RyR2 gate 
independently but are connected through a local subspace (the SR calcium-release 
space; SRS), representing the microdomain in the vicinity of the RyR2 with high local 
calcium concentrations during systole. 
 
Figure 4.1: Simulated single-channel properties of ryanodine receptor channel type-2 (RyR2) in Ctl and POAF 
model variants. (A) Comparison of simulated RyR2 single-channel open probability in Ctl and POAF models 
with experimental data from Heijman et al. (327) under diastole-like conditions (150 nmol/L free cytosolic 
calcium). (B) Comparison of RyR2 open probability in Ctl and POAF in the absence or presence of simulated 
IL-1β application. Simulated effects of IL-1β included a 25% increase in RyR2 open probability based on 
experimental data showing increased calcium-spark frequency during IL-1β application (328). 
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Parameter optimization was performed to minimize the quantitative 
differences between the Ctl model and the experimentally observed calcium-handling 
properties using the published values as a starting point. These optimizations in 
calcium diffusion, SERCA, NCX and RyR2 (Table 4.1) allowed the model to 
quantitatively reproduce all major calcium-handling properties observed under 
voltage-clamp conditions (RyR2 open probability, CaT amplitude and decay, SR calcium 
content and SERCA activity; Figure 4.1-4.3). Finally, the extracellular calcium 
dependence of NCX was adjusted to prevent excessive calcium overload during 
simulations with 5 mmol/L extracellular calcium and maximal conductance of two ion 
channels (IK1 and INaK) were adjusted based on experimental data obtained under 
current clamp conditions (Table 4.1). 
 
Figure 4.2: Validation of computational models. (A) Simulated voltage-clamp protocol (top), whole-cell 
calcium transient (CaT, middle) and total membrane current (bottom) in Ctl and POAF model variants. (B) 
Comparison of diastolic and systolic calcium levels, and CaT amplitude; (C) Time constant () of CaT decay; 
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(D) Sarcoplasmic reticulum (SR) calcium load measured as integrated NCX current (INCX) during the caffeine-
induced CaT (cCaT); (E) SERCA activity estimated as the difference in decay rates between the CaT and cCaT, 
in Ctl and POAF model variants (bars) with experimental data (symbols). 
 
4.2.2 POAF model variant 
We subsequently developed a new POAF model variant by incorporating the major 
differences in calcium handling between Ctl and POAF patients: numerically higher 
SERCA activity and RyR2 open probability. In particular, maximal SERCA2a activity 
(JSERCA,max) was increased by 30%, and RyR2 open probability was increased by 
adjusting P[0]RyR (+37.7%) and P[5]RyR (+348%), in line with our simulations of higher 
RyR2 open probability in paroxysmal AF (32). Finally, the interaction between RyR2 
was adjusted by lowering the diffusion of calcium from the SRS to the cytosol (𝜏diff,SRS  
cyt, -16.67%) in order to maintain normal SR calcium release in the presence of altered 
RyR2 gating. With the changes in these 4 parameters (Table 4.1, grey rows), the model 
accurately reproduced the higher SERCA activity and RyR2 open probability (Figure 
4.1A, Figure 4.2E and Figure 4.4A). Moreover, simulated diastolic and systolic calcium 
concentrations, CaT amplitude, time constant of CaT decay and SR calcium load (Figure 
4.2), as well as relative SR calcium leak (Figure 4.3) in the POAF model variant were 
quantitatively similar to our experimental data, further establishing the validity of this 
novel model variant. 
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Figure 4.3: Simulated sarcoplasmic reticulum (SR) calcium leak protocol in Ctl and POAF model variants. (A) 
Voltage-clamp protocol (top), whole-cell calcium (middle) and membrane current (bottom) during simulated 
application of the Shannon protocol (329) to measure SR calcium leak and SR calcium load. The effects of 
tetracaine and caffeine were simulated by blocking the RyR2 by >99% and setting RyR2 open probability to 
1.0, respectively. SR calcium leak was quantified as the decrease in cytosolic calcium during tetracaine 
application and SR calcium load was quantified as the amplitude of the caffeine-induced calcium transient. 
(B) Relative [load normalized] SR calcium leak in Ctl and POAF compared to experimental data from Heijman 
et al. (327). 
 
4.2.3 Simulating experimental protocols 
Extracellular ionic concentrations and voltage-clamp protocols were set to match 
experimental conditions for each simulation. During ruptured-patch voltage-clamp 
simulations, intracellular sodium levels were clamped to 8.5 mmol/L as previously 
described (32). The effects of tetracaine and caffeine on RyR2 were simulated by 
acutely setting RyR2 open probability to 1.0 (in the case of caffeine) or blocking the 
RyR2 by >99% (in the case of tetracaine). After the application of tetracaine or caffeine, 
RyR2 gating was released and open probability was again determined by cytosolic and 
SR calcium concentrations. 
Experimental data on the acute effects of (post-operative) inflammation on 
cardiomyocyte calcium-handling are scarce, particularly for human atrial 
cardiomyocytes. Accordingly, we opted for a parsimonious approach with a minimal 
number of parameter changes to simulate IL-1β application. Reduced CaT amplitude is 
a highly consistent finding in response to acute (5 min – 24 hours) stimulation with IL-
1β, IL-6 or tumor necrosis factor- (TNF) (328, 330-333). In several (but not all (333)) 
studies the reduced CaT amplitude is accompanied by a reduced SR calcium content and 
increased incidence of SCaEs (328, 331). Furthermore, conflicting evidence exists about 
SERCA function, with reports of both unchanged (333) and decreased (331, 332) 
SERCA2a expression, as well as decreased expression of the SERCA2a inhibitory 
subunit phospholamban (334), which could potentially normalize SERCA function in 
the presence of decreased expression. Similarly, both unchanged (330) and reduced 
(331) ICa,L in response to IL-1β, IL-6 or tumor necrosis factor- (TNF) stimulation have 
been reported. Taking into account differences in inflammatory factors and stimulus 
durations, these data suggest increased RyR2-mediated SR calcium leak as a potential 
mechanism underlying reduced CaT amplitude and increased incidence of SCaEs. 
Accordingly, we simulated IL-1β stimulation as an additional 25% increase in RyR2 
open probability (Figure 4.1) and slower diffusion of calcium from the SRS to the 
cytosol (𝜏diff,SRS  cyt) to promote SCaEs (Table 4.1). With this minimal set of changes 
in 3 parameters, the model could quantitatively reproduce the experimentally observed 
difference in SCaE incidence between Ctl and POAF during acute stimulation with 40 
ng/mL IL-1β (Figure 4.4). Since the effects of IL-1β application are associated with a 
slight delay due to the activation of the intracellular signaling cascades that eventually 
lead to alterations in calcium-handling proteins, the parameter changes were 
implemented gradually over a period of 10 seconds. 
 
4.3 Results 
We employed computational modeling to examine potential cause-effect relationships 
and predict arrhythmogenic consequences of previously observed POAF-associated 
remodeling. We adjusted our previously-developed human atrial cardiomyocyte model 
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with spatial calcium-handling (4, 32) to reproduce key calcium-handling properties 
observed in Ctl cardiomyocytes (Figure 4.1-4.3). We developed a POAF version by 
incorporating altered RyR2-gating and increased SERCA function, based on 
experimental data in Heijman et al. (327) (Figure 4.4A). With this limited set of 
experimentally-guided changes, the POAF model fully recapitulated the reduction in 
CaT amplitude despite unaltered SR calcium-load (assessed by integrated INCX during 
simulated caffeine) and the increase in SR calcium-leak (Figure 4.4B). The POAF-model 
also validated the increased SCaE incidence in POAF (Figure 4.4C-D), with simulated 
IL-1β causing a large increase in SCaE-incidence in POAF vs. Ctl (+509% vs +122% with 
and without simulated IL-1β, respectively; Figure 4.4C-D). These findings indicate that 
increased SR calcium-leak and enhanced SERCA activity are sufficient to recapitulate 
the altered calcium-handling observed in POAF.  
 
Figure 4.4: Computational modeling of calcium-handling abnormalities, consequences of inflammatory 
signaling and cellular arrhythmogenesis. (A) The novel POAF version of the human atrial cardiomyocyte 
model was developed by implementing the experimentally observed increases in RyR2 open-probability 
(top) and SERCA function (bottom). Full model parameters are provided in Table 1. (B) Calcium-handling 
properties (CaT-amplitude, SR calcium-load and SR calcium-load-normalized SR calcium-leak) in Ctl and 
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POAF models (bars) compared to experimental data (symbols). (C) Whole-cell CaT and longitudinal line-scan 
of depolarization-induced (arrows) or spontaneous SR calcium-release events (SCaEs) in Ctl (top row) and 
POAF (bottom row) models under voltage-clamp conditions with 0 mmol/L sodium and 0 mmol/L calcium 
(left; experimental conditions in Heijman et al. (327)) or 5 mmol/L calcium followed by acute application of 
IL-1β (experimental conditions in Heijman et al. (327)). (D) Validation of SCaE-incidence in both model 
variants (bars) compared to experimental data obtained under the same condition (symbols). 
We then employed the model to predict the potential occurrence of 
proarrhythmic DADs during current-clamp simulations. The Ctl model showed a limited 
number of SCaEs with corresponding DADs, both in the absence or presence of 
simulated IL-1β (Figure 4.5A and Figure 4.6). Although the incidence of SCaEs was 
reduced in the Ctl-model following IL-1β stimulation, total SR calcium-leak was 
increased (Figure 4.7), suggesting that IL-1β-mediated SR calcium-leak does not 
translate into proarrhythmic calcium-waves without pre-existing RyR2 dysfunction. 
DADs, but not SCaEs, were abolished after removal of extracellular calcium and sodium, 
whereas SCaEs disappeared during simulated RyR2-inhibition (Figure 4.6), confirming 
the causal roles of RyR2-mediated SR calcium-leak and the generated depolarizing INCX 
in the proarrhythmic response. The model with the pre-existing POAF substrate also 
showed an increased SCaE incidence (+45%), but in the absence of IL-1β, the SCaEs 
were small and too dispersed to produce clear DADs (Figure 4.5). The presence of 
simulated IL-1β, mimicking post-operative conditions, in the POAF-model resulted in a 
large increase in SCaEs (+84%) and more large-amplitude DADs (+47%), which 
disappeared with simulated RyR2-block (Figure 4.5B and Figure 4.6). 
 
Figure 4.5: Computational modeling of calcium-handling abnormalities, consequences of inflammatory 
signaling and cellular arrhythmogenesis during current-clamp protocol. (A) Simulated action potentials (top 
panels), longitudinal line-scans (middle panels) and whole-cell CaTs (bottom panels) at 0.5-Hz and follow-up 
showing SCaEs and corresponding delayed afterdepolarizations (DADs) in Ctl, Ctl+IL-1β, POAF, and POAF+IL-
1β models. (B) Quantification of SCaE (top) and DAD (bottom) incidence in Ctl, Ctl+IL-1β, POAF, POAF+IL-1β 
and POAF+IL-1β+RyR2 block models. 
 
A B 
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Figure 4.6: Current-clamp simulations during 0.5 Hz pacing (arrows) and post-pacing follow-up period to 
assess spontaneous sarcoplasmic reticulum calcium-release events (SCaEs) and corresponding delayed 
afterdepolarizations (DADs) in the Ctl (left) and POAF (right) model variants. (A) Membrane potential (VM, 
top), whole-cell calcium-transient (middle) and longitudinal line scan through the center of the virtual 
cardiomyocyte (bottom) under control conditions (2.0 mmol/L extracellular calcium). (B) Similar to panel A 
in the presence of simulated IL-1β application during the follow-up. (C) Similar to panel B, but in the absence 
of extracellular calcium and sodium to inhibit transmembrane calcium fluxes. (D) Similar to panel B with 
inhibition of ryanodine receptor channel type-2 (RyR2)-mediated calcium release. 
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Figure 4.7: Simulated sarcoplasmic reticulum (SR) calcium-leak protocol in the absence or presence of 
interleukin-1β (IL-1β) stimulation. (A) Voltage-clamp protocol (top) and whole-cell calcium (bottom) during 
simulated application of the Shannon protocol (329) to measure SR calcium-leak and SR calcium-load in the 
Chapter 4 
 
Henry Sutanto | 103     
 
C
h
ap
te
r 
4
 
Ctl model in the absence (black line) or presence (red line) of IL-1β. The effects of tetracaine and caffeine 
were simulated by blocking the RyR2 by >99% and setting RyR2 open probability to 1.0, respectively. (B) 
Similar to panel A for the POAF model version. (C) Top: Quantification of SR calcium-leak and incidence of 
spontaneous SR calcium-release events (SCaEs). Bottom: SR calcium-load (amplitude of the caffeine-induced 
calcium transient, cCaT) and SR calcium-leak/load in Ctl and POAF with and without IL-1β stimulation. 
 
4.4 Conclusion 
Overall, computational modeling supports the notion that post-operative inflammation 
acting on a pre-existing arrhythmogenic substrate may elicit proarrhythmic responses 
leading to POAF. 
 
 
 
 
Calcium-dependent regulation of atrial ionic currents 
104 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 5
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 5 
 
Henry Sutanto | 105     
 
C
h
ap
te
r 
5
 
 
Chapter 5 
 
Calcium-dependent regulation of cardiac ionic 
currents modulates atrial electrophysiology and 
arrhythmogenesis: insights from computational 
modeling  
 
H. Sutanto, D. Dobrev, E. Grandi, P.G.A. Volders and J. Heijman. 
In Preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calcium-dependent regulation of atrial ionic currents 
106 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 5
 
ABSTRACT  
Calcium is essential for cardiac excitation-contraction coupling. Under pathological 
conditions, calcium-handling abnormalities can promote cardiac arrhythmias through 
several pathways, including direct regulation of cardiac ion channels. The calcium-
dependent regulation of cardiac ionic currents, including the inward-rectifying 
potassium current (IK1), slow delayed-rectifier potassium current (IKs), small-
conductance calcium-activated potassium current (ISK) and calcium-activated chloride 
current (IClCa) has been demonstrated experimentally, but its consequences for atrial 
electrophysiology are unknown. Here, we perform multiscale in silico studies to reveal 
the role of this regulation in atrial electrophysiology and arrhythmogenesis under 
physiological and pathological conditions.  
We incorporated calcium-dependent regulation of IK1 and IKs based on 
published experimental data in the state-of-the-art 2020 version of the Grandi human 
atrial cardiomyocyte model, which also includes ISK and IClCa. We then investigated the 
role of calcium-dependent regulation of these ion channels on the action potential (AP) 
and the genesis of delayed afterdepolarizations (DADs). A phenomenological model of 
stochastic ryanodine receptor gating was implemented to simulate spontaneous 
calcium releases and DADs. Finally, two-dimensional tissue simulations were 
performed to study the role of calcium-dependent regulation of ionic currents on 
ectopic activity and the behavior of reentrant waves.  
Calcium-dependent ion-channel regulation synergistically reduced the atrial 
AP duration, primarily at slow pacing rates, which was diminished following 
progressive L-type calcium current inhibition. Calcium-dependent regulation also 
reduced DAD amplitude and the vulnerable window for reentry under physiological 
conditions. However, in the presence of atrial fibrillation-related electrical remodeling, 
calcium-dependent ion-channel regulation stabilized reentry and increased the 
vulnerable window, mainly via IK1 and ISK.  
In conclusion, calcium-dependent regulation of atrial ionic currents has 
substantial impact on arrhythmogenesis by inhibiting triggered activity. On the other 
hand, under disease conditions, this regulation stabilizes reentrant arrhythmias. 
Altering calcium-dependent regulation of ion channels might represent a future 
therapeutic strategy for atrial arrhythmias. 
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5.1 Introduction 
As extensively discussed in Chapter 2, calcium is a key regulator of cardiac 
electromechanical function that interacts with many proteins and signaling molecules 
to regulate excitation-contraction coupling (335). Calcium enters the cardiomyocyte 
through L-type calcium channels (LTCC), triggering a more abundant calcium release 
from the sarcoplasmic reticulum (SR) through a process called calcium-induced calcium 
release (CICR). Subsequently, calcium interacts with contractile machineries to initiate 
cardiomyocyte contraction. In addition, calcium activates various signaling cascades 
within the cardiomyocyte, such as calcium/calmodulin-dependent protein kinase-II 
(CaMKII) and calcineurin/NFAT. During diastole, calcium is transported back into the 
SR via the SR calcium-ATPase (SERCA) and partly extruded from the cell via the sodium-
calcium exchanger (NCX) (335).  
Under pathological conditions, calcium-handling abnormalities can promote 
cardiac arrhythmias through at least 3 processes: the formation of delayed 
afterdepolarizations (DADs), ion-channel modulation, and structural remodeling (335). 
In addition to activating calcium-dependent signaling cascades, calcium also directly 
modulates several cardiac ion channels (55, 56, 336, 337). Some of these, such as small-
conductance calcium-activated potassium (SK or K,Ca) channels, are now considered as 
potential therapeutic targets for cardiac arrhythmias (45, 338). Calcium-dependent 
regulation of the inward-rectifying potassium current (IK1) results in increased systolic 
IK1 and reduced diastolic IK1 in the presence of low calcium (56). Similarly, IK1 was 
significantly increased in isolated canine cardiomyocytes following a rise of 
intracellular calcium (55). Meanwhile, intracellular calcium also enhanced rabbit 
ventricular slow delayed-rectifier potassium current (IKs) by negatively shifting its 
voltage-dependent activation and slowing channel deactivation (336), whereas the 
rapid delayed-rectifier potassium current (IKr) was unaffected by high intracellular 
calcium. Finally, the calcium-dependent chloride current (IClCa) is activated in response 
to increased intracellular calcium concentrations, via alteration of the electrostatic 
properties of the ion-conduction path and conformational changes of the α-helix, 
enabling calcium to interact with the binding site in the transmembrane domain (339). 
The role of IClCa in arrhythmogenesis is not fully understood. It was reported to 
contribute to action potential (AP) alternans in atrial cardiomyocytes (337) and 
implicated in DADs. Inhibition of IClCa prevented the transformation of DADs into 
triggered activities (TAs) (337). Due to the large number of calcium-sensitive processes 
and the simultaneous interaction between calcium-regulated ion channels via changes 
in membrane potential, it is experimentally challenging to study the impact of calcium-
dependent ion-channel regulation on cardiac electrophysiology.  
Employing the perfect control and observability provided by computational 
modeling (4), we aimed to investigate the role of calcium-dependent regulation of these 
ionic currents, focusing on their impact on atrial electrophysiology and 
arrhythmogenesis. We show that calcium-dependent regulation of atrial ionic currents 
modulates AP duration and DADs. Using a novel simplified model of stochastic 
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ryanodine receptor (RyR) gating, we next investigated the consequences of subcellular 
spontaneous SR calcium releases (SCaEs) and their effects on calcium-dependent ion-
channel gating on tissue-level ectopy. Together, our multiscale in silico study provides 
insight on the impact of calcium-dependent ion-channel regulation on atrial 
electrophysiology, under both physiological and pathological conditions. 
 
Figure 5.1: Incorporation and optimization of calcium-dependent regulation of IK1 and IKs in the Grandi 
human atrial cardiomyocyte model. A,B) Calcium-dependent regulation of IK1 optimized to experimental data 
by Nagy et al. (55) for membrane voltages from -90 mV to -30 mV (A) and by Zaza et al. (56) at -65 mV and 
+30 mV (B). C) Calcium-dependent regulation of peak (left) and tail (right) IKs optimized to experimental data 
by Bartos et al. (336). 
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5.2 Methods 
In this study, we employed the state-of-the-art 2020 version of Grandi human atrial 
cardiomyocyte model (340, 341), which incorporated several newly-investigated 
channels, such as the 4-transmembrane 2-pore-region potassium (K2P) channels and SK 
channels (342, 343). We extended this model with calcium-dependent regulation of IK1 
and IKs based on previously published experimental data (55, 56, 336) (Figure 5.1). All 
simulations in this study were performed using Myokit (344). The cellular AP 
simulations were performed in two groups: the control model in which the calcium 
observed by the current of interest was clamped to the diastolic value of 190 nmol/l to 
nullify calcium dependence and the dynamic model (with active calcium-dependent 
regulation). Zero-dimensional (single-cell) simulations were performed at various 
pacing frequencies to assess the rate-dependence of calcium-dependent regulation. 
Two-dimensional tissue simulations were performed in 4x4 cm of virtual tissue 
(simulated using 200x200 units). An S1S2 induction protocol was used to induce 
reentrant spiral waves. In the S1S2 protocol, the first stimulus (S1) is applied to generate 
a normal excitation wave. The second stimulus (S2) is then applied to part of the tissue, 
generating an additional wave-front that can interact with the tail of the preceding wave, 
producing reentry in a vulnerable substrate. In this study, the S1 was initiated from left 
to right and the S2 was applied to the upper-left quadrant of the tissue. The isotropic 
conduction velocity was set to 50 cm/s.  
To study the effect of calcium-dependent regulation of atrial ionic currents on 
DADs, we employed both a deterministic approach (by inducing a predefined amount 
of SR calcium release at a specific moment), as well as a simplified stochastic RyR gating 
model that captures the behavior observed in more complex models with spatial 
calcium handling based on the approach by Colman (97). In brief, at the start of every 
AP, a time point for SCaE initiation was stochastically generated using a function 
controlled by the SR calcium concentration. If this random time point occurred before 
the next stimulus, SR calcium release was initiated by temporarily increasing RyR2 
open probability. The properties of this SR calcium release (amplitude and duration) 
were similarly randomly-assigned through stochastic functions at the start of each AP. 
Parameters for the stochastic functions were chosen to qualitatively reproduce 
experimentally observed SCaE properties. Using this new method, SCaEs were 
simulated and their effect on DAD properties was studied in the absence or presence of 
calcium-dependent ion-channel regulation. Furthermore, we incorporated the models 
with simplified stochastic RyR gating in two-dimensional tissue models to enable the 
simulation of DADs and ectopic activities at the tissue level during a long observation 
periods of 8 s following pacing at 2 Hz. The model is freely accessible in Myokit format 
at our GitHub page (www.github.com/jordiheijman). Statistical analyses were 
performed using Mann-Whitney test for non-normally distributed data and results 
were considered statistically significant for P<0.05. 
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Figure 5.2: Rate-dependent effects of calcium-dependent ion-channel regulation on the human atrial action 
potential. A-G) The effects of calcium-dependent modulation on AP, calcium transient, calcium-dependent 
currents, and intracellular sodium level for different pacing frequencies, from 1 Hz to 3 Hz. H-J) Parameter 
sensitivity analysis of the individual contributions of calcium-dependent currents. The relationship between 
pacing rate and absolute APD90 (H), relative APD90 (I, normalized to 0.25 Hz) and RMP (J) are shown. (APD = 
action potential duration; RMP = resting membrane potential) 
 
5.3 Results 
5.3.1 The effects of calcium-dependent ion-channel regulation on atrial action 
potentials 
First, we simulated the effects of calcium-dependent regulation of 4 atrial ionic currents 
(IK1, IKs, ISK, and IClCa) on AP properties during 1 Hz pacing. The dynamic model displayed 
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a 46 ms (17.4%) shorter AP duration (APD) at 1 Hz pacing than the control model due 
to a substantial calcium-dependent increase in all 4 currents (Figure 5.2A-G). 
Accelerating the pacing frequency from 0.25 Hz to 4 Hz reduced APD by 33% and 19% 
in control and dynamic models, respectively (Figure 5.2H). Accordingly, calcium-
dependent APD regulation was augmented at slow pacing rates (20.5% APD reduction 
at 0.25 Hz compared to 11.4% APD reduction at 3 Hz), highlighting the predominance 
of calcium-dependent ion-channel regulation at slow pacing frequencies (Figure 5.2H-
I) despite the rate-dependent increase in intracellular calcium concentrations. By 
contrast, the dynamic model hyperpolarized the resting membrane potential (RMP) 
primarily at fast pacing rates (Figure 5.2J). Parameter sensitivity analyses revealed 
that calcium-dependent regulation of IK1 and ISK were the major determinants of APD 
and RMP changes, with minor contribution from IClCa and negligible support from IKs.  
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Figure 5.3: Calcium-dependent regulation of atrial ionic currents under L-type calcium current (ICa,L) block. 
A) The AP and calcium transient of control and dynamic models for increasing levels of ICa,L block from 0% to 
100%. B) The individual contributions of calcium-dependent currents to the relationship between the degree 
of LTCC block and AP properties (APD90 and RMP). (APD = action potential duration; RMP = resting membrane 
potential) 
Next, we investigated the effect of calcium-dependent ion-channel regulation 
under altered intracellular calcium concentrations. These alterations were achieved 1) 
by limiting calcium-influx into atrial cardiomyocytes by blocking LTCC and 2) by 
limiting calcium-efflux from cardiomyocytes by blocking the sodium-potassium-
ATPase (NKA), which indirectly inhibits calcium extrusion via NCX. Increasing LTCC 
block from 0% to 100% resulted in progressive APD reduction (73% in control and 
66% in the dynamic model) and calcium-transient amplitude in both models (Figure 
5.3). The shorter APD in the dynamic model at baseline (Figure 5.2H) was diminished 
with 100% LTCC block (Figure 5.3B), confirming the involvement of calcium in the 
observed APD reduction in the dynamic model. Blocking LTCC up to 100% also 
depolarized the RMP due to a reduction in calcium-dependent regulation of IK1. The 
impact of LTCC block on calcium-dependent currents and calcium-handling proteins 
are depicted in Figures 5.4-5.5.  
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Figure 5.4: Calcium-dependent currents in the presence of L-type calcium current (ICa,L) block. The effects of 
incremental ICa,L block from 0% to 100% on the calcium-dependent IK1, IKs, ISK, and IClCa in the dynamic model 
was compared to the control model. 
Next, we increased intracellular calcium by blocking NKA, which limits the 
efflux of calcium via NCX. Progressive NKA block from 0% to 100% had minor effects 
on APD (Figures 5.6-5.8). Up to 70% NKA block, APD in both control and dynamic 
models were slightly prolonged (by 5% and 6%, respectively; Figure 5.6B). With 
higher levels of NKA block, RMP became strongly depolarized, significantly altering AP 
morphology and duration, and several episodes of DADs and TAs were documented. In 
the dynamic model, RMP depolarization was slightly less pronounced due to calcium-
dependent augmentation of IK1.  
 
Figure 5.5: Calcium-handling properties of control and dynamic models during L-type calcium current (ICa,L) 
block. The effects of incremental ICa,L block from 0% to 100% on calcium-handling in the dynamic model was 
compared to the control model. 
Finally, we assessed the role of calcium-dependent regulation of atrial ionic 
currents under pathological conditions, i.e., in the presence of atrial remodeling related 
to long-standing persistent “chronic” atrial fibrillation (cAF). With cAF-related 
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remodeling, the dynamic model similarly exhibited shorter APD than the control model 
at 1 Hz pacing (by 28 ms; 25%), with an increase in all 4 calcium-dependent currents 
(Figure 5.9A-G). In the presence of cAF-related remodeling, the difference between 
APD-rate dependence in the control and dynamic models was blunted (25% and 27% 
APD reduction between 0.25 and 4.0 Hz, respectively). The calcium-dependent APD-
shortening effect observed in the dynamic cAF model was similar for all pacing rates, 
reflecting the absence of rate-dependence in calcium handling in the presence of cAF-
related remodeling. Parameter sensitivity analysis revealed IK1 and ISK as the primary 
mediators of APD shortening, similar to what we observed in the non-diseased atrium. 
The dynamic cAF model also hyperpolarized RMP, with predominance at fast pacing 
frequencies (Figure 5.9J), controlled mainly by calcium-dependent regulation of IK1. 
 
Figure 5.6: Calcium-dependent regulation of atrial ionic currents under NKA block. A) The AP and calcium 
transient of control and dynamic models under incremental NKA (INaK) block from 0% to 100%. B) The 
individual contributions of calcium-dependent currents to the relationship between the degree of NKA block 
and AP properties (APD90 and RMP). (APD = action potential duration; RMP = resting membrane potential) 
 
5.3.2 Calcium-dependent ion-channel regulation alters DAD properties 
DADs are a major mechanism of ectopic activity, occurring as a consequence of diastolic 
SCaEs (4, 345). DAD properties are modulated by many factors, including the balance 
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between repolarizing IK1 and depolarizing NCX. In case of hypokalemia, when the RMP 
is hyperpolarized, a larger stimulus is needed to activate INa and trigger an AP (345). In 
the previous section and in Figure 5.2J, we observed a slightly lower RMP in the 
dynamic model compared to the control model due to calcium-dependent regulation of 
IK1. These data suggest that calcium-dependent regulation of atrial ionic currents during 
SCaEs may also affect DAD properties. We employed two approaches to trigger DADs in 
the Grandi human atrial cardiomyocyte model. First, we altered RyR flux (JRyR) in the 
model in a predefined, deterministic manner, similar to a caffeine-induced calcium-
release effect observed in experiments. Second, we implemented a state-of-the-art 
approach that phenomenologically reflects subcellular stochastic RyR gating, as 
proposed by Colman (97).  
 
Figure 5.7: Calcium-dependent currents under NKA block. The effects of incremental NKA block from 0% to 
100% on the calcium-dependent IK1, IKs, ISK, and IClCa in the dynamic model was compared to the control model. 
Using the predefined, deterministic approach, we demonstrated that calcium-
dependent regulation of atrial ionic currents in the dynamic model lowered the DAD 
amplitude, preventing the occurrence of TA for an SR calcium release that did trigger 
an AP in the control model (Figure 5.10A, green line). As such, a slight rightward-shift 
was observed in the ΔCaT-ΔVM curve (Figure 5.10B). Traces of calcium-dependent 
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currents and calcium-handling parameters during simulated DADs are shown in 
Figures 5.11-5.12.  
To investigate the effects of calcium-dependent ion-channel modulation on the 
behavior of dynamic DADs occurring after the cessation of pacing, we extended the 
human atrial model by incorporating a simplified stochastic RyR model. We calculated 
the DAD incidence as previously reported using a more complex and detailed spatial 
subcellular calcium-handling model (4) for various amplitude, latency and duration of 
RyR-mediated SR calcium release. As depicted in Figure 5.13A-C, using this stochastic 
approach (N=60 simulations), the model with dynamic calcium-dependent ion-channel 
regulation had a lower TA incidence with a slight increase in DAD incidence compared 
to the control model. Consistent with the phenomenological approach, the average and 
maximum DAD amplitudes were also reduced in the dynamic model (Figure 5.13D-E), 
highlighting the RMP-stabilizing role of calcium-dependent modulation of ionic 
currents.  
 
Figure 5.8: Calcium-handling properties of control and dynamic models under NKA block. The effects of 
incremental NKA block from 0% to 100% on calcium handling in the dynamic model was compared to the 
control model. 
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Next, we investigated the impact of calcium-dependent ion-channel regulation 
on DAD properties in cAF, incorporating the AF-induced electrical remodeling and 
previously documented AF-associated changes in calcium-handling properties (Table 
5.1; Figure 5.14A-B) (94). The cAF model showed a substantial increase in the 
incidence of DADs in the absence and presence of calcium-dependent regulation 
compared to the non-diseased model (Figure 5.14C), consistent with the increased RyR 
open probability in AF. The dynamic model produced a statistically significant 
reduction in DAD incidences and maximum DAD amplitudes, without significant 
differences in TA incidences and the average DAD amplitudes compared to the control 
model (Figure 5.14D-E). These findings suggest an attenuation of the membrane-
stabilizing effect of calcium-dependent ion-channel regulation under pathological 
conditions. 
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Figure 5.9: Rate-dependent effects of calcium-dependent regulation of atrial ionic currents on action 
potential in chronic AF. A-G) The effects of calcium-dependent ion-channel modulation on AP, calcium 
transient, calcium-dependent currents, and intracellular sodium level for different pacing frequencies (1 Hz 
to 3 Hz). H-J) Parameter sensitivity analysis revealing the individual contributions of calcium-dependent 
currents on the relationship between pacing rate and absolute APD90 (H), relative APD90 (I) and RMP (J). (APD 
= action potential duration; RA = right atrium; RMP = resting membrane potential) 
 
Figure 5.10: The impact of calcium-dependent regulation of atrial ionic currents on DAD amplitude. A) 
Membrane potential and intracellular calcium of both control and dynamic models for predefined degrees of 
SR calcium release due to alterations in RyR flux. Green traces represent conditions producing triggered 
activity in the control model (arrows), but not in the dynamic model. B) The individual contribution of 
calcium-dependent currents on DAD amplitude, shown as ΔCaT-ΔVM curves. (CaT = calcium transient; VM = 
membrane potential) 
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Figure 5.11: Calcium-dependent currents during pre-defined, controlled SR calcium-release simulations. The 
calcium-dependent IK1, IKs, ISK, and IClCa in the dynamic model during simulations with various amounts of SR 
calcium release were compared to the control model. 
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Figure 5.12: Calcium-handling proteins during pre-defined, controlled SR calcium-release simulations. The 
calcium-handling proteins in the dynamic model during simulations with various amounts of SR calcium 
release were compared to the control model. 
 
 
Figure 5.13: The cellular consequences of calcium-dependent regulation of ionic currents on DAD properties 
(stochastic RyR gating approach). A-B) Membrane potential, cytosolic and sarcoplasmic reticulum calcium 
levels and RyR calcium flux (top to bottom) showing 3 paced beats followed by simulated spontaneous 
calcium releases and consequent DADs and TAs in the control (A) and dynamic (B) models. C) The comparison 
of DAD and TA incidence between control and dynamic models. D-E) The comparison of average (D) and 
maximum (E) DAD amplitude between control and dynamic models. (*) indicates statistical significance 
(p<0.05) (DAD = delayed afterdepolarization; SR = sarcoplasmic reticulum; TA = triggered activity) 
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Figure 5.14: The cellular consequences of calcium-dependent regulation of cardiac ion channels on DAD 
properties in cAF (stochastic RyR gating approach). A-B) Simulated DADs and TAs by the simplified stochastic 
RyR gating approach in the control cAF model as compared to the dynamic cAF model. C) The comparison of 
DAD and TA incidence between control and dynamic models in normal right atrium and cAF. D-E) The 
comparison of (average and maximum) DAD amplitude between control and dynamic models. (*) indicated 
the statistical significance (p<0.05) (DAD = delayed afterdepolarization; RA = right atrium; SR = sarcoplasmic 
reticulum; TA = triggered activity) 
 
RyR gating parameter Non-diseased RA model cAF model 
Mean latency of calcium 
release 
1.5 s 1.5 s 
Latency SD 0.1 s 0.1 s 
Calcium-release threshold 0.45 mmol/l 0.2 mmol/l 
Amplitude of calcium release 2.0 5.0 
Duration of calcium release 0.15 s 0.15 s 
Interval of RyR Po 0.5 s 0.25 s 
SERCA function 100% 75% 
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Table 5.1: The RyR gating parameters employed in the simplified subcellular stochastic RyR gating model. 
Several changes on the RyR gating parameters were made to fit in the experimental DADs shown in non-
diseased atria (4) and AF (32, 94). 
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Figure 5.15: Calcium-dependent regulation of atrial ionic currents and reentrant arrhythmias. A, D) The 
snapshots of reentrant spiral waves in non-diseased right atrium (RA, panel A) and cAF model (D) at specific 
S1S2 intervals, comparing the control, dynamic (all 4 calcium-dependent currents), calcium-dependent IK1 
only, calcium-dependent IKs only, calcium-dependent ISK only and calcium-dependent IClCa only models. B, E) 
The vulnerable windows of the reentry for different S1S2 interval. The span of the window represents 
inducibility of reentry, while the color of the heatmap defines the stability of reentry. C, F) The sum (Σ) of 
vulnerable windows as a quantitative assessment of total arrhythmogenic risk. 
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Figure 5.16: Dynamic changes in calcium-dependent ionic currents during reentrant spiral waves in the cAF 
model. The membrane potential (VM), calcium transient, and all 4 calcium-dependent currents in the dynamic 
model (right panels) were compared to the control model (left panels). The red arrows indicate the changes 
in corresponding current density over time. 
 
 
Figure 5.17: Dynamic changes in the maximum amplitude of calcium-dependent ionic currents during 
reentrant spiral waves in the cAF model. The membrane potential (VM) and the amplitudes of calcium 
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transient and all 4 calcium-dependent currents in the dynamic model (right panels) were compared to the 
control model (left panels). The red lines represent a non-linear regression fit and reflect the changes in 
amplitude of ionic currents over time. 
 
5.3.3 Calcium-dependent ion-channel regulation affects reentrant arrhythmia 
maintenance 
As described in Chapter 2, calcium-handling abnormalities can promote reentry 
through several pathways, including direct ion-channel modulation (335). Therefore, 
we investigated the role of calcium-dependent ion-channel regulation on the 
inducibility and maintenance of reentrant arrhythmias in two-dimensional tissue 
simulations. The vulnerable windows, reflecting the duration of reentry induced for 
different S1S2 intervals, were evaluated to assess both the inducibility and stability of 
reentrant arrhythmias under different conditions. The size of the vulnerable windows 
indicates the inducibility of reentry (i.e., the number of S1S2 intervals producing 
reentry) and the duration of reentry within the vulnerable windows reflects the 
stability of reentrant arrhythmias. Since reentry durations can be distinct for different 
S1S2 intervals, both factors were combined into a total arrhythmogenic risk parameter 
by summing the reentry durations over the entire vulnerable window to provide a 
single quantitative assessment. Consistent with our previous study using the 
Courtemanche human atrial model (346), no stable reentry could be induced in the non-
diseased Grandi human right atrial model (Figure 5.15A-B). However, reentrant spiral 
waves persisting for multiple seconds could be induced in the presence of cAF-induced 
ion channel remodeling (Figure 5.15C-D). In the non-diseased atrium, calcium-
dependent ion-channel regulation in the dynamic model shifted the vulnerable 
windows to earlier S1S2 intervals and slightly reduced the total arrhythmogenic risk 
(Figure 5.15B-C). By contrast, in the cAF model, the calcium-dependent regulation of 
atrial ionic currents stabilized the reentrant waves and shifted the vulnerable windows 
to earlier S1S2 intervals. As a consequence, the total arrhythmogenic risk was increased 
in the dynamic cAF model (Figure 5.15E-F). The effects observed both in the presence 
and absence of cAF-related remodeling were due to calcium-dependent regulation of 
IK1 and ISK, similar to our results at the cellular level. The dynamic changes in calcium-
dependent regulation of ionic currents during reentry in the cAF model can be seen in 
Figures 5.16-5.17. During reentry, the intracellular calcium rose due to the increased 
activation rate in both control and dynamic models (Figure 5.16, red arrows). In the 
presence of calcium-dependent regulation this dynamic increase was paralleled by 
ionic currents. As such, the dynamic model resulted in larger ionic current densities, 
shortening the refractory period and stabilizing the reentrant waves (Figure 5.17).  
Next, we investigated the impact of calcium-dependent ion-channel regulation 
on TA at the tissue level by simulating several S1 stimuli followed by a long observation 
period of 8 s in 2 Hz pacing in our two-dimensional tissue model with stochastic RyR 
(Figure 5.18). Random SCaEs and DADs occurred at the cellular level, which under 
particular conditions resulted in ectopic activities at the tissue level. This 
transformation from cell-level SCaEs/DADs to tissue-level ectopic activities depended 
on RyR-gating properties, such as the duration of calcium release, the amplitude of 
calcium release, and the mean latency of calcium release, as well as the standard 
deviation (SD) of calcium release latency between cells. As shown in Figure 5.18B, 
reducing the latency SD 10-fold synchronized the SCaEs throughout the tissue, thereby 
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initiating TAs in the control model. However, a 10-fold reduction in the latency SD alone 
was insufficient to initiate TA in the dynamic model (Figure 5.18D) due to the RMP-
stabilizing effect of calcium-dependent regulation of atrial ionic currents, in line with 
our results at the cellular level. In some cases, especially during higher calcium-release 
amplitude and reduced latency SD, these SCaE-mediated ectopic activities could induce 
reentrant spiral waves (Online Video 1, Figure 5.19) although those modifications 
were not adequate to maintain a stable reentry. 
 
Figure 5.18: Impact of calcium-dependent regulation of atrial ionic currents on DAD properties and triggered 
activity in tissue-level simulations (stochastic RyR gating approach). A,B) Membrane potential (VM), cytosolic 
and sarcoplasmic reticulum calcium for 3 stimulated beats and an 8-second follow-up period in the control 
model with 100 ms (A) or 10 ms (B) standard deviation (SD) of RyR latency. Smaller latency SD produces a 
more synchronous calcium release in the tissue. C,D) Similar to panels A,B for the dynamic model. All traces 
were recorded at the center of the virtual tissue (i.e., coordinate x=100, y=100) of the 2-dimensional tissue. 
Snapshot of the entire virtual tissue at specific moments in time are shown above the traces. 
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Figure 5.19: Synchronization of cellular DADs leads to the initiation of non-sustained reentrant arrhythmias. 
The upper panel of the figure shows the membrane potential (VM) of control model and the snapshots of 
reentry as presented in Online Video 1 were displayed on the lower panels. To induce reentrant spiral wave, 
the SD of the latency of calcium release was set to 0.01 s and the amplitude of calcium release was increased 
to 5. To maintain the sustainability of reentrant wave, the conduction velocity was reduced to 30 cm/s. The 
white (*) signs indicate the origin of ectopy and the red arrows denote the direction of propagating waves. 
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Finally, we varied the duration, amplitude, mean latency and latency SD of 
calcium release to further compare and characterize the effects of calcium-dependent 
ion-channel regulation with different RyR-gating properties (Figure 5.20). The 
dynamic model consistently showed a lower average and maximum DAD amplitudes, 
while inducing higher numbers of DADs. Increasing the amplitude of calcium release 
(Figure 5.20A) increased the number of DADs, amplified the average and maximum 
DAD amplitudes in both control and dynamic models. However, an increased amplitude 
alone was insufficient to trigger TA. Similarly, the reduction of latency SD (resulting in 
more synchronous SCaEs between cells) increased the average and maximum DAD 
amplitudes. In this subset of simulations, TA could only be induced in the control model 
with very low latency (Figure 5.20B). However, the combination of both RyR gating 
properties (amplitude and latency) had synergistic effects, initiating stronger and more 
synchronous calcium releases, permitting several episodes of TAs to occur in both 
control and dynamic models (Figure 5.20C). Additionally, the alteration of mean 
latency of calcium release lowered the average and maximum DAD amplitudes in both 
control and dynamic models without producing TA (Figure 5.20D). Increasing the 
duration of RyR opening to allow more calcium release produced a slightly larger 
average and maximum DAD amplitudes (Figure 5.20E). In general, employing tissue 
level simulations with stochastic RyR, we demonstrated that large, synchronous 
calcium releases are required for TA and that calcium-dependent regulation of atrial 
ionic currents stabilized the RMP and reduced the likelihood of TA. 
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Figure 5.20: Properties of spontaneous calcium releases, DADs and TA in control (black) and dynamic (blue) 
models for different RyR-gating properties. A-E) Number of TA and DAD, average and maximum DAD 
amplitude (top to bottom) in response to increasing calcium-release amplitude (A), alteration of latency SD 
of RyR opening (B), highlighting the synergy between amplitude and latency SD in producing stronger and 
more synchronous calcium release (C), alterations in mean latency of RyR opening (D) and altered duration 
of RyR opening (E). Default values are indicated by red dotted lines (also provided in Table 5.1). (DAD = 
delayed afterdepolarization; RyR = ryanodine receptor; SD = standard deviation; TA = triggered activity) 
 
5.4 Discussion 
Our multiscale in silico study aimed to improve the understanding of the impact of 
calcium-dependent ion-channel regulation on atrial electrophysiology under 
physiological and pathological conditions. To achieve this goal, we modified the 2020 
version of the Grandi human atrial cardiomyocyte model, enabling the simulation of 
calcium-dependent regulation of 4 ionic currents: IK1, IKs, ISK, and IClCa. The 
computational modeling study was performed under various experimental conditions 
and from cell to tissue level. We developed a simplified subcellular model of stochastic 
RyR gating to study how calcium-dependent ion-channel modulation alters DAD 
properties. To the best of our knowledge, our study was the first to investigate the 
consequences of altered subcellular RyR gating properties in the presence of calcium-
dependent ion-channel regulation on tissue-level ectopic activities. Using the 
advantages offered by this computational modeling approach, we show that calcium-
dependent regulation of cardiac ionic currents shortened APD, hyperpolarized RMP 
and increased all 4 calcium-dependent currents. Calcium-dependent ion-channel 
regulation also stabilized RMP and therefore reduced the DAD amplitude in the non-
diseased atrium. At the tissue level, the arrhythmogenic effects of calcium-dependent 
ion-channel modulation depended on the presence of concomitant disease. In the 
absence of AF-related remodeling, calcium-dependent ion-channel regulation slightly 
reduced the total arrhythmogenic risk, while in cAF, it increased arrhythmogenic risk. 
Both effects were due to the contributions of IK1 and ISK. Finally, a stronger, more 
synchronous calcium release was required to initiate tissue-level ectopic activities in 
the presence of calcium-dependent ion-channel regulation compared to the control 
model. 
 
5.4.1 Calcium-dependent regulation of cardiac ionic currents and cardiac 
arrhythmias 
For more than a decade, calcium-dependent regulation of cardiac ion channels has been 
documented experimentally. In 1998, Zaza et al. (56) demonstrated that systolic IK1 was 
increased and diastolic IK1 was reduced in the presence of low calcium. Although 
calcium-induced effects only represented a small fraction of total IK1 rectification, they 
were adequately large to affect excitability and repolarization. Another study in canine 
cardiomyocytes similarly reported that high intracellular calcium led to the 
augmentation of IK1, which was partly mediated by a CaMKII-dependent pathway and 
might function as a protective mechanism against cardiac arrhythmias due to calcium 
overload (55). These findings are consistent with our multiscale in silico study. In 
Figure 5.2, we have shown that calcium-dependent regulation shortened atrial APD in 
the dynamic model and hyperpolarized the RMP, requiring a stronger stimulus to 
activate the fast sodium channel and providing a protective effect against DADs and TAs, 
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as shown in Figures 5.10, 5.13. Altering the intracellular calcium concentrations by 
blocking LTCC and NKA revealed that the RMP-hyperpolarizing effect was diminished 
with full LTCC block and augmented by full NKA block, in line with their effects on 
intracellular calcium levels (Figures 5.3, 5.6). At the tissue level, we also investigated 
the effect of calcium-dependent regulation on reentrant arrhythmias. In the non-
diseased atrium, the dynamic model slightly reduced the total arrhythmogenic risk. 
However, these protective tissue-level effects were cancelled by cAF-induced ion-
channel remodeling, resulting in an increased total arrhythmogenic risk in the presence 
of calcium-dependent ion-channel regulation. This finding is consistent with previous 
publications highlighting the significance of IK1 (347) and ISK (348) in reentry 
stabilization.  
In addition to IK1, our study also underlined the contribution of ISK to the 
cellular- and tissue-level effects. SK channels are solely activated by intracellular 
calcium and found more abundantly in the atria than in the ventricles. SK channels alter 
cardiac repolarization and their inhibition prolongs atrial APD. SK2 knockout mice 
demonstrated a significant APD prolongation prominently in the late phase of 
repolarization in atrial cardiomyocytes (47). Moreover, SK channels are upregulated in 
heart failure and (in some studies) atrial fibrillation, and are therefore considered a 
potential therapeutic target against AF (45). Overexpression of SK3 in mouse models 
resulted in significant shortening of atrial APD and effective refractory period, together 
with an increased susceptibility to AF (47). Furthermore, pharmacological inhibition of 
SK channel in AF animal models have shown promising antiarrhythmic properties (45), 
although its proarrhythmic potential has also been documented (47, 335). Our findings 
demonstrated that the atrial APD-shortening effect observed in the dynamic model was 
partly due to ISK, aligned with the aforementioned role of SK channel in atrial 
repolarization. The role of ISK in reentry stabilization (Figure 5.15) has also been 
reported (348). 
 
5.4.2 The limited contributions of calcium-dependent regulation IKs and IClCa 
In contrast, we observed very minor contributions of calcium-dependent IKs and IClCa on 
atrial electrophysiology. Experiments in rabbit ventricular cardiomyocytes provided 
direct evidence that intracellular calcium was critical for IKs function. In its physiological 
range, intracellular calcium dynamically regulated IKs, increasing its amplitude, 
negatively shifting voltage-dependent activation and lowered deactivation. Such effects 
were augmented during β-adrenergic stimulation (336). Our result revealed an 
elevated IKs amplitude (almost doubling of IKs current density in the dynamic model 
following ~200nM increase of intracellular calcium; Figure 5.2E), consistent with 
experimental findings (336). However, we observed minimal changes in repolarization 
due to the calcium-dependent effect, likely due to the very low basal IKs density in 
human atrium compared to the ventricle (340, 349). We observed similar calcium-
dependent regulation of IKs in cAF. Although IKs was upregulated in cAF, the much lower 
calcium-transient in cAF also produced lower calcium-dependent augmentation and 
therefore, resulted in a negligible change on AP (Figure 5.9).   
The role of IClCa in atrial arrhythmogenesis remains unclear. IClCa was reported 
to contribute to AP alternans in rabbit atrial cardiomyocytes. Furthermore, in sheep 
Purkinje fibers and ventricular cardiomyocytes, it was implicated in DAD formation, 
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with its inhibition preventing the transformation of DADs into TAs (337). However, to 
date, there is no documented data on the effect of IClCa on arrhythmogenesis in humans, 
although the gene encoding the ClCa channel (hTMEM16A), is expressed in multiple 
human tissues, including the heart (350). Although IClCa contributes to transient 
outward rectification in rabbit atrial cardiomyocytes (351), available data do not 
support a role of IClCa in the human transient outward current (352). The role of IClCa in 
phase-1 repolarization and the generation of afterdepolarizations of either normal or 
failing human heart was also very limited, limiting the clinical relevance of IClCa 
inhibition (350). In agreement, our computational study also showed that the calcium-
dependent regulation of IClCa had a minor impact on the AP properties, both under 
physiological and pathological conditions (Figures 5.2, 5.9). 
 
5.4.3 Potential applications of calcium-dependent regulation of atrial ionic 
currents 
Our results suggest that calcium-dependent regulation of atrial ionic currents could be 
an adaptive mechanism of the non-diseased atrium against intracellular calcium 
overload, by stabilizing the membrane potential and lowering DAD amplitude, 
preventing TA. Moreover, we show that such protective effects could be diminished in 
pathological situations, such as AF, even producing potentially proarrhythmic behavior 
by stabilizing reentrant arrhythmias. Therefore, a pharmacological intervention that 
can alter this direct calcium-dependent regulation (or its remodeling) might be 
beneficial in atrial pathology. Several publications have reported the association of 
calcium-dependent ion-channel regulation with CaMKII-dependent pathways and β-
adrenergic stimulation (55, 336), therefore CaMKII inhibition, either directly or via β-
blockers might be effective. Indeed, inhibition of CaMKII-mediated phosphorylation of 
RyR2 prevented AF induction in FKBP12.6-/- mice by suppressing SR calcium leak and 
DADs (353). Moreover, calmodulin / CaMKII inhibition improved intercellular 
communication and impulse propagation in the heart, destabilizing and terminating 
reentrant spiral waves in Langendorff-perfused rabbit hearts (354). Similarly, β-
blockers are also effective in AF, preventing afterdepolarizations and atrial reentry 
(355). Nevertheless, a more specific pharmacological agent may be needed to prevent 
unwanted effects of the inhibition of such vast and complex pathways (356). 
 
5.4.4 Study limitations 
Our study employed the state-of-the-art 2020 version of Grandi human atrial 
cardiomyocyte model, which was well-validated and, to the best of our knowledge, has 
the most accurate common-pool representation of atrial calcium handling. However, 
model-dependent effects cannot be ruled out, because the variability of ion channel 
distributions across different in silico models could affect the result, particularly the 
sensitivity of membrane potential to SCaEs, which determines the incidence of DAD and 
TA. Similarly, intra- and inter-subject variability can also affect the results. We have 
partly overcome this limitation with the application of our novel simplified subcellular 
stochastic RyR gating, which produces random calcium releases depending on its SR 
calcium concentration. However, more extensive validation of SCaE properties 
obtained with this phenomenological approach is warranted. 
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Due to the limited availability of experimental data, we optimized the calcium-
dependent regulation of IKs based on rabbit ventricular data, which might be different 
compared to the human atria. Since the basal magnitude of IKs in the human atrial model 
was almost negligible, this interspecies diversity is unlikely to affect our results and 
conclusions. However, such differences may become relevant under conditions with 
increased IKs (e.g., during sympathetic stimulation). Similarly, we optimized the 
calcium-dependent regulation of IK1 based on two animal models data: guinea-pig and 
canine ventricular cardiomyocytes, due to limited available data. Due to the larger IK1 
density in dogs compared to human (357), we cannot rule out the potential influence of 
such interspecies diversity on our findings.  
Additionally, in this study, tissue-level simulations were performed in isotropic 
virtual tissue in the absence of structural remodeling. Such structural remodeling can 
potentially modulate the proarrhythmic consequences of (subtle) electrophysiological 
remodeling, as already demonstrated in Chapter 6 of this thesis (346). 
 
5.5 Conclusions 
Our multiscale in silico study demonstrated that calcium-dependent regulation of atrial 
ionic currents alters human atrial electrophysiology at the cellular and tissue level. It 
has protective effects in non-diseased atrium by stabilizing the membrane potential and 
lowering DAD amplitude, preventing the occurrence of TA. However, in the presence of 
cAF-related remodeling, the calcium-dependent regulation of atrial ionic currents is 
proarrhythmic due to its APD-shortening and RMP-hyperpolarizing effects, stabilizing 
reentrant waves. Parameter sensitivity analyses revealed that IK1 and ISK are the major 
contributing factors to our findings and future pharmacological interventions to alter 
calcium-dependent regulation of IK1 and ISK might constitute novel therapeutic 
strategies for AF. 
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from multiscale in silico analyses  
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ABSTRACT 
Acute excessive ethyl alcohol (ethanol) consumption alters cardiac electrophysiology 
and can evoke cardiac arrhythmias, e.g., in ‘holiday heart syndrome’. Ethanol acutely 
modulates numerous targets in cardiomyocytes, including ion channels, calcium-
handling proteins and gap junctions. However, the mechanisms underlying ethanol-
induced arrhythmogenesis remain incompletely understood and difficult to study 
experimentally due to the multiple electrophysiological targets involved and their 
potential interactions with preexisting electrophysiological or structural substrates. 
Here, we employed cellular- and tissue-level in-silico analyses to characterize the acute 
effects of ethanol on cardiac electrophysiology and arrhythmogenesis. 
Acute electrophysiological effects of ethanol were incorporated into human 
atrial and ventricular cardiomyocyte computer models: reduced INa, ICa,L, Ito, IKr and IKur, 
dual effects on IK1 and IK,ACh (inhibition at low and augmentation at high concentrations), 
and increased INCX and SR calcium leak. Multiscale simulations in the absence or 
presence of preexistent atrial fibrillation or heart-failure-related remodeling 
demonstrated that low ethanol concentrations prolonged atrial action-potential 
duration (APD) without effects on ventricular APD. Conversely, high ethanol 
concentrations abbreviated atrial APD and prolonged ventricular APD. High ethanol 
concentrations promoted reentry in tissue simulations, but the extent of reentry 
promotion was dependent on the presence of altered intercellular coupling, and the 
degree, type, and pattern of fibrosis. 
Taken together, these data provide novel mechanistic insight into the potential 
proarrhythmic interactions between a preexisting substrate and acute changes in 
cardiac electrophysiology. In particular, acute ethanol exposure has concentration-
dependent electrophysiological effects that differ between atria and ventricles, and 
between healthy and diseased hearts. Low concentrations of ethanol can have anti-
fibrillatory effects in atria, whereas high concentrations promote the inducibility and 
maintenance of reentrant atrial and ventricular arrhythmias, supporting a role for 
limiting alcohol intake as part of cardiac arrhythmia management. 
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6.1 Introduction 
Acute and chronic alcohol (i.e., ethanol) consumption are major risk factors for 
cardiovascular diseases, particularly cardiac arrhythmias and sudden cardiac death 
(358). (Heavy) Episodic alcohol drinking is a major public health issue, affecting 1 in 6 
adults and more than 30% of college-age individuals in the United States and Europe 
(359, 360). Acute excessive ethanol intake can promote cardiac arrhythmias, a 
phenomenon known as ‘holiday heart syndrome’ (361). For example, the MunichBREW 
study performed at the 2015 Munich Octoberfest showed that acute ethanol 
consumption led to cardiac arrhythmias in 30.5% of individuals, with a prevalence of 
atrial fibrillation (AF) of 0.8% (362). Abstinence from excessive ethanol intake reduced 
AF recurrence and lowered AF burden over 6-months follow-up in a multicenter study 
of 140 patients (363). Numerous cases of ventricular arrhythmias and sudden cardiac 
death have also been reported following acute excessive ethanol intake, further 
highlighting its proarrhythmic potential (361, 364).  
Acute ethanol exposure alters multiple cardiac ion channels and calcium-
handling proteins, including the fast sodium current (INa), L-type calcium current (ICa,L), 
transient-outward potassium current (Ito), rapid delayed-rectifier potassium current 
(IKr), inward-rectifier potassium current (IK1), ultra-rapid delayed-rectifier potassium 
current (IKur), acetylcholine-activated inward-rectifier potassium current (IK,ACh), 
sodium/calcium-exchange current (INCX), and sarcoplasmic reticulum (SR) calcium leak 
(365-370). Ethanol induces these effects in a dose-dependent manner through a variety 
of pathways, including reactive oxygen species and downstream signaling cascades like 
c-Jun N-terminal kinase and calcium/calmodulin-dependent kinase-II (CaMKII) (371, 
372). These acute electrophysiological effects exhibit complex interactions via 
intracellular ion concentrations and membrane potential, and are accompanied by 
changes in gap-junction coupling and associated intercellular coupling disturbances. In 
addition, the effects of ethanol-dependent alterations in ion-channel function may 
depend on the preexisting structural or electrophysiological substrate, e.g., disease-
related ion-channel remodeling or the amount of fibrosis.  
Because of these complex (sub)cellular and tissue-level effects of acute ethanol 
exposure, its exact proarrhythmic mechanisms remain incompletely understood. 
Moreover, the complex interactions between preexisting substrate, altered ionic 
currents and gap-junction remodeling pose a challenge for experimental studies into 
the mechanisms and consequences of ethanol-induced arrhythmogenesis. Here, we 
employ multiscale computational modeling to characterize potential anti- and 
proarrhythmic effects of ethanol and their underlying ionic mechanisms. These data 
provide novel insights in a common cause of cardiac arrhythmias and provide a 
framework to study the complex interactions between preexisting substrate and 
dynamic triggers of atrial and ventricular arrhythmias. 
 
6.2 Methods 
Experimentally observed ethanol-induced acute electrophysiological changes were 
incorporated in two in-silico models: the Courtemanche human atrial cardiomyocyte 
model (373) and the Passini human ventricular cardiomyocyte model (374). Multiscale 
(cellular and tissue) simulations were performed in Myokit (344) and model code is 
available from www.github.com/jordiheijman. Concentration-dependent effects of 
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ethanol on cardiac ion channels (INa, ICa,L, Ito, IK1, IKr and INCX for atrium and ventricle, as 
well as IKur and IK,ACh for atrium) and SR calcium leak were implemented (Figure 6.1, 
Figure 6.2) based on published experimental data, as shown in the Appendix C. To 
simulate the effects of ethanol in the setting of long-standing persistent (‘chronic’) AF 
(cAF) and heart failure (HF), cAF- and HF-associated remodeling of cardiac ion channels 
and calcium-handling proteins were implemented as previously described (340, 375). 
Reentrant spiral waves were simulated using an S1S2 induction protocol in 
homogeneous tissue of 8x8 cm (400x400 units) and in the presence of structural 
remodeling (fibrosis). In the S1S2 protocol, the first stimulus (S1) is applied to generate 
a normal excitation wave. The second stimulus (S2) is then applied to part of the tissue, 
generating an additional wave-front that can interact with the tail of the preceding wave, 
producing reentry in a vulnerable substrate. In this study, the S1 was initiated from left 
to right and the S2 was applied to the upper-left quadrant of the tissue. The patterns of 
fibrosis were generated randomly using a Gaussian Random Field approach (376), with 
or without border-zone (BZ)-associated remodeling. In the presence of BZ, both 
previously reported cellular electrophysiological changes and alterations in conduction 
velocity were applied to the HF cardiomyocyte model (375, 377, 378).  
To evaluate the robustness of our findings and assess potential consequences 
of intra- and inter-subject variability on the electrophysiological effect of ethanol, the 
maximum conductance of 10 major ionic currents (INa, INaL, ICa,L, Ito, IK1, IKr, IKs, INCX and 
INaK in both atrial and ventricular models, as well as IKur in the atrial model) were scaled 
based on a normal distribution with mean 1.0 and standard deviation 0.2, to create 
populations of models, as previously described (379, 380). In brief, 1000 variants of 
both models were created and the variants displaying “non-physiological” AP 
properties (defined as APD90 or RMP outside the range of 3 standard deviations of 
experimental APD90 and RMP from (381, 382)) were excluded. In total, 40 out of 1000 
atrial models and none of the ventricular models were excluded. The non-normally 
distributed data are presented as median and inter-quartile ranges (IQR). 
 
6.3 Results 
6.3.1 Acute concentration-dependent effects of ethanol on cardiomyocyte ion 
channels and action potentials 
Ethanol reduces INa, ICa,L, Ito, IKur, and IKr (365, 368, 369) and exhibits dual effects on IK1 
and IK,ACh (366, 367), with inhibition of these latter currents at low concentrations and 
augmentation at high concentrations. Moreover, ethanol also enhanced INCX, 
sarco/endoplasmic reticulum calcium-ATPase (SERCA) function and SR calcium leak, 
increasing proarrhythmic spontaneous calcium release events (370). These 
experimental findings were reproduced in human right atrial (RA) (373) and left 
ventricular (LV) (374) cardiomyocyte models (Figure 6.1A-B, Figure 6.2). The SR 
calcium leak was calculated using a simulated tetracaine protocol in the presence of 0 
mmol/L extracellular sodium and calcium to prevent trans-sarcolemmal calcium fluxes. 
The ethanol-induced augmentation of SR calcium leak in atrial and ventricular models 
was comparable to the experimental data (Figure 6.1B, Figure 6.2B). Finally, 
concentration-dependent effects of ethanol on cardiac ion channels were incorporated 
based on published experimental data (Figure 6.1C).  
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Figure 6.1: Concentration-dependent effects of ethanol on human atrial cardiomyocyte ion channels. The 
Courtemanche human atrial cardiomyocyte model reproduced the experimentally-observed acute effects of 
ethanol on cardiac ion channels. A) Top row: The normalized current-voltage relationship (I-V curves) of INa, 
ICa,L, Ito, IK1 and IKur at baseline (0 mM ethanol; black lines) or in the presence of ethanol (blue lines) in the 
human atrial cardiomyocyte model compared to experimental data (black and blue dots) from several 
publications ([*] = (365), [#] = (366), [%] = (368)). Bottom panels: peak currents of different ion channels 
relative to the baseline condition (not shown) with 0mM ethanol. Experimental data are shown in white bars 
([*] = (365), [#] = (366), [%] = (368), [^] = (369), [@] = (367), [&] = (370)), and simulated counterparts in 
blue bars. For IK1 and IK,ACh the relative change is shown for both the inward current (at -120 mV and -110 
mV) and the outward current at (-40 mV and -50 mV) through these channels. The ethanol-induced effect on 
INCX was assessed using the relative change in the time-constant of the caffeine-induced transient (tau-cCaT), 
as reported experimentally (370). A decrease in tau-cCaT represents an increase in NCX-mediated calcium 
extrusion. B) The tetracaine-caffeine protocol, involving inhibition of SR calcium leak with tetracaine in the 
absence of extracellular sodium and calcium to block trans-sarcolemmal calcium fluxes and caffeine-induced 
calcium release to assess SR calcium load, was simulated (top panels). The relative change in SR calcium leak 
in the presence of 130 mM ethanol in the model (blue bar) was compared to experimental data (white bar) 
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(370). C) Concentration-dependent effect of ethanol on relative current densities of potassium currents 
(bottom panel) and other ionic targets (top panel) in the model (lines) and experiments (symbols). (Exp = 
experiment; GP = guinea-pig; INa = fast sodium current; ICa,L = L-type calcium current; Ito = transient-outward 
potassium current; IK1 = inward-rectifier potassium current; IKur = ultra-rapid delayed-rectifier potassium 
current; IKr = rapid delayed-rectifier potassium current; IK,ACh = acetylcholine-activated inward-rectifier 
potassium current; INCX = sodium/calcium-exchange current; NT = normal Tyrode) 
 
Figure 6.2: The concentration-dependent effects of ethanol on human ventricular cardiomyocyte ion 
channels. The Passini human ventricular cardiomyocyte model reproduced the experimentally-observed 
acute effects of ethanol on cardiac ion channels. A) Top panel: The current-voltage relationship (I-V curves) 
of ethanol-dependent regulation of INa, ICa,L, Ito and IK1 of the ventricular model (blue lines) relative to baseline 
(0 mM ethanol; black lines) were compared to the experimental data (black and blue dots) from several 
publications ([*] = (365), [#] = (366)). Bottom panel: The peak currents of ion channels derived from 
experiments (white bars; [*] = (365), [#] = (366), [^] = (369), [&] = (370)), relative to the baseline condition 
with 0mM ethanol (not shown), compared to the simulated counterparts (blue bars). The INCX was calculated 
from the time-constant of the caffeine-induced transient (tau cCaT) as reported experimentally (370). A 
decrease in tau-cCaT represents an increase in NCX-mediated calcium extrusion. B) The tetracaine-caffeine 
protocol was simulated to evaluate SR calcium leak in the model and compared to experimental data (370). 
(Exp = experiment; INa = fast sodium current; ICa,L = L-type calcium current; Ito = transient-outward potassium 
current; IK1 = inward-rectifier potassium current; IKr = rapid delayed-rectifier potassium current; INCX = 
sodium/calcium-exchange current; NT = normal Tyrode) 
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Figure 6.3: The effect of ethanol on atrial and ventricular cardiomyocyte action potentials (APs). A) Acute 
effect of ethanol on APs in human right atrial (RA) cardiomyocyte model for 1, 2 and 3 Hz pacing. B) AP 
duration (APD) and resting membrane potential (RMP) at baseline and for 0.8, 80 and 400 mM ethanol during 
1-Hz pacing (top), as well as APD and RMP rate dependence (bottom). C, D) Similar to panels A-B for the 
human left ventricular (LV) cardiomyocyte model. E) Impact of ethanol (80 mM)-dependent regulation of 
individual ion currents on APD and RMP in RA (left) and LV (right) models. Dotted horizontal line represents 
values of the baseline model (100%), for comparison. (APD = action potential duration; INa = fast sodium 
current; ICa,L = L-type calcium current; Ito = transient-outward potassium current; IK1 = inward-rectifier 
potassium current; IKur = ultra-rapid delayed-rectifier potassium current; IKr = rapid delayed-rectifier 
potassium current; IK,ACh = acetylcholine-activated inward-rectifier potassium current; INCX = sodium/calcium-
exchange current; LV = left ventricle; RA = right atrium; RMP = resting membrane potential)  
Subsequently, single-cell simulations incorporating ethanol-dependent 
regulation of all these cardiac ion channels were performed using both the 
Courtemanche human RA and Passini human LV cardiomyocyte models. Binge alcohol 
drinking is defined as blood alcohol concentrations above 0.8‰, with values exceeding 
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5‰ resulting in a high possibility of coma or death (383). Blood alcohol concentrations 
in the MunichBREW study ranged from 0 to 2.94‰ with a mean of 0.85‰. Accordingly, 
we analyzed low (0.8 mM, corresponding to ~0.04‰) and high (80 mM, corresponding 
to ~3.64‰) ethanol concentrations. In addition, 400 mM ethanol was applied to study 
the maximal cellular effect (Figure 6.1C). Compared to the baseline atrial model 
without ethanol effects, 0.8 mM ethanol prolonged APD at 90% of repolarization 
(APD90) by 15 ms (4.6%) at 1 Hz pacing and slightly depolarized the resting membrane 
potential (RMP) by 0.7 mV (0.9%) in the human RA cardiomyocyte model, without 
affecting ventricular APs. Meanwhile, 80 and 400 mM ethanol reduced APD90 in the 
atrial model by 28 ms and 52 ms (8.4% and 15.4%), but prolonged the APD90 in the 
ventricle by 28 and 78 ms (10.2% and 28.3%; Figure 6.3). The potential influence of 
ethanol-induced heart-rate changes were assessed by simulating elevated pacing rates 
(2 and 3 Hz). The ethanol-induced alterations in atrial and ventricular APDs were 
reduced compared to 1-Hz pacing for all cellular concentrations. By contrast, the effects 
of ethanol on RMP in the human RA model were slightly augmented at fast rates (Figure 
6.3).  
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Figure 6.4: Effects of ethanol on a population of models reflecting intra- and inter-subject variability. The 
population was built from 1000 models by scaling the maximum conductance of 10 major ionic currents (INa, 
ICa,L, INaL, Ito, IK1, IKr, IKs, INCX, INaK and IKur) based on a normal distribution with sigma = 0.2. A) Action potentials 
(APs) for the 1000 human right atrial (RA) models at baseline (0 mM ethanol) and in the presence of 0.8 or 
80 mM ethanol. Non-physiological APs with APD90 shorter or longer than 3 standard deviations of 
experimental data obtained from (381, 382) (shown in grey), were excluded. B) Histogram of absolute APD90 
for the 3 ethanol concentrations (0, 0.8 and 80 mM) of the 960 included models. C) Histogram of ΔAPD90 
(relative to baseline). The dark grey shaded area represents APD reduction, while light grey corresponds to 
APD prolongation. D-F) Similar to panels A-C for the human left ventricular (LV) cardiomyocyte model based 
on 1000 included models. 
To address the effects of intra- and inter-subject variability, populations of 
1000 RA and LV models were simulated and analyzed. Following the exclusion of “non-
physiological” APs, 960 atrial models and 1000 ventricular models were used (Figure 
6.4A). The frequency distributions of APD90 with 0, 0.8 and 80 mM ethanol (Figure 
6.4B) and the histogram of relative ethanol-induced APD90 changes (Figure 6.4C) 
revealed consistent atrial APD-prolonging effect at low concentrations (Median: 
104.3% of baseline, IQR: 103.6-105.2) and atrial APD-shortening at high concentrations 
(Median: 90% of baseline, IQR: 87-93). In the ventricles, low concentrations of ethanol 
produced consistent minor APD prolongation (Median: 100.9%, IQR: 100.8-100.9), 
while high concentrations of ethanol demonstrated a wide range of effects on APD 
(Median: 102.5%, IQR: 101.1-104.2; Figure 6.4E-F). Thus, the results obtained with the 
default models appear representative for a wide range of ion-current densities, 
representing different virtual genotypes.  
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Figure 6.5: The effect of ethanol on cardiac action potentials (APs) of the diseased heart. A) Acute effect of 
ethanol on APs in long-standing persistent atrial fibrillation (cAF) cardiomyocyte model for 1, 2 and 3 Hz 
pacing. B) AP duration (APD) and resting membrane potential (RMP) for 0.8, 80 and 400 mM ethanol during 
1-Hz pacing (top), as well as APD and RMP rate dependence (bottom). C, D) Similar to panels A and B for the 
heart failure (HF) cardiomyocyte model. (APD = action potential duration; RMP = resting membrane 
potential) 
To investigate the effects of ethanol in remodeled cardiomyocytes, 
electrophysiological remodeling observed in cAF (340) and HF (375) were 
incorporated into the Courtemanche RA and Passini LV model, respectively. Cellular 
simulations using these remodeled cardiomyocyte models showed qualitatively similar 
ethanol-induced electrophysiological changes as the control models: low 
concentrations of ethanol prolonged APD in the cAF model, while high concentration of 
ethanol shortened the APD in the cAF and prolonged APD in the HF model (Figure 6.5). 
The ethanol-induced changes in relative APD were slightly larger in the presence of 
disease-related remodeling than in the control models. These results indicate that the 
cellular effects of ethanol are robust and may potentially have proarrhythmic 
consequences under a wide range of conditions. 
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Figure 6.6: Individual contributions of ethanol-induced ion channel remodeling on cardiac cellular 
electrophysiology (focused on low concentration of ethanol). Each line represented the acute effect of ethanol 
on all currents (red) and single current (other colors, see legends), compared to the baseline with no ethanol-
induced ion-channel remodeling (black). 
 
Figure 6.7: Individual contributions of ethanol-induced ion channel remodeling on cardiac cellular 
electrophysiology (focused on high concentration of ethanol). Each line represented the acute effect of 
ethanol on all currents (red) and single current (other colors, see legends), compared to the baseline with no 
ethanol-induced ion-channel remodeling (black). 
Exploiting the perfect control offered by computational modeling, the 
individual contribution of each ethanol-dependent ion-channel alteration to the change 
in cardiomyocyte AP was assessed. The APD prolongation and slight RMP 
depolarization observed with 0.8 mM ethanol in the atrial cardiomyocyte model were 
entirely due to the inhibition of IK1 (Figure 6.6). At high ethanol concentrations, a 
complex, cell-type-specific interplay among ionic currents was identified. For example, 
the APD prolongation in the human LV model resulted from the interaction between 
INCX and IKr. On the other hand, the atrial APD shortening was mainly due to the ethanol-
induced increase in IK1, opposed by the APD-prolonging effects of INCX and IKr (Figure 
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6.3E, lower panel). The complete overview of the individual ionic contributions to 
ethanol-induced AP changes is provided in Figures 6.6-6.8. 
 
Figure 6.8: The sensitivity analysis of ethanol-induced ion channel remodeling. The cellular effect of ethanol 
on cardiac ion channels were evaluated independently and compared to the base model and the model with 
combined effect. The APD, RMP and calcium-transient amplitude for both low and high concentration of 
ethanol are shown. 
 
6.3.2 The acute effects of ethanol on reentrant arrhythmias 
Two-dimensional tissue simulations were performed using both atrial and ventricular 
models to investigate the acute effects of ethanol on reentrant arrhythmias induced 
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using an S1S2 pacing protocol (Figure 6.9). Previously described ethanol-induced 
reductions in intercellular coupling (364, 384, 385) were incorporated into the models 
based on a Hill equation with an IC50 of 320 mM and Hill coefficient of 1 (see Appendix 
C). The vulnerable windows, reflecting the duration of reentry induced for different S1S2 
intervals, were evaluated to assess both the inducibility and stability of reentrant 
arrhythmias under different conditions (Figure 6.9). The size of the vulnerable 
windows indicates the inducibility of reentry (i.e., the number of S1S2 intervals 
producing reentry) and the duration of reentry within the vulnerable windows 
indicates the stability of reentrant arrhythmias. Since reentry durations can be distinct 
for different S1S2 intervals, both factors were combined into a total arrhythmogenic risk 
parameter by summing the reentry durations over the entire vulnerable window 
(Figure 6.9) to provide a single quantitative assessment of the proarrhythmic effects 
of ethanol under a given condition.  
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Figure 6.9: Acute effects of ethanol on reentrant arrhythmias. The 2-dimensional in-silico studies were 
performed in homogenous 8x8 cm tissue of 4 different models: the human right atrial (A, left), the human left 
ventricular (A, right), the long-standing persistent (“chronic”) AF and the heart failure models (B, left and 
right, respectively). Reentrant spiral waves were assessed in the presence of 0, 0.8 and 80 mM ethanol for 
various S1S2 intervals, where the first stimulus (S1) was initiated from left to right, and the second stimulus 
(S2) excited the upper left quadrant of the tissue. The top panels show snapshots of reentrant waves at 
designated S1S2 intervals (330 ms in RA-control, 320 ms in LV-control, 220 ms in RA-chronic AF, and 400 ms 
in LV-Heart Failure), while the bottom panels show the complete vulnerable windows and the sum (Σ) of 
reentry duration for all S1S2 intervals tested, quantifying the total arrhythmogenic risk. Reentry persisting for 
more than 12 s was considered stable (colored as black in the heatmap of the vulnerable windows). (Ctl = 
control; LV = left ventricle; RA = right atrium) 
In the control human RA model, 0.8 mM ethanol reduced the duration of 
reentry and shifted the vulnerable window for reentry induction towards longer S1S2 
intervals (Figure 6.9A, left panel). On the other hand, 80 mM ethanol produced a slight 
increase in reentry duration and shifted the vulnerable window to shorter S1S2 intervals 
(Figure 6.9A, left panel). Stable reentry (i.e., reentry that persists after 12 s) could not 
be induced in the control RA model. In the control LV model, 0.8 mM ethanol did not 
have any effect on either the vulnerable window or the duration of reentry (Figures 
6.9A, right panels), consistent with the cellular results (Figure 6.3C-D). However, 80 
mM ethanol shifted the vulnerable window to longer S1S2 intervals, without a noticeable 
effect on reentry duration (Figure 6.9A, right panel). In general, reentry was more 
stable with a less meandering rotor core in the ventricular compared to the atrial model 
(Figure 6.10).  
 
Figure 6.10: Acute effects of ethanol on rotor tip trajectories of the reentrant waves. The 2-dimensional in-
silico studies were performed in homogenous 8x8 cm tissue of 4 different models: the human right atrial (RA) 
control model (A, left), the human left ventricular (LV) control model (A, right), the RA model with long-
standing persistent (“chronic”) AF and the LV model with heart failure (B, left and right, respectively). 
Reentrant spiral waves were assessed in the presence of 0, 0.8 and 80 mM ethanol for the indicated S1S2 
intervals, corresponding to the longest duration of reentry in each model. CV = conduction velocity. 
Compared to the control atrial model, the cAF model exhibited a more variable 
pattern of reentry durations for different S1S2 intervals: for some intervals, reentry was 
short, whereas for others, it was long (Figure 6.9B, left panel). Both low and high 
concentrations of ethanol increased reentry duration in the cAF model, with several 
S1S2 intervals producing stable reentry for both ethanol concentrations, suggesting an 
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ethanol-induced promotion of arrhythmia maintenance. Furthermore, the larger 
vulnerable window for high ethanol concentrations indicates an ethanol-induced 
increase in reentry inducibility in the cAF model. At high ethanol concentrations, the 
rotors of the cAF model also exhibited a more meandering core, highlighting the 
dynamicity of the reentrant waves (Figure 6.10B, left panel).  
To simulate the effect of ethanol on reentrant arrhythmias in the setting of HF, 
a 40% reduction in intercellular coupling was applied to simulate HF-related gap-
junction remodeling (386, 387), in addition to the ion-channel remodeling (375). 
Consequently, the conduction velocity was reduced from 50 cm/s in the control LV 
model to 31 cm/s in the HF model (Figure 6.10A-B, right panels), consistent with 
previous experimental data (386). HF-associated remodeling increased reentry 
duration at baseline and for all ethanol concentrations and produced a larger window 
of stable reentry (Figure 6.9B, right panel). Consistent with the control LV model, low 
ethanol concentrations did not affect reentry in the HF model, whereas high ethanol 
concentrations resulted in a larger window of stable reentry (Figure 6.9B, right panel), 
highlighting the proarrhythmic role of high ethanol concentrations in HF. Thus, at the 
tissue level, ethanol’s proarrhythmic effects are more outspoken in the presence of 
disease-related remodeling. 
To investigate if these proarrhythmic effects also occur in the presence of 
ethanol concentrations closer to the cut-off value for heavy episodic drinking (0.8‰), 
we investigated the consequence of 20 and 40 mM ethanol (~0.91‰ and ~1.82‰, 
respectively) on reentrant arrhythmias in the cAF and HF models. In cAF, ethanol 
produced a concentration-dependent increase in the duration of reentry with several 
episodes of stable reentries at 20 and 40 mM (Figure 6.11). In HF, both 20 and 40 mM 
ethanol produced a larger window of stable reentry compared to the baseline HF model 
(Figure 6.11). These results confirm the potential proarrhythmic effects of ethanol at 
these concentrations.  
 
Figure 6.11: The concentration-dependent effects of ethanol on vulnerable windows for reentrant 
arrhythmias. Two ethanol concentrations were added to represent the moderate-low (20 mM) and moderate-
high (40 mM) concentrations of ethanol. The S1S2 induction protocol was performed in cAF and HF models 
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without structural remodeling. The vulnerable windows (upper panels) and the sum (Σ) of vulnerable 
windows (lower panels) were shown and compared with base, low and high ethanol concentrations. (RA = 
right atrium; LV = left ventricle) 
To study the effect of intra- and inter-subject variability on the ethanol-
dependent promotion of reentrant arrhythmias, models with the shortest and longest 
APD90 were selected from both the atrial and ventricular populations (Figure 6.12). As 
expected, vulnerable windows were shifted to longer S1S2 intervals and stability of 
reentrant waves was reduced in the models with long APDs, while short APDs 
promoted reentry. In general, the ethanol-induced effects on reentry in the maximum 
APD models (Figure 6.12A-B, middle panels) and minimum APD models (Figure 
6.12A-B, right panels) were consistent with the default models, displaying 
proarrhythmic effects in the presence of high concentrations of ethanol. 
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Figure 6.12: The effect of variability of the ionic currents on ethanol-associated reentrant arrhythmias. We 
extended the analysis of intra- and inter-subject variability using the populations of models depicted in Figure 
6.4 to 2-dimensional homogenous tissue simulations. The shortest and the longest action potential duration 
(APD90) in the population were chosen and reentries were simulated for three different ethanol 
concentrations (0, 0.8, and 80 mM). A) Action potentials of the default model, model with longest APD and 
model with the shortest APD in the presence of 0 (black), 0.8 (red) or 80 (green) mM ethanol. B) Vulnerable 
windows for the three different ethanol concentrations for the default model, the model with longest APD90 
and the model with shortest APD90. C) The sum (Σ) of atrial vulnerable windows, quantifying the total 
arrhythmogenic risk for the three models and three different concentrations of ethanol. D, E, F) Similar to 
panels A-C for the human LV model. The changes (in %) in the ionic current maximum conductances for the 
models with shortest and longest APD are shown in the small tables below the bar charts. 
 
6.3.3 The role of gap-junction remodeling in ethanol-induced promotion of 
reentrant arrhythmias 
Altered intercellular coupling is an important feature of HF (386, 387). Therefore, we 
investigated how ethanol- and HF-induced altered intercellular coupling interact. The 
comparison of HF models with (Figure 6.13, left panel) and without (Figure 6.13, 
middle panel) ethanol-induced gap-junction remodeling revealed no significant 
differences in reentry inducibility or stability for the baseline model and 0.8 mM 
ethanol. However, with 80 mM ethanol, the absence of ethanol-induced gap-junction 
remodeling reduced the occurrence of stable reentry and shortened the vulnerable 
window (Figure 6.13, left and middle panels), highlighting the critical role of reduced 
intercellular communication in ethanol-induced reentry promotion in HF. Conversely, 
the absence of ethanol-induced remodeling of intercellular coupling in both the control 
and cAF RA models did not significantly alter the effect of ethanol on atrial reentrant 
arrhythmias (Figure 6.14).  
 
Figure 6.13: The role of gap-junction remodeling in ethanol-induced reentry promotion in heart failure. 
Human LV models representing the setting of heart failure with both ethanol- and HF-induced (left panels), 
without ethanol-induced (middle panels) and without both ethanol- and HF-induced (right panels) gap-
junction remodeling in the presence of different concentrations of ethanol. For each condition, the rotor tip 
trajectories (top), vulnerable windows (middle) and the sum (Σ) of vulnerable windows (bottom), were 
determined. (Ctl = control; CV = conduction velocity; LV = left ventricle) 
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Figure 6.14: Acute effects of ethanol on reentrant arrhythmias in the absence of ethanol-induced intercellular 
coupling abnormalities. The 2-dimensional in-silico studies were performed in homogenous 8x8 cm tissue of 
human right atrial (left panel) and long-standing persistent (“chronic”) AF models (right panel). The tip 
trajectories are shown in the upper panels. The vulnerable windows were assessed for 0, 0.8 and 80 mM 
ethanol (middle panels) and bottom panels quantify total arrhythmogenic risk as the sum (Σ) of vulnerable 
windows (i.e., the sum of reentry duration for all S1S2 intervals tested). Reentry persisting for more than 12 s 
was considered stable (black bars in the vulnerable windows). (Ctl = control; CV = conduction velocity; LV = 
left ventricle; RA = right atrium) 
The absence of HF-related gap-junction remodeling also drastically reduced 
the episodes of stable reentry in two-dimensional simulations of the HF model for all 
concentrations of ethanol (compare Figure 6.13, middle and right panels). Strikingly, 
no stable reentry could be induced in the HF model without gap-junction remodeling 
(by either HF or ethanol) in the presence of simulated high ethanol concentrations 
(Figure 6.13). The inability to induce stable reentry in the LV model without gap-
junction-associated remodeling was due to the APD-prolonging effect of ethanol-
induced IKr inhibition and INCX augmentation (Figure 6.15). 
 
6.3.4 The interaction between ethanol and structural remodeling modulates 
reentrant arrhythmia stability 
Structural remodeling, notably cardiac fibrosis, is a key feature of cAF and HF and may 
act as a substrate for cardiac arrhythmias, favoring reentrant waves to occur and persist 
(64, 388). In addition, long-term ethanol abuse can produce structural remodeling, 
promoting alcoholic cardiomyopathy (364, 372, 389). As such, we assessed the acute 
effects of ethanol in the presence of mild (4% fibrotic tissue), moderate (11% fibrotic 
tissue) and extensive (20% fibrotic tissue) structural remodeling (Figure 6.16A). In the 
cAF models with 0 or 0.8 mM ethanol, extensive fibrosis slightly reduced the duration 
of reentry compared to mild fibrosis, whereas in the presence of high ethanol 
concentrations, moderate and extensive fibrosis resulted in a substantial reduction of 
stable reentry (Figure 6.16B, green bars). By contrast, in the ventricle, extensive 
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fibrosis increased the duration and improved the stability of reentry for all ethanol 
concentrations tested (Figure 6.16C, Online Videos 1-2). Subsequent analyses 
revealed that the differences between atrial and ventricular models were likely due to 
the stronger meandering of rotors in the atrial model compared to the ventricle, which 
increases the likelihood of wave break, collisions and subsequent termination of 
reentrant waves in the presence of extensive fibrosis. Overall, these data show that the 
proarrhythmic effects of ethanol depend on ethanol concentration, cell-type, as well as 
underlying structural remodeling. 
 
Figure 6.15: The analysis of the potential antiarrhythmic effect of high concentration of ethanol in the Passini 
human left ventricular model without ethanol-associated gap-junction remodeling. 1) Baseline model, 2) Low 
concentration of ethanol, 3) High concentration of ethanol with all documented ion channel remodeling 4) 
High concentration of ethanol without ethanol-induced INCX change 5) High concentration of ethanol without 
ethanol-induced IKr inhibition 6) High concentration of ethanol without both ethanol-induced INCX change and 
IKr inhibition. 
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Figure 6.16: Impact of fibrosis on reentrant arrhythmias in the absence or presence of ethanol. Three degrees 
of fibrosis (mild, moderate and extensive) were simulated and the effects of ethanol in the presence of such 
structural remodeling were simulated. A) Random patterns of mild, moderate and extensive fibrosis. B) The 
vulnerable windows for reentry for the three degrees of fibrosis in baseline (0 mM), low (0.8 mM) and high 
(80 mM) ethanol concentrations in the right-atrial (RA) model with chronic atrial fibrillation (AF)-related 
remodeling. Bottom panels quantify total arrhythmogenic risk as the sum (Σ) of vulnerable windows (i.e., the 
sum of reentry duration for all S1S2 intervals tested). C) Similar to panel B for the human left-ventricular (LV) 
cardiomyocyte model with heart failure-related remodeling. (LV = left ventricle; RA = right atrium) 
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Subsequently, we investigated the potential impact of border-zone 
cardiomyocytes in HF after myocardial infarction (MI) on reentry in the presence of 
different concentrations of ethanol. Border-zone-associated electrical remodeling of 
cardiac ion channels (Figure 6.17) and a 50% reduction in intercellular coupling with 
border-zone cardiomyocytes was simulated as previously reported (375, 377, 378). 
The effect of ethanol was subsequently investigated when the border zone was applied 
to the fibrotic tissue for the three different degrees of fibrosis presented in Figure 
6.16A. The mild fibrosis model contained 7% border zone, the moderate fibrosis model 
contained 21% border zone and the extensive fibrosis model contained 27% border 
zone (Figure 6.18A). Surprisingly, the presence of border-zone cardiomyocytes did not 
have a significant impact on reentry in the presence of mild or moderate fibrosis, 
independent of the absence or presence of ethanol. With extensive fibrosis, the 
presence of border-zone cells even reduced the duration of reentry and resulted in 
fewer episodes of stable reentry, particularly in the presence of ethanol (Figure 6.18B). 
Under these conditions, electrical conduction through a number of conduits between 
patches of fibrosis was blocked in the presence of border zone-related conduction 
abnormalities, thus reducing the likelihood of stable reentry (Online Video 3). 
 
Figure 6.17: The simulated cardiomyocyte APs comparing the control model, the heart failure model (remote 
area) and the border zone. The Passini human left ventricular model was employed and subsequent ionic 
changes as reported by Hegyi et al. (375) were applied. The ionic changes employed to the model were shown 
in the table. The border-zone ionic changes were displayed relative to control. 
Acute effects of alcohol on cardiac electrophysiology and arrhythmogenesis 
156 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 6
 
 
Figure 6.18: The impact of border-zone-associated remodeling on ethanol-dependent modulation of 
reentrant arrhythmias. A) Random patterns of mild, moderate and extensive fibrosis with border zone (light 
green color). Border zone was incorporated by applying both cellular remodeling and 50% reduction of 
intercellular coupling, as previously reported (375, 377, 378). B) Reentry vulnerable windows of conditions 
with border zone, as well as the sum (Σ) of vulnerable windows comparing conditions without (hatched bars, 
from Figure 6.16C) and with border zone, for baseline, low (0.8 mM) and high concentration (80 mM) of 
ethanol. (BZ = border zone; LV = left ventricle) 
Besides the degree of fibrosis, we also investigated the effects of different types 
of randomly generated fibrosis (patchy, compact and diffuse (390)) on ethanol-
associated reentrant arrhythmias (Figure 6.19A). We initially simulated a mild degree 
of fibrosis (4-5% fibrosis) for all three fibrosis types. However, as previously reported 
(391), the 4% diffuse fibrosis significantly impaired wave propagation. Therefore, we 
had to reduce the amount of fibrosis to 1.2% to maintain wave propagation throughout 
the tissue. Nevertheless, the effects of ethanol on reentry were consistent among the 
three types of fibrosis, with a reduction of total arrhythmogenic risk for low ethanol 
concentrations and an increased risk with high ethanol concentrations in the atria 
(Figure 6.19B). In the ventricles, low ethanol concentrations did not affect 
arrhythmogenic risk, whereas high concentrations increased the risk substantially 
(Figure 6.19C). The three fibrosis patterns produced different behaviors of reentrant 
waves, which was partly influenced by the rotor tip stability (Figure 6.10) and ethanol-
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induced ion channel remodeling (Online Video 4-6). Online Video 5 displays three 
types of reentrant waves that can occur with different ethanol concentrations in the 
presence of compact fibrosis: stable reentry anchored to the fibrosis, functional reentry 
occurring independent from the fibrosis and unstable reentry with multiple wavelets. 
The latter two only occurred in the presence of high concentrations of ethanol.  
 
Figure 6.19: Ethanol-induced reentrant arrhythmias in the presence of different types of fibrosis. A) Three 
types of fibrosis: patchy, compact and diffuse fibrosis, all representing mild structural remodeling. B) The 
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vulnerable windows for reentry for the three types of mild fibrosis at baseline (0 mM) and for low (0.8 mM) 
and high (80 mM) ethanol concentrations in the right-atrial (RA) model with chronic atrial fibrillation (AF)-
related remodeling. Bottom panels quantify total arrhythmogenic risk as the sum (Σ) of reentry duration for 
each vulnerable window. C) Similar to panel B for the human left-ventricular (LV) cardiomyocyte model with 
heart failure-related remodeling. (LV = left ventricle; RA = right atrium) 
 
Figure 6.20: Fibrosis pattern and ethanol-induced reentrant arrhythmias. A) Three random patterns of 
fibrosis, all representing mild structural remodeling. B) The vulnerable windows for reentry for the three 
patterns of mild patchy fibrosis in baseline (0 mM), low (0.8 mM) and high (80 mM) ethanol concentrations 
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in the right-atrial (RA) model with chronic atrial fibrillation (AF)-related remodeling. Bottom panels quantify 
total arrhythmogenic risk as the sum (Σ) of reentry duration for each vulnerable window. C) Similar to panel 
B for the human left-ventricular (LV) cardiomyocyte model with heart failure-related remodeling. (LV = left 
ventricle; RA = right atrium) 
Finally, we investigated whether the configuration of patchy fibrosis also 
affected reentry behavior in the absence or presence of ethanol. Three different random 
patterns of patchy fibrosis with similar mild degrees of fibrosis (4-5%) were generated 
(Figure 6.20A). As shown in Figure 6.20B, all patterns demonstrated markedly 
different reentry behavior with pattern 2 being the most proarrhythmic pattern of the 
three random fibrosis patterns tested, exhibiting stable reentries for all ethanol 
concentrations, even in the baseline cAF model (0 mM ethanol). Consistent with our 
simulations in the absence of structural remodeling, high concentrations of ethanol 
increased the stability of reentrant waves and led to more episodes of stable reentry in 
all patterns (Figure 6.20B), highlighting the proarrhythmic effects of ethanol in high 
concentrations, independent of the pattern of fibrosis. However, the 
electrophysiological effects of low ethanol concentrations were pattern dependent, 
with proarrhythmic effects in some patterns (Figure 6.20B, pattern 2) similar to the 
results in homogeneous cAF tissue (Figure 6.9B), and antiarrhythmic effects in other 
patterns.  
In the HF model, pattern 2 also presented the most proarrhythmic behavior, 
resulting in several isolated S1S2 intervals with stable reentry surrounded by intervals 
with unstable or no reentry (Figure 6.20C, Online Video 7-8). By contrast, pattern 3, 
which numerically has the largest amount of fibrosis (5%), resulted in the lowest total 
reentry vulnerability. In line with the effects in homogeneous tissue, ethanol shifted the 
vulnerable window towards longer S1S2 intervals in all patterns. However, the effect of 
ethanol on total reentry vulnerability was pattern dependent, with limited 
concentration-dependent effects in pattern 1, but a strong concentration-dependent 
effect in pattern 3 (Figure 6.20C). 
 
6.4 Discussion 
In this study, we evaluated the acute effects of ethanol on cardiac electrophysiology and 
reentrant arrhythmias using a multiscale computational modeling approach. To the 
best of our knowledge, our study is the first to exploit the perfect control and 
observability offered by a multiscale in-silico approach to unravel the arrhythmogenic 
consequences of ethanol-induced ion-channel and gap-junction regulation in the 
absence and presence of a preexisting substrate. Using this approach, we demonstrated 
that ethanol had concentration-dependent electrophysiological effects, with high 
concentrations of ethanol promoting both the inducibility and stability of reentrant 
arrhythmias, particularly in the presence of disease-associated remodeling. The exact 
proarrhythmic effects were cell-type dependent and influenced by disease-related gap-
junction remodeling, as well as the degrees, types, and patterns of structural 
remodeling commonly accompanying underlying pathologies. 
 
6.4.1 Ethanol and cardiac ion channels 
Ethanol dose-dependently affects multiple cardiac ion channels, including INa, ICa,L, Ito, 
IK1, IKr and INCX in both atrium and ventricle, as well as IKur and IK,ACh in atrium (Figure 
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6.1A). Although the exact molecular mechanisms of ethanol-dependent ion-channel 
regulation have not been fully elucidated, several publications have shown that ethanol 
can alter ionic-current gating properties, leading to changes in channel open 
probabilities. For example, ethanol reduced the open probability and availability of 
cardiac sodium channel at moderate to high concentrations (392). The family of G-
protein coupled inward-rectifier potassium channels is activated by alcohols through a 
hydrophobic alcohol-binding pocket in the cytoplasmic domain in a 
phosphatidylinositol-4,5-bisphosphate (PIP2)-dependent manner. However, mutations 
in the proposed alcohol-binding pocket of Kir2.1 channels did not affect ethanol-
dependent inhibition of IK1, suggesting potentially different binding sites for activation 
and inhibition of IK1 by ethanol (393).  
In addition to direct ion-channel modifications, ethanol can activate 
intracellular signaling pathways, e.g., through oxidative stress and CaMKII, altering 
calcium-handling proteins, including SERCA2a activity and SR calcium leak, as well as 
reducing calcium-transient amplitude and myofilament calcium sensitivity (370, 371). 
These calcium-handling abnormalities may then affect transmembrane ion channels via 
their calcium-dependent regulation (394) and therefore, contribute to ethanol-induced 
AP changes.  
By reproducing whole-cell ion-currents measured in cardiomyocytes in the 
presence of different concentrations of ethanol, our computational approach 
incorporates all functional consequences of ethanol on these ion channels, independent 
of the exact underlying molecular mechanism. 
 
6.4.2 The potential cardioprotective effects of low ethanol concentrations 
The potential protective effects of low and moderate alcohol intake on cardiovascular 
health has been studied for decades. Moderate alcohol consumption lowered the 
morbidity and mortality risks from cardiovascular diseases, and led to more favorable 
cardiovascular health profiles (358, 395). Moreover, although ethanol consumption 
was associated with an increased risk of AF, the attributable risk of ethanol 
consumption within recommended limits without acute excessive episode (binge) 
drinking was insignificant (396).  
Our in-silico study employing both human RA and LV models demonstrated the 
antiarrhythmic effect of acute low concentrations of ethanol in the RA model. Low 
ethanol concentrations slightly prolonged the atrial APD, depolarized the RMP and 
reduced the reentry duration, without significantly affecting ventricular 
electrophysiology. The atrial APD prolonging effect is retained in the presence of cAF-
related remodeling, although in the two-dimensional tissue simulations, the 
antiarrhythmic effect was diminished. Ethanol-induced IK1 inhibition was responsible 
for the effects on atrial APD and reentry, consistent with previous experimental and 
computational studies highlighting the importance of IK1 in rotor stabilization and 
fibrillation termination (347, 397). However, the reduction in IK1 by low concentrations 
of ethanol could not overcome the cAF-induced increase in IK1 (340), which removed 
the protective effects of ethanol at the tissue level and led to an increased stability of 
reentrant waves in cAF. In addition, differences in ion-channel properties and 
distribution (e.g., higher availability of INa, lower expression of the ancillary subunit β1 
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of NaV1.5 and greater IK1) in the LV compared to RA may explain the absence of 
protective effects of low ethanol concentrations in the LV model (398). In general, 
extrapolation of these findings to long-term cardioprotective effects of low alcohol 
intake is challenging given ethanol’s many systemic effects. 
Our computer simulations also suggested potential protective effects of high 
concentrations of ethanol in the LV models without ethanol-induced gap-junction 
remodeling (Figure 6.13). This effect was achieved due to APD prolongation derived 
from ethanol-induced IKr block and INCX augmentation (Figure 6.15). Although 
epidemiological data have suggested possible benefits of moderate drinking on the risk 
of HF and mortality after onset of HF (399), our in-silico study indicates that acute 
antiarrhythmic effects were only present in the absence of substantial alterations to the 
intercellular coupling, which would only apply to the earliest stage of HF (386). These 
data are consistent with known antiarrhythmic effects of class-III antiarrhythmic drugs, 
as well as with their proarrhythmic potential in the presence of structural remodeling. 
 
6.4.3 The detrimental effects of high ethanol concentrations 
The detrimental effects of acute excessive ethanol consumption have been described in 
many studies (358, 362, 363, 372, 395). Ethanol alters cardiac cellular 
electrophysiology, acutely slowing the conduction velocity (364, 385). Chronically, 
ethanol further impairs excitation-contraction coupling and promotes structural 
remodeling, including LV dilatation, reduced LV wall thickness and increased LV mass. 
In advanced stages, this leads to a reduction in LV ejection fraction and the development 
of an alcoholic cardiomyopathy (372, 389). Here, we confirmed the acute detrimental 
effects of high ethanol concentrations and provide new insights on the underlying 
mechanisms. In particular, high ethanol concentrations shortened APD and 
hyperpolarized the RMP in the atrial model, promoting reentry. These effects resulted 
mainly from the ethanol-induced increase of IK1, opposed partially by increased INCX and 
decreased IKr. The ethanol-induced hyperpolarization of the RMP in the atria is vital, as 
it may increase the availability of INa and further enhances cardiac excitability (397). By 
contrast, ethanol-induced augmentation of INCX and inhibition of IKr prolonged APD in 
the ventricle, both in the control and HF models. The ethanol-induced conduction 
velocity slowing in cardiac tissue further increased the propensity for reentrant 
arrhythmias. Particularly in HF, the combination of disease- and ethanol-induced INa 
and gap-junction remodeling produced substantial conduction slowing, consistent with 
experimental observations (387).  
Ethanol also promotes SR calcium leak and increases SERCA uptake and NCX 
function, promoting diastolic SR calcium release events and reduces the calcium-
transient amplitude (370). The latter then alters excitation-contraction coupling and 
impairs cardiac contractility. Although more detailed, spatial calcium-handling models 
are required to simulate spontaneous SR calcium release events (394), in our in-silico 
study, the Passini human LV model similarly showed an ethanol-dependent reduction 
of calcium-transient amplitude (Figures 6.7-6.8). Despite similar concentration-
dependent regulation of INCX and SR calcium leak by ethanol in the atrial and ventricular 
models (Figure 6.1C), the ethanol-dependent reduction in calcium-transient amplitude 
was not present in the RA model, likely due to baseline differences in calcium handling 
between both models and the complex interplay and counteracting effects of ethanol-
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dependent regulation of SERCA, NCX and SR calcium leak (Figure 6.21). The larger 
calcium-transient amplitude in the RA model than in the LV model (Figure 6.21) also 
contributes to the large effect of ethanol-dependent INCX regulation in the RA model 
(Figure 6.3E). 
 
Figure 6.21: The acute effects of ethanol on calcium-handling proteins. As reported by Mustroph et al. (370), 
in addition to the increase of INCX, ethanol also increased the SERCA uptake and SR calcium leak. The 
implication of ethanol-induced remodeling of SERCA and SR calcium leak on calcium-handling proteins was 
analyzed. The upper panel showed the combination of both increased SERCA uptake and SR calcium leak. The 
middle panel showed the effect of increasing SR calcium leak only. The lower panel displayed the effect of 
increasing SERCA uptake only. All simulations were performed under high concentration of ethanol (80 mM) 
in both control human right atrial and human left ventricular models. 
 
6.4.4 The role of multiscale computational modeling in predicting the impact of 
ethanol-induced arrhythmias 
Despite the strong clinical association between excessive alcohol consumption and 
cardiovascular morbidity and mortality, the interaction between disease-related 
cardiac remodeling and ethanol-induced changes in cardiac electrophysiology has not 
been fully elucidated. Using the perfect control and observability provided by 
computational modeling, we were able to predict the acute effect of ethanol in the 
presence of cAF or HF-related ion-channel and calcium-handling remodeling, as well as 
in the presence of different degrees, types and patterns of structural remodeling (i.e., 
fibrosis). We show that the degree, type and pattern of fibrosis play an important role 
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in the proarrhythmic effects of ethanol. In particular, our analyses reveal that the 
impact of fibrosis depends significantly on the baseline rotor behavior. For example, 
extensive fibrosis has a smaller effect on a stable rotor core compared to a meandering 
core, because collisions with fibrotic tissue and subsequent wave break occur more 
frequently in the latter condition. This effect can be seen in Figure 6.16, where the high 
concentration of ethanol reduced the duration of reentry in cAF model (which exhibited 
a more meandering core) yet increased it in HF model (which showed a more stable 
core) with extensive fibrosis. Thus, at the tissue level, the potential proarrhythmic 
effects of high ethanol concentrations strongly depend on the preexisting substrate. 
This highlights the potential benefit of a personalized computational modeling 
approach to accurately address the clinical implication of ethanol-induced arrhythmias. 
Cardiac imaging modalities, such as magnetic resonance imaging (MRI) can provide 
personalized scar patterns, including the border zone area. Such imaging information 
may function as an input for modeling work, replacing the randomly assigned fibrosis 
that was used in the present study. However, the spatial resolution of MRI is still 
relatively limited and may not be sufficient to capture detailed fibrotic patterns, 
although specialized sequences with improved resolution are being developed (400). 
 
6.4.5 Study limitations 
We investigated the effects of ethanol using extensively validated and well accepted 
human atrial and ventricular cardiomyocyte models. However, the available in-vitro 
data for the acute effects of ethanol on cardiac ion channels were obtained in different 
animal models. We assumed that the relative changes were similar across species. 
Furthermore, significant cell-to-cell variability in the acute effects of ethanol have been 
described (366, 367) and may result in diverse effects at higher scales (Figure 6.22) 
(401). For example, although one study showed a dual effect of ethanol on IK1 (366), 
another study failed to show any significant effect of ethanol on the channel formed by 
Kir2.1 subunits (402), which prevail in the ventricles. Some of the variability may be 
due to differences in the stoichiometry of the ion channels (403), although the exact 
mechanism needs to be further investigated. Our simulations using populations of 
models show that cell-to-cell variability in ion-channel expression (Figure 6.12), as 
well as variability in ethanol-dependent IK1 regulation can principally affect reentry 
vulnerability (Figure 6.22), but since the pattern of variability in ethanol-dependent 
regulation in tissue is unknown, this aspect was not elaborated further. 
In this study, we primarily simulated low (0.8 mM) and high (80 mM) cellular 
ethanol concentrations. However, in vivo, the local ethanol concentrations observed by 
cardiomyocytes depend on a variety of dynamic pharmacokinetic factors. 
Pharmacokinetics/-dynamics models exist and, in the future, could be implemented to 
obtain a more precise simulation of the electrophysiological consequences of different 
ethanol consumption patterns.  
In our models, the disease- and border zone-associated, as well as the ethanol-
induced alterations of intercellular coupling were equal in the transversal and 
longitudinal directions. However, anisotropy is acknowledged as an important 
determinant of reentry (347). Together with the structural heterogeneity of the cardiac 
tissue (e.g., fibrosis / scar), it alters the initiation and maintenance of reentrant waves. 
Similarly, the complex electrophysiological effects of ethanol may also be supported by 
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autonomic remodeling including acute activation of the sympathetic nervous system 
and vagal inhibition (364), which can produce spatial heterogeneous alterations in 
cardiac electrophysiology that have not been taken into account in our model. However, 
both components are expected to exacerbate the potential proarrhythmic effects that 
we characterized here. Finally, the role of potential atrioventricular interactions in 
generating cardiac arrhythmias has not been accommodated in our cell and tissue 
simulations. In the future, such interactions could be studied using whole-heart 
modeling approaches. 
 
Figure 6.22: The consequence of cell-to-cell variability of IK1 on the ethanol-induced reentrant arrhythmias. 
The experimental cell-to-cell variability of IK1 is shown on the left as black dots. The purple line indicates the 
mean IC50 values used as a modeling input. Two-dimensional tissue simulations were performed at 8mM 
ethanol and divided into 4 groups: The group incorporating only the maximum value of ethanol-induced IK1 
remodeling, i.e., +65% (red box), the minimum only, i.e., -20% (green box), the mean value (purple) and the 
heterogenous group, incorporating mixed IK1 densities from -20% to +65% (min to max) that were applied 
randomly and distributed uniformly (blue). 
 
6.5 Conclusions 
Our multiscale in-silico study provides new insights into the acute effects of ethanol on 
cardiac electrophysiology and arrhythmogenesis, demonstrating that ethanol has 
concentration-dependent electrophysiological effects that differ between atria and 
ventricles, and in the absence or presence of disease-related remodeling. Low 
concentrations of ethanol could have antiarrhythmic effects in the atria whereas high 
concentrations may promote reentrant arrhythmias. Ethanol-induced gap-junction 
remodeling is an important determinant of ethanol-induced reentrant arrhythmias. The 
exact proarrhythmic risk depends on the degree, type and pattern of disease-associated 
structural remodeling, and may be modulated by other co-factors, including autonomic 
nervous influences. Together, these findings highlight the necessity for a personalized 
multiscale computational modeling approach to better predict the consequences of 
ethanol on cardiac electrophysiology in humans. 
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ABSTRACT 
Cardiac arrhythmias are a global health burden, contributing significantly to morbidity 
and mortality worldwide. Despite technological advances in catheter ablation therapy, 
AADs remain a cornerstone for the management of cardiac arrhythmias. Experimental 
and translational studies have shown that commonly used AADs exert multiple effects 
in the heart, the manifestation of which strongly depends on the exact experimental or 
clinical conditions. This diversity makes the clinical application of AADs challenging. 
Here, we present a novel computational tool designed to facilitate a better 
understanding of the complex mechanisms of action of AADs (the Maastricht 
ANTiarrhythmic drug evAluator, MANTA). In this tool, we integrated published 
computational cardiomyocyte models from different species (mouse, guinea pig, rabbit, 
dog, and human), regions (atrial, ventricular, and Purkinje cells) and disease conditions 
(atrial fibrillation- and heart failure-related remodeling). Subsequently, we 
investigated the effects of clinically available AADs (Vaughan-Williams Classes I, III, IV 
and multi-channel blockers) on AP properties and the occurrence of proarrhythmic 
effects such as early afterdepolarizations. Steady-state drug effects were simulated 
based on a newly compiled overview of published IC50 values for each cardiac ion 
channel and by integrating state-dependent block of the cardiac sodium current by 
Class I AADs using a Markov-model approach. Using MANTA, we demonstrated and 
characterized important species-, rate-, cell-type-, and disease-state-specific AAD 
effects, including 1) a stronger effect of Class III AADs in large mammals than in rodents; 
2) a rate-dependent decrease in upstroke velocity with Class I AADs and reverse rate-
dependent effects of Class III AADs on action potential duration; 3) ventricular-
predominant effects of pure IKr blockers; 4) preferential reduction in atrial AP upstroke 
velocity with vernakalant; and 5) excessive AP prolongation with Class III AADs other 
than amiodarone under heart failure conditions. 
In conclusion, the effects of AADs are highly complex and strongly dependent 
on the experimental or clinical conditions. MANTA is a powerful and freely available 
tool reproducing a wide range of AAD characteristics that enables analyses of the 
underlying ionic mechanisms. Use of MANTA is expected to improve our understanding 
of AAD effects on cellular electrophysiology under a wide range of conditions, which 
may provide clinically-relevant information on the safety and efficacy of AAD treatment. 
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7.1 Introduction 
Cardiovascular diseases are the leading cause of death and disability worldwide, with 
cardiac arrhythmias significantly contributing to cardiovascular deaths (404). Despite 
advances in catheter ablation therapy, AADs remain widely used for the treatment of 
arrhythmias. However, currently available AADs have limited efficacy and important 
safety limitations, notably an increased risk of ventricular proarrhythmia and extra-
cardiac toxicity (405-407). Traditionally, AADs have been classified into Vaughan 
Williams Classes I-IV, targeting sodium channels, β-adrenoceptors, potassium channels 
and LTCC for Classes I, II, III and IV, respectively. However, experimental and 
translational research performed over the last 30 years has revealed that most AADs 
exert effects on multiple molecular targets and alternative classifications have been 
developed (5, 408, 409). In addition, the effects of AADs strongly depend on 
experimental/clinical conditions. For example, AADs exhibit species-dependent effects 
due to the distinct contribution of ion currents to the cardiac AP across species (410), 
which hinder the clinical translation of animal studies (411). Moreover, many AADs 
block ion channels in a rate- (or use-) dependent manner (412, 413). Some AADs (e.g. 
vernakalant and ranolazine) have preferential effects on atrial versus ventricular 
cardiomyocytes by targeting ion channels that are only expressed in the atria or 
preferentially inhibiting atrial sodium channels through state-selective blocking 
properties (414). Finally, disease-related remodeling can also influence the effects of 
AADs. These condition-dependent effects make a detailed understanding of the clinical 
efficacy of AADs highly challenging and contribute to the suboptimal use of currently 
available AADs under dynamic clinical conditions. Moreover, such effects may hinder 
the development of novel, more effective and safer AADs. 
Computational models can integrate experimental and pharmacological 
findings, and provide perfect control and observability of parameters, enabling in silico 
experiments in a controlled setting (10, 12, 94). Several software tools have been 
developed to enhance the understanding of cardiovascular (patho) physiology, ranging 
from cellular electrophysiology to hemodynamics in the entire cardiovascular system 
(12). For example, the CircAdapt® model simulates cardiovascular mechanics and 
hemodynamics to study (patho)physiology of heart and circulation (415) and ECGSIM 
solves the forward problem of electrocardiology to compute electrograms at the body 
surface that result from user-defined electrical activity at the heart surface (416). Both 
have also been used for educational purposes. However, to simulate AAD effects, 
detailed models of cardiac cellular electrophysiology are needed. Several relatively 
user-friendly tools have been developed to simulate cardiac cellular electrophysiology 
(417-421). However, these tools often focus on a single model and are limited in their 
ability to compare (state-dependent) AAD effects. Thus, despite the relevance of 
understanding the complex effects of AADs under various conditions, there is, to the 
best of our knowledge, no software tool available that addresses this critical issue. 
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Figure 7.1: Maastricht Antiarrhythmic Drug Evaluator (MANTA) and its components. MANTA is developed 
as an extension of Myokit, a software tool designed for cardiac AP simulations (344). MANTA enables analyses 
of the effects of AADs on the AP under user-defined experimental settings by integrating a large number of in 
silico cardiomyocyte models of various species with a newly compiled overview of pharmacodynamic 
properties of AADs from different Vaughan-Williams Classes. (APD: action potential duration, RMP: resting 
membrane potential, dV/dtmax: upstroke velocity, ERP: effective refractory period, IC50: half-maximal 
inhibitory concentration; INa: sodium current) 
Here, we present a novel, user-friendly software tool (the Maastricht 
ANTiarrhythmic drug evAluator; MANTA) that enables analyses of species- and 
condition-dependent effects of a wide range of clinically relevant AADs on cardiac ion 
currents, as well as their downstream effects on AP and CaT properties (Figure 7.1). 
MANTA may facilitate a better understanding of the complex effects of AADs, thereby 
promoting improved use of these drugs during experiments as well as increased 
awareness of their limitations under specific clinical conditions. Finally, it can provide 
insight into the proarrhythmic side-effects of some AADs. In addition to its research use, 
MANTA can be employed to teach students about the mechanism-of-action of currently 
available AADs. 
 
7.2 Methods 
7.2.1 The Maastricht antiarrhythmic drug evaluator (MANTA) 
MANTA was developed as an extension of Myokit, a python-based software tool 
designed for cardiac AP simulations (344). MANTA integrates a wide range of published 
cardiomyocyte models and AADs (based on their affinity for different cardiac ion 
channels, including state-dependent block of sodium channels, as detailed below). A 
graphical user interface was created, which provides easy access to settings, enabling 
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simulations of AAD effects under different conditions. A Python package was generated 
to facilitate installation of MANTA from the Python Package Index (PyPI) on Microsoft 
Windows-based platforms.  
MANTA displays simulation results of two in silico cardiomyocyte models side-
by-side (Figure 7.2A). By default, the AP and CaT are shown for both models, but drop-
down lists enable visualization of all model variables, including intracellular ion 
concentrations and ion currents. Simulation of up to two clinically available AADs at 
user-defined concentrations enables comparison of the electrophysiological effects of 
these agents. In “custom” mode, the activity of individual ion channels can be adjusted 
to study the effect of these changes on the AP, enabling simulations of novel AADs. 
Moreover, in the “options” panel, several properties of the experimental environment 
can be adjusted (Figure 7.2B), including the number of pre-paced beats, pacing 
frequency and extracellular ionic concentrations ([K+]o, [Na+]o, and [Ca2+]o). The AP 
duration (APD), maximum AP upstroke velocity (dV/dtmax) and CaT amplitude are 
automatically calculated for each model and condition. MANTA also enables the user to 
perform an S1S2 protocol simulation to calculate the frequency-dependent effective 
refractory period (ERP), which is defined as the shortest interval after the start of the 
last stimulus allowing the generation of a new AP. We considered a new AP to be 
generated when maximal membrane potential after 75% of the current APD90 exceeded 
80% of the peak of the current AP. Since this threshold may not be appropriate for all 
models and/or stimuli, manual confirmation of ERP detection is recommended. 
Subsequently, the results can be exported as comma-separated value (.csv) or text (.txt) 
files for further analysis (Figure 7.2B). 
 
7.2.2 Incorporation of computational models of cardiac cellular electrophysiology 
To investigate the effects of AADs at the cellular level, 17 previously published and 
validated in silico cardiomyocyte models (78, 263, 374, 422-430), reflecting different 
species, regions of the heart and disease-related remodeling, were incorporated into 
MANTA. Each model contains a number of ion currents and transporters with various 
degrees of complexity, ranging from basic Hodgkin-Huxley mathematical models to 
more complex Markov models. An overview of the computational cardiomyocyte 
models is provided in Table 7.1. 
 
7.2.3 AADs available in the current version of MANTA 
In total, 25 AADs belonging to Vaughan-Williams Classes I, III and IV, and exhibiting 
diverse cardiac ion-channel-blocking properties were included in MANTA (Table 7.2). 
AADs commonly used in clinical practice (flecainide, amiodarone) as well as more 
recent multi-channel blockers (e.g., vernakalant), were incorporated, but Class II AADs 
(β-blockers) were excluded from the tool due to the absence of β-adrenoceptor-
signaling components in most of the available cardiomyocyte models. To model the 
effect of an AAD on a cardiac ion channel, its maximal conductance was scaled based on 
the given drug concentration and a sigmoidal Hill curve based on previously reported 
IC50, as summarized in Table 7.2. Validation of each drug based on an overview of 
Maastricht antiarrhythmic drug evaluator (MANTA) 
172 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 7
 
published IC50 values and dose-response curves is provided in Table 7.3 and Figure 
7.3A-Y. Moreover, based on these IC50 values, AAD-induced changes in APD were 
largely consistent with experimental data in most models (Figure 7.4). 
 
Figure 7.2: The MANTA graphical user interface. MANTA displays two cardiomyocyte models side-by-side 
and enables comparison of up to two AADs at a user-defined concentration. A) Main MANTA screen, 
comparing the simulation results of two different computational models side-by-side, whilst automatically 
calculating the APD, dV/dtmax, and CaT amplitude. B) Additional tabs in the MANTA interface enabling 
alterations in simulation settings (including pacing frequency and different extracellular ionic 
concentrations), alterations in the IC50 and/or Hill coefficients of the selected drug for each ion-channel target, 
as well as allowing users to export the simulation results to comma-separated values (.csv) files for further 
analysis or data extraction. 
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No Species Region First Author Year Citation 
1 Mouse 
LV 
Bondarenko 2004 (422) 
2 
Guinea Pig 
Luo 1991 (423) 
3 Faber 2000 (424) 
4 Rabbit Mahajan 2008 (425) 
5 
Canine 
Decker 2009 (426) 
6 Heijman 2011 (78) 
7 
Human 
LV (Endo) 
O’Hara 2011 (263) 
8 Passini 2016 (374) 
9 LV(Mid) O’Hara 2011 (263) 
10 LV (Epi) O’Hara 2011 (263) 
11 HF LV (Endo) Passini 2016 (374) 
12 
RA 
Courtemanche 1998 (427) 
13 Schmidt 2015 (428) 
14 
cAF RA 
Courtemanche 1998 (427) 
15 Schmidt 2015 (428) 
16 
Purkinje 
Stewart 2009 (429) 
17 Sampson 2010 (430) 
Table 7.1: The computational cardiomyocyte models available in MANTA. LV: left ventricle, RA: right atrium, 
Endo: Endocardium, Mid: Midmyocardium, Epi: Epicardium, HF: heart failure, cAF: long-standing persistent 
(‘chronic’) atrial fibrillation. 
 ICa,L IK1 IKr IKs IKur Ito INa INa,L INaK INCX 
Class Ia 
Ajmaline 70  1  1.7 14 28    
Cibenzoline 20 33.7 15    15 45   
Disopyramide 1037  11   21 168.4    
Procainamide 340 33 300 810   646    
Quinidine 10  0.7 5 5 3.5 12 10   
Quinine 27  5 37  79 24 
11 
(h=0.4) 
  
Class Ib 
Lidocaine       20 10.8   
Phenytoin 22.07  120    80.41    
Ranolazine 250  12 100   200 8  91 
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Class Ic 
Flecainide 27.1  1.6  2.9 
10 
(h=0.8) 
6.5 
20 
(h=0.6) 
  
Propafenone 1.55  0.44 16  7.2 2.5 4   
Class III 
Ambasilide   3.6  35 23     
Acute amiodarone 
1.5 
(h=0.6) 
 3.0 100  
3.8 
(h=0.4) 
5 
9 
(h=0.4) 
 3.4 
Chronic 
amiodarone 
1.5 
(h=0.6) 
 
0.8 
(h=0.6) 
20 
(h=0.6) 
 
3.8 
(h=0.4) 
5 
9 
(h=0.4) 
 3.4 
Bepridil 2.8  0.16 6.1   2.2 1.8   
Dofetilide 26.7  0.008 415   150    
Dronedarone 4  2 10   
1 
(h=1.7) 
   
E-4031   0.008        
Ibutilide 62.5  0.02    42.5    
Niferidil 100 203 0.0382 28 60 203     
Sotalol 2100 2500 100 3500   7000    
Vernakalant 84  20  15 15 90 14   
Class IV 
Diltiazem 0.45  13    22    
Nitrendipine 0.025 417 20 19.5   21.5    
Verapamil 0.2  0.5  2.2  35    
Table 7.2: List of AADs and their IC50 values (in µM) and Hill coefficients for individual drug targets 
incorporated into MANTA. In total, MANTA includes 25 AADs, corresponding to Classes I, III and IV of the 
Vaughan-Williams classification, which can affect 10 major ion currents. Results are presented as IC50 and Hill 
coefficient or IC50 value only in case of a Hill coefficient of 1.0. 
 
7.2.4 Incorporation of state-dependent sodium current block in cardiomyocyte 
models 
Since Class I AADs have markedly different affinities for individual states of the sodium 
channel (open, closed, and inactivated) (431-433), we introduced a state-of-the-art 
sodium channel Markov model enabling simulation of state-dependent sodium channel 
block (Figure 7.5) (431) in each of the 17 cardiomyocyte models. The parameters of 
the baseline sodium current (INa) Markov models were optimized to produce similar 
peak amplitude, non-inactivating late current, voltage dependence of activation and 
inactivation, time constants of inactivation and recovery from inactivation of INa, along 
with upstroke velocity during current-clamp simulations as the original Hodgkin-
Huxley models in the absence of AADs. Details of the INa Markov model and the results 
of the optimization procedure are provided in Figure 7.5, 7.6. 
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The baseline Markov model was extended with drug-blocked states for neutral 
and charged fractions of Class I AADs, which have distinct affinities for open, closed and 
inactivated states (Figure 7.5) (431). In line with the approach by Moreno et al. (431), 
the parameters representing the affinities of flecainide and lidocaine for open, closed 
and inactivated states were fixed and parameters reflecting state transitions within 
blocked states were subsequently numerically optimized to reproduce experimentally 
observed drug-block properties for individual baseline INa Markov models (Appendix 
B). In particular, drug-induced shifts in steady-state availability, tonic block and rate-
dependent block at 5 Hz for various AAD concentrations, as well as frequency 
dependence from 1 to 10 Hz and recovery from rate-dependent block by flecainide and 
lidocaine could be reproduced using this Markov model (Figure 7.7). Parameters for 
vernakalant were similarly optimized to reproduce the tonic, rate-dependent and 
voltage-dependent block observed in experimental studies (434). 
Table 7.3: Published experimental IC50 values of antiarrhythmic drugs and final values used in MANTA 
D
R
U
G
 
SAMPLE 
ORIGIN 
IC50 OF CARDIAC ION CHANNELS (µM) 
REF 
ICa,L IK1 IKr IKs IKur Ito INa INa,L INaK INCX 
A
JM
A
L
IN
E
 
Rat (V) 
70.8± 
0.09 
  
61.0± 
1.10 
  
25.9± 
2.91 
27.8±
1.1 
(holdi
ng -
75 
mV), 
47.2±
1.1 
(holdi
ng -
120 
mV) 
   (435) 
Oocytes     186±
31.4 
292±
2.85   
   (436) 
CHO     1.70±
0.82 
2.66±
2.8   
   (436) 
HEK293 71  1.04  
    8.2 
   (437) 
MANTA 70  1  1.7 14 28     
A
M
B
A
SI
L
ID
E
 
Human (A)     
34.2±
2.9 
22.6±
1.9 
    (438) 
Canine (A)     
37.5±
1.6 
     (439) 
Human (A)      23.3     (440) 
CHO   3.6        (441) 
MANTA   3.6  35 23      
A
C
U
T
E
 
A
M
IO
D
A
R
O
N
E
 Rabbit (V)   2.8 
mini
mal 
      (442) 
Oocytes   38 300       (442) 
Oocytes   9.8        (443) 
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MANTA 1.5  3.0 100  3.8 5 9  3.4  
C
H
R
O
N
IC
 A
M
IO
D
A
R
O
N
E
 
HEK/CHO 1.28  0.94   3.76 4.58 9.423   (444) 
HEK/CHO 1.9  0.86    15.9    (445) 
HEK293 0.27  0.03    4.8    (437) 
Human (A)       
59% 
at 
3µM 
(4.3) 
   (446) 
Rabbit (A)       
1.8± 
1.1 
   (447) 
Rabbit (V)       
40.4±
11.9 
   (447) 
Guinea pig 
(A) 
         
3.3-
3.6 
(448) 
N/A   1        (449) 
ChanTest 1.903 342.9 0.863 47.20   15.85    (450) 
MANTA 1.5  0.8 20  3.8 5 9  3.4  
B
E
P
R
ID
IL
 
ChanTest 1.048 87.72 0.159 6.156   2.271    (450) 
HEK/CHO 2.8  0.2    2.9 1.814   (444) 
HEK/CHO 1  0.16    2.3    (445) 
HEK293 0.211  0.033    3.7    (437) 
N/A   0.6        (449) 
HEK/CHO 0.175  0.074    0.517 0.411   (451) 
MANTA 2.8  0.16 6.1   2.2 1.8    
C
IB
E
N
Z
O
L
IN
E
 
Guinea pig 
(V) 
30          (452) 
HEK/CHO   2.097    21.75 46.58   (444) 
N/A   23        (449) 
HEK293 30  22.6    7.8    (437) 
Guinea pig 
(V) 
14.4 33.7 23    7.8    (453) 
MANTA 20 33.7 15    15 45    
D
IL
T
IA
Z
E
M
 
HEK/CHO 0.112  6.569    >12.5    (444) 
Native heart 
cell 
  17.3        (454) 
N/A   10        (449) 
HEK/CHO 0.76  13.2    22.4    (445) 
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HEK293 0.45  17.3        (437) 
ChanTest 0.763 900 13.18 68.99   22.44    (450) 
MANTA 0.45  13    22     
D
IS
O
P
Y
R
A
M
ID
E
 
N/A   1.8        (449) 
Rat (V)   
37.2±
0.17 
  
20.9±
0.13 
    (455) 
CHO   
7.23±
0.72 
       (456) 
Model 1037  
10.66
±0.04 
  259 168.4    (457) 
HEK/CHO 1037  14.4    168.4    (445) 
MANTA 1037  11   21 168.4     
D
O
F
E
T
IL
ID
E
 
HEK/CHO >0.01 >0.01 0.002 >0.01  >0.01 >0.01 >0.01   (444) 
HEK/CHO 26.7  0.03    162.1    (445) 
HEK/CHO 26.7  0.005 415.8   147.9    (451) 
Oocytes   
0.11±
0.01 
       (458) 
Guinea pig 
(V) 
  
0.009
± 
0.002 
       (458) 
CHO   
0.01±
0.002 
       (458) 
HEK293   0.036        (459) 
AT1-cells   
11.2±
1.9 
       (460) 
AT1-cells   0.012        (461) 
N/A   0.005        (449) 
HEK293   0.039        (462) 
HEK293 60  0.005    300    (437) 
MANTA 26.7  0.008 415   150     
D
R
O
N
E
D
A
R
O
N
E
 
Human (A)       
INa 
77% 
at 0.3 
µM, 
3% at 
3 µM 
(0.55) 
   (446) 
Guinea pig 
(V) 
0.18 >30 2 10       (463) 
Canine (V) 
24% 
at 10 
µM 
(3.2) 
         (464) 
MANTA 4  2 10   1     
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E
-4
0
3
1
 
Human (A)     N.S. N.S.     (438) 
Oocytes   
0.17±
0.03 
       (458) 
Guinea pig 
(V) 
  0.010        (458) 
CHO   0.006        (458) 
Model   0.016        (457) 
MANTA   0.008         
F
L
E
C
A
IN
ID
E
 (
♠
) 
HEK/CHO >20  0.7 >20  9.27 6.7 18.9   (444) 
Oocytes       41    (465) 
HEK/CHO 27.1  1.5    6.2    (445) 
HEK293   
3.91±
0.68 
       (466) 
Human (A)     N.S. 12     (467) 
HEK293   1.7    11    (459) 
RVW       10.7    (468) 
Canine (A)     
2.9± 
0.24 
     (439) 
N/A   3.91        (449) 
HEK293     
38.14
±1.06 
     (469) 
MANTA 27.1  1.6  2.9 10 6.5 20    
IB
U
T
IL
ID
E
 
Oocytes   0.028        (470) 
Mouse  
AT-1 cell 
  0.02        (461) 
N/A   0.010        (449) 
HEK/CHO 62.5  0.018    42.5    (445) 
ChanTest 62.5 75.6 0.018 192.4   42.42    (450) 
MANTA 62.5  0.02    42.5     
L
ID
O
C
A
IN
E
 (
♠
) 
HEK/CHO       >15 10.8   (444) 
Oocytes       521    (465) 
HEK293   N.S.        (466) 
Human       
Resti
ng = 
96.21, 
Inact 
state 
= 
17.12 
   (471) 
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hNav1.5-
CW 
      
Resti
ng = 
606±
15, 
Open 
= 
35.3±
2.7 
   (472) 
MANTA       20 10.8    
N
IF
E
R
ID
IL
 
Guinea pig 
(A) 
  0.001        (473) 
Guinea pig 
(V) 
  0.038        (473) 
Mouse (V) 100 203  28 60 203     (474) 
MANTA 100 203 0.038 28 60 203      
N
IT
R
E
N
-D
IP
IN
E
 
ChanTest 0.025 417.1 20.09 19.52   21.58    (450) 
HEK293 0.002  10    36    
(437, 
475) 
HEK/CHO 0.025  24.6    21.6    (445) 
N/A   10        (449) 
MANTA 0.025 417 20 19.5   21.5     
P
H
E
N
Y
T
O
IN
 
N/A   100        (449) 
HEK293 103  100    49    (437) 
HEK/CHO 21.9  147    72.4    (445) 
ChanTest 22.07 470.6 147.2 227.5   80.41    (450) 
MANTA 22.07  120    80.41     
P
R
O
C
A
IN
A
M
ID
E
 
Guinea pig         13700  (476) 
HEK/CHO   310        (449) 
N/A 389.5  272.4    746.6    (445) 
ChanTest 341.3 33.51 272.9 813.2   646.3    (450) 
MANTA 340 33 300 810   646     
P
R
O
P
A
F
E
N
O
N
E
 
HEK293   
0.44±
0.07 
       (466) 
Ionworks       1.2    (477) 
N/A   0.44        (449) 
HEK/CHO 1.55  0.481 16  35.76 3.886 4.036   (444) 
HEK293 1.8  0.44    1.19    (437) 
Rabbit   
0.80±
0.14 
  
7.27±
0.53 
    (478) 
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Human (A)      
4.8± 
0.4 
    (479) 
MANTA 1.55  0.44 16  7.2 2.5 4    
Q
U
IN
ID
IN
E
 
HEK/CHO >5.4  0.34 4.9  3.49 >5.4 >5.4   (444) 
Guinea pig         560  (476) 
Oocytes       198    (465) 
HEK/CHO 6.4  0.72    14.6    (445) 
HEK293 15.6  0.3    16.6    (437) 
HEK293   
0.41±
0.04 
       (466) 
tsA201   0.32  6.0      (480) 
HEK293       12    (459) 
Human (A)     ~5.0 ~7.0     (467) 
Oocytes   
16.8±
2.2 
       (458) 
Guinea pig 
(V) 
  
1.4± 
0.2 
       (458) 
CHO   
1.0± 
0.2 
       (458) 
AT-1   
1.0± 
0.4  
       (460) 
Canine (A)     
5.03±
0.34 
     (439) 
hiPSC-CM 15.2      16.6    (481) 
N/A   0.3        (449) 
Model 
14.9 
±1.5 
 
0.62±
0.03  
4.899   3.487  14.6 
12.0±
0.7  
  (457) 
ChanTest 6.364 574.1 0.716 48.51   14.62    (450) 
MANTA 10  0.7 5 5 3.5 12 10    
Q
U
IN
IN
E
 
HEK/CHO 27.18  5.17 37.45  79.25 24.15 11.05   (444) 
MANTA 27  5 37  79 24 11    
R
A
N
O
L
A
Z
IN
E
 
HEK/CHO   6.49   >69  7.88   (444) 
Canine (V) 296  12 
<20% 
at 30 
µM 
   6  91 (482) 
ChanTest 215.1 2267 10.7 1038   101.8    (450) 
Canine (V)       294 6.5   (483) 
KPQ murine 
CM 
      135 15   (484) 
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HEK293       259.3    (485) 
HEK293       259    (486) 
HEK293   14.4     6.9   (487) 
Rabbit (V)        16.5   (488) 
tsA201          1.7 (489) 
Rabbit (V)          
> 
100 
(490) 
MANTA 250  12 100   200 8  91  
S
O
T
A
L
O
L
 
Human (A)     N.S. N.S.     (438) 
HEK/CHO 2100 2100 86.3 2100       (444) 
HEK/CHO 193.3  111.4    7014    (445) 
HEK293   1200        (459) 
N/A   74        (449) 
ChanTest 360.0 2504 111.4 3569   1180    (450) 
MANTA 2100 2500 100 3500   7000     
V
E
R
A
P
A
M
IL
 
HEK/CHO 0.202  0.5    >1    (444) 
HEK/CHO 0.2  0.25    32.5    (445) 
Canine (A)     
2.2± 
0.3 
     (439) 
HEK293   0.68        (459) 
HEK293 0.1  0.143    41.5    (437) 
Guinea pig 
(V) 
0.6          (452) 
Ionworks       9.3    (477) 
Native heart 
cells 
  0.143        (454) 
N/A   0.140        (449) 
HEK/CHO 0.079  0.813    7.221 6.093   (451) 
ChanTest 0.108 9034 0.250 69.96   32.45    (450) 
MANTA 0.2  0.5  2.2  35     
V
E
R
N
A
K
A
L
A
N
T
 
Rat (V) 220     15     (434) 
HEK293   21  13 30 
30-
200 
   (434) 
Human (A) 84    15 15 90    (491) 
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HEK293 42  21        (491) 
HEK293     
13.35
±0.93 
     (469) 
FDA 
N/A 
 >100 7-21 >100 3-13 5-30 
31-
107 
14   (492) 
MANTA 84  20  15 15 90 14    
(♠) State-dependent block of INa is available for flecainide and lidocaine. 
Figure 7.3A-Y: Comparison of experimental dose-response curves of antiarrhythmic drugs with dose-
response curve used in MANTA for different antiarrhythmic drugs. (Hill coefficient of MANTA (h) = 1, unless 
stated differently) 
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B. Ambasilide 
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C. Acute amiodarone 
 
Chapter 7 
 
Henry Sutanto | 185     
 
C
h
ap
te
r 
7
 
D. Chronic amiodarone 
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E. Bepridil 
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F. Cibenzoline 
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G. Diltiazem 
 
 
H. Disopyramide 
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I. Dofetilide 
 
J. Dronedarone 
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M. Ibutilide 
 
 
N. Lidocaine 
 
  
Maastricht antiarrhythmic drug evaluator (MANTA) 
192 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 7
 
O. Niferidil 
 
 
P. Nitrendipine 
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Q. Phenytoin 
 
 
R. Procainamide 
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S. Propafenone 
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T. Quinidine 
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U. Quinine 
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V. Ranolazine 
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Figure 7.4: Comparison of relative APD changes produced by different antiarrhythmic drugs between 
previously published experimental data and computational models available in MANTA. 
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Sotalol (459, 521-523) 
 
Verapamil (451, 459, 505) 
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Vernakalant (491, 523, 524) 
 
 
 
Figure 7.5: Structure of the INa Markov model (adapted from Moreno et al (431)) incorporated into all action 
potential models. The markov INa consists of three parts: the drug-free states (black), the neutral-drug-bound 
states (blue) and the charged-drug-bound states (red). The inactivated, trapped states (DpIT / DIT) are 
active in the presence of flecainide, but not for lidocaine, in line with Moreno et al. (431). 
 
  
Chapter 7 
 
Henry Sutanto | 211     
 
C
h
ap
te
r 
7
 
Figure 7.6: Optimization of INa properties (I-V curve, steady-state inactivation, recovery from inactivation, 
action potential and upstroke velocity; left to right) in the drug-free component of the Markov model (red 
lines) compared to the original models’ INa formulation (black lines) for different action potential models. 
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Figure 7.7: Simulated inhibition of relative INa by flecainide and lidocaine compared to published 
experimental results for various voltage-clamp protocols (details in Moreno et al. (431)). 
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7.3 Results 
7.3.1 Species differences in AAD effects 
Numerous animal models have been used to study AADs and species differences in AAD 
effects may hinder the clinical translation of experimental findings (525). Therefore, we 
investigated the species-dependent effects of AADs on the APs of mouse, guinea pig, 
rabbit, dog and human left ventricular (LV) cardiomyocyte models using MANTA. 
Application of the Class Ic AAD flecainide resulted in a concentration-dependent 
prolongation of APD and reduction in dV/dtmax in all species. However, the extent of 
APD prolongation and dV/dtmax reduction were species dependent, with the largest APD 
prolongation in the Passini human LV cardiomyocyte model (29% increase with 1 µM 
and 72% increase with 3 µM flecainide) and the smallest APD prolongation in the Faber 
guinea pig LV and Mahajan rabbit LV model (+5% with 1 µM and +9% with 3 µM). On 
the other hand, the biggest reduction of dV/dtmax was achieved by the Faber guinea pig 
LV model (51 mV/ms (-14%) and 116 mV/ms reduction (-32%) with 1 µM and 3 µM 
flecainide; Figure 7.8A). 
Similarly, the effects of dofetilide, a Class III AAD with primarily IKr-blocking 
properties, were highly species dependent. Low (6 nM) and high (12 nM) 
concentrations of dofetilide did not prolong APD in the Bondarenko mouse LV model 
(Figure 7.8B) and produced minor prolongation in the Faber guinea pig LV model 
(+7% and +11%) and the Mahajan rabbit LV model (+5% and +8%). In dog and human 
models, the same concentrations of dofetilide led to a much larger APD prolongation, 
with 38% and 84% increase in APD in the Passini human LV model and the occurrence 
of proarrhythmic EADs in the Decker canine LV model with 12 nM dofetilide. No change 
in dV/dtmax was observed with dofetilide (Figure 7.8B), consistent with IKr inhibition 
as primary mechanism of action. 
Verapamil is a Class IV AAD (calcium channel blocker) with additional IKr, IKur 
and INa-blocking effects (437, 439, 444, 445, 451, 452, 454, 459, 477). In the Bondarenko 
mouse LV model, a 17% increase in APD was observed with 2.0 µM Verapamil, while in 
the Faber guinea pig LV model, APD decreased by 25% and 35% with 0.4 µM and 2.0 
µM verapamil, respectively (Figure 7.8C). An APD reduction (of 60% and 73%) was 
also obtained in the Mahajan rabbit LV model. On the other hand, in the canine and 
human models, verapamil showed various degrees of APD prolongation depending on 
the proportional balance between ICa,L- and IKr-block. For example, in the Decker canine 
LV model, low concentrations of verapamil resulted in 42% APD prolongation, while 
high concentrations only slightly increased APD, with ICa,L inhibition offsetting APD-
prolonging effects with higher concentrations of verapamil. By contrast, the Passini 
human LV model showed a larger APD prolongation with 2.0 µM verapamil (+137%) 
compared to 0.4 µM (+28%). These results highlight the complex concentration- and 
species-dependent effects of AADs. 
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Figure 7.8: The effects of flecainide, dofetilide and verapamil on APD and dV/dtmax of various species. A) APs 
at baseline and with 1 and 3 µM flecainide (top) and quantification of APD and dV/dtmax changes relative to 
baseline (bottom) for mouse, guinea pig, rabbit, dog and human left-ventricular (LV) cardiomyocyte models. 
B) Similar to panel A for baseline, 6 nM and 12 nM dofetilide. C) Similar to panel A for 0.4 µM and 2.0 µM 
verapamil. 
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7.3.2 Rate-dependence and reverse rate-dependence of AADs 
Class I AADs have pronounced rate-dependent properties due to state-dependent 
sodium channel block. Most Class I AADs primarily block the sodium channel during 
open and inactivated states, leading to increased inhibition at faster pacing rates (412). 
In the closed state, the drug unbinds, losing its ability to block the sodium channel (526, 
527). At slow rates, the channel spends more time in the closed state, promoting greater 
drug unbinding. By contrast, Class III AADs exhibit the strongest APD-prolonging effect 
at slow rates, a concept termed reverse rate-dependence (412, 528). Reverse rate-
dependence can potentially increase the risk of ventricular proarrhythmia, particularly 
during bradycardia. Several mechanisms may contribute to this property of Class III 
drugs, including state-dependent interactions with potassium channels (432); rate-
dependent changes in the contribution of potassium channels to repolarization (529), 
e.g., accumulation of incompletely deactivated IKs during fast pacing frequencies (412, 
530); or accumulation of potassium in the sarcolemmal cleft during fast pacing, 
reducing the APD-prolonging effect of potassium channel blockers (460). Finally, 
reverse rate-dependence is not restricted to pacing rates, but is an intrinsic property of 
the AP resulting from the interaction between APD and net membrane current, 
whereby a fixed reduction in membrane current results in a stronger APD-prolonging 
effect when the initial/baseline APD is long enough (as is the case at slow rates) (413, 
531). 
We employed MANTA to demonstrate the (reverse) rate-dependence of Class I 
and III AADs in the canine and human LV cardiomyocyte models (Figure 7.9). 
Simulated application of 3 µM flecainide decreased dV/dtmax the most at higher pacing 
frequencies in both canine and human LV models, highlighting the rate-dependent 
behavior of Class I AADs. The IKr-blocking property of flecainide also resulted in 
prolongation of APD, which was most pronounced at slower pacing rates, consistent 
with the reverse rate-dependence of traditional IKr-blocking drugs (Figure 7.9A, C). 
Together, the reverse rate-dependent APD prolongation and rate-dependent reduction 
of excitability, leading to post-repolarization refractoriness, resulted in a prolongation 
of ERP in both models, with the largest effect at slow pacing frequencies (Figure 7.9B, 
D). On the other hand, simulated application of 100 µM sotalol (simulated without β-
blocking effects) resulted in a clear reverse rate-dependent pattern in both models, 
with more pronounced APD prolongation with decreasing pacing frequency (Figure 
7.9E–H). Sotalol did not directly affect dV/dtmax in the canine model and had a minor 
indirect effect on dV/dtmax in the human model at fast rates due to a shorting of the 
diastolic interval and less time for recovery from inactivation of INa (Figure 7.9G–H). 
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Figure 7.9: The effect of flecainide and sotalol on upstroke velocity (dV/dtmax) and effective refractory period 
(ERP) of canine and human LV models. A–D) APs and CaTs during steady-state pacing at 1, 2, or 3 Hz in the 
absence (black solid lines) or presence (dashed lines) of 3 µM flecainide in the Decker canine LV model (A) 
and Passini human LV model (C). Panels B and D show frequency dependence of dV/dtmax and ERP in both 
models, highlighting a rate-dependent reduction in dV/dtmax. E-H) Similar to panels A–D for 100 µM sotalol, a 
Class III AAD, showing a reverse rate-dependence of ERP prolongation, without significant effects on dV/dtmax. 
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7.3.3 Atrial specificity of AADs 
AF is the most common clinically relevant heart rhythm disorder and despite advances 
in catheter ablation therapy, pharmacological management with anticoagulants and 
AADs remains a cornerstone for the treatment of symptomatic AF (532-534). However, 
the use of currently available AADs is limited by an increased risk of ventricular 
proarrhythmia (535). The development of atrial-specific AADs has been proposed to 
enable a safer, more effective pharmacological treatment of AF (405, 414). We 
employed MANTA to compare AAD effects on atrial and ventricular APs and assessed 
potential proarrhythmic side effects. The Class III AAD ibutilide (0.01 µM) prolonged 
the APD of the human RA model by 27 ms (Figure 7.10A), while in the human LV 
endocardium model, APD was increased by 68 ms at 1 Hz pacing (Figure 7.10B), 
suggesting a ventricular-predominant effect with associated risk for drug-induced 
“torsade-de-pointes” arrhythmias. On the other hand, vernakalant has been shown to 
exhibit atrial predominant effects (414, 469, 492) by blocking IKur, which is found 
exclusively in atrial cardiomyocytes, and favoring inhibition of INa at fast rates, as would 
occur during rapid atrial rhythms like AF. Simulated application of 10 µM vernakalant 
in both atrial and ventricular models at 3 Hz pacing frequency prolonged the ERP by 
50 ms and 40 ms, respectively (Figure 7.10C, D). Similarly, the reduction in maximum 
upstroke velocity was more pronounced in atrial compared to ventricular 
cardiomyocyte models (185 mV/ms vs. 91 mV/ms reduction at 2 Hz), suggesting a 
slight atrial-predominant effect of vernakalant in these models, although this effect was 
less pronounced than observed experimentally (434, 491, 523). 
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Figure 7.10: The effects of ibutilide and vernakalant on upstroke velocity (dV/dtmax) and effective refractory 
period (ERP) of human RA and LV cardiomyocyte models. A–B) APs, CaTs and IKr during steady-state pacing 
at 1, 2, or 3 Hz in the absence (black solid lines) or presence (dashed lines) of 0.1 µM ibutilide in the Schmidt 
human RA model (A) and Passini human LV model (B). Rightmost panels show frequency dependence of 
dV/dtmax and ERP in both models, highlighting a ventricle-predominant effect of ibutilide. C–D) Similar to 
panels A–B for 10 µM vernakalant. In these models, vernakalant exhibits a slight atrial-predominant effect, 
with larger reduction of dV/dtmax and more ERP prolongation in the human RA model during 3 Hz pacing. 
 
7.3.4 Changes in AAD effects in cardiovascular diseases 
Cardiovascular diseases such as AF and HF produce extensive ion channel (electrical) 
remodeling, which may modulate the effect of AADs. For example, all Class III AADs 
except amiodarone are contraindicated for rhythm control of AF in patients with 
concomitant HF due to increased risk of ventricular proarrhythmia under these 
conditions (408). Amiodarone has differential acute and chronic electrophysiological 
effects (Table 7.3). We compared the steady-state effects of chronic amiodarone, as 
would be used for long-term rhythm control, dofetilide and sotalol on APD in Passini 
human LV cardiomyocyte models with and without HF-related electrical remodeling, as 
reported by (536) (Figure 7.11). HF-related electrical remodeling resulted in reduced 
IKr, prolonged APD and CaT duration, reduced CaT amplitude, and increased diastolic 
calcium levels (Figure 7.11A, B) (374). Inhibition of IKr by sotalol and dofetilide 
produced a concentration-dependent increase in APD, which was more pronounced in 
the heart failure compared to the control model. For example, simulated application of 
sotalol (125 µM) resulted in a larger APD prolongation (286 ms) in the HF model 
compared to the control model (169 ms). Similarly, dofetilide (8 nM) prolonged APD by 
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222 ms and 136 ms in the HF and control models, respectively. This excessive 
concentration-dependent APD prolongation in the setting of HF-related remodeling 
was less pronounced during simulated application of chronic amiodarone (Figure 
7.11C), consistent with its lower proarrhythmic risk in heart failure patients. 
 
Figure 7.11: The effects of sotalol, dofetilide and chronic amiodarone on the APD of Passini human 
ventricular cardiomyocyte models with or without HF-related electrical remodeling. Degree of HF-related 
electrical remodeling was based on (536). A–B) APs, CaTs and IKr in models without (control, A) and with (B) 
HF-related electrical remodeling in the absence or presence of sotalol, dofetilide or chronic amiodarone (left 
to right). Sotalol, dofetilide and chronic amiodarone prolonged APD in all models by blocking IKr. C) 
Quantification of APD changes induced by various concentrations of sotalol, dofetilide and chronic 
amiodarone in control (black bars) and HF (grey bars) models. Sotalol and dofetilide produced a more 
pronounced concentration-dependent APD prolongation in the HF model compared to the control (non-HF) 
model, which was not observed with chronic amiodarone. 
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We also employed MANTA to investigate the steady-state electrophysiological 
effects of AADs in the Schmidt human RA cardiomyocyte model with and without long-
standing persistent (‘chronic’) AF (cAF)-related remodeling (Figure 7.12). Simulated 
application of sotalol during 2 Hz pacing resulted in a similar concentration-dependent 
prolongation of APD in both the model with and without cAF-related remodeling (18 ms 
and 53 ms increase with 50 µM or 400 µM sotalol in cAF vs. 19 ms and 47 ms in control). 
High concentrations of sotalol also reduced dV/dtmax due to inhibition of IK1, leading to 
depolarization of resting membrane potential, as well as slight INa inhibition. This effect 
was less pronounced in the presence of cAF-related remodeling (21 mV/ms vs. 
45 mV/ms), which reduces the resting membrane potential. The effects of the Class Ic 
AAD flecainide also depended on the disease condition. In the model with cAF-related 
remodeling paced at 2 Hz, APD prolongation was smaller (46 ms and 81 ms increase 
with 2 µM or 8 µM flecainide, respectively) compared to the control model (53 ms and 
95 ms). In addition, the flecainide-induced reduction of dV/dtmax was smaller 
(11 mV/ms and 35 mV/ms reduction with 2 µM and 8 µM flecainide) compared to the 
control model (27 mV/ms and 76 mV/ms) due to hyperpolarization of the resting 
membrane potential, further highlighting the disease-specific effects of AADs. By 
contrast, simulated application of 0.5 µM chronic amiodarone had similar effects on 
dV/dtmax in the cAF model and the control model (22 mV/ms reduction), although the 
APD-prolonging effects at this concentration were minimal. These observations are 
consistent with in vivo measurements in AF patients showing unaltered monophasic 
APD but reduced intra-atrial conduction velocity in the presence of amiodarone (537), 
although APD-prolonging effects have also been described (538). The fact that 
amiodarone-induced electrophysiological effects are preserved in cAF may contribute 
to the superior clinical effectiveness of this AAD for long-term rhythm control in AF 
patients compared to sotalol and flecainide (407). 
 
7.4 Discussion 
Understanding the effect of AADs in the heart can often be challenging yet is needed for 
better arrhythmia management. In this study, we presented MANTA, a novel 
computational tool to predict the cellular effects of AADs in various species, regions of 
the heart and experimental settings. Our simulations reproduce a number of key 
characteristics: 1) species-specific effects of AADs, 2) rate-dependent effects of AADs, 
3) the atrial specificity of vernakalant, and 4) the superiority of chronic amiodarone as 
an antiarrhythmic therapy in the setting of heart failure and cAF. Our data establish 
MANTA as a useful tool to analyze the mechanisms underlying a wide range of AAD 
properties and to illustrate the distinct properties of AADs for educational purposes. 
 
7.4.1 Diversity of AAD actions 
AAD therapy plays a major role in cardiac arrhythmia management but choosing the 
optimal AAD for an individual patient is highly challenging. Several AADs, including 
quinidine, flecainide, dofetilide and sotalol can promote ventricular proarrhythmia 
(532). Since quinidine was introduced as one of the first AADs more than a century ago 
(539), significant efforts have therefore been made to develop new AADs with increased 
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efficacy and fewer adverse side-effects. However, progress has been limited, likely in 
part due to an incomplete understanding of both the underlying arrhythmia 
mechanisms and complex electrophysiological effects of AADs (540). Using MANTA, we 
could demonstrate that AADs have pronounced species-dependent effects, which were 
due to the differential expression of cardiac ion channels, resulting in distinct APD/ERP 
prolongation across species (410, 541), as well as in different regions of the heart (1, 
542). Such species-dependent effects make the selection of appropriate animal models 
for AAD testing essential. In addition, simulated application of Class I and III AADs 
resulted in rate-dependent electrophysiological effects due to their (reverse) rate-
dependent behavior (413). Cardiovascular diseases such as AF and HF produce 
abnormalities in cardiac electrophysiology and calcium handling (3, 32, 121), which 
may change the pharmacodynamics of AADs. We demonstrated preserved 
electrophysiological effects during simulated application of chronic amiodarone in 
cardiomyocyte models with cAF- or HF-related electrical remodeling, illustrating how 
MANTA can be used to assess disease-specific AAD effects. 
 
Figure 7.12: The effects of sotalol, flecainide and chronic amiodarone on APD and upstroke dV/dtmax of 
Schmidt human RA models with and without long-standing persistent (‘chronic’) atrial fibrillation (cAF)-
related electrical remodeling. A) APs at baseline and with 50 and 400 µM sotalol (left), 2 and 8 µM flecainide 
(center) and 0.1 and 0.5 µM chronic amiodarone for control (top) and cAF (bottom) cardiomyocyte models. 
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B) Quantification of APD changes compared to baseline (top) and difference in dV/dtmax compared to baseline 
(bottom) for control (black) and cAF (grey) cardiomyocyte models. 
Nonetheless, the wide spectrum of comorbidities associated with these 
cardiovascular diseases may also affect the pharmacokinetics of AADs, potentially 
altering drug absorption, metabolism or excretion and making it more difficult to 
develop AADs with strong efficacy without evoking major adverse events. Together, 
these complex interactions between AAD properties and actual clinical conditions make 
it challenging to intuitively predict whether the antiarrhythmic actions of AADs would 
outweigh their potential proarrhythmic tendencies (412). AADs with atrial-
predominant effects might provide safer options for pharmacological treatment of AF. 
In general, the atrial specificity of these AADs is achieved by their IKur blocking effect, a 
higher affinity for the inactivated state of the cardiac sodium channel and fast sodium 
channel dissociation kinetics (543). Atrial cardiomyocytes have a more depolarized 
resting membrane potential compared to ventricular cardiomyocytes, particularly at 
fast rates such as during AF, which promotes the atrial-predominant effect of these 
AADs (434, 523, 543). In agreement, we could demonstrate ventricular-predominant 
effects of Class III AADs and a slight atrial-predominant effect of simulated vernakalant. 
Moreover, MANTA makes it easy to adjust the affinity of an AAD for individual targets, 
enabling investigations of the optimal AAD properties for a given clinical condition, for 
example to achieve AF-predominant effects. 
 
7.4.2 Role of computational modeling in cardiac arrhythmia management 
In the last few decades, computational modeling of cardiac electrophysiology has 
contributed to a better understanding of cardiac arrhythmogenesis. Until now, more 
than 50 computational cardiomyocyte models of different species and regions of the 
heart have been developed to investigate cardiac electrophysiology and 
(patho)physiology. Based on these advances, in silico modeling has also become a 
central element in the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative to 
assess the safety profile of new drugs (544). For example, the Virtual Assay (421) 
provides a framework for in silico proarrhythmic toxicity trials in a population of 
calibrated human ventricular cardiomyocyte models and can predict clinical risk of 62 
reference compounds with high accuracy. In addition, the U.S. Food and Drug 
Administration (FDA) aims to transform computational modeling from a scientific tool 
into a valuable regulatory instrument in which digital evidence is being used instead of 
other types of evidence (545). Moreover, whole-heart modeling has recently been 
employed to support the decision-making process prior to catheter ablation of AF (546). 
Thus, several novel clinical and regulatory applications of computational modeling are 
starting to emerge. 
In addition, several educational tools have been developed to teach cardiac 
(cellular) electrophysiology. For example, LabHEART® provides a user-friendly tool to 
simulate ion currents and calcium transport proteins in a rabbit ventricular myocyte 
(417), the MioLab® simulator describes calcium dynamics and contractile forces 
during contraction and relaxation of cardiomyocytes (418), and the web-based 
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simulation platform eSolv enables teachers to load a cardiomyocyte CellML model and 
generate simulations adapted to the students’ level by defining whether and to what 
extent model parameters can be changed (419). Although it is possible to perform 
simulations with ion-channel blockers in both eSolv and MioLab®, as well as in the 
more generic cardiomyocyte simulation tools Myokit (344) and LongQt (420), these 
computational tools are limited in their ability to compare the effects of AADs on the AP 
under various conditions in a user-friendly way. They do not contain a library of 
cardiomyocyte models, nor do they come with multiple AADs, which effects can be 
simulated simultaneously in a reasonably short period of time. Moreover, these tools 
do not incorporate the state-dependent effects of AADs, which are particularly relevant 
for Class I AADs. MANTA was developed to facilitate analyses of the cellular effects of 
currently available AADs under user-defined experimental settings. It also serves as a 
library of commonly used cardiomyocyte models and AADs, with a capability to 
simulate the cellular effects of AADs using either state-dependent regulation or IC50-
based inhibition of cardiac ion channels. MANTA also enables a direct comparison of 
the effects of two AADs on two different cardiomyocyte models. Finally, MANTA 
combines these features in a user-friendly interface, so that the users can operate 
MANTA without extensive guidance and/or modeling skills. As such, MANTA can 
function as an educational tool to help students understand the cellular mechanism of 
AADs, as well as their species- and condition-dependent effects. As MANTA facilitates 
comparison between two AADs under user-defined experimental/environmental 
settings, including heart rate / pacing frequency and electrolyte concentrations, it 
enables simulations to dissect, for example, why AADs are contraindicated under 
certain simulated pathophysiological conditions such as hypo/hyperkalemia or 
bradycardia. 
  
7.4.3 Potential limitations 
We employed 17 previously published cellular cardiomyocyte models, each with their 
own limitations, which likely affect the outcome of AAD simulations. For example, the 
original Luo-Rudy Guinea pig model (423) does not consider different potassium 
channel subtypes, precluding reliable analyses of Class III AADs in this particular model. 
Similarly, we enable the users to change the extracellular calcium, potassium, and 
sodium to observe the effects of different extracellular ionic concentrations on the AP. 
However, the effects might not be representative if the range of applicability of a 
particular model is exceeded, as previously shown by Severi et al (150) for changes in 
extracellular calcium. Such model limitations should be considered when interpreting 
simulation results. On the other hand, the ability to quickly compare drug effects in two 
models of the same species/region in MANTA may help to highlight such limitations. 
We simulated the effects of AADs on individual cardiac ion channels based on 
previously published experimental IC50 values, which may be influenced by various 
experimental conditions, including the cell type, temperature, ionic concentrations and 
voltage-clamp protocols (547-549). Indeed, as seen in Figure 7.3, there are differences 
in the reported IC50 values between studies and the availability of data in human 
cardiomyocytes is rather limited. As such, some validation of the state-dependent INa 
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inhibition was adapted from non-human experimental data, which may bias the results. 
In addition, there is evidence that dynamic state-dependent block may also be relevant 
for other ion channels (e.g. IKur, IKr and ISK) (10, 76, 380, 550, 551), so as more 
experimental data become available, future work might consider replacing the IC50-
based inhibition of ion currents with state-dependent inhibition using detailed Markov 
models. Nevertheless, the cellular electrophysiological response (e.g., APD 
prolongation) of several AADs and models was consistent with experimental data 
(Figure 7.4), strongly suggesting that the current approach provides a reasonable 
approximation. Finally, in the current version of MANTA, we incorporated drug effects 
on 10 major cardiac ion currents. However, data about AAD effects on several additional 
cardiac ion channels is emerging, including the acetylcholine-activated inward-rectifier 
potassium channel and two-pore domain potassium channel (428), hyperpolarization-
activated cyclic nucleotide-gated (HCN) channel (552), transient receptor potential 
(TRP) channels (553) and voltage-gated KV1.1 channels (554), which are not included 
in most current cardiomyocyte models. Therefore, it is currently not possible to 
simulate the effect of AADs such as ivabradine (552), BMS914392 (555), NIP-151 (556) 
and tertiapin (557), which exert their function mainly through those channels. Similarly, 
the absence of β-adrenoceptor-signaling components in almost all cardiomyocyte 
models precludes simulation of the effects of Class II AADs and makes it difficult to 
simulate exercise, which is a well-known proarrhythmic trigger (3, 78, 558, 559), 
although MANTA allows users to simulate the effects of AADs during higher pacing 
frequencies. 
Importantly, although MANTA can provide useful general information about 
species- and condition-specific AAD effects, there is pronounced inter-individual 
variability in cardiac electrophysiology and pharmacokinetics that can influence AAD 
effects. Although population-based approaches have been proposed to simulate inter-
individual variability (421), patient-specific risk assessment or recommendation of 
AAD therapy is currently not feasible. 
 
7.4.4 Future outlook and potential contributions of MANTA 
We have shown that MANTA can reproduce a large number of clinically relevant AAD 
characteristics at the cellular level and can be used to investigate the underlying ionic 
mechanisms. However, various publications have shown that the cellular effects of an 
AAD can be different from organ-level effects due to cell-to-cell interactions, spatial 
heterogeneities in electrical properties and additional factors, such as autonomic 
innervation (409, 541, 560-562). Importantly, arrhythmias are inherently tissue-level 
phenomena and to study pro- or antiarrhythmic actions of AADs the tool would have to 
be extended to tissue or whole-heart simulations. At present, these simulations are 
computationally demanding, limiting the educational use of the tool. However, as 
processor speeds increase, future versions of MANTA may be able to accommodate 
such simulations, significantly increasing the clinical relevance of the tool. Additionally, 
MANTA simulates the effects of AADs based on a given cellular concentration. At the 
moment, it is hard to determine the appropriate concentration based on the clinical 
drug dose due to the different pharmacokinetics of each AAD. Pharmacokinetic models 
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for different cardiovascular drugs have been established that enable simulation of 
plasma concentrations over time (563, 564). In the future, MANTA could incorporate 
such pharmacokinetic models to investigate the electrophysiological effects of various 
dosing strategies for different AADs. 
 
7.5 Conclusions 
The effects of AADs are complex and highly dependent on the experimental or clinical 
conditions. MANTA is a powerful, freely available tool able to reproduce a wide range 
of AAD characteristics including species-, rate-, and disease-dependent effects. MANTA 
enables analyses of the underlying ionic mechanisms as well as investigations of novel 
AADs with specific affinities for one or more targets. MANTA can facilitate a better 
understanding of AAD effects on cellular electrophysiology under a wide range of 
conditions, which may provide educational and/or clinically-relevant information on 
the safety and efficacy of AAD treatment. 
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ABSTRACT 
The antimalarial drug chloroquine and antimicrobial drug azithromycin have received 
significant attention during the COVID-19 pandemic. Both drugs can alter cardiac 
electrophysiology and have been associated with drug-induced arrhythmias. 
Meanwhile, sympathetic activation is commonly observed during systemic 
inflammation and oxidative stress (e.g., in SARS-CoV-2 infection), and may influence the 
electrophysiological effects of chloroquine and azithromycin.  
Here, we investigated the effect of β-adrenergic stimulation on proarrhythmic 
properties of chloroquine and azithromycin using detailed in silico models of 
ventricular electrophysiology. Concentration-dependent alterations in ion-channel 
function were incorporated into the Heijman canine and O’Hara-Rudy human 
ventricular cardiomyocyte models. Single and combined drug effects on action-
potential (AP) properties were analyzed using a population of 1000 models 
accommodating inter-individual variability. Sympathetic stimulation was simulated by 
increasing pacing rate and experimentally validated isoproterenol-induced changes in 
ion-channel function.  
In the canine ventricular model at 1 Hz pacing, therapeutic doses of 
chloroquine and azithromycin (5 and 20 µM, respectively) individually prolonged AP 
duration (APD) by 33% and 13%. Their combination produced synergistic APD 
prolongation (+161%) with incidence of proarrhythmic early afterdepolarizations in 
53.5% of models. Increasing the pacing frequency to 2 Hz shortened APD and together 
with 1 µM isoproterenol counteracted the drug-induced APD prolongation. No 
afterdepolarizations occurred following increased rate and simulated application of 
isoproterenol. Similarly, chloroquine and azithromycin individually prolonged APD by 
43% and 29% in the human ventricular cardiomyocyte model, while their combination 
prolonged APD by 76% without causing early afterdepolarizations. Consistently, 1 µM 
isoproterenol at 2 Hz pacing counteracted the drug-induced APD prolongation. 
Increasing the ICa,L window current produced afterdepolarizations, which were 
exacerbated by isoproterenol. In both models, reduced extracellular potassium reduced 
the repolarization reserve and increased drug effects.  
In conclusion, chloroquine- and azithromycin-induced proarrhythmia is 
promoted by conditions with reduced repolarization reserve. Sympathetic stimulation 
limits drug-induced APD prolongation, suggesting the potential importance of heart 
rate and autonomic status monitoring in particular conditions (e.g., COVID-19). 
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8.1 Introduction 
Nine-months after its first identification in Wuhan, China in December 2019, Severe 
Acute Respiratory Syndrome-associated Coronavirus type-2 (SARS-CoV-2) infection 
(i.e., Coronavirus Disease 2019 / COVID-19) has contributed to more than 850,000 
deaths worldwide and has been declared a pandemic with significant global 
socioeconomic impact (565). At the moment, the exact pathophysiology of the disease 
remains unclear and no definitive therapy is available. Several drugs are considered 
effective in preclinical studies and are currently being tested against SARS-CoV-2 in the 
clinic (e.g., the antivirals lopinavir, ritonavir, and remdesivir; the antimicrobial 
azithromycin; the antimalarial drugs chloroquine and hydroxychloroquine, and more 
recently antiparasitic ivermectin) (566-568). Of those, chloroquine (CQ) and 
azithromycin (AZM) have gained significant attention due to their high accessibility and 
low cost. Nonetheless, their effectivity against COVID-19 has not been confirmed by any 
large clinical trial and their use is controversial. Some studies reported the benefit of 
those drugs (569-572), while others reported no effect (573-575). This controversy is 
further complicated by the retraction of papers demonstrating the absence of benefit of 
these drugs in COVID-19 (573), potential issues with study design and analysis (576, 
577), and the termination of their emergency use by the United States Food and Drug 
Administration (FDA) due to their potential proarrhythmic effects (578).  
CQ is a widely-used antimalarial drug that inhibits multiple cardiac ion-
channels (444). It has been suggested to prevent the viral entry, transport and post-
entry events in COVID-19, most likely via its effects on endosomal pH and the resulting 
under-glycosylation of angiotensin-converting enzyme 2 (ACE2) receptors that are 
required for viral entry, although the exact mechanisms remain incompletely 
understood (579, 580). Meanwhile, AZM is a broad-spectrum macrolide antibiotic that 
is believed to potentiate the effect of CQ, reducing the replication capabilities of SARS-
CoV-2 (579). Similar to CQ, AZM also inhibits multiple cardiac ion-channels in a dose-
dependent manner (444). Therefore, the administration of CQ and AZM, alone or in 
combination, can prolong the ventricular cardiomyocyte action potential (AP) duration 
(APD) and thereby the QT interval on the electrocardiogram. Experimentally, the APD-
prolonging effect of CQ and AZM, alone and in combination, has been shown in 
anaesthetized guinea-pig model (581). Moreover, excessive QT-interval prolongation 
has been implicated in drug-induced malignant arrhythmias such as Torsade de Pointes, 
by promoting early afterdepolarizations (EADs) and a heterogeneous repolarization 
substrate, and consistently observed in COVID-19 patients with CQ and AZM (578, 582-
585).  
Although the cardiac pathophysiology of COVID-19 remains incompletely 
understood, several aspects point towards increased incidence of cardiac arrhythmias 
(586). SARS-CoV-2 induces systemic inflammation, leading to cytokine storm (587), 
which is expected to increase oxidative stress by releasing reactive oxygen species 
(ROS). Moreover, CQ may itself promote oxidative stress (588). Both inflammation and 
oxidative stress have been associated with increased arrhythmogenic risk (589), e.g., 
through activation of calcium/calmodulin-dependent protein kinase II (CaMKII) (590, 
591) and NLRP3 inflammasome (592), as observed in COVID-19 (593). Troponin-T, a 
marker for myocardial injury, has been shown to increase in groups of COVID-19 
patients with malignant arrhythmias, denoting the major detrimental impact of SARS-
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CoV-2 on the cardiovascular system (594). Moreover, COVID-19 may activate the β-
adrenergic signaling cascade in cardiomyocytes via the stimulation of the sympathetic 
nervous system (587). Palpitation, which is commonly associated with the activation of 
β-adrenergic response, has been reported to be the main symptom of COVID-19 (594). 
Altogether, these processes may increase the propensity for cardiac arrhythmias by 
altering cardiomyocyte calcium-handling and modulating ion-channel properties 
(Figure 8.1) (335).  
 
Figure 8.1: The multifactorial effects of COVID-19 in the ventricular cardiomyocyte and the ionic targets of 
chloroquine and azithromycin. The SARS-CoV-2 virus leads to the endocytosis and internalizations of the 
transmembrane ACE2 receptors, preventing the conversion of angiotensin I and II into their metabolites. 
Thus, angiotensin II binds to the AT-II receptor, initiating PKC-dependent pathways, which may further 
activate CaMKII-dependent signaling cascades. In COVID-19, the systemic inflammation and cytokine storm 
can also increase oxidative stress, leading to ROS-mediated CaMKII activation. CQ and AZM alter action 
potential properties through inhibition of multiple cardiac ion channels (INa, INaL, IKr, IKs, IK1, Ito, ICa,L). (AC = 
adenylyl cyclase; ACE = angiotensin converting enzyme; Ang II = angiotensin II; ATP = adenosine 
triphosphate; CaM = calmodulin; CaMKII = calcium/calmodulin-dependent protein kinase II; cAMP = cyclic 
adenosine monophosphate; DAG = diacyl glycerol; IL = interleukin; IP3 = inositol triphosphate; PDE = 
phosphodiesterase; PIP2 = phosphatidylinositol biphosphate; PKA = protein kinase A; PKC = protein kinase 
C; PLC = phospholipase C; ROS = reactive oxygen species; Tn-I = troponin-I) 
 
To the best of our knowledge, previous experimental and observational studies 
of the potential proarrhythmic effects of CQ and AZM have not considered the role of β-
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adrenergic receptor stimulation. Computational modeling has increasingly been used 
in cardiac safety pharmacology to predict the proarrhythmic effect of novel compounds 
(595-597). Therefore, this study aimed to assess the potential cellular proarrhythmic 
effects of CQ and AZM in both the absence and presence of β-adrenergic receptor 
stimulation using a population of detailed in silico models of ventricular 
electrophysiology. 
 
8.2  Methods 
Concentration-dependent CQ and AZM-induced alterations in 7 ion-channels (fast 
sodium current (INa), late sodium current (INaL), L-type calcium current (ICa,L), transient-
outward potassium current (Ito), inward-rectifier potassium current (IK1), rapid 
delayed-rectifier potassium current (IKr) and slow delayed-rectifier potassium current 
(IKs)) (444) (Figure 8.2) were incorporated into the Heijman canine ventricular 
cardiomyocyte model (78) with β-adrenergic receptor signaling and O’Hara-Rudy 
(ORd) human ventricular epicardial cardiomyocyte model (263). The Heijman canine 
ventricular model was employed in this study because it is one of the few 
cardiomyocyte models of a large mammal incorporating detailed β-adrenergic signaling 
cascades, including PKA- and CaMKII-mediated phosphorylation of cardiac ion 
channels. Meanwhile, the ORd human ventricular model was chosen because it is the 
most widely used human ventricular cardiomyocyte model that works over a wide 
range of experimental conditions. To simulate the electrophysiological effects of β-
adrenergic stimulation in the human ventricular model, the experimentally validated 
changes in ionic current properties in response to 1 μM isoproterenol (ISO, (598)) were 
applied to the ORd model and further calibrated based on recent data (599) to improve 
the model accuracy during maximal ISO stimulation (1 μM). 
A drug concentration within the therapeutic range of CQ and AZM was selected 
(5 and 20 µM, respectively (600, 601)) and cellular simulations were performed in 
Myokit (344). The effects of the drugs alone and in combination (assuming independent 
drug-binding sites) on AP properties were assessed. Sympathetic stimulation was 
simulated by an increase in pacing rate and experimentally validated ISO-induced 
changes in ion-channel function (78, 81). All results are presented during steady-state 
pacing at the indicated pacing frequencies (after 1000 beats of prepacing). To evaluate 
the robustness of our findings and assess potential consequences of intra- and inter-
subject variability on the electrophysiological effect of CQ and AZM, the maximum 
conductance of 9 major ionic currents (INa, INaL, ICa,L, IKr, IKs, IK1, Ito, INCX and INaK) were 
scaled based on a normal distribution with mean 1.0 and standard deviation 0.2, to 
create populations of models, as previously described (346, 379). In brief, 1000 variants 
of the model were created and the variants displaying “non-physiological” AP 
properties were excluded. Non-physiological was defined as APD90 or RMP outside the 
range of 3 standard deviations of experimental APD90 and RMP from (382, 602), based 
on previous studies (381, 382). In total, 592 out of 1000 canine ventricular models and 
all 1000 human ventricular models were included. The non-normally distributed data 
are presented as median and inter-quartile ranges (IQR). The model code is available at 
www.github.com/jordiheijman.  
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Figure 8.2: The concentration-dependent effects of chloroquine and azithromycin on cardiac ion channels. 
A) chloroquine mainly blocks IKr and IK1, with minor effects on INa, INaL, Ito, ICa,L and IKs. B) azithromycin mainly 
blocks IKr and Ito, with minimal effects on INa, INaL, ICa,L, IK1 and IKs. The experimental data (black symbols) were 
obtained from previous experiments (444) and were fitted using Hill equations in the model (black lines). 
Bar charts show percentage inhibition of different ion channels using the clinically relevant concentrations 
employed in subsequent simulations. 
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8.3  Results 
8.3.1 The effects of chloroquine and azithromycin on canine ventricular 
electrophysiology 
During 1 Hz pacing, application of 5 µM CQ in the Heijman canine ventricular epicardial 
cardiomyocyte model prolonged APD by 70 ms (+33%), while 20 µM AZM prolonged 
APD by 27 ms (+13%). The combination of both drugs showed a synergistic effect with 
an APD prolongation of 339 ms (+161%) and the occurrence of an EAD, as shown in 
Figure 8.3A, upper panels. Subsequently, the contributions of β-adrenergic-
dependent signaling cascades were assessed in two ways: by increasing the pacing 
frequency and through the simulated application of a maximal concentration of the β-
adrenergic receptor agonist isoproterenol (ISO; 1 µM) in combination with the 
escalation of pacing rate. Increasing the pacing rate from 1 to 2 Hz reduced the APD in 
all groups, with APD reduction of 14 ms (-7%) in the non-treated, 28 ms (-10%) in the 
CQ, 21 ms (-9%) in the AZM and 261 ms (-47%) in the combined groups. The previously 
observed EAD in the combined group was not observed following the increase in pacing 
rate (Figure 8.3A, middle panels). The combination of simulated ISO application and 
increased pacing rate further reduced APD, with APD reduction of 40 ms (-19%) in the 
non-treated, 84 ms (-30%) in the CQ, 53 ms (-22%) in the AZM and 341 ms (-62%) in 
the combined groups compared to APD during 1 Hz pacing (Figure 8.3A, lower 
panels). Increasing the pacing rate up to 4 Hz further reduced APD and lowering the 
pacing rate from 1 to 0.25 Hz prolonged the APD and resulted in EADs in the combined 
CQ+AZM group (Figure 8.3B, left and middle panels). At 4 Hz, calcium transient and 
AP alternans was observed in the non-treated, CQ alone and AZM alone groups, and its 
occurrence was prevented in the presence of ISO (Figure 8.4). Furthermore, at pacing 
rates >1 Hz, AZM slightly hyperpolarized the RMP, which was opposed by the RMP-
depolarizing effect of β-adrenergic activation, while CQ with or without ISO consistently 
showed a slight depolarization of RMP, likely due to its inhibition of IK1 (Figure 8.2). 
The RMP modulating effect was attenuated at slow pacing rates (Figure 8.3B, right 
panel).  
The β-adrenergic-induced modification of 9 ionic currents (INa, INaL, ICa,L, Ito, IKr, 
IKs, IK1, INCX and INaK) can be seen in Figure 8.5, highlighting the significantly increased 
IKs during β-adrenergic stimulation. Indeed, ISO-induced phosphorylation of IKs and ICa,L 
was key for the observed APD reduction in the model, as previously documented (78) 
and preventing such phosphorylation resulted in repolarization failure (RF) in the 
CQ+AZM group in the presence of simulated β-adrenergic stimulation (Figure 8.6).  
Next, we investigated concentration-dependent effects of ISO on APD in both 
non-treated (control) and CQ+AZM groups at 1 Hz pacing. In the control group, ISO 
produced a mild APD shortening at concentrations >10 nM, as previously demonstrated 
(78). In the combined CQ+AZM group, low concentrations of ISO up to 0.3 nM did not 
prevent EADs. At 0.3-1.0 nM ISO abbreviated APD and diminished the occurrence of 
EADs. Further increasing the ISO concentration to 50 nM produced a progressive 
reduction in APD from 378 ms at 1 nM to 250 ms at 50 nM (-34%). ISO concentrations 
>50 nM produced minor additional changes in APD (Figure 8.7). The cellular effect of 
1 nM ISO in all 4 treatment groups can be seen in Figure 8.8, upper panels.  
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Figure 8.3: The effects of chloroquine and azithromycin on AP properties of canine ventricular epicardium. 
A) The AP and calcium transient of non-treated, chloroquine 5 µM, azithromycin 20 µM and combined groups. 
The dashed vertical lines indicate the end of the AP with 1 Hz pacing to provide a clearer depiction of the 
effects of increasing pacing rate and ISO on APD. The EAD is indicated with an arrow. B) APD and RMP for 
different pacing rates in the four groups with and without simulated β-adrenergic stimulation. The 
occurrence of alternans at 4 Hz pacing is marked with an arrow. (AP = action potential; APD = action potential 
duration; Ctl = control; ISO = isoproterenol; RMP = resting membrane potential) 
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Figure 8.4: Action potential and calcium-transient alternans at 4 Hz pacing. The upper panels exemplify the 
AP and calcium-transient alternans at 4 Hz pacing in non-treated, CQ alone and AZM alone groups. The 
application of 1 µM ISO abolishes the alternans, as shown in the lower panels. (AP = action potential; AZM = 
azithromycin; Ctl = control; CQ = chloroquine; ISO = isoproterenol) 
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Figure 8.5: The effects of β-adrenergic stimulation on cardiac ion channels of canine ventricular epicardium. 
The effects were assessed in 4 groups: non-treated, chloroquine, azithromycin and combined groups. The 
blue lines represent the ionic currents during 1 Hz pacing, the red lines represent the ionic currents during 2 
Hz pacing and the green lines represent the currents during 2 Hz pacing with ISO 1 µM. The fast sodium 
current (INa), L-type calcium current (ICa,L) and transient-outward potassium current (Ito) are shown at an 
expanded scale in the insets. (Ctl = control; ISO = isoproterenol) 
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Figure 8.6: The impact of IKs and ICa,L phosphorylation on the action potential of canine ventricular epicardium 
in the presence of chloroquine (CQ) and azithromycin (AZM). The effect of CQ 5 µM in combination with AZM 
20 µM in the presence of ISO-induced IKs and ICa,L phosphorylation is shown in solid green lines. The green 
dashed lines represent the effect of CQ 5 µM in combination with AZM 20 µM in the absence of ISO-induced 
IKs and ICa,L phosphorylation. 
 
Figure 8.7: The concentration-dependent effect of ISO on APD of canine ventricular epicardium. The APD in 
the presence of various concentrations of ISO from 0.1 nM to 1µM in non-treated group (blue line) was 
compared to the combined group (Chloroquine 5 µM + Azithromycin 20 μM; red line). The simulations were 
performed with 1 Hz pacing. (APD = action potential duration; Ctl = control; ISO = isoproterenol) 
 
Figure 8.8: The effects of chloroquine and azithromycin on canine AP in the presence of an intermediate 
concentration of ISO. The AP and calcium transient of non-treated, chloroquine 5 µM, azithromycin 20 µM 
and combined groups with 1 Hz pacing and 1 nM ISO in the presence of low extracellular potassium ([K+]o = 
4.0 mM) were compared to [K+]o = 5.4 mM. The dashed vertical lines indicate the end of AP in models with 
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[K+]o = 5.4 mM to provide a clearer depiction of the effects of reduced extracellular potassium on APD. (AP = 
action potential; APD = action potential duration; Ctl = control; ISO = isoproterenol) 
Alteration of cardiac repolarization by a pharmacological agent is frequently 
observed. However, sole administration of a drug rarely induces arrhythmias unless 
other predisposing factors aggravate the proarrhythmic risk by challenging the 
repolarization reserve (e.g., preexisting disease, concomitant drugs, or hypokalemia). 
We employed the Heijman canine ventricular cardiomyocyte model to investigate the 
effect of alterations to repolarization reserve, particularly in the setting of low 
extracellular potassium (hypokalemia). As shown in Figure 8.9, the simulated 
application of CQ+AZM with [K+]o of 4.0 mM (instead of the default 5.4 mM) prolonged 
APD and caused RF in the absence of ISO and slight APD prolongation with 1 µM ISO. 
Moreover, the RMP was slightly hyperpolarized in the presence of hypokalemia. With 
4.0 mM extracellular potassium, higher concentrations of ISO are needed to restore 
these repolarization abnormalities: 1 nM ISO prevents EADs and RF with 5.4 mM 
extracellular potassium, but not with 4.0 mM (Figure 8.8). These data highlight the 
importance of baseline repolarization reserve for the cellular proarrhythmic effects of 
CQ and AZM.  
 
Figure 8.9: The impact of reduced extracellular potassium on the action potential of canine ventricular 
epicardium in the presence of chloroquine and azithromycin. The left panels show the effect of CQ 5 µM in 
combination with AZM 20 µM with 5.4 mM [K+]o. The right panels show the effect of CQ 5 µM in combination 
with AZM 20 µM in the presence of reduced [K+]o (4.0 mM). 
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Next, a population-based study was conducted to accommodate intra- and 
inter-individual variability. A population of 1000 models was created by varying the 
conductances of 9 ionic currents as described in the Methods. After the exclusion of 
models with non-physiological baseline APs, 592 models were included in the 
population (Figure 8.10A, upper panels, blue lines and Figure 8.10G). To simulate 
β-adrenergic activation, various concentrations of ISO that produced maximum β-
adrenergic response were assigned to each model. Consistent with the default model 
without variability, at 1 Hz pacing, CQ (5 µM) prolonged the APD by a median 73.3 ms 
(IQR 67.5-82.3). Similarly, AZM 20 µM prolonged the APD by a median 28.7 ms (IQR 
25.5-36.3) and the combination of CQ and AZM prolonged the APD with median 146.5 
ms (IQR 92.1-334.7). During 2 Hz pacing, CQ, AZM and CQ+AZM prolonged the APD with 
median 59 ms (IQR 56.7-62), 22.7 ms (IQR 20.8-25.5), and 95.2 ms (IQR 84.2-109.3), 
respectively. Finally, following the addition of ISO, the APD prolongation was further 
reduced with median prolongation of 26.5 ms (IQR 25.3-27.9) in CQ, 13.5 ms (IQR 13.1-
14.2) in AZM and 37.6 ms (IQR 35.7-40.7) in combined groups (Figure 8.10A-E).  
Finally, the incidence of EADs and RF in the population of models was 
calculated (Figure 8.10F). During 1 Hz pacing, no EAD/RF was documented in the non-
treated group, while 6.4% of models in the CQ group, 2.4% of models in the AZM group, 
and 53.5% of models in the combined group exhibited EADs/RFs. Following the 
increase in pacing rate to 2 Hz, the incidence of EAD/RF was reduced to 0.5%, 0.7% and 
11.5%, respectively. No EAD/RF was observed in any of the groups following the 
application of ISO during 2 Hz pacing.  
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Figure 8.10: The cellular effects of chloroquine and azithromycin in the population of 1000 canine 
ventricular epicardial myocyte models. A) The APs of 592 models included in the study, with the 408 excluded 
non-physiological APs shown as grey lines. B-E) The frequency distribution of APD in non-treated, 
chloroquine, azithromycin and combined groups. F) The incidence of EAD/RF observed in the population-
based study (as percentage of models). G) Boxplot showing the distribution of relative changes in ionic 
currents to accommodate the interindividual variability. (AP = action potential; APD = action potential 
duration; Ctl = control; EAD = early afterdepolarization; ISO = isoproterenol; RF = repolarization failure) 
 
8.3.2 The effects of chloroquine and azithromycin on human ventricular 
electrophysiology 
Although the dog is a commonly used animal model with relatively similar 
electrophysiological properties to humans, some differences in ion-channel expression 
and AP profile exist, which may modulate drug effects (603, 604). As such, we also 
studied the impact of CQ and AZM on the human ventricular AP. During 1 Hz pacing, 
application of 5 µM CQ in the ORd human ventricular epicardium model prolonged APD 
by 100 ms (+43%), while 20 µM AZM prolonged APD by 68 ms (+29%). The 
combination of both drugs showed a synergistic effect with an APD prolongation of 177 
ms (+76%; Figure 8.11A, upper panels), similar to the canine ventricular model. 
Likewise, increasing the pacing rate from 1 to 2 Hz reduced the APD in all groups (by 
11%, 14%, 14% and 16% in the non-treated, CQ, AZM and combined groups, 
respectively; Figure 8.11A, middle panels). The combination of simulated ISO 
application and increased pacing rate reduced APD by 49 ms (-21%) in the non-treated, 
106 ms (-32%) in the CQ, 95 ms (-32%) in the AZM and 164 ms (-40%) in the combined 
groups compared to APD during 1 Hz pacing (Figure 8.11A, lower panels). At fast 
pacing rates, the RMP in the CQ and CQ+AZM groups without ISO displayed a marked 
depolarization due to incomplete repolarization within a single cycle length (Figure 
8.11B, right panel). Overall, no EAD or RF was observed on ORd human ventricular 
model. Similar to the canine ventricular model, ISO-induced phosphorylation of IKs and 
ICa,L contributed to the previously observed APD reduction in the model and preventing 
such phosphorylation resulted in similar APDs in the CQ+AZM group with 1 µM ISO and 
the CQ+AZM group at 2 Hz pacing (Figure 8.12). 
In the population-based study, all 1000 models were included in the study 
(Figure 8.13A, left panels, blue lines). Consistent with the default model without 
variability, at 1 Hz pacing, APD prolonged by a median 99.4 ms (IQR 94.7-104.8) with 
CQ (5 µM), 65.4 ms (IQR 61.5-68.9) with AZM (20 µM) and 175.5 ms (IQR 166.2-184.2) 
with the combination. During 2 Hz pacing, CQ, AZM and CQ+AZM prolonged the APD 
with median 79.9 ms (IQR 75.9-83.7), 51.2 ms (IQR 48.8-53.9), and 139.8 ms (IQR 
132.9-147.1), respectively. Finally, following the addition of ISO, the APD prolongation 
was further reduced with median prolongation of 42.4 ms (IQR 39.6-45.3) in CQ, 21.5 
ms (IQR 19.7-23.6) in AZM and 62.3 ms (IQR 57.6-67.6) in combined groups (Figure 
8.13A-E). 
To investigate the effect of CQ+AZM on the human AP in the presence of altered 
repolarization reserve during severe hypokalemia, we lowered the [K+]o to 2.0 mM. 
Severe hypokalemia prolonged the APD while hyperpolarizing the RMP. However, no 
EAD was induced by this reduction in repolarization reserve (Figure 8.14). Therefore, 
we extended the analysis using a population modeling approach to evaluate whether 
EADs could be induced during hypokalemia in the population of models with variations 
in ionic current conductance. However, as shown in Figure 8.13F-G, no EAD was 
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documented in the population of 1000 models despite the extremely long APD (>600 
ms) in some models.  
 
Figure 8.11: The effects of chloroquine and azithromycin on AP properties of human ventricular epicardium. 
A) The AP and calcium transient of non-treated, chloroquine 5 µM, azithromycin 20 µM and combined groups 
with 1 Hz pacing (blue), 2 Hz pacing (red) or 2 Hz pacing with electrophysiological effects of maximal β-
adrenergic stimulation (green). The dashed vertical lines indicate the end of AP with 1 Hz pacing to provide 
a clearer depiction of the effects of increasing pacing rate and ISO on APD. B) APD and RMP for different 
pacing rates in the four groups with and without simulated β-adrenergic stimulation. (AP = action potential; 
APD = action potential duration; Ctl = control; ISO = isoproterenol; RMP = resting membrane potential) 
Since EAD formation has been attributed to the reactivation of ICa,L (605), we 
increased the ICa,L window current by leftward shifting the steady-state activation so 
that the channels get activated at more negative potentials and rightward shifting the 
steady-state inactivation so that channels start to recover from inactivation at more 
positive potentials. Using this approach, we were able to induce EADs in the population 
of models, both in the absence and presence of severe hypokalemia (Figure 8.15A-B). 
Interestingly, in contrast with the EADs resulting from reduced repolarization reserve 
seen in the canine ventricular model, the EADs generated by the increased ICa,L window 
could not be prevented by β-adrenergic stimulation. As depicted in Figure 8.15C, while 
Beta-adrenergic receptor stimulation and drug-induced proarrhythmia 
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the 2 Hz pacing alone reduced the incidence of EADs and RFs, the application of 1 µM 
ISO resulted in a marked increase in the EAD/RF incidence, affecting more than 50% of 
the models. Interestingly, this phenomenon occurred in the presence of ISO-induced 
APD reduction, highlighting the significance of the ICa,L window for the generation of 
EADs. 
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Figure 8.12: The impact of IKs and ICa,L phosphorylation on the action potential of human ventricular 
epicardium in the presence of chloroquine (CQ) and azithromycin (AZM). The effect of CQ 5 µM in 
combination with AZM 20 µM in the presence of ISO-induced IKs and ICa,L phosphorylation is shown in solid 
green lines. The green dashed lines represent the effect of CQ 5 µM in combination with AZM 20 µM in the 
absence of ISO-induced IKs and ICa,L phosphorylation. 
 
Figure 8.13: The cellular effects of chloroquine and azithromycin in the population of 1000 human 
ventricular epicardial myocyte models in the absence and presence of hypokalemia. [A-E] The effects of CQ 
and AZM on the human ventricular myocyte AP in normokalemia ([K+]o = 5.4 mM). A) The APs of 1000 models 
included in the study under Ctl conditions, with 5 µM chloroquine, 20 µM azithromycin, or a combination (top 
to bottom) at 1 Hz pacing, 2 Hz pacing or 2 Hz pacing with electrophysiological effects of maximal β-
adrenergic stimulation (left to right). B-E) The frequency distribution of APD in non-treated, chloroquine, 
azithromycin and combined groups. F-G) The effects of CQ and AZM in the presence of severe hypokalemia 
([K+]o = 2.0 mM). on human ventricular APs (F) and the frequency distributions of APD (G). (AP = action 
potential; APD = action potential duration; Ctl = control; ISO = isoproterenol) 
 
8.4  Discussion 
Here, we investigated the potential proarrhythmic effects of CQ and AZM in the 
ventricular cardiomyocyte in the absence or presence of β-adrenergic stimulation using 
an in silico approach. First, both our canine and human models indicate that CQ and AZM 
can significantly prolong the APD even within their therapeutic range. Moreover, their 
combination resulted in a synergistic APD prolongation, leading to the initiation of 
proarrhythmic EADs, which was more pronounced in the presence of reduced 
repolarization reserve due to reduced extracellular potassium. Second, β-adrenergic 
stimulation reduced APD prolongation in both canine and human models, and 
prevented EAD formation in the canine model via the upregulation of IKs and ICa,L. Third, 
Beta-adrenergic receptor stimulation and drug-induced proarrhythmia 
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our population-based study confirmed the robustness of these findings and showed 
that β-adrenergic stimulation completely cancelled the initiation of EADs and RFs in 
canine model variants. Finally, we presented the interesting observation that β-
adrenergic stimulation could increase the incidence of EADs and RFs in the human 
model with increased ICa,L window current, highlighting a potential important role for 
β-adrenergic activity in modulating drug-induced proarrhythmia by CQ and AZM.  
 
Figure 8.14: The impact of severe hypokalemia on the action potential of human ventricular epicardium in 
the presence of chloroquine and azithromycin. The left panels show the effect of CQ 5 µM in combination with 
AZM 20 µM in the absence of hypokalemia ([K+]o = 5.4 mM). The right panels show the effect of CQ 5 µM in 
combination with AZM 20 µM in the presence of severe hypokalemia ([K+]o = 2.0 mM). 
 
8.4.1 Chloroquine and azithromycin exhibit a synergistic APD-prolonging effect 
CQ and AZM block multiple ion channels, including the rapid delayed-rectifier 
potassium current (IKr) (444), which dose-dependently prolongs the APD and increases 
the propensity for EADs, creating a substrate for cardiac arrhythmias. In the clinic, they 
are known to prolong the QT interval, increasing the susceptibility for life-threatening 
arrhythmias such as Torsade de Pointes. Anaesthetized guinea-pig experiment revealed 
that CQ indeed has an APD-prolonging effect, while the combination with AZM did not 
cause further APD prolongation (581). This finding is different from a recent 
prospective observational study which showed that the maximum corrected QT 
interval during treatment was significantly longer in the combination group compared 
to the monotherapy group, highlighting the synergy between CQ and AZM (583), in 
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agreement with our results. Several studies have also reported the potential 
proarrhythmic effects of CQ and AZM in COVID-19 patients (578, 582, 583, 585). This 
discrepancy might be due to differences in heart or pacing rate at which the APD-
prolonging effects were evaluated as well as interspecies differences in cardiac ion-
channel properties, as previously discussed (603, 604). Nonetheless, further 
experiments are needed to confirm the origin of the inconsistency.  
 
Figure 8.15: The impact of severe hypokalemia on the population of 1000 human ventricular epicardium APs 
with increased ICa,L window in the presence of chloroquine and azithromycin. A) The effect of CQ 5 µM in 
combination with AZM 20 µM in the absence of hypokalemia ([K+]o = 5.4 mM; left panel) and in the presence 
Beta-adrenergic receptor stimulation and drug-induced proarrhythmia 
248 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 8
 
of severe hypokalemia ([K+]o = 2.0 mM; right panel). B) A 3 mV shift in the steady-state activation and 
inactivation of ICa,L were introduced in the human ventricular epicardium model to increase the ICa,L window 
(shift from black to purple lines). C) The incidence of EAD/RF observed in the population-based study (as 
percentage of models). (EAD = early afterdepolarization; ICa,L = L-type calcium current; ISO = isoproterenol; 
RF = repolarization failure; VM = membrane potential) 
Employing a computational canine ventricular cardiomyocyte model, we 
confirmed the potentially harmful ventricular APD-prolonging effect of CQ and AZM. 
Within the therapeutic range, the incidence of EADs was relatively low (6.4% in CQ 
group and 2.4% in AZM group). Nonetheless, the combination of both drugs, as 
proposed in the treatment of COVID-19, produced a synergistic APD-prolonging effect 
that further increased the likelihood of EADs, particularly at slow heart rates, 
suggesting the need for close monitoring of the QT interval during the administration 
of these drugs in the clinic. The simulations using a human ventricular model also 
showed a significant APD prolongation, although no EADs were documented. This was 
in agreement with recent data that reported trivial instances of drug-induced Torsade 
de Pointes or arrhythmogenic death following the administration of CQ+AZM despite 
significant QT prolongation (583, 584, 606).  
Our results also revealed that hypokalemia further augmented the drug-
induced APD prolongation and reduced repolarization reserve. Lowering the [K+]o to 
4.0 mM produced RF in the canine model without β-adrenergic stimulation (Figure 8.9). 
Similarly, the simulation of severe hypokalemia also prolonged the APD in the human 
ventricular model, highlighting the importance of baseline repolarization reserve for 
the proarrhythmic effects of CQ and AZM and the potential for hypokalemia correction 
to minimize arrhythmia risk in COVID-19 patients under CQ and AZM therapy (580).   
 
8.4.2 Beta-adrenergic activation reduces the APD and modulates the cellular 
proarrhythmic risk of chloroquine and azithromycin 
Beta-adrenergic agonists have been used as an antidote against CQ intoxication for a 
long time (607, 608). Their benefit in the management of CQ-induced arrhythmia has 
been experimentally demonstrated in anaesthetized rats, showing that the CQ-infused 
group treated with isoprenaline (a selective β-adrenergic receptor agonist) displayed 
longer time to the onset of arrhythmias and death (609). Conversely, the administration 
of propranolol (a β-adrenergic receptor blocker) potentiated the electrocardiographic 
effects of CQ, indicating that β-adrenergic receptor blockade might render the heart 
more vulnerable to the actions of CQ (610).  
In this study, we demonstrated that β-adrenergic stimulation could be a 
potential protective factor against CQ- and AZM-induced proarrhythmia by lowering 
the APD prolongation and therefore, preventing the occurrence of afterdepolarizations. 
Our population-based study using cellular models of canine ventricular 
electrophysiology showed that the protective effects of β-adrenergic stimulation are 
robust, reducing the incidence of EADs and RFs for a large number of virtual genotypes 
and with a relatively wide range of simulated isoproterenol concentrations. Similar 
APD-reducing effects of β-adrenergic stimulation were also demonstrated in the 
population of human ventricular models, restoring the drug-induced reduction in 
repolarization reserve. We also showed that the APD-reducing effect of β-adrenergic 
stimulation was due to the PKA-mediated phosphorylation of ICa,L and IKs. 
Phosphorylation of IKs increases the current density during β-adrenergic stimulation, 
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promoting repolarization. Meanwhile, phosphorylation of ICa,L abbreviated APD 
through the elevation of the plateau potential due to increased ICa,L, promoting 
additional voltage-dependent activation of repolarizing potassium currents (e.g., IKs; 
(611)), as demonstrated in Figure 8.6. Moreover, stronger calcium-dependent ICa,L 
inactivation (CDI) during β-adrenergic stimulation due to increased calcium loading 
(Figure 8.3A and 8.11A, lower panels), together with ICa,L phosphorylation, may give 
larger peak ICa,L current density but also a reduction in the persistent, APD-prolonging 
component. Genetic mutations altering IKs phosphorylation, as reported in long-QT 
syndrome type 1, may be responsible for prolonging the AP with β-adrenergic 
stimulation, especially at slower cycle lengths (598, 612, 613). Although extrapolation 
of these findings to the clinical setting is challenging, they suggest that the concomitant 
sympathetic stimulation in COVID-19 patients may reduce the likelihood of drug-
induced Torsade de Pointes, or arrhythmogenic death in COVID-19 patients despite the 
presence of marked QT interval prolongation, in line with observational studies (583).  
On the other hand, our results suggest that β-adrenergic stimulation might also 
be harmful in the presence of increased ICa,L window current. Such conditions may arise 
from gain-of-function mutations in the L-type calcium channel (LTCC)-encoding genes, 
underlying e.g., long-QT syndrome type 8 (Timothy syndrome; (614)). Increased ICa,L 
window current has also been reported in failing human and rat ventricular myocytes, 
where a redistribution of functional LTCCs, increased open probability, and CaMKII-
mediated phosphorylation of the channel occurred (172). In our in silico analyses, 
isoproterenol-induced EAD promotion occurred irrespective of the APD-reducing effect 
of β-adrenergic stimulation, indicating the importance of ICa,L reactivation in 
maintaining EAD. This finding suggests the need for careful consideration of β-
adrenergic stimulation under disease conditions that potentially enlarge the ICa,L 
window. Moreover, long-term β-adrenergic stimulation promotes cardiac remodeling, 
including hypertrophy, fibrosis and the downregulation of several ion channels via 
transcriptional and post-translational modifications, potentially creating a substrate 
for cardiac arrhythmias (335, 615, 616). The present study revealed that transient 
activation of the β-adrenergic response may be beneficial against drug-induced 
proarrhythmia and β-blockers might not be appropriate under such circumstances. On 
the other hand, β-blockers could be used to reduce the detrimental effect of long-term 
β-adrenergic stimulation or to reduce the complications of COVID-19-induced systemic 
inflammation in the absence of medications with proarrhythmic behavior. 
 
8.4.3 Limitations of the study 
Here, we performed a computational study using an established canine ventricular 
cardiomyocyte model with β-adrenergic signaling (78, 81) and a human ventricular 
cardiomyocyte model (263) phenomenologically incorporating the maximum 
electrophysiological effect of β-adrenergic stimulation (598, 599). Despite similarities 
between canine and human electrophysiology, future studies integrating all signaling 
components of β-adrenergic cascades in a human cardiomyocyte model are warranted. 
Although EADs are an established proarrhythmic mechanism, extrapolation of the 
current findings to tissue- or organ-level simulations, taking into account the 
heterogeneous nature of sympathetic innervation, would be required to confirm the 
pro- and antiarrhythmic effects identified at the cellular level and to identify potential 
markers of proarrhythmic risk. These were not performed due to the computational 
Beta-adrenergic receptor stimulation and drug-induced proarrhythmia 
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costs associated with the complexity of the cardiomyocyte model and the relatively 
slow time-course of β-adrenergic stimulation-induced electrophysiological modulation 
(requiring long simulations). 
In this study, we used cellular concentrations of CQ and AZM, i.e., 
concentrations employed during in vitro experiments where specific drugs produce 
certain measured effects at the cellular level. However, it can be challenging to correlate 
these cellular concentrations to the clinically relevant doses due to variability in the 
pharmacokinetics and -dynamics of the drugs, particularly in severely ill patients. 
Pharmacokinetics/-dynamics models exist and, in the future, could be implemented to 
obtain a more precise simulation of the electrophysiological consequences of the drugs. 
The drug-induced ion-channel modifications incorporated in this study 
(Figure 8.2) were derived from a previous publication using heterologous expression 
systems (in Chinese hamster ovary / human embryonic kidney cells), which could 
display different results from human cardiomyocytes (444). Since these data are the 
only available data to date, we assumed that the relative drug effects are retained across 
species and cell types.   
 
8.5  Conclusions 
CQ and AZM exhibit synergistic APD-prolonging effects, potentially resulting in 
increased proarrhythmic risk, although the severity of the electrophysiological effects 
depends on the baseline repolarization reserve. Transient activation of the sympathetic 
nervous system may prevent CQ- and AZM-induced proarrhythmia by reducing their 
APD-prolonging effect, highlighting the importance of preserving β-adrenergic 
response in the presence of such proarrhythmic medications and the potential 
significance of heart-rate and autonomic-status monitoring in particular conditions 
such as COVID-19. 
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9.1 Introduction 
Cardiomyocyte calcium handling is the key mediator of cardiac excitation-contraction 
coupling. In the healthy heart, calcium controls both electrical impulse propagation by 
shaping the cardiac action potential and myofilament cross-bridge cycling, providing 
synchronous and adequate contraction of cardiac muscles (Chapters 1-2). Due to the 
complex and tight interactions between calcium and other molecules within a 
cardiomyocyte (335), it remains experimentally challenging to study the exact 
contributions of calcium-handling abnormalities to arrhythmogenesis. Therefore, 
multiscale computational studies are increasingly being used together with laboratory 
experiments to unravel the exact mechanisms of calcium-mediated arrhythmogenesis. 
This thesis describes various examples of how integrative computational modeling 
makes it possible to unravel the arrhythmogenic consequences of alterations to cardiac 
calcium handling at subcellular, cellular and tissue levels (Figure 9.1). 
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Figure 9.1: Alterations to calcium handling as a key determinant of cardiac arrhythmias. Subcellular calcium-
handling abnormalities may initiate delayed afterdepolarizations (DADs) and triggered activity. At the 
cellular level, modifications of calcium-handling proteins can directly or indirectly affect cardiac ion-channel 
function, leading to substantial changes in AP properties. At higher spatial scales, calcium-handling 
abnormalities may promote structural remodeling, allowing the generation of reentrant waves. Together, 
those processes may create vulnerable substrates for cardiac arrhythmias. 
First, Chapter 2 of this thesis summarized the numerous roles of 
cardiomyocyte calcium handling in health and disease, and showed the potential 
synergy between in vitro experiments and in silico models of cardiomyocyte calcium 
handling (335). Chapter 3 discussed our state-of-the-art subcellular model of human 
atrial cardiomyocyte calcium handling to investigate the impact of subcellular 
distributions of calcium-handling proteins (e.g., RyR2 and LTCC) on atrial 
electrophysiology (4). Chapter 4 demonstrated the application of the previously 
developed subcellular model to elucidate the mechanisms and cause-effect relationship 
between calcium-handling abnormalities, acute transient inflammation and POAF 
(327). Chapter 5 revealed the significance of direct calcium-dependent regulation of 
atrial ionic currents on cardiac electrophysiology under physiological and pathological 
conditions (61). Chapter 6 illustrated a multiscale computational framework to 
investigate complex arrhythmias (i.e., ethanol-associated reentrant arrhythmia), 
incorporating the in vitro electrophysiological data of acute ethanol-induced electrical 
remodeling into multiscale in silico simulations under different conditions (346). 
Chapter 7 presented MANTA (603), a novel, easy-to-use educational tool to better 
understand the cellular effects of AADs, incorporating the currently available in silico 
models of cardiac cellular electrophysiology and various classes of AADs (Vaughan-
William I, III, IV and multi-channel blockers). Finally, Chapter 8 exemplified the role of 
computational models of canine and human ventricular cardiomyocytes to study the 
effect of β-adrenergic receptor stimulation in the presence of repolarization reserve-
reducing medications (e.g., chloroquine and azithromycin) (617). 
 
9.2 Cardiomyocyte calcium handling: The complex hub of excitation 
and contraction 
As extensively discussed in Chapters 2, calcium plays a major role in both excitation 
and contraction of a cardiomyocyte. The influx of calcium via LTCC mediates a much 
larger SR calcium release through CICR, which initiates myriads of processes within a 
cardiomyocyte, including activation of calcium-dependent signaling molecules (e.g., 
calmodulin, calcineurin, calpain, etc.), transmembrane ion channels, calcium-handling 
proteins and, last but not least, contractile machineries of the cardiomyocyte. During 
diastole, calcium ions are partly stored back in the SR and partly extruded from the cell 
via NCX. Under pathological conditions, these complex processes can be disrupted, 
creating substrates and triggers for cardiac arrhythmias (335). There are three major 
calcium-dependent arrhythmogenic mechanisms: initiation of afterdepolarizations (i.e., 
EADs and DADs leading to TA), direct and indirect ion-channel modulation, and the 
promotion of structural remodeling (335). Those pathological processes can modify AP 
properties (e.g., APD, RMP and ERP) and cell-to-cell coupling, further altering tissue-
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level conduction velocity. In turn, these electrophysiological alterations may promote 
ectopic activity, reentrant waves and cardiac arrhythmias (Figure 9.1). 
Due to the complex interacting and tightly-controlled calcium-mediated 
processes within the heart, it is experimentally challenging to study the exact role of 
calcium in arrhythmogenesis. There are several controversial topics related to the roles 
of calcium and calcium-handling proteins in cardiac pathologies. For example, SERCA 
upregulation has been considered proarrhythmic by increasing calcium leak and SCaEs 
due to store overload-induced calcium release (SOICR) (26). However, at the same time, 
evidence suggests that SERCA stimulation may reduce the likelihood of SCaEs and 
triggered activity by impairing the communication between RyR2 clusters, elevating 
the intra-SR threshold for the generation of calcium waves and slowing calcium-wave 
propagation (33). This antiarrhythmic behavior of SERCA stimulation was documented 
in several studies using HF rats (34) and ischemia-reperfusion porcine models (35). 
Similarly, in atrial cardiomyocytes from patients with long-standing persistent AF, 
some studies reported RyR2 dysfunction and increased SCaE incidence (121, 124, 137-
139), while the others showed reduced SCaE incidence and calcium-signaling silencing 
(Figure 9.2) (130, 140-142). These two examples highlight the complexity of calcium-
mediated processes within a cardiomyocyte, which laboratory experiments have not 
been able to fully resolve. 
 
Figure 9.2: The proposed mechanisms involved in low intracellular sodium-induced calcium silencing. The 
reduction of LTCC function following rapid atrial pacing / persistent AF has been proposed as the cause of 
low intracellular sodium, which further induced the calcium extrusion via NCX and lowered the frequency of 
SR calcium leak and SCaEs, ultimately leading to calcium-signaling stabilization / silencing in the long term. 
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9.3 Integrative experimentation: Is it necessary? 
There are at least three types of laboratory experiments in cardiovascular research: in 
vitro, ex vivo (e.g., the whole-heart Langendorff setup) and in vivo experiments. 
Although these experiments have been instrumental in investigating different aspects 
of calcium-mediated arrhythmogenesis, each of them has their own limitations. In vitro 
experiments are widely used to study the arrhythmogenic consequences of calcium-
handling abnormalities at the subcellular and cellular levels. Due to the limited 
availability of human cardiomyocytes, heterologous expression systems and, more 
recently, human induced pluripotent stem cells, have been widely used (618). However, 
these systems are not identical to human cardiomyocytes, and may present potentially 
different calcium-dependent effects. Moreover, the absence of complete and mature 
signaling pathways within those cells may also affect the findings. However, even when 
using adult human cardiomyocytes, several limitations have to be considered. The 
availability of undiseased donor hearts is limited, so, samples from patients undergoing 
cardiac surgery who have an extensive history of cardiovascular disease, are commonly 
used. In addition, isolated cardiomyocytes lack regulation by systemic modulators, such 
as the autonomic nervous and humoral systems, which have been shown to hold an 
important role in calcium-mediated arrhythmogenesis. Furthermore, single-cell 
experiments also lack intercellular coupling, which might modify the observed cellular 
effects. The role of electrotonic coupling has previously been studied in canine wedge 
preparation, in which cells close to the site of pacing experienced the greatest 
electrotonic load and therefore had the maximum attenuation of action potential 
upstroke amplitude. When electrotonic load due to propagation was reduced, upstroke 
amplitude was markedly enhanced (619). Similarly, the inhibition of Ito significantly 
reduced calcium-transient amplitude in single-cell simulations, while the reduction of 
calcium-transient amplitude following Ito blockade was minimal in tissue simulations 
due to electrotonic load (426).  
Although ex vivo experiments could potentially solve some of the 
aforementioned limitations of in vitro experiments, several challenges remain. Because 
the examined heart has to be detached from the body, it has to be denervated and 
therefore might lose some of the autonomic nervous control. Moreover, this type of 
experiment does not allow to study the underlying cause of the calcium-dependent 
arrhythmia, which are commonly found at more microscopic scales, at the exact 
timescale when the arrhythmia occur or in the same cells. Simultaneous optical 
mapping can be performed in Langendorff-perfused hearts to capture the membrane 
potential and the intracellular free calcium at the same time (620-622). However, at the 
moment, this approach is limited to these two parameters (membrane potential and 
bulk calcium transient), has limited spatial and temporal resolution, and is unable to 
image the depth of the cardiac walls. Therefore, it is often unable to unravel the 
causality of calcium-dependent cardiac arrhythmias. Moreover, it is currently 
challenging to non-invasively visualize calcium in vivo. Some efforts using multiphoton 
microscopy technique (623) and optical mapping (624) have enabled recordings of 
membrane potential and calcium in an autonomically intact heart. However, they 
required surgical access to the heart, hindering the application of the techniques in 
humans. In the future, noninvasive photoacoustic imaging (625) might be useful to 
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visualize and quantify the electrophysiological determinants at molecular and cellular 
levels (411). Despite the ability of in vivo experiments to show the contribution of 
autonomic nervous system to various calcium-dependent processes, several limitations 
remain, including ethical considerations, cost and preparation time. These limitations 
typically preclude the use of large numbers of samples, which potentially reduces the 
significance of the findings. Therefore, currently available non-integrative laboratory 
experiments are not adequate to fully elucidate the mechanisms underlying calcium-
mediated arrhythmogenesis and another means of integrative experimentation is 
required to unravel the exact pathophysiology of calcium-induced arrhythmia. 
 
9.4 Why do we need integrative computational modeling? 
For more than 40 years, computational modeling of cardiac cellular electrophysiology 
has been shown to be beneficial in identifying the drivers of cardiac arrhythmias at the 
cellular scale. Employing the perfect control and observability of in silico models, the 
key determinants of arrhythmogenesis can be identified and managed. Computational 
modeling is also cost-effective, and with the advancement of computational power and 
the development of in silico tools such as Myokit (344), computational modeling enables 
the simulations of complex cellular models in a fairly short timeframe. In this thesis, we 
demonstrated some of the benefits of computational modeling to better understand the 
pathophysiology of calcium-dependent arrhythmia. First, in Chapter 3, employing our 
state-of-the-art spatial calcium-handling model, we showed that heterogeneity of the 
distributions of calcium-handling proteins has a significant impact on the propensity of 
SCaEs. Moreover, using our model, we were able to manipulate the arrangement of the 
axial tubules, attach and detach the concomitant RyR2 hyperphosphorylation, and 
selectively modify the subcellular distributions of these calcium-handling components, 
which at present cannot be done experimentally. With this approach, we could show, 
for the first time, the consequences of different locations and number of axial tubules 
for atrial calcium wave propagation, the magnitude of the contribution of RyR2 
hyperphosphorylation, and the role of lateral RyR2 bands and inter-band RyR2 clusters 
in calcium wave propagation and how they may contribute to the susceptibility of SCaEs 
and DADs. Second, in Chapter 4, we employed this spatial calcium-handling model to 
investigate the consequences of both calcium-handling abnormalities and acute 
transient inflammation on the propensity of SCaEs in the setting of POAF. Our findings 
confirmed that inflammation is a prerequisite to trigger cellular proarrhythmicity in the 
vulnerable preexisting substrate of POAF patients. Third, in Chapter 7, we showed 
using our novel tool (MANTA) that interspecies differences in ion-channel function may 
significantly affect the cellular response to AADs. Furthermore, our tool may also 
provide a hint on the potential drug-induced proarrhythmia exhibited by various 
classes of AAD. Similarly, Chapter 8 also demonstrated the difference between canine 
and human ventricular cardiomyocytes in facilitating EAD generation in the presence 
of reduced repolarization reserve. Furthermore, using population of 1000 models, we 
also showed that β-adrenergic stimulation may limit the proarrhythmic behavior of 
APD-prolonging drugs by restoring the repolarization reserve, although in the presence 
of increased ICa,L window, β-adrenergic stimulation could be detrimental.      
Despite the benefits of subcellular or cellular in silico models, the clinical 
applicability of such findings is limited. Although we showed an increase in SCaEs at the 
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(sub)cellular level, their effects at higher levels, such as tissue and organ levels, are 
unknown. Likewise, although our tool was able to demonstrate potential drug-induced 
arrhythmia at the cellular level, the effect might be eliminated by strong intercellular 
electrotonic coupling or cell-to-cell variability at higher scales (Figure 9.3). Therefore, 
the integration of in silico models into a multiscale modeling approach is needed. In this 
thesis, we dedicated Chapter 5 and 6 to highlight the advantage of such an integrative 
modeling approach. In Chapter 5, we demonstrated that the incorporation of a 
simplified stochastic RyR2-gating model reproducing behavior from detailed spatial 
calcium-handling models into an atrial cellular electrophysiological model was able to 
provide new insight into calcium-mediated arrhythmogenesis. In particular, we showed 
that calcium-dependent regulation of atrial ionic currents could stabilize the resting 
membrane potential, increasing the threshold for DADs in healthy atria. However, in an 
electrically-remodeled atrium, such membrane-stabilizing effects were attenuated. The 
integration of subcellular, cellular and tissue-level atrial models in Chapter 5 further 
showed that synchronization of diastolic SR calcium release across cells is needed to 
transform the cellular-level DADs into tissue-level ectopic activities. Moreover, 
employing our integrative modeling approach, we directly demonstrated that calcium-
induced ectopic activity is able to develop into a non-sustained reentrant arrhythmia. 
Chapter 6 has also demonstrated the benefits of integrative modeling in investigating 
complex arrhythmias. Ethanol is known to alter multiple cardiac ion channels, calcium-
handling proteins and gap-junction coupling. Using our multiscale model, we could 
show that ethanol-induced remodeling of IK1 contributed to the protective effects 
produced by low ethanol concentrations by slightly prolonging atrial APD and lowering 
the total arrhythmogenic risk at the tissue level. We also showed the consequences of 
disease-associated electrical and structural remodeling on the ethanol-induced 
arrhythmogenesis. Finally, we showed that cell-to-cell variability in ethanol-induced IK1 
remodeling was an important determinant for the tissue phenotype. Therefore, 
characterization of such variability is needed to accurately predict the effect of ethanol 
in cardiac electrophysiology. 
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Figure 9.3: Schematic illustration of multiscale computational modeling and positioning of the chapters in 
this PhD thesis. To integrate individual modeling scales into a holistic model, a subcellular model of 
cardiomyocyte calcium handling is coupled with other cardiac ion channels to form a cellular model. 
Subsequently, cell models propagate the electrical impulse through gap junctions to form a 1-dimensional 
strand or 2-dimensional tissue model. At the organ level, different types of tissues, representing different 
regions and layers of the heart (e.g., epicardium, mid-myocardium, endocardium, Purkinje fibers, etc.) are 
combined with fiber orientation and structural remodeling. 
 
9.5 All models are wrong, but some are useful 
George E.P. Box, a British statistician, once said “all models are wrong, but some are 
useful”, which indicates that no in silico model is perfect and that each model has its own 
limitations and uncertainties. Indeed, models can become irrelevant over time, e.g., due 
to the discoveries of new experimental findings, allowing newer and more advanced 
models to develop. However, all existing cardiomyocyte models have been constructed 
based on the available experimental data at the moment when the models were 
developed and they have been useful to address the specific research questions that 
they were intended to answer. Moreover, the most interesting lessons are learned when 
a model is discovered to be incorrect, as this reflects a gap in knowledge or error in our 
underlying assumptions. As such, one could consider that the statement “All models are 
imperfect, but they are nonetheless useful” would be more appropriate. Nevertheless, 
several areas for improvement remain. Here, we describe three common limitations of 
integrative in silico models, which require additional attention in future research: 
interspecies diversity, temperature dependence and intra-/inter-individual 
heterogeneities. 
 
9.5.1 Interspecies diversity 
The availability of human cardiomyocyte samples is often limited. Therefore, 
experimental cardiac cellular electrophysiological research may benefit from the use of 
heterologous expression system (e.g., HEK293, CHO, Xenopus laevis oocytes, etc.), in 
which a specific ion-channel of interest can be analyzed using patch-clamp experiments. 
Alternatively, cardiomyocytes can be obtained from various animal models, including 
mouse, rat, rabbit, guinea-pig, pig, and dog. However, each species has a different 
composition of cardiac ion channels that may affect the observations and experimental 
results. For example, mice express little IKr and IKs, which limits their use for drug-
induced proarrhythmia research (604, 626). In Chapter 7, we demonstrated such 
interspecies difference on the AP response to AADs using MANTA. Following the 
application of dofetilide (a class III AAD, primarily blocking IKr), canine LV and human 
LV models revealed the biggest APD prolongation, while the mouse LV model showed 
no effect on AP properties. Similarly, the calcium-channel blocker verapamil (a class IV 
AAD) displayed species-specific responses in the models. In mouse models, the drug 
slightly prolonged the APD, while in the guinea-pig and rabbit, it shortened APD. 
Interestingly, in the canine model, the drug demonstrated an opposing effect at low and 
high concentrations, with low concentrations prolonging APD and high concentrations 
shortening APD. Thus, understanding the characteristics (i.e., ion-channel 
compositions) of the species / models of interest is essential.  
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Unfortunately, the availability of experimental data from humans (or even 
from the same animal model) for computational analysis are often limited. Therefore, 
most in silico models are optimized using experimental data from multiple animal 
models, which could potentially influence the behavior of in silico models (627, 628). In 
these models, we often assume that the observed effects are conserved across species. 
Although in some cases this assumption is valid, prudent interpretation of the results is 
necessary. 
 
9.5.2 Temperature dependence  
It is essential for in vitro experiments to be conducted at body temperature (approx. 34-
37 degrees Celsius) to produce results closest to physiological conditions. However, 
sometimes it is challenging due to the increased cell instability at higher temperatures, 
which forces the experiments to be done at much lower temperature (e.g., room 
temperature). It has been shown that temperature differences alter the function of 
several calcium-handling proteins. For example, an increase in temperature from 24 to 
37 degrees Celsius increased the rate-constant of decay of the calcium-transient (CaT) 
and caffeine-induced calcium-transient (cCaT) in both rat and guinea-pig 
cardiomyocytes, reflecting altered NCX and SERCA function at higher temperature 
(629). Similarly, temperature changes have been reported to affect the properties of 
calcium-sparks in rat cardiomyocytes. A reduction of experimental temperature from 
35 to 10 degrees Celsius increased the frequency of calcium sparks and reduced their 
amplitude, while prolonging the time-to-peak and decay of calcium sparks (630). Such 
findings emphasize the need to carefully observe the data prior to the incorporation 
into in silico models.  
To accommodate thermodynamic effects, several computational models have 
incorporated scaling factors, typically based on a Q10 factor (the change in rate for a 10-
degree increase in temperature), into the ionic-current equations. However, the data to 
validate these factors are scarce and thus may affect the robustness of computational 
studies when simulations are performed at temperatures other than those at which the 
data were obtained. Moreover, the temperature-dependent effects may be distinct for 
different model components and experimental data from different sources may be 
obtained at different temperatures, making their integration in computational models 
challenging. 
 
9.5.3 Intra- and inter-individual heterogeneities 
The pathogenesis of cardiac arrhythmias has not been fully elucidated due to the 
complex interaction between signaling molecules, calcium-handling proteins, ion 
channels and other proarrhythmic substrates within the heart. In particular, there are 
considerable intra- and inter-individual heterogeneities in cardiac electrophysiological 
properties, which limit the effectiveness and safety of currently available one-size-fits-
most therapeutic strategies for cardiac arrhythmias (5). Inter-individual variability is 
evident even among healthy individuals. However, the clinically observed magnitude of 
such inter-individual heterogeneities might be overestimated due to the considerable 
overlap with unexplored intra-individual heterogeneity. Intra-individual variation can 
be the result of distinct interactions between electrical impulse determinants at the 
cellular, tissue (e.g., gap-junction coupling and anisotropy) and organ levels (e.g., fiber 
arrangement, wall thickness and structural remodeling). At the molecular level, the 
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heterogeneity of the distribution and expression of ion channels and signaling 
molecules, as well as the interactions between two or more tightly co-expressed genes 
and the integration of multiple proteins in macromolecular complexes may contribute 
to the functional variability observed at the cellular and tissue levels (631). In the 
healthy heart, the effect of single-cell variability may be cancelled out by strong 
electrotonic coupling (632), while in the diseased heart with altered intercellular 
coupling, the effect of such variability is unknown and yet to be investigated. 
Comprehensive characterizations of this molecular and cellular heterogeneity have so 
far not been performed.  
Computationally, inter-individual heterogeneity is (partly) addressed by 
employing a population of models, incorporating variability of specific parameters of 
interests (typically the maximum conductance of ionic currents, reflecting differences 
in the expression level of ion channels) (382). Using this population-based approach, 
the inter-individual variability of ionic currents can be accommodated and more 
representative results can be obtained. However, the exact magnitude of such 
variability is unknown and therefore relies on predefined assumptions. In Chapter 6, 
in addition to the population modeling approach to confirm our cellular findings, we 
also performed multiscale in silico simulations to study the role of cell-to-cell variability 
at the tissue level. We aimed to study whether the ethanol-associated increase in 
reentrant arrhythmia vulnerability is affected by the variability of ethanol-induced IK1 
remodeling. Our simulations revealed that the proportion of cells incorporating an 
ethanol-induced increase or decrease of IK1 in the virtual tissue modulated the behavior 
of the reentrant arrhythmias (346). This finding highlights the need for considering cell-
to-cell variability to improve the accuracy of the computational model at the higher 
scale (e.g., tissue or organ level). 
 
9.6 The future outlook of integrative in silico modeling 
9.6.1 Organ-level modeling 
In specific cases, 2-dimensional tissue simulations may be adequate to address the 
arrhythmogenic consequences of calcium handling abnormalities. By employing such 
tissue simulations, the significance of cell-to-cell interaction can be elucidated with a 
fairly reasonable computational cost (633). However, the results may not be 
representative of the actual condition in the organ level due to the absence of other 
supporting components, such as extracellular matrices, Purkinje fibers, muscle-fiber 
orientation and spatial gradients in electrophysiological properties (e.g., between left 
and right, or between endocardial, mid-myocardial and epicardial layers) (634). Those 
organ-level components might also play an important role in wave propagation within 
the heart (635). Therefore, organ-level modeling incorporating detailed structures of 
cardiac electrophysiology may ultimately be needed for studying cardiac arrhythmias. 
However, despite its potential benefit for arrhythmia research, organ-level 
modeling is computationally intense and requires supercomputing clusters to operate, 
which hinders its broad application (634). To overcome this issue, (sub)cellular models 
have had to be significantly simplified. As an illustration, on a normal personal 
computer, a simulation using the detailed spatial calcium-handling model as described 
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in Chapter 3 could take more than 12 hours to complete, while a cellular simulation 
using a common-pool AP model would only take less than two minutes to compute. 
Meanwhile, a simulation of 400x400 cells with detailed ionic currents could last for 
more than 8 hours. This definitely limits the use of such detailed models at tissue- and 
organ-level scales. Simpler alternatives have been proposed at the cost of losing realism 
in the mathematical description, e.g., using phenomenological models, which reduce the 
number of state-variables substituting the actual ionic current descriptions by simple 
mathematical equations (634). In this thesis (Chapter 5), we have applied a similar 
simplification to bypass the complexity of subcellular components of cardiomyocyte 
calcium handling to investigate the consequences of SCaEs at the cellular and tissue 
levels. However, such simplifications may limit the ability of the organ-level model to 
mimic the precise conditions observed experimentally, particularly in the presence of 
genetic mutations altering the gating components of specific cardiac ion channels or 
calcium-handling proteins. Therefore, until now, the application of organ-level 
modeling in pathologies requiring complex biophysical details has been limited to a few 
studies by a handful of labs worldwide. Moreover, the models in these studies are often 
used to address issues in which the changes to the ion channels or calcium-handling 
proteins can be implemented by modifying the maximum conductance of the currents 
(e.g., to simulate arrhythmogenic consequences of myocardial infarction / ischemia). 
Nonetheless, computing power continues to advance and organ-level modeling will 
likely become feasible to investigate the arrhythmogenic consequences of calcium-
handling abnormalities. 
 
9.6.2 Integrative personalized modeling 
Despite the limitations of current integrative computational modeling approaches, 
there is a growing demand for more personalized modeling approaches that 
accommodate interindividual heterogeneities to unravel patient-specific mechanisms 
and develop tailored therapy of cardiac arrhythmias. Although for now this is still far 
from reality, in the future, arrhythmia research would benefit from such a personalized 
approach. Ideally, a patient-specific “bottom-up” framework can be initiated by 
extracting cardiomyocytes from a patient, in which a comprehensive in vitro 
characterization of cardiac ion-channels can be made. Advances in induced pluripotent 
stem cell and automated patch-clamp technologies have provided first steps in this 
direction. Subsequently, such experimental data could be used as input for 
computational studies at the cellular level. Next, patient-specific intercellular / gap-
junction conduction can be assessed and incorporated in a personalized tissue model. 
Using advanced imaging techniques, the detailed geometry of the heart, as well as 
patient-specific fibrosis patterns can be mapped to create a personalized cardiac mesh 
for the 3-dimensional organ-level model. Combined with database-derived human 
Purkinje network and fiber orientation from diffusion tensor imaging, a patient-specific 
3-dimensional heart model can be developed and employed for patient-specific 
research. Finally, the standard 12-lead electrocardiogram, as well as invasive 
electrophysiological studies and non-invasive electrocardiographic mapping may 
provide important functional data to personalize the model’s electrophysiological 
properties at the organ level (Figure 9.4).  
Chapter 9 
 
Henry Sutanto | 265     
 
C
h
ap
te
r 
9
 
Such comprehensive personalized approaches have been partially performed, 
for example to guide catheter ablation in atrial fibrillation (636) and ventricular 
fibrillation (637). In these translational studies, the patient-specific fibrotic regions 
were incorporated into organ-level models and the appropriate target ablation site was 
identified in the model, which was then confirmed during a clinical electrophysiological 
study. Using this personalized modeling approach, lengthy electrical mapping 
procedure could potentially be avoided and the accuracy of targeted ablation could be 
improved. Conceptually, the future management of complex inherited arrhythmia 
syndromes, for example arrhythmogenic cardiomyopathy (AC), may similarly benefit 
from a personalized modeling approach. The cardiomyocytes from an AC patient could 
be extracted and characterized. Then, the results could be incorporated in a cellular 
electromechanical model. Meanwhile, advanced imaging and tissue optical mapping 
could be performed to identify fibrotic regions and assess the intercellular conduction 
and anisotropy. At the organ level, the fibrofatty infiltration, trabeculation and fiber 
arrangement could be assessed. All of those findings could then be incorporated into 
the whole-heart electromechanical and hemodynamic model and subsequently, the 
predisposing factors for arrhythmogenesis in this particular patient could be identified, 
the pathophysiology of the disease could be explained and the best treatment strategy, 
either pharmacological, interventional, or a combination of those two, could be applied. 
 
Figure 9.4: A schematic illustration summarizing multiscale integration of patient-specific data. The “bottom-
up” approach starts from the ionic current / molecular level up to the organ level. At each scale, the acquired 
Discussion 
266 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
C
h
ap
ter 9
 
data can be utilized as an input for computational modeling. Ultimately, a personalized 3-dimensional 
computational model can be developed and used for patient-specific arrhythmia research. 
 
9.7 Conclusions 
Calcium-handling abnormalities have multiscale implications that may promote cardiac 
arrhythmias. Computational modeling is a powerful tool to investigate the 
arrhythmogenic mechanisms and consequences of alterations in cardiac calcium 
handling. In this thesis, we demonstrated how integrative computational modeling of 
calcium handling can provide new insights into arrhythmia mechanisms, although 
some challenges remain. Future arrhythmia research will benefit from organ-level 
modeling of calcium-handling abnormalities, and, more importantly, an integrative 
patient-specific modeling approach. Such advances will certainly improve the accuracy 
and predictability of computational models and increase their clinical relevance. John 
von Neumann stated that “With four parameters I can fit an elephant, and with five I can 
make him wiggle his trunk”. In the end, one extra sentence deserves to be added to this 
statement: “… but even with thousands of parameters, I cannot make him alive.”, 
indicating that in silico models will always be in silico and therefore, synergy between 
modeling, biological experiments and clinical research remains an absolute 
prerequisite. 
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Summary 
Cardiomyocyte calcium handling is a major determinant of excitation-contraction 
coupling. Alterations in one or more calcium-handling proteins may induce 
arrhythmias through the formation of ectopic activity, direct and indirect ion-channel 
regulation, and structural remodeling. Due to the complex and tight interactions 
between calcium and other molecules within a cardiomyocyte, it remains 
experimentally challenging to study the exact contributions of calcium-handling 
abnormalities to arrhythmogenesis. Multiscale computational studies performed in 
close collaboration with laboratory experiments create new opportunities to unravel 
the mechanisms of arrhythmogenesis. This thesis describes the roles of integrative 
computational modeling in unraveling the arrhythmogenic consequences of calcium-
handling abnormalities. 
In Chapter 2, we reviewed the complex mechanisms and proarrhythmic 
consequences of calcium-dependent ion-channel regulation, SCaEs, post-translational 
calcium-signaling pathways, and long-term transcriptional regulation of calcium 
handling. We also discussed potential advantages of combined in vitro and in silico 
studies to address such complexities.  
In Chapter 3, we employed the perfect control and observability provided by 
computer models to elucidate the subcellular determinants of cardiomyocyte calcium 
handling. Our findings highlighted the importance of subcellular RyR2 and LTCC 
distributions in the genesis of SCaEs and DADs, which are well-known triggers of 
cardiac arrhythmias. Importantly, whole-cell calcium handling properties are 
determined by non-linear interactions between heterogeneities in the expression and 
phosphorylation of both LTCC and RyR2, highlighting the need for detailed 
immunocytochemistry and functional studies to explain differences in whole-cell 
calcium handling between conditions. 
Chapter 4 illustrated the application of the spatial calcium-handling model 
from Chapter 3 to support the notion that post-operative inflammation acting on a pre-
existing arrhythmogenic substrate may elicit SCaEs and DADs that could initiate POAF. 
Meanwhile, in Chapter 5, our multiscale in silico study demonstrated that 
calcium-dependent regulation of atrial ionic currents alters human atrial 
electrophysiology at the cellular and tissue level. It has protective effects in non-
diseased atrium by stabilizing the membrane potential, lowering DAD amplitude and 
preventing TA. However, in the presence of cAF-related remodeling, calcium-
dependent ion-channel regulation has proarrhythmic APD-shortening and RMP-
hyperpolarizing effects, stabilizing reentrant waves. We identified IK1 and ISK as the 
major ionic contributing factors. 
Chapter 6 of this thesis showed how our multiscale in-silico study provides 
new insights into the acute effects of ethanol on cardiac electrophysiology and 
arrhythmogenesis, demonstrating that ethanol has concentration-dependent 
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electrophysiological effects that differ between atria and ventricles, and in the absence 
or presence of disease-related remodeling. Low concentrations of ethanol had 
antiarrhythmic effects in the atria, whereas high concentrations promoted reentrant 
arrhythmias. In this chapter, we also showed that the exact proarrhythmic risk depends 
on ethanol-induced gap-junction remodeling and the degree, type and pattern of 
disease-associated structural remodeling, highlighting the need for personalized 
multiscale computational modeling to better predict the consequences of ethanol on 
cardiac electrophysiology in humans. 
Chapter 7 introduced MANTA, a powerful, freely available tool to reproduce a 
wide range of AAD characteristics including species-, rate-, and disease-dependent 
effects. MANTA enables analyses of the underlying ionic mechanisms as well as 
investigations of novel AADs with specific affinities for one or more targets. MANTA can 
facilitate a better understanding of the complex effects of AADs on cellular 
electrophysiology under a wide range of conditions, which may provide educational 
and/or clinically-relevant information on the safety and efficacy of AAD treatment. 
Chapter 8 demonstrated the synergistic APD-prolonging effect of CQ and AZM, 
which potentially increases the proarrhythmic risk, although the severity of the 
electrophysiological effects depends on the baseline repolarization reserve. 
Additionally, we showed that transient activation of the sympathetic nervous system 
may prevent CQ- and AZM-induced proarrhythmia by reducing their APD-prolonging 
effect, highlighting the importance of preserving β-adrenergic response in the presence 
of such proarrhythmic medications, and the potential significance of heart-rate and 
autonomic-status monitoring in conditions such as COVID-19. 
Finally, Chapter 9 wrapped up this thesis with an aide-mémoire that calcium-
handling abnormalities have multiscale implications that may promote cardiac 
arrhythmias. Integrative computational modeling enables investigations into the 
arrhythmogenic mechanisms and consequences of alterations in cardiac calcium 
handling, although some challenges remain. Future arrhythmia research would benefit 
from organ-level, and, more importantly, integrative personalized / patient-specific 
modeling approaches, which will certainly improve the accuracy and clinical 
applicability of computational models.  
In the end, in silico models will always be in silico. Therefore, synergistic 
interactions with clinical studies and biological experiments are an absolute 
prerequisite to address unmet needs of current arrhythmia research. 
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Summary figure: Three pillars of cardiovascular research. In the future, an integrative synergy between 
clinical studies, laboratory experiments and computational modeling would be beneficial in addressing the 
knowledge gaps and unmet needs of current arrhythmia research. 
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Impact 
Cardiovascular disease is a leading global cause of death, contributing to approximately 
17.8 million deaths in 2017. This number is expected to grow to more than 22.2 million 
by 2030 (638). In accordance, the prevalence of atrial fibrillation (AF) is estimated to 
be 1-2% of the general population in developed countries (e.g. North America, Europe 
and Japan) and about 0.5-1% in developing countries, turning AF into the most 
commonly found arrhythmia in the clinic, affecting more than 33 million people 
worldwide (639). Despite decades of research, a large number of unmet needs and 
knowledge gaps remain, preventing more effective management of patients at risk of 
arrhythmias (540). At the moment, the insights on the pathophysiology of arrhythmias 
in an individual patient are incomplete, affecting our available approaches to identify 
the actionable patient-specific molecular arrhythmia mechanisms, to detect and target 
key dynamic modulators of cardiac arrhythmias, to achieve atrial targeting of specific 
molecular arrhythmic mechanisms with drugs, and to integrate studies of specific 
molecular/cellular AF pathophysiology (411, 540).  
The chapters in this thesis aimed to address a number of current knowledge 
gaps by employing the perfect control and observability of computational modeling to 
better understand the role of cardiomyocyte calcium handling in arrhythmogenesis. 
 
Scientific impact 
To recapitulate, Chapters 1 and 2 of this thesis summarized the roles of cardiomyocyte 
calcium handling in health and disease. Chapter 3 discussed our state-of-the-art 
subcellular model of the human atrial cardiomyocyte to investigate the impact of 
subcellular distributions of calcium-handling proteins on atrial electrophysiology. 
Chapter 4 employed this subcellular model to elucidate the cause-effect relationship 
between calcium-handling abnormalities, acute transient inflammation and POAF. 
Chapter 5 evaluated the consequences of calcium-dependent ion-channel regulation 
on atrial electrophysiology under physiological and pathological conditions. Chapter 6 
presented a multiscale computational framework to investigate ethanol-associated 
reentrant arrhythmia in both healthy and remodeled hearts. Chapter 7 presented 
MANTA, a novel, easy-to-use educational tool to better understand the cellular effects 
of AADs. Finally, Chapter 8 highlighted the significance of β-adrenergic receptor 
stimulation in modulating the cellular proarrhythmic effects of chloroquine and 
azithromycin.  
Of the 8 scientific chapters in this thesis, 7 have been published in international 
peer-reviewed journals and 1 is still in the process of submission. Chapter 1 has been 
published in Frontiers for Young Minds in 2019 (640), and due to its unique concept and 
reasonably high societal impact, this chapter will be discussed separately in the next 
section. Chapter 2 has been published in Progress in Biophysics and Molecular Biology 
in 2020 (335). This publication was the first that extensively discussed the potential 
synergy between in vitro and in silico studies of cardiomyocyte calcium handling on 
cardiac cellular electrophysiology. It has been accessed >1500 times in the first 6-
months since its publication. Chapter 3 has been published in Frontiers in Physiology in 
2018 (4) and the subcellular calcium handling model has been used to address specific 
molecular/cellular AF pathophysiology as illustrated in Chapter 4. Chapter 4 has been 
published in Circulation Research in 2020 (327) as part of a comprehensive study 
Impact 
278 | Integrative computational modeling of calcium handling and cardiac arrhythmias 
 
involving both in vitro and in silico experiments. Chapter 6 of this thesis was published 
in Journal of Molecular and Cellular Cardiology in 2020 (346), and during its first month 
of publication, it has become the journal’s most read publication, with a high interest 
from the general community. This study was the first that employed multiscale 
computational modeling to study the acute effects of ethanol in cardiac 
electrophysiology. Moreover, this extensive in silico study provides a general 
framework to computationally investigate other complex arrhythmias. Chapter 7 was 
published in Pharmacological Research in 2019 (603), and was the first easy-to-use 
educational tool to better understand the effects of antiarrhythmic drugs (AADs) on 
cardiac cellular electrophysiology. MANTA has been used in several other unpublished 
projects to give an overview on how AADs may behave in specific in silico models and it 
is currently used as part of the Master Systems Biology program at Maastricht 
University. Finally, Chapter 8 of this thesis was published in Frontiers in Physiology in 
2020 (617). The study was the first to identify the role of β-adrenergic stimulation in 
the presence of altered repolarization reserve, for example during the administration 
of chloroquine and azithromycin. The study was conducted during the COVID-19 
pandemic, a disease state in which the sympathetic nervous and β-adrenergic response 
activation were expected to occur, and thus might interact with such proarrhythmic 
medications. Of note, all of our (Maastricht-led) publications and models are freely 
accessible, reflecting our commitment and support to the open science initiative.  
One way through which computational models can have scientific impact is the 
identification of arrhythmia mechanisms based on the perfect control of model 
parameters. For example, the study in Chapter 3 was the first to employ computational 
modeling of subcellular calcium handling to investigate the role of the distributions of 
calcium-handling proteins in atrial electrophysiology. It is at present not possible to 
selectively modulate the location of individual proteins experimentally. Using our state-
of-the-art subcellular model of cardiomyocyte calcium handling, we could show that 
increased heterogeneity of RyR2 clusters contributed to the propensity for SCaEs and 
DADs, and future targeting of this arrhythmogenic substrate might be advantageous to 
treat arrhythmia, for example in heart failure and AF, where increased heterogeneity of 
RyR2 clusters size has been documented (158, 159). Employing the perfect control of 
computational modeling, we also unraveled the significance of lateral RyR2 bands and 
interbands on the atrial wave propagation, something that could also only be addressed 
by in silico modeling. Although there are at present no therapeutic options to target 
these factors involved in arrhythmogenesis, altering the localization of proteins might 
be possible in the future, e.g., by modulating targeting of trafficking mechanisms 
through existing gene-editing technologies, including CRISPR-Cas9.  
In addition to its strong educational impact, Chapter 7 of this thesis also helps 
the scientific community on highlighting the interspecies diversity of AAD effects and 
therefore, the importance of selecting the most appropriate animal model for particular 
arrhythmia research. In the future, MANTA, as well as the other computer models 
developed in this thesis, can be used as a preliminary screening tool to reduce 
unnecessary animal experimentations, in line with the spirit of World Medical 
Association Declaration of Helsinki.  
Meanwhile, Chapter 6 illustrated the future use of multiscale integrative 
computational modeling to investigate specific risk factors (in this particular case, 
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alcohol consumption) under different conditions (e.g., the absence or presence of heart 
failure or AF-related remodeling). We could show that the degree, type and pattern of 
fibrosis had a significant impact on the behavior of reentrant arrhythmias, therefore 
indicating the need for a more personalized modeling approach. Such personalized 
modeling is expected to become increasingly used in patient care, as already 
demonstrated in for computationally guided catheter ablation (636, 637). This, 
together with the FDA-approved comprehensive in vitro proarrhythmia assay (CiPA) 
initiative (444, 595) to develop safer future pharmacological agents, are steadily 
bringing computational modeling towards clinically relevant applications. The work 
presented in this thesis underscores the importance of model personalization 
(Chapters 6 and 7) and provides novel approaches to simulate patient-specific triggers 
(e.g., post-operative triggers in Chapter 4). 
Lastly, computational modeling in general and the publications in this thesis in 
particular have enriched internal and external research collaborations. Computational 
modeling is inherently collaborative work since the models are built together and 
improved by computer modelers all over the world and rely on experimental data from 
many research. For example, the original O’Hara-Rudy dynamic model developed at 
Washington University in St. Louis, MO (263) has been modified, recalibrated and 
widely employed by modelers across the globe, highlighting such vast collaborations in 
the field of computational modeling. As part of this thesis, collaborations were 
established between the Departments of Cardiology, Physiology, Biomedical 
Engineering, and Genetics & Cell Biology at Maastricht University. Externally, among 
others, international partnerships were built with University Duisburg-Essen (DE), 
Masaryk University (CZ), and University of California Davis (CA). 
 
Societal impact 
During the PhD, we also put emphasis on the potential societal impact of our projects 
and publications. We intentionally designed our projects to not only provide specific 
scientific insights to the field, but also to improve the basic understanding of calcium 
handling and the relevance of its dysfunction in the general community. Chapter 1 of 
this thesis is one of the examples of these efforts. Frontiers for Young Minds is an 
international journal that aims to disseminate science and new scientific findings to 
general audiences, especially the future scientists. It is peer-reviewed by children in the 
range of 8-15 years to stimulate their curiosity and expose them to the world of science, 
guided by a science mentor. To support this initiative, the author of this thesis has 
become a science mentor for the journal during his PhD. In the first year after its 
publication, Chapter 1 of this thesis has received a huge interest from people around 
the world, reflected by its high read index (more than 20,000 reads to date; see the map 
below), turning the paper into one of the top 2% of all Frontiers publications. Moreover, 
it has received a reasonably good response on social media platforms, such as Twitter, 
Reddit, Facebook and Mendeley. 
In addition to Chapter 1, almost all of our publications have received high 
interests from both scientific and general communities on social media, supporting our 
aforementioned commitment in disseminating our research. The most interesting 
example is Chapter 6 of this thesis that touched on a very sensitive issue: alcohol 
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drinking. Alcohol drinking is a habit in Western and Eastern societies. Therefore, 
despite the clear clinical-experimental-computational evidence that in high 
concentrations it can be proarrhythmic, alcohol abuse remains common. Our findings 
contributed to the ongoing debate on the adverse effects of ethanol. This example shows 
how our computational study can be as attractive and influential as other forms of 
research. Of course, lots of work remains to be done to improve the understanding of 
the general community on the role of calcium in the heart and this, for sure, motivates 
us to improve our knowledge and perform further research to strengthen our 
comprehension on the complex connection between calcium-handling abnormalities 
and cardiac arrhythmias. 
 
Impact figure: The world map per August 2020 showing the demography of reads of Chapter 1 in this thesis. 
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“Success isn’t about how much money you make; it’s about the difference you make in 
people’s lives.” 
 
Michelle LaVaughn Robinson Obama 
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Appendix A 
ACTτ = 0.59 + 0.8 ∙
exp(0.052 ∙ (Vm +  13))
1 + exp(0.132 ∙ (Vm +  13))
 
ACT∞ =
1
(1 + exp (−
Vm −  13.56
P1
)) ∙ (1 + exp (−
Vm + 25
5
))
 
αCa,L =
ACT∞
ACTτ
, βCa,L =
1 − ACT∞
ACTτ
 
IV,∞ =
1
1.2474
∙ (0.2474 +
1
1 + exp((Vm + P5)/P6)
) 
IsV,∞ =
1
1.001
∙ (0.001 +
1
1 + exp((Vm + P5)/P6)
) 
IV,τ =
1
1
70.0 ∙ (1 + exp((Vm + P2)/P3))
+
1
P4 ∙ (1 + exp(−(Vm + 0.213)/10.807))
 
IsCa
s,m = P7 −
P8
1 + (
3.500 ∙ 10−4
[Ca2+]obs
s,m )
4 
IsV,τ
s,m
=
1
1
70.0 ∙ (1 + exp((Vm + 49.10)/10.349))
+
1
IsCa
s,m = (1 + exp(−(Vm + 0.213)/10.807))
 
xCa,L =
IV,∞
IV,τ
, yCa,L =
1 − IV,∞
IV,τ
 
xsCa,L
s,m =
IsV,∞
IsV,τ
, ysCa,L
s,m =
1 − IsV,∞
IsV,τ
 
 
δCa,L
s,m =
P9
1 + (
P10 ∙ 10
−3
[Ca2+]obs
s,m )
4 , θCa,L = 1 
θICa,L = 1.0 ∙ 10
−6, δICa,L
s,m = θICa,L ∙
xCa,L ∙ ysCa,L
s,m ∙ δCa,L
s,m
yCa,L ∙ xsCa,L
s,m ∙ θCa,L
  
 
PCa,L = 1.7 ∙ 10
−4  
cm
s
, γCa,i = 1.0, γCa,o = 0.341 
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IC̅a,L
s,m = PCa,L ∙ (zCa)
2 ∙
Vm ∙ F
2
R ∙ T
∙
γCa,i ∙ [Ca
2+]obs
s,m ∙ exp (zCa ∙ Vm ∙
F
R ∙ T
) − γCa,o ∙ [Ca
2+]o
exp (zCa ∙ Vm ∙
F
R ∙ T
) − 1
 
ICa,L
s,m = IC̅a,L
s,m ∙ (OCa,L
s,m + OsCa,L
s,m ) 
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Appendix B 
All cardiomyocyte models were extended with a state-of-the-art Markov model 
allowing simulation of state-dependent sodium channel block. Optimized parameters 
for the baseline part of the model as well as for the drug-specific transition rates in the 
drug-bound states are shown below for two human cardiomyocyte models; the Passini 
human left ventricular endocardium (374) and Schmidt human right atrium model 
(428). The parameters were optimized using Nelder-Mead optimization protocol and 
have been incorporated into each MANTA model. In brief, experimental voltage-clamp 
protocols were reproduced in the models and a sum-of-squares error criterion 
incorporating the difference between Markov model and original INa formulation (for 
the baseline model), and between simulated and experimental data (431) (in the case 
of drug-induced INa inhibition) was minimized.  
 
Param. 
Passini human LV model Schmidt human RA model 
Flecainide Lidocaine Vernakalant Flecainide Lidocaine Vernakalant 
diffusion 5500 500 170.867 5500 500 3.104e+3 
gNa 241.1554 13.4338 
pKa 9.3 7.6 5.4 9.3 7.6 5.4 
d1 11.2e-6 318e-6 340e-6 11.2e-6 318e-6 111.3e-6 
d2 400e-6 400e-6 484e-6 400e-6 400e-6 206.3e-6 
d3 5.4e-6 3.4e-6 9.6e-6 5.4e-6 3.4e-6 1.7e-6 
d4 800e-6 900e-6 46.2e-6 800e-6 900e-6 39.9e-6 
d5 1 1 1 1 1 1 
actshift -2.8424 -32.2217 
h1 4.8746 1.6000 
p1 1.6442 9.3467 
p2 3.0690e-2 1.4800e-1 
p3 15.7108 9.7715 
p4 11.2671 18.6939 
p5 5.2551 10.3420 
p6 7.6230e-1 5.9074e-1 
p7 826.5339 227.7919 
p8 4.4492e-2 7.9261e-2 
p9 38.4111 8.2196 
p10 3.9229e-1 3.3248 
p11 4.9252 5.9433 
p12 6.2475e-1 6.0556e-1 
p13 13.8297 13.6961 
p14_new -77.2417 -69.9611 
p15_new 5.3593 3.5994 
p16_new 1.0499e-1 1.4914e-1 
p17_new 2.4121e-1 2.5403e-1 
p18 13.8089 1.3906 
p19 43.5223 44.7185 
p20 3.4316e-2 3.5427e-2 
p21 1.8094e-2 1.8070e-2 
p01 49.8798 41.2656 
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p22 57.4011 78.0104 124.6093 57.7163 78.0104 10.1425 
p23 2.9659e+4 1.1578e+6 1.2723e+6 2.9173e+4 1.1578e+6 1.0116e+5 
p24 6.2665e-5 6.2444e-7 6.6659e-7 6.1653e-5 6.2444e-7 1.8922e-7 
p25 7.8794e-8 6.4698 4.8201 7.7977e-8 6.4698 1.7325 
p26 3.1056e-1 127.9276 33.1729 3.1198e-1 1.2793e-1 2.5909 
p27 1.6768e+3 6.5611e-6 7.4354e-6 1.7691e+3 6.5611e-6 3.1667e-6 
p28 41.8116 1.6713e-5 2.1151e-5 41.5737 1.6713e-5 5.0896e-6 
p29 9.4642e-7 1.7842e-5 1.9869e-5 8.8738e-7 1.7842e-5 2.1747e-5 
p30 2.1620 4.3909 4.8477e-2 2.1543 4.3909 6.0619 
p31 1.7963e-4 15.9639 12.6802 1.9328e-4 15.9639 3.3801 
p32 2.7543 0 0 2.9155 0 0 
p33 2.6235e-1 0 0 2.6661e-1 0 0 
p34 1.0624e-3 0 0 1.0711e-3 0 0 
p35 2.1450e-2 0 0 2.1258e-2 0 0 
 
Equations for Markov INa formulations: 
F = Faraday constant (96485 C/mol) 
R = Universal gas constant (8314 J/kmol/K) 
T = Temperature (295 K) 
pH = 7.4 
[D] = Drug concentration (mol) 
 
kd_open = d1 * exp(-0.7 * V * F/R*T) 
portion = 1/(1+10^(pH-pKa)) 
[D+] = portion * [D] 
[Dn] = portion * [D] 
kon = [D+] * diffusion 
kcon = kon 
koff = kd_open * diffusion 
kcoff = koff 
k_on = [Dn] * diffusion 
k_off = d2 * diffusion 
ki_on = k_on / 2 
ki_off = d3 * diffusion 
kc_on = k_on / 2 
kc_off = d4 * diffusion 
Tfactor = 1 / (d5 ^ ((37 – (T – 273)) / 10)) 
 
Transition rates : 
a11 = Tfactor * p1 / (p2 * exp(-(V - actshift) / p3) + p6 * exp(-(V - actshift) / p7)) 
a12 = Tfactor * p1 / (p2 * exp(-(V - actshift) / p4) + p6 * exp(-(V - actshift) / p7)) 
a13 = Tfactor * p1 / (p2 * exp(-(V - actshift) / p5) + p6 * exp(-(V - actshift) / p7)) 
b11 = Tfactor * p8 * exp(-(V - actshift) / p9) 
b12 = Tfactor * p10 * exp(-(V - actshift - p11) / p9) 
b13 = Tfactor * p12 * exp(-(V - actshift - p13) / p9) 
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a3_ss = 1/(1+exp((V - p14_new) / p15_new)) 
a3_tau = h1 + p01 * exp(p16_new * (V - p14_new)) / (1 + exp(p17_new * (V - p14_new))) 
a3 = Tfactor * a3_ss / a3_tau 
b3 = Tfactor * (1 - a3_ss) / a3_tau 
a2 = Tfactor * p18 * exp(V / p19) 
b2 = (a13*a2*a3) / (b13*b3) 
ax = p20 * a2 
bx = p21 * a3 
a13c = p22 * a13 
b13c = if(kon>0, (b13 * kcon * koff * a13c) / (kon * kcoff * a13), 0) 
a13n = p23 * a13 
b13n = if(k_on>0, (b13 * kc_on * a13n * k_off) / (kc_off * a13 * k_on), 0) 
ax1 = p24 * ax 
bx1 = p25 * bx 
ax2 = p26 * ax 
bx2 = if(ki_on>0, (bx * k_on * ax2 * ki_off) / (ax * ki_on * k_off), 0) 
a22 = p27 * a2 
a_22 = p28 * a2 
b22 = if(b13c>0, (a13c * a22 * a33) / (b13c * b33), 0) 
b_22 = if(b13n>0, (a_33 * a13n * a_22) / (b_33 * b13n), 0) 
b33 = p29 * b3 
b_33 = p30 * b3 
a33 = p31 * a3 
a_33 = if(ki_on>0, (ki_off * a3 * kc_on * b_33) / (ki_on * kc_off * b3), 0) 
a44 = p32 * a2 
b44 = p33 * a3 
a_44 = p34 * a2 
b_44 = p35 * a2 
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Appendix C 
Published IK,ACh formulation from (641) was incorporated into the Courtemanche 
human atrial model to study the acute effects of ethanol on the channel, as previously 
reported (367). To simulate the concentration-dependent effects of ethanol on cardiac 
electrophysiology, several IC50 and EC50 values were extrapolated based on previously 
published data. The details are as following: 
INa, ICa,L, Ito, IKr and IKur: 
Current block = 
𝑑𝑟𝑢𝑔𝐻𝑖𝑙𝑙
𝑑𝑟𝑢𝑔𝐻𝑖𝑙𝑙+𝐼𝐶50𝐻𝑖𝑙𝑙
 
Ionic current IC50 (mM) Hill coefficient 
INa 446 3.1 
ICa,L 600 1.3 
Ito 2188 1.1 
IKr 608 0.99 
IKur 494.6 0.6437 
 
IK1 and IK,ACh (accommodating the dual effects): 
IK1 block = ((0.0919 ∗
drug3
drug3+0.18543
) − (0.3112 ∗
drug1.8
drug1.8+7.4611.8
)) 
IK,ACh block = ((0.0906 ∗
drug8.281
drug8.281+0.74428.281
) − (0.2651 ∗
drug4.064
drug4.064+9.1864.064
)) 
INCX and Ileak: 
Current factor = 1 + ((drugHill) ∗
Variable
drugHill+EC50Hill
) 
Ionic current EC50 (mM) Hill coefficient Variable 
INCX / Ileak (Atria) 16.43 1.088 1.067 
INCX / Ileak (Ventricle) 35.32 2.282 1.238 
 
Ethanol-induced gap-junction remodeling = 
𝑑𝑟𝑢𝑔𝐻𝑖𝑙𝑙
𝑑𝑟𝑢𝑔𝐻𝑖𝑙𝑙+𝐼𝐶50𝐻𝑖𝑙𝑙
, with IC50 = 320 mM and 
Hill coefficient = 1 
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